



CHANDAN HEALTHCARE LIMITED

Reg Off. Add: Biotech Park, Sector- G, Jankipuram, Kursi Road, Lucknow-226021

CIN: L85110UP2003PLC193493

TEL NO.: - 8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

Date: 07-09-2026

To,

The Manager – Listing Department

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G, Bandra Kurla Complex,

Bandra (East), Mumbai – 400 051

Scrip Symbol: CHANDAN | ISIN: INE0B2N01016

Sub: Submission of the Annual Report for the financial year 2025-26 along with the Notice convening the 23rd Annual General Meeting – Regulation 34(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 34(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed a copy of the Annual Report of the Company for the financial year 2025-26, together with the Notice convening the 23rd Annual General Meeting of the Members of the Company scheduled to be held on Wednesday, 30 September 2026 at 04:00 P.M. (IST) through Video Conferencing / Other Audio-Visual Means.

The Annual Report along with the Notice is being sent today by electronic mode to those Members whose e-mail addresses are registered with the Company, the Registrar and Share Transfer Agent or the Depository Participants. The same is also available on the website of the Company at www.chandandiagnostic.com.

You are requested to take the above on record.

Thanking you,

Yours faithfully,

For Chandan Healthcare Limited

RAJEEV NAIN
Digitally signed
by RAJEEV NAIN
Date: 2026.09.07
18:14:55 +05'30'

Rajeev Kumar Nain

Company Secretary & Compliance Officer

Membership No.: A35449

Encl: As above



Twenty-Third Financial Year

ANNUAL REPORT

2025-26

CHANDAN HEALTHCARE LIMITED

C O R P O R A T E I D E N T I T Y N U M B E R

L85110UP2003PLC193493

R E G I S T E R E D O F F I C E

Biotech Park, Sector G, Jankipuram, Kursi Road,
Lucknow – 226021, Uttar Pradesh, India

Tel.: +91 8069366666

Email: secretarial@chandan.co.in

Website: www.chandandidiagnostic.com

L I S T E D A T

NSE Emerge · Symbol: CHANDAN · ISIN: INE0B2N01016



CHANDAN DIAGNOSTICS

Concept & Design: studioband.com | +91 9918066556

Biotech Park, Kursi Road, Lucknow, Uttar Pradesh-226021 | **080693 66666**



@ChandanDiag



www.chandandiagnostic.com



Chandan 24x7 App



CHANDAN DIAGNOSTICS

Most
Promising
Diagnostic Chain In India



080693 66666



@ChandanDiag



www.chandandiagnostic.com



Chandan 24x7 App



Where Accuracy Meets Excellence

INDEX

Chandan Group Of Companies	01
Message From The Chairman	02
Message From The Managing Director	03
Our Presence	04
Chandan Diagnostics Milestones	05-06
Vision Mission & Values	07
Chandan Pharmacy Overview	08
NABL, NABH & ISO Certified	09
Affiliations	10
Awards	11
Lists Of Tests	12-15
Chandan Family Loyalty Programme	16
Chandan 24x7 App	17
Home Sample Collection	18
Logistics Managment	19
Franchise Business	20
Quality Assurance Program	21
3 Years Expansion Strategy	22

Key Strengths Driving Sustainable Growth	23
Investment Rationale	24
Key Facts & Figures	25
Management Declaration Q1, 2026-27 Results	26
Multi Segment Model Driving Growth Across B2C, B2B & B2G	27
Expanding Footprint Across India	28
Ganome Lab	29
PET Scan	30
Top Comprehensive Diagnostic Centres	31-32
Chandan Healthcare Ltd.- Diagnostics F.Y. 2025-26 & Q1, F.Y. 2026-27	33-34
Infrastructure	35
Q1, F.Y. 2026-27	36
F.Y. 2025-26 & Q1, F.Y. 2026-27	37-38
Chandan's Core Business Verticals F.Y. 2025-26 & Q1, F.Y. 2026-27	39-40
Financial Results (F.Y. 2025-26)	41
Consolidated Balance Sheet (F.Y. 2024, 2025 & 2026)	42
Consolidated Profit & Loss Statement (F.Y. 2024, 2025 & 2026)	43
Q1, F.Y. 2026-27 Results	44
Board of Directors & Top Management	45-46
Future Roadmap: Chandan Healthcare Limited	47
Thank You	48



Chandan Healthcare Limited



Cendana Pharmaceuticals Pvt Ltd



Chandan Hospital Limited



Chandan Superspecialty Hospital Limited



Chandan Pharmacy Limited



Chandan Cradle Ltd.

MESSAGE FROM THE Chairman



From Chairman's Desk

FY 2026 marked a period of robust growth, with revenue Increasing by 20.43% to ₹280.67 Cr with profitability remaining strong. This performance was supported by consistent volume growth, better business mix, and disciplined cost management. Expansion momentum and rising diagnostic volumes strengthened margins and overall financial performance.

During the year, we expanded our network with new state-of-the-art Diagnostic Centres in 15 states and continued to scale our Chandan Medical Centres to reach more communities. These additions enhanced patient access and reinforced our commitment to quality and affordable healthcare.

Looking ahead, we plan to accelerate our pan-India expansion through a mix of owned and franchise-led collection centres. Chandan Healthcare has also entered into an exclusive strategic partnership with Jeena Sikho Lifecare Limited to establish diagnostic centres across all existing and upcoming Jeena Sikho Hospitals and Clinics across India. Jeena Sikho Lifecare Limited (JSL) is one of India's leading Ayurvedic healthcare providers with over a decade of experience in holistic wellness. With a clear strategy and strong foundation, Chandan Healthcare remains focused on steady, profitable, and sustainable growth in the years ahead.

Chandan Healthcare Limited is one of India's leading service providers of Diagnostic and Pharmacy services and a key entity within the Chandan Group. The company offers a comprehensive range of NABL/NABH accredited pathology and radiology services across 15 states in India. It's service portfolio includes a wide array of diagnostic solutions such as Blood tests, MRIs, CT scans, X-rays, Ultrasounds, ECGs, TMT and other specialized investigations, ensuring accurate, reliable and high-quality patient care.

Chandan operates through a diversified business model encompassing B2C (Retail customers), B2B (Institutional Partnerships), and B2G (Government PPP Contracts) segments, all under a company-owned model that ensures consistent service standards and strong operational control. In F.Y. 2025-26, Chandan has entered in Franchise business as well. Chandan has also started online services in Diagnostic and Pharmacy. Chandan has been awarded 14 PPP contracts in Radiology at Punjab, Haryana and Assam.

Chandan Healthcare Limited was got listed on NSE Emerge on 17th February, 2025.

Dr. Amar Singh
Promoter, Chairman and Managing Director

MESSAGE FROM THE
**Managing
Director**



From The Managing Director

This year has been a landmark year of growth and transformation for Chandan Healthcare Limited. As we reflect on our journey, I take immense pride in the progress we have made in strengthening our healthcare ecosystem, expanding access to quality diagnostics in 15 states, and creating sustainable value for all our stakeholders.

During the year, we continued to enhance our presence through strategic expansion, technology-led innovation, and an unwavering commitment to patient-centric care. Our teams across diagnostics, radiology, and retail pharmacy remained dedicated to excellence, enabling us to serve a growing number of patients, healthcare institutions, and communities. Supported by strong operational execution and a focus on quality, we delivered healthy growth while further strengthening the trust that patients and healthcare professionals place in the Chandan Healthcare brand.

A defining milestone during the year was our successful listing, marking the beginning of an exciting new chapter in our journey. This achievement reflects the confidence of our investors and reinforces our commitment to the highest standards of governance, transparency, and sustainable growth.

Looking ahead, we remain focused on building a future-ready healthcare organization. Over the next three years, we aim to establish more than 100 laboratories under our "One District, One Lab" initiative and expand our franchise network to over 1,000 centers.


In line with our commitment to innovation and clinical excellence, we are also establishing a state-of-the-art Genome Sequencing Laboratory in Lucknow, expected to be operational in 2026. This facility will enhance our capabilities in advanced molecular diagnostics and precision healthcare, further strengthening our position as a trusted healthcare partner.

I extend my heartfelt gratitude to our patients, doctors, institutional partners, business associates, investors, and employees for their continued trust and support. Their confidence inspires us to strive for greater excellence every day.

Together, we will continue advancing our mission of improving healthcare outcomes, building healthier communities, and creating enduring value for generations to come.

Asmita Singh
Managing Director

Our
Presence



CHANDAN Diagnostics MILESTONES

1991

1st Diagnostic Centre
in Lucknow, Uttar Pradesh

1996

1st Diagnostic Centre in
outside Lucknow,
Allahabad, Uttar Pradesh

1999

1st Diagnostic Centre
in Uttar Pradesh to
acquire Spiral CT

2003

Awarded ISO 9001: 2015
for Diagnostic Services

2006

1st Retail Pharmacy
in Shahjahanpur,
Uttar Pradesh

2007

1st Diagnostic Centre
in Haldwani, Uttarakhand

2009

1st Diagnostic chain in
Uttar Pradesh to provide
Online Reports

2013

Chandan Speciality
Lab Inaugurated

2021

Free Diagnostic Services
in all district hospitals
CHCs and PHCs in
Uttarakhand

2024

- 1st Diagnostic centre
in Jaipur, Rajasthan
and 50th overall
- Crossed 30 Retail
Pharmacies

2025

- Chandan Healthcare Ltd.
listed on NSE Emerge
- Acquisition of X-Life
Diagnostics and
Research Centre in
Patna, Bihar
- First Diagnostic
Centre in New Delhi
- First Diagnostic Centre
in Bhopal, Madhya
Pradesh
- 16 NABL Labs
- Crossed 50 Retail
Pharmacies

2026

- 2 Diagnostic Centres in
Chandigarh
- 1st Diagnostic Centre in
Kolkata, West Bengal
- 1st Diagnostic Centre in
Mumbai, Maharashtra
- 1st Diagnostic Centres in
Bengaluru, Karnataka
- Diagnostic Centres in
Ahmedabad, Vadodara,
and Surat, Gujarat
- Diagnostic Centres in
Kota and Udaipur,
Rajasthan
- 1st Diagnostic Centre in
Kurukshetra, Haryana
- 1st Diagnostic Centre in
Raipur, Chattisgarh
- Acquired Nishkam
Diagnostic Centre in
New Delhi
- PPP with Punjab Health
Corporation
- PPP with Medical
Corporation Ltd.,
Haryana
- PPP with NFR, Guwahati

CHANDAN Diagnostics MILESTONES



Major Highlights

- **30+ million** Patients served
- **150+ million** Tests Performed
- **23** Comprehensive Diagnostic Units
- **18** Diagnostic Centres
- **1000+** Collection Points
- **24** Standalone Labs & **80** Centres
- **3500+** Pathology & Radiology Tests
- **40,000+** Referring Doctors
- **15** Radiology Centres
- **325+** Franchises (adding 100+ every month)

Other Highlights

- Employee Strength **1900+**
- **16 NABL** Accredited Labs
- **6** NABH (HIS) Accredited Radiology Centres
- **30 AERB** Licensed Radiology Centres
- All Centres ISO 9001:2015 Certified
- Online Reports on Chandan **24x7 App**
- 2 Central Reference Labs in Lucknow, Uttar Pradesh and Haldwani, Uttarakhand

VISION
Mission
& VALUES



Vision

Our vision is to ensure comprehensive diagnostics coverage to every corner of the country in the coming years. We are committed to maintaining uncompromising quality while offering affordable rates, ensuring access to essential healthcare services for all.

Mission

To build value, performance, and trust for delivering quality diagnostic services while maintaining the highest ethical and social standards.

Core Values

- We believe in a work approach that puts "the customer first". Over 35 years of experience tells us that if we serve our clients well, success is the only outcome that follows.
- Our people and reputation for quality are our assets.
- Business integrity is a way of life at Chandan. We aim at providing world-class services by adopting fair means and expect our employees to maintain high ethical standards.
- We collaborate with trust, respect, and shared responsibility to achieve excellence together.
- We try to keep in pace with the changing needs of our clients and keep on embracing innovative solutions for the enhancement of services to meet them.
- We ensure the protection of the confidential information that our clients entrust us with.
- Because of our passion for excellence, we nurture our employees by providing them continuous training and education.

CHANDAN
Pharmacy
OVERVIEW



40 Pharmacy Stores



250+ Employees

[NABL Labs]



[NABH-MIS Accreditation]



Affiliations



Expanding Access Through 200+ Trusted Affiliations



Awards



Most Innovative Healthcare Service Provider, 2018



Leadership Excellence Award 2024



Pride of India Awards Best Employer Brand 2018



Amar Ujala Excellence Award 2024



Shri Abdul Kalam Inspiration Excellence Award 2026



World HRD Congress Best Employer Brand 2017-2018



Dare to Dream Awards 2025

LISTS OF Tests

Laboratory

-  Hematology
-  Microbiology
-  Biochemistry & Immunoassay
-  Histopathology
-  Immunohistochemistry
-  Cytogenetic
-  Clinical Pathology
-  Genome Sequencing
-  Molecular Diagnostics

LISTS OF
Tests



Radiology Tests

-  Pet CT scan & Gamma Camera
-  MRI
-  CT scan
-  Ultrasonography
-  Digital X-ray
-  Digital Mammography
-  Fibroscan
-  OPG
-  Bone Mineral Density

LISTS OF
Tests



Cardiology

-  CT Cardiac Angiography
-  TMT
-  2D Echo with TEE
-  ECG
-  Holter

LISTS OF Tests



Other Tests



EEG & Video EEG



EMG, BERA, NCV



Audiometry



EBUS & EUS



Vertigo Lab



PFT, DLCO & Sleep Studies



Uroflowmetry



Bronchoscopy, Endoscopy, Colonoscopy

CHANDAN Family LOYALTY PROGRAMME



Full Body Checkup

HIM-1 (52 Tests)

MRP- ₹ 3550/-
₹ 999/-

Advance Full Body Checkup

HIM-2 (76 Tests)

MRP- ₹ 5550/-
₹ 1499/-

Complete Health Checkup

HIM-3 (80 Tests)*

MRP- ₹ 8550/-
₹ 2499/-

* Available in selected Locations

Whole Body Checkup

HIM-4 (86 Tests)*

MRP- ₹ 33,000/-
₹ 9999/-

* Available in selected Locations



Additional 25% Discount for Family Members for Booking on same day & on same registered Mobile number

Affordable Healthcare. Stronger Patient Loyalty

A patient-centric healthcare membership ecosystem designed to improve affordability, accessibility, and long-term care engagement.

Key Benefits at a Glance:

1. One Complimentary Health Checkup at the time of joining
2. More than 70% Discount on Health Checkups
3. Up to 40% Discount on Medicines
4. Easy access to the reports via Chandan 24x7 App and WhatsApp

Growing Patient Engagement



40 Lakhs+
Members Enrolled




25,000+
New Members Added Monthly



Strategic Value Creation

1. Enhances customer retention & repeat visits
2. Enables cross-service healthcare adoption
3. Strengthens recurring revenue streams
4. Expands patient outreach across India

CHANDAN
24x7
APP



Transforming Patient Experience Through Technology

1. Unified access to diagnostics, pharmacy & consultations
2. Seamless online and offline healthcare integration
3. Centralized medical records & digital reports
4. Faster appointment booking & home sample collection
5. Real-time patient support and engagement

Users till date **3 Lakhs+**

Users added every month **10,000+**

Patient-Centric Digital Features

1. Book Online Consultations
2. Book OPD consultations
3. Schedule Health Check-ups & tests with ease
4. Download Reports anytime, anywhere
5. Quick and easy medicine ordering with free Home Delivery
6. Real Time tracking of medicine delivery
7. Real time ambulance tracking

HOME
Sample
COLLECTION



Enhanced Customer Experience in Home Collection

1. Real Time Slot Confirmation to Patient
2. Real Time Phlebotomist tracking
3. Auto allocation of bookings to nearest available Phlebotomists

Logistics MANAGEMENT



Best in Class Logistic Management



Real Time Sample Tracking



Real Time Phlebotomist Tracking



Automated Cash Collection Process
with Clients



Efficient turn-around time



Temperature controlled logistics
maintaining sample integrity

Franchise BUSINESS



India's Most Trusted and Rewarding Diagnostic Franchise Networks

1. Fully IT driven operations for stress free management
2. Low Initial Investment
3. Quality Assurance
4. Quick turnaround time in processing & reporting
5. Do Business On the Go- Manage with a mobile app
6. Reputed Brand serving the nation's populace for 35 years
7. Comprehensive array of over 3500 tests and profiles
8. Extensive Network
9. State-of-the-art laboratories
10. Constant Guidance & Support

Total Franchises **325+**

100+ Franchises Added
every month

Target For F.Y. 2026-27 **1000+**

QUALITY Assurance PROGRAM



- All our Centres are **ISO 9001:2015 Certified** and we have **16 NABL Accredited Labs**.
- Stringent quality control parameters along with intelligent IT enabled systems.
- State-of-art equipment to provide best quality testing service.
- Monitoring of pre-analytical, analytical and post-analytical errors.
- Periodic maintenance of equipment and use of world class consumables.

Internal Quality Assurance Program

- Daily internal quality controls from Bio-rad and other reputed companies.
- Control charts (LJ charts) are plotted for internal quality control and are monitored for trends and shifts to have better control over testing system.
- Emphasis over automation to avoid human errors.
- Regular training programs done for skill upgradation.

External Quality Assurance Program

Quality Assessment is done periodically by External Agencies like:-

- Christian Medical College, Vellore
- Bio-Rad Laboratories, USA

3 YEARS Expansion STRATEGY



40 Comprehensive
Diagnostic Centres



50 Diagnostic
Centres



3000+ Franchises
in 17 States



50 Standalone Labs (One District, One Lab)
Total Labs: 155



100+ Chandan
Medical Centres




Genome Sequencing
Lab in Lucknow



2 PET Scans in Gorakhpur & Kanpur


[Key Strengths Driving Sustainable Growth]



Investment Rationale



-  Integrated Diagnostics Chain offering both Pathology and Radiology services under one roof, driving patient stickiness and cross-selling opportunities.
-  Widespread Presence with operations in 15 states, enabling deep regional penetration and first-mover advantage in underserved areas.
-  Focused Expansion in Tier 2/3 Markets, including recent entry into Delhi, Madhya Pradesh and Chhattisgarh, targeting high-growth diagnostics demand.
-  Volume-Led Growth Strategy with a scalable model anchored in in-house labs, B2B referral partnerships, and low-cost collections infrastructure.
-  Core Diagnostics Business Drives Revenue, supported by strong unit economics, high margin radiology services, and rising test volumes.
-  Experienced Promoter-Led Team with 35+ years in healthcare operations, marketing, and diagnostics strategy.
-  Accredited Infrastructure including NABL-certified central labs, ensuring quality, compliance, and eligibility for government and insurance linked programmes.



Management Declaration On Q1, 2026-27 Results

We are thrilled to present our performance for the first quarter of the new financial year, 2026-27, a period marked by robust financial expansion, rapid network scaling, and strategic refinement aimed at long-term value creation.

From our beginnings as a single diagnostic centre in 1991, our brand has built a legacy of clinical excellence and trust. Today, we stand as a major diagnostic powerhouse spanning 15 states, rapidly expanding our presence beyond North India to national market.

Our core business segments delivered exceptional growth across both top-line and bottom-line metrics by having **revenue Growth of 19.62%** year-over-year, **EBITDA Growth 42.27%** increase y-o-y, reflecting significant operational leverage. **PAT Growth increased to 29.51%** y-o-y in Q1.

This stellar performance is driven by a diversified business model spanning Referrals from doctors, nursing home and hospitals. Corporate business from government, public sector units and insurance companies. Preventive healthcare (Health checkups), Government Contracts, Franchise Networks and Online Business.

In this quarter alone, we had the privilege of serving **0.6 million** patients by performing **3.19 million** tests, backed by a network of over 40,000 referring doctors and more than 200 corporate affiliations.

Our footprint across 15 states is powered by a high-capacity, multi-tiered infrastructure of 400 centres includes 23 Comprehensive diagnostic centres, 18 Diagnostic centres, 21 standalone Labs, 15 radiology centres and 324 franchisee. We have approx **15 lakhs sq.ft. rental space** and **21,000 sq.ft. company owned space**.

Our newly launched franchise model has achieved unprecedented momentum, onboarding over 324 franchisees within its first 4 months. Paired with our fast-growing online booking platform, we are drastically expanding patient accessibility and brand reach.

To maximize capital efficiency and sharpen our operational focus, the company has taken a strategic decision to exit the pharmacy business. This realignment allows us to dedicate 100% of our management bandwidth and resources to high-margin diagnostic opportunities.

Specialized High-End Diagnostics includes installation of two **advanced PET Scan facilities at Gorakhpur and Kanpur** within the next 4 months and Genomics Lab, a state-of-the-art Genome Lab slated within the next 6 months to capture growing demand in personalized medicine.

We are aggressively positioning the business for sustainable, high-margin growth through a clear growth trajectory by having >1,000 franchisees, >100 standalone labs and >30 comprehensive diagnostic centres by the end of this financial year.

Our journey from a local centre to a global diagnostic brand is built on clinical accuracy, operational agility, and shareholder value creation. With a sharp focus on our core diagnostic strengths, high-margin specialized testing, and an asset-light franchise expansion strategy, we remain fully committed to maintaining strong momentum and delivering sustainable profitability in the years ahead.

Asmita Singh
Managing Director

[Multi Segment Model driving growth across B2C, B2B & B2G]

Diversified revenue streams ensure stability, scalability and reduced risk.



B2C (Retail Diagnostics)

- Walk-in services across **15 states**
- **18L+ Patients served** in FY 26
- Strong brand recall, reliable service and affordable care
- 40,000 Referring Doctors

FY 26 Revenue
Share- 41.5%
YOY Growth- 29.57%



B2B (Institutional Clients)

- 230+ Hospitals, Clinics, Corporates, Insurance companies, TPAs & Laboratories as partners
- Recurring, long-term relationships
- Steady revenue from integrated tie-ups

FY 26 Revenue
Share- 26.88%
YOY Growth- 50.58%




B2G (Government PPPs)

- Public-Private Partnerships with **state governments**
- Diagnostic services in government hospitals
- Long-term contracts ensure stable cash flow & credibility

FY 26 Revenue
Share- 31.82%
Growth- 3.64%

[Expanding Footprint Across India]



Network Expansion Plan

- Addition of **100 labs** across **15 states** over the next 3 years
- Expanding presence through 3,000 franchises in the next 3 years
- Enhancing accessibility and strengthening nationwide reach



Expansion Highlights

- **New States:** Entry into Assam, Chandigarh, Chhattisgarh, Delhi, Gujarat, Haryana, Karnataka, Madhya Pradesh, Maharashtra, Punjab & West Bengal.
- **Strengthening Presence:** Deepening network in **Uttar Pradesh & NCR**
- **Strategic Focus:** Addressing **diagnostic gaps** in mid-sized cities & suburban regions



Strategic Partnership with Jeena Sikho Lifecare Limited

- Chandan Healthcare to act as the **Exclusive Diagnostics partner** across 15 states and 100+ cities
- Extends to upcoming Jeena Sikho facilities as their network expands
- Providing end-to-end pathology and radiology services for IPD and OPD patients



Growth via Chandan Medical Centres (CMC)

- Plan to open new CMCs under structured, long-term strategy
- CMCs act as sample collection centre as well
- Sale of medicines
- Distribution of group company **Cendana Pharmaceutical Pvt. Ltd.** Products.

Genome LAB

*"Powered by Innovation.
Guided by Expertise.
Focused on Every Patient."*

The Future Of Precision Diagnostics Is Arriving

Introducing a State-of-the-Art Clinical Genomics Laboratory

Decoding DNA. Delivering Diagnostic Confidence.

At Chandan Genomics, we are bringing the next generation of clinical genomics to healthcare. Our state-of-the-art laboratory combines advanced high-throughput sequencing technology, world-class molecular diagnostics, and expert clinical interpretation to provide accurate, timely, and reliable genomic testing that supports informed medical decisions and improved patient outcomes.

Why Choose Us?

Advanced Technology

High-throughput Next Generation Sequencing (NGS) | Automated sample processing | Robust bioinformatics and data analysis | High accuracy with rapid turnaround times

Expert Clinical Team

Molecular geneticists | Clinical scientists | Bioinformaticians | Genetics professionals dedicated to quality and precision

Patient-Centered Care

Every sample represents a patient and a family seeking answers. We are committed to delivering trustworthy genomic insights that support better diagnosis, personalized treatment, and improved healthcare outcomes.

Expert Clinical Team

Molecular geneticists | Clinical scientists | Bioinformaticians | Genetics professionals dedicated to quality and precision

Our Clinical Genomic Services

Hereditary Disease Testing | Cancer Genomics | Rare Disease Diagnostics | Whole Exome Sequencing (WES) | Whole Genome Sequencing (WGS) | Targeted Gene Panels | Tpharmacogenomics | Carrier & Prenatal Screening

Our Commitment

Combining cutting-edge technology with scientific expertise, we deliver genomic diagnostics that clinicians can trust and patients can rely on.

Advancing Healthcare

Through Precision Genomics Every Gene. Every Insight. Every Patient.

PET Scan



Strengthening its commitment to bringing cutting-edge healthcare closer to patients, Chandan Diagnostics is set to launch two state-of-the-art PET-CT centres in Kanpur and Gorakhpur over the next four months. This expansion marks another significant milestone in the organization's mission to make advanced diagnostic services more accessible across Uttar Pradesh while enhancing the region's cancer care infrastructure.

Equipped with next-generation PET-CT technology, the new centres will deliver exceptional image quality, superior diagnostic accuracy, shorter scan times, and enhanced patient comfort. Supported by a team of experienced nuclear medicine physicians, radiologists, and highly skilled technologists, these facilities will provide comprehensive molecular imaging services while upholding the highest standards of clinical excellence, quality, precision, and patient safety.

With the addition of these two advanced PET-CT centres, Chandan Diagnostics continues to strengthen its position as a trusted leader in diagnostic healthcare. By bringing world-class molecular imaging closer to patients, the organization aims to reduce travel, enable earlier and more accurate diagnosis, facilitate timely treatment decisions, and ultimately improve patient outcomes. This expansion reflects Chandan Diagnostics' unwavering commitment to innovation, accessibility, and excellence in healthcare delivery.

[Top Comprehensive Diagnostic Centres]



Indira Nagar, Lucknow, Uttar Pradesh



Ashiyana, Lucknow, Uttar Pradesh



Rikabganj, Ayodhya, Uttar Pradesh



Deokali, Ayodhya, Uttar Pradesh



DC Road, Lakhimpur Kheri, Uttar Pradesh



Jaipur, Rajasthan



Bhopal, Madhya Pradesh




Prashant Vihar, New Delhi



Dehradun, Uttarakhand

[Top Comprehensive Diagnostic Centres]



Nainital Road, Haldwani, Uttarakhand



Chatrasangh Chauraha, Gorakhpur, Uttar Pradesh



Katra, Prayagraj, Uttar Pradesh



Chitaipur, Varanasi, Uttar Pradesh




Heera Nagar, Haldwani, Uttarakhand



Patna, Bihar

[Chandan Healthcare Ltd.- Diagnostics]


F.Y. 2025–26



Government Corporate Online
Franchise Referral

DIVISION WISE SALES

Division	Share	Growth
Corporate	25.15%	41.83%
Referral	40.61%	26.79%
Government	31.82%	-3.64%
Franchise	1.53%	First Year
Online	0.89%	First Year




B2C B2B B2G

SEGMENTAL SALE

Segment	Share	Growth
B2C	41.50%	29.57%
B2B	26.88%	50.58%
B2G	31.82%	-3.64%

[Chandan Healthcare Ltd.- Diagnostics]


Q1, F.Y. 2026–27



Corporate General Government Franchise

DIVISION WISE SALES

Division	Share	Growth
Corporate	23.79%	44.58%
General	37.92%	20.05%
Government	30.19%	21.75%
Franchise	8.09%	First Year



B2C B2B B2G

SEGMENTAL SALE

Segment	Share	Growth
B2C	37.89%	20.05%
B2B	31.69%	93.47%
B2G	30.19%	21.75%



Infrastructure

STRATEGIC FOOTPRINT

(SF)

Company Owned Space: Approx 50,000 sq. ft.

Rental Space: Approx 15 lakh sq. ft.

INTEGRATED NETWORK

(IN)

Comprehensive Diagnostic Centres: 23

Diagnostic Centres: 18

Standalone Labs: 24

Radiology Centres: 15

Franchise: 325+

CLINICAL INFRASTRUCTURE

(CI)

MRI Machines: 16

CT Machines: 20

USG Machines: 28

Digital X-ray Machines: 35

BMD: 9

OPG: 7

Mammography: 3

ECG: 54


TMT: 22

NCV: 3

NABL Labs: 16


NABH Centres: 8

[Q1, F.Y. 2026-27]




Comprehensive Diagnostic Centres **1** | Standalone Labs **3** | Franchise **134**

Ticket Size/patient **₹ 600**



● Government ● Corporate ● Online
● Franchise ● Referral




● Government ● Corporate ● Online
● Franchise ● Referral

PATIENTS SERVED


Division	Share	Growth
Corporate	14.33%	23.48%
Referral	31.28%	14.57%
Government	53.55%	7.6%
Online	0.1%	First Year
Franchise	0.73%	First Year

TESTS PERFORMED

Division	Share	Growth
Corporate	28.49%	32.67%
Referral	26.19%	40.05%
Government	44.07%	3.18%
Franchise	1.19%	First Year
Online	0.05%	First Year



● Corporate ● General ● Government ● Franchise



● Corporate ● General ● Government ● Franchise

PATIENTS SERVED

Division	Share	Growth
Corporate	12.69%	24.02%
General	31.53%	29.58%
Government	49.78%	13.96%
Franchise	6%	First Year

TESTS PERFORMED

Division	Share	Growth
Corporate	22.92%	30.67%
General	28.62%	93.89%
Government	38%	21.95%
Franchise	10.46%	First Year

**[Chandan's Core Business Verticals
F.Y. 2025-26]**



PATHOLOGY
40.95%



RADIOLOGY
16.25%



PHARMACY
42.80%

**[Chandan's Core Business Verticals
Q1, F.Y. 2026-27]**



PATHOLOGY
43%



RADIOLOGY
15%



PHARMACY
42%

[Board of Directors]



Dr Amar Singh
Chairman & Managing Director



Vinay Lamba
Non Executive Director



Asmita Singh
Managing Director

[Independent Directors]



Amit Singh
Non Executive Independent Director



Brahma Nand Bhartiya
Non Executive Independent Director



Dr Vinod Jain
Independent Director

[Top Management]



Rajeev Kumar Nain
CFO & Company Secretary



Aasti Singh
Director (Finance)



Anant Singh
Managing Director (Pharmacy)



Shailendra Singh
Director (Pharmacy)



Amit Srivastava
Director (Corporate)



Dr Brahma Prakash
Director (Quality)



Deepak Kumar Sirohi
Vice President (Operations)



Rajeev Lochan
Director (Sales)



Rajesh Srivastava
Head (Sales)



Rajive Kumar
Director (Infrastructure)



Sandeep Kumar Saraswat
Director (Infrastructure)



Shipra Singh
Senior Compliance Manager



Shweta Lamba
Director (Accounts)



Vijay Singh
Director (IT)



Vikalp Dixit
Director (Maintenance)



Vikas Lamba
Director
(Government Compliance)



Vishal Lamba
Director (Legal)



Ajeet Maurya
Vice President (IT)




Dr. Divya Singh
Director (Lab Management)
Head (Microbiology &
Genome Labs)



Umesh Chandra
Head (Pharmacy)

Future Roadmap: Chandan Healthcare Limited



THANK YOU

Chandan Healthcare Limited
 Biotech Park, Kursi Road, Lucknow 226021 Uttar Pradesh, India
Email: care@chandan.co.in
Phone: 08069366666
Website: www.chandandiagnostics.com

Disclaimer: While the information and data presented here primarily relate to the financial year ended March 31, 2026, certain figures, information and developments may pertain to the period subsequent to the close of the financial year and up to the date of this Report.

INDEX

01	CHAIRMAN'S MESSAGE	3
02	BOARD'S REPORT	7
03	SECRETARIAL AUDIT REPORT	28
04	MANAGEMENT DISCUSSION & ANALYSIS REPORT	42
05	REPORT ON CORPORATE GOVERNANCE	54
06	AUDIT REPORT OF THE STANDALONE FINANCIAL RESULTS	79
07	STANDALONE FINANCIAL STATEMENTS	82
08	AUDIT REPORT OF THE CONSOLIDATED FINANCIAL RESULTS	137
09	CONSOLIDATED FINANCIAL STATEMENTS	140
10	NOTICE OF ANNUAL GENERAL MEETING	192

Dear Shareholders,

It gives me immense pleasure to connect with you once again and share the progress and achievements of Chandan Healthcare Limited during the Financial Year 2025–26.

India's healthcare landscape is undergoing significant transformation, driven by increasing health awareness, growing demand for preventive healthcare, wider access to medical services and advancements in diagnostic technology. At Chandan Healthcare, we believe that quality diagnostics are fundamental to effective healthcare delivery. Our endeavour remains focused on providing reliable, accurate and affordable diagnostic services to an increasing number of people.

A Year of Growth and Expansion

FY 2025–26 has been an important year for your Company. We continued to strengthen our core diagnostic business while expanding our presence across new geographies. Our performance reflects the resilience of our business model, increasing diagnostic volumes, disciplined cost management and the growing trust of patients and healthcare professionals in the Chandan brand.

During the year, we expanded our operations across important markets including Lucknow, Ayodhya, Bhopal, Delhi, Mumbai, Kolkata, Kota and other locations. These centres are aimed at bringing comprehensive diagnostic services closer to patients and strengthening our regional and national footprint.

Our expansion is focused not merely on increasing the number of centres, but on developing integrated diagnostic centres equipped with advanced laboratory and imaging capabilities, enabling patients to access a comprehensive range of services under one roof.

Building an Integrated Healthcare Platform

Our vision extends beyond diagnostics. We are steadily developing an integrated healthcare ecosystem encompassing diagnostics, medical centres and allied healthcare services.

During the year, we continued to expand our Chandan Medical Centres, enhancing access to healthcare services across our operating markets. We also entered into a strategic partnership with Jeena Sikho Lifecare Limited to establish diagnostic centres across its existing and upcoming hospitals and clinics. Such partnerships enable us to leverage complementary strengths and extend our diagnostic capabilities to a wider patient base.

Our objective remains to build a scalable and sustainable healthcare platform while preserving the quality and trust associated with the Chandan name.

Technology, Quality and Patient-Centricity

Technology plays an important role in improving healthcare outcomes. We continue to invest in modern diagnostic infrastructure, advanced equipment, laboratory capabilities and technology-enabled processes to enhance accuracy, efficiency and turnaround time.

Our integrated diagnostic model brings together laboratory diagnostics and imaging services, including X-ray, ultrasound, CT scans, MRI and other diagnostic modalities, offering greater convenience to patients and supporting clinical decision-making.



Quality remains non-negotiable. We continue to strengthen quality-control systems, standardise processes and enhance the capabilities of our people to ensure dependable and timely diagnostic services.

Our People

The progress of Chandan Healthcare is a result of the commitment and dedication of our employees, doctors, technicians, healthcare professionals and support teams.

As we expand our footprint, we remain focused on developing talent, strengthening our organisational culture and fostering an environment of accountability, learning and excellence. I sincerely appreciate every member of the Chandan Healthcare family for their contribution during the year.

Looking Ahead

India's healthcare sector presents significant long-term opportunities. Increasing health awareness, preventive healthcare, rising demand for quality diagnostics, growing healthcare expenditure and technological advancement are expected to support continued sectoral growth.

We see considerable opportunities to expand through a combination of owned, acquired and partnership-led centres. Our objective is to build a wider diagnostic network while maintaining operational discipline and ensuring that growth remains profitable and sustainable.

Going forward, our priorities will remain expansion, quality, technology, accessibility and sustainable value creation. We will continue to strengthen our existing markets, enter new geographies selectively, enhance our service portfolio and invest in technology and people, while maintaining strong financial discipline and governance standards.

Corporate Governance

As a listed healthcare organisation, we recognise that sustainable growth must be supported by strong governance, transparency and accountability.

We remain committed to the highest standards of corporate governance and ethical conduct. We believe that good governance is integral to building lasting relationships with our patients, employees, investors, business partners and other stakeholders.

A Note of Gratitude

I extend my sincere gratitude to all our shareholders for their continued trust and confidence in Chandan Healthcare Limited.

I also thank the Board of Directors for their guidance and support, and our doctors, employees, healthcare professionals and associates for their dedication and hard work. My appreciation also goes to our patients, business partners, bankers, auditors, advisors and other stakeholders for their continued support.

The journey ahead presents significant opportunities. With a strong foundation, an expanding network, a committed team and the continued support of our stakeholders, I am confident that Chandan Healthcare will continue to grow responsibly, create sustainable value and contribute meaningfully to the healthcare ecosystem.

I look forward to your continued support as we embark on the next phase of our journey together.

With warm regards,

Sd/-

Dr. Amar Singh
Chairman & Managing Director
Chandan Healthcare Limited

CORPORATE INFORMATION

CHANDAN HEALTHCARE LIMITED
CIN: L85110UP2003PLC193493

BOARD OF DIRECTORS

MR. AMAR SINGH

Chairman & Managing Director

MS. ASMITA SINGH

Managing Director

MR. VINAY LAMBA

Non-Executive Director

MR. AMIT GUPTA

Independent Director

MR. BRAHMA NAND BHARTIYA

Independent Director

MR. VINOD JAIN

Independent Director

BOARD COMMITTEES

Audit Committee

Mr. Amit Gupta, Chairman
Mr. Brahma Nand Bhartiya
Mr. Vinod Jain

Nomination and Remuneration Committee

Mr. Vinod Jain, Chairman
Mr. Amit Gupta
Mr. Brahma Nand Bhartiya

Stakeholders' Relationship Committee

Mr. Vinod Jain, Chairman
Mr. Amar Singh
Ms. Asmita Singh

Corporate Social Responsibility Committee

Mr. Amar Singh, Chairman
Mr. Brahma Nand Bhartiya
Mr. Vinay Lamba

COMPANY SECRETARY & COMPLIANCE OFFICER

Mr. Rajeev Kumar Nain

STATUTORY AUDITORS

M/s. MSNT & Associates LLP
Chartered Accountants
A-40, I-Thum, Tower-B, 10th Floor,
Unit No. 1033, Sector 62,
Noida – 201005, Uttar Pradesh

COST AUDITORS

M/s. Rahul Jain & Associates
Cost and Management Accountants
Office No. 606, Signature Global Mall,
Vaishali, Sector-3,
Ghaziabad – 201010, Uttar Pradesh

REGISTERED OFFICE

Biotech Park, Sector G, Jankipuram,
Kursi Road, Lucknow – 226021,
Uttar Pradesh, India
Tel.: +91 8069366666
Email: secretarial@chandan.co.in
Website: www.chandandiagnostic.com

LISTED AT:

National Stock Exchange of India Limited
NSE Emerge Platform
NSE Symbol: CHANDAN
ISIN: INE0B2N01016

SECRETARIAL AUDITOR

M/s Umesh Kumar & Associates
Company Secretaries
301, Sagar Plaza-II, Third Floor, Plot No. 27,
Behind M2K Cinema, DDA Complex,
Near Rani Bagh, Road No. 44, Pitampura,
New Delhi – 110034

INTERNAL AUDITORS

M/s. Renu Agrawal & Co.
Chartered Accountants
Unit No. 302, Vipul Trade Centre,
Sector 48, Sohna Road,
Gurgaon – 122018, Haryana

REGISTRAR AND TRANSFER AGENT

KFin Technologies Limited
Selenium Tower-B, Plot 31 & 32,
Gachibowli, Financial District, Nanakramguda,
Serilingampally, Hyderabad – 500032, Telangana
Email: chl.ipo@kfintech.com
Website: www.kfintech.com

BOARD'S REPORT

02

To,

The Share Holders,

Your Directors have pleasure in presenting the company's 23rd Board Report on the business and operations of the Company along with the Audited Balance Sheet and Profit & loss Account for the year ended 31st March 2026.

FINANCIAL YEAR 2025-26 AT GLANCE

The Financial results of the Company for Financial year have been summarized herein below for the reference of the members:


(Amount in 'Lakhs')

PARTICULARS	STANDALONE		CONSOLIDATED	
	F.Y. 2025-26	F.Y. 2024-25	F.Y. 2025-26	F.Y. 2024-25
Revenue from Operations	15,664.73	12,916.42	27,639.44	23,012.08
Other Income	412.50	204.89	427.85	293.51
Total Income	16,077.23	13,121.31	28,067.29	23,305.59
Less: Total Expenses before Depreciation, Finance Cost and Tax	11,021.61	9,305.62	22,382.92	18,966.96
Profit before Depreciation, Finance Cost and Tax	5,055.62	3,815.69	5,684.37	4,338.63
Less: Depreciation	951.43	642.24	977.98	674.48
Less: Finance Cost	442.89	356.90	588.19	457.60
Profit Before Extraordinary & Exceptional Items and Tax	3,661.30	2,816.55	4,118.20	3,206.55
Less: Extraordinary & Exceptional Items	270.97	-	291.54	-
Profit before tax	3,390.33	2,816.55	3,826.66	3,206.55
Less: Current Tax	780.51	683.00	903.83	813.44
Less: Earlier Years Tax	30.48	17.14	30.48	17.14
Less: Deferred tax Liability (Asset)	45.21	38.61	36.99	24.34
Profit after Tax	2,534.13	2,077.80	2,855.36	2,351.63

The Total Revenue for the year ended, March 31, 2026 was INR 16,077.23 lakhs as compared to INR 13,121.31 lakhs during the previous year ended March 31, 2025. The Profit after tax for the year ended March 31, 2026 was INR 2,534.13 lakhs as compared to INR 2,077.80 lakhs.

Your Directors are committed to achieve higher revenues and profits for its stakeholders in the coming year and hence are in the continuous process of developing new products and tailor-made services for its customers.

The above figures are extracted from the Financial Statements prepared in accordance with generally accepted accounting Principles in India. The applicable mandatory Accounting Standards as amended specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 of India have been followed in preparation of these financial statements and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), as amended.



DIVIDEND

The Company is in the growth phase and expanding organically as well as inorganically. In order to save the profit earned during the year for future expansion of the Company, your directors do not recommend any dividend for the financial year ended March 31, 2026.

TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR EDUCATION AND PROTECTION FUND

There was no amount outstanding to be an Unclaimed Dividend to Investor Education and Protection Fund during the FY 2025-2026.

TRANSFER TO GENERAL RESERVE

Your Directors do not propose to transfer any amount to General Reserves.

BRIEF DESCRIPTION OF THE STATE OF THE COMPANY’S AFFAIRS

The Company is engaged in the business of providing pathology and radiology diagnostic services and retail pharmacy services. There has been no change in the nature of the business of the Company during the year under review.

During the year the Company recorded growth across all its principal service lines. The Company operates through a network of comprehensive diagnostic units, standalone laboratories, radiology centres, collection points and franchise centres, supported by central reference laboratories at Lucknow (Uttar Pradesh) and Haldwani (Uttarakhand). Services are delivered through three channels – retail (B2C), institutional partnerships (B2B) and government public-private partnership contracts (B2G).

Key operating parameters of the Company's network as at the close of the year under review are set out in the Management Discussion and Analysis Report annexed to this Report as Annexure VI.

The Company has contracted with a large number of smaller laboratories to perform tests on their behalf using its technology and equipment base, and continues to enhance service quality through its patient feedback programme and an in-house quality team applying current industry quality controls. The Company is pursuing both vertical and horizontal expansion.

CHANGE IN NAME AND STATUS OF THE COMPANY

During the year under review, pursuant to the listing of the equity shares of the Company on the NSE Emerge Platform, the Corporate Identification Number (CIN) of the Company was changed from U85110UP2003PLC193493 to L85110UP2003PLC193493.

The Board further clarifies that there has been no change in the name of the Company. The change is limited to the Corporate Identification Number (CIN), consequent upon the change in the listing status of the Company.

ISSUE OF FULLY CONVERTIBLE WARRANTS

During the year under review, the Board of Directors approved the issuance of up to 44,50,000 Fully Convertible Warrants on a preferential basis, each carrying a right to subscribe to or be converted into one fully paid-up equity share of the Company having a face value of Rs.10/- each, at an issue price of Rs.234/- per warrant (including premium), aggregating up to Rs.104.13 crore, in accordance with the provisions of the Companies Act, 2013 and Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended. The warrants are convertible into equity shares within a period of 18 months from the date of allotment, subject to the terms and conditions of the issue.

Subsequently, on February 3, 2026, the Board allotted 44,50,000 Fully Convertible Warrants to the identified allottees on a preferential basis. The proceeds of the preferential issue are proposed to be utilized towards pursuing strategic business opportunities, funding the Company's growth and expansion plans, and meeting general corporate purposes.

The successful completion of the preferential issue reflects the confidence reposed by the investors and stakeholders in the Company's long-term growth strategy and business prospects.

STATEMENT OF DEVIATION(S) OR VARIATION(S)

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the applicable SEBI Circulars, the Company has submitted the Statement of Deviation(s) or Variation(s) in respect of the utilisation of proceeds raised through the Initial Public Offer ("IPO") and the Preferential Issue of Fully Convertible Warrants.

During the year under review, there was no deviation or variation in the utilisation of the proceeds from either the IPO or the Preferential Issue from the objects stated in the respective offer documents and shareholders' approval. The Audit Committee has reviewed the utilisation of the proceeds and confirmed that the funds have been utilised in accordance with the approved objects.

The utilisation of the IPO proceeds as on 31 March 2026 is summarised below:

PARTICULARS	ORIGINAL ALLOCATION (RS. IN LAKHS)	AMOUNT UTILISED (RS. IN LAKHS)
Setting up of New Flagship Diagnostic Centre at Jankipuram, Lucknow	3,281.58	1,627.01
Setting up of Central Reference Laboratory at Ayodhya, Uttar Pradesh	710.23	710.23

PARTICULARS	ORIGINAL ALLOCATION (RS. IN LAKHS)	AMOUNT UTILISED (RS. IN LAKHS)
Setting up of Central Reference Laboratory at Ashiyana, Lucknow	710.11	710.11
General Corporate Purposes	1,672.45	1,672.45
Issue Related Expenses	670.27	670.27
Total	7,044.64	5,390.07

Further, pursuant to the preferential issue of 44,50,000 Fully Convertible Warrants aggregating to Rs.10,413.00 Lakhs, the Company had utilised Rs.1,217.54 Lakhs towards the object of Business Expansion as on 31 March 2026 and Rs.475.54 Lakhs towards the General Corporate Purposes. No amount had been utilised towards the object of Acquisitions during the year. There was no deviation or variation in the utilisation of the proceeds from the approved objects. The balance issue proceeds are receivable upon conversion of the warrants in accordance with the terms of issue.

DEMATERIALISATION OF SHARES

As on March 31, 2026, the share of the Company held in demat form represents 98.85% of the total issued and paid-up capital of the Company.

The Company ISIN No. is INE0B2N01016.

M/s. KFin Technologies Limited act as the Registrar and Share Transfer Agent of the Company.

MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE COMPANY WHICH HAVE OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR OF THE COMPANY TO WHICH THE FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT

Except as otherwise disclosed elsewhere in this Report, there have been no material changes or commitments affecting the financial position of the Company which have occurred between the end of the financial year to which the financial statements relate and the date of this Report.

ALTERATION OF MEMORANDUM AND ARTICLES OF ASSOCIATION

During the year under review, the shareholders approved the increase in the Authorised Share Capital of the Company and, consequently, Clause V (Capital Clause) of the Memorandum of Association of the Company was altered.

SL. NO.	DATE OF EXTRAORDINARY GENERAL MEETING	INCREASE IN AUTHORISED SHARE CAPITAL	
		From (Rs.)	To (Rs.)
1	November 06, 2025	25,00,00,000	30,00,00,000

Accordingly, the Authorised Share Capital of the Company stands increased from Rs.25,00,00,000 (Rupees Twenty-Five Crore Only) divided into 2,50,00,000 equity shares of Rs.10 each to Rs.30,00,00,000 (Rupees Thirty Crore Only) divided into 3,00,00,000 equity shares of Rs.10 each to facilitate future fund raising, and the Capital Clause of the Memorandum of Association was amended accordingly.

SUBSIDIARIES

During the Financial Year 2025-26, Chandan Healthcare Projects Private Limited was incorporated as a Wholly Owned Subsidiary of the Company. Accordingly, it became a subsidiary of the Company during the year under review. Further, no company ceased to be a Subsidiary or Associate of the Company during the Financial Year 2025-26.

The Company had the following subsidiaries [as defined under Section 2(87) of the Companies Act, 2013] as on 31 March 2026:

S.NO	NAME	STATUS SUBSIDIARY Z/JV/ ASSOCIATE COMPANY	DATE OF BECOMING SUBSIDIARY/ JV/ ASSOCIATE COMPANY	DATE OF CEASING AS SUBSIDIARY/ JV/ ASSOCIATE COMPANY
1	Indra Diagnostic Centre & Blood Bank Limited	Subsidiary Company	30/06/2017	-
2	Chandan Diagnostic Limited	Subsidiary Company	31/03/2017	-
3	Chandan Pharmacy Limited	Subsidiary Company	26/02/2022	-
4	Chandan Healthcare Projects Private Limited	Subsidiary Company	08/03/2026	-

Pursuant to the first proviso to Section 129(3) of the Act read with Rule 5 of the Companies (Accounts) Rules, 2014, a statement containing the salient features of the financial statements of the subsidiary companies in Form AOC-1 is annexed to this Report as Annexure IX and forms part of it.

Report on the performance and financial position of the subsidiaries

Pursuant to Rule 8(1) of the Companies (Accounts) Rules, 2014, a report on the performance and financial position of each of the subsidiaries is set out below:

(Rs. in Lakhs)

NAME OF THE SUBSIDIARY	TURNOVER	PROFIT / (LOSS) BEFORE TAX	PROFIT / (LOSS) AFTER TAX	TOTAL ASSETS	% HOLDING
Indira Diagnostic Centre & Blood Bank Limited	—	(0.93)	(0.93)	37.07	100.00
Chandan Pharmacy Limited	12,022.02	437.38	322.28	6,807.76	53.56
Chandan Diagnostic Limited	—	(0.13)	(0.13)	48.69	67.99
Chandan Healthcare Projects Private Limited	Operations had not commenced as of March 31, 2026.				

Chandan Pharmacy Limited, which operates the Group's retail pharmacy business, was the principal contributor to consolidated turnover among the subsidiaries during the year. Indira Diagnostic Centre & Blood Bank Limited and Chandan Diagnostic Limited did not record turnover during the year and reported marginal losses arising from routine maintenance costs.

In terms of Section 136 of the Act, the audited financial statements of the subsidiary companies are available on the website of the Company and will be provided to any member on request. The financial statements of the subsidiaries are open for inspection by the members.

SHARE CAPITAL

- Authorized Capital

The Authorized share Capital of the Company, as at closure of financial year 2025-26, was INR 3,000.00 Lakhs divided into 3,00,00,000 Equity Shares of INR 10.00 each.

- Issued, Subscribed & Paid-up Capital

The Issued, Subscribed and Paid-up Share Capital of the Company as at 31 March 2026 stood at Rs.2,445.21 Lakhs, comprising 2,44,52,064 Equity Shares of face value Rs.10/- each.

During the year under review, there was no change in the Issued, Subscribed and Paid-up Share Capital of the Company. However, the Company allotted 44,50,000 Fully Convertible Warrants on a preferential basis in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The warrants are convertible into an equivalent number of equity shares within 18 months from the date of allotment, subject to the terms and conditions of the issue. Accordingly, the amount received towards the warrants has been disclosed under "Money Received Against Share Warrants" in the financial statements.

During the year under review, following changes took places in paid-up capital of the Capital:

- Buy Back of Securities:

Company has not bought back any of its securities during the year under review.

- Sweat Equity:

Company has not issued any Sweat Equity Shares during the year under review.

- Rights Issue:

During the year under review, there was no Right issue of shares by the company.

- Bonus Issue:

Company has not issued any Bonus Shares during the year under review.

- Preferential Issue of Fully Convertible Warrants:

During the year under review, the Company allotted 44,50,000 Fully Convertible Warrants on a preferential basis at an issue price of Rs.234 per warrant, aggregating to Rs.104.13 Crore, in accordance with the provisions of the Companies Act, 2013 and Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Each warrant is convertible into one fully paid-up equity share of face value Rs.10/- each within a period of 18 months from the date of allotment, subject to the terms and conditions of the issue. As on 31 March 2026, no warrants had been converted into equity shares, and accordingly, there was no change in the Issued, Subscribed and Paid-up Share Capital of the Company on account of the said allotment.

BOARD MEETING

Regular meetings of the Board are held, inter-alia, to review and discuss the various businesses that require the approval of the Board. Additional Board meetings are convened, as and when required, to discuss and decide on various business policies, strategies and other businesses. The Board meetings are generally held at registered office of the Company.

During the year under review, Board of Directors of the Company met 11 (Eleven) times, viz

MONTH	NO. OF MEETINGS HELD	DATES
April 2025	0	-
May 2025	1	27 May

MONTH	NO. OF MEETINGS HELD	DATES
June 2025	0	-
July 2025	0	-
August 2025	1	5 August
September 2025	1	5 September
October 2025	1	10 October
November 2025	1	14 November
December 2025	1	31 December
January 2026	2	20 January, 31 January
February 2026	3	3 February, 14 February, 26 February
March 2026	0	-

The gap between two consecutive meetings was not more than one hundred and twenty days as provided in section 173 of the Companies Act, 2013.

ATTENDANCE OF DIRECTORS AT THE BOARD MEETINGS

As per standard 9 of the Secretarial Standard on Meetings of the Board of Directors ('SS-1') issued by the Institute of Company Secretaries of India ('ICSI'), the attendance of Directors at Board meetings held during the financial year 2025-26 are as under:

SI. NO.	NAME OF DIRECTOR	NO. OF BOARD MEETING ATTENDED
1	Mr. Amar Singh	11
2	Mr. Vinay Lamba	11
3	Mrs. Asmita Singh	11
4	Mr. Amit Gupta	9
5	Mr. Vinod Jain	1
6	Mr. Brahma Nand Bhartiya	1

GENERAL MEETING

During the year under review, the following General Meeting were held:

SI. NO.	TYPE OF MEETING	DATE OF MEETING	TOTAL NUMBER OF MEMBERS ENTITLED TO ATTEND MEETING	ATTENDANCE	
				Number of members Attended	% of attendance
1.	EGM	06 November 2025	1358	23	1.69
3.	AGM	29 September 2025	1248	29	2.32

MEETING OF THE INDEPENDENT DIRECTORS

During FY 2025-26, 2 (two) meeting of Independent Directors were held without the presence of the Executive Directors or Management Personnel on 04th August 2025 and 23rd February 2026. At such meeting, the Independent Directors have discussed, among other matters, the challenges faced by the Company, growth strategies, flow of information to the Board, strategy, leadership strengths, compliance, governance, HR related matters and performance of Executive Directors.

SI. NO.	DATE OF INDEPENDENT DIRECTORS MEETING	TOTAL NUMBER OF MEMBERS ASSOCIATED AS ON THE DATE OF MEETING	ATTENDANCE	
			Number of members Attended	% of attendance
1.	4 August, 2025	3	3	100
2.	23 February, 2026	3	3	100

PARTICULARS OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

The Board received a declaration from all the Directors under Section 164 and other applicable provisions, if any, of the Companies Act, 2013 that none of the Directors of the Company is disqualified under the provisions of the Companies Act, 2013 ("Act") or under the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015.

The Board of Directors of the Company, at present, comprises of 6 Directors, who have wide and varied experience in different disciplines of corporate functioning. The present composition of the Board consists of two Managing Director, one non- Executive Director and Three Non-Executive Independent Directors.

During the year under review, there was no change in the constitution of the Board of Directors of the Company. The composition of the Board remained in compliance with the applicable provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 throughout the year.;

NAME	DATE OF CHANGE	DATE OF APPROVAL BY THE BOARD	DATE OF APPROVAL BY THE SHAREHOLDERS	NATURE OF CHANGE
No Change				

In accordance with the provisions of the Articles of Association of the Company and Section 152 of the Companies Act, 2013, Mrs. Asmita Singh (Managing Director), being liable to retire by rotation at the ensuing Annual General Meeting, offers herself for re-appointment.

The Board recommends her re-appointment. The requisite resolution seeking shareholders' approval forms part of the Notice convening the ensuing Annual General Meeting.

KEY MANAGERIAL PERSONNEL

In accordance with the provisions of Section 203 of the Companies Act, 2013, during the year under review and as on the date of this Report, the following are the Key Managerial Personnel of the Company:

- Mr. Amar Singh – Managing Director
- Mrs. Asmita Singh – Managing Director
- Mr. Rajeev Nain – Chief Financial Officer, Company Secretary & Compliance Officer

There was no change in the Key Managerial Personnel of the Company during the Financial Year 2025-26.

INDEPENDENT DIRECTORS

In terms of Section 149 of the Companies Act, 2013 and rules made there under, the Company had three Non-Executive Independent Directors in line with the Companies Act, 2013. Further, all of the Independent Directors of the Company had registered themselves in the Independent Directors' Data Bank.

Separate meetings of Independent Directors were held on 4 August, 2025 and 23 February, 2026, to review the performance of Non-Independent Directors, the Board as a whole, and the performance of the Chairperson of the Company, including the assessment of the quality, quantity, and timeliness of the flow of information between the Company management and the Board.

The terms and conditions of appointment of Independent Directors and Code for Independent Director are incorporated on the website of the Company at www.chandandiagnostics.com.

DECLARATION BY INDEPENDENT DIRECTOR

The Company has received necessary declaration from each independent director under Section 149(7) of the Companies Act, 2013 that they meet the criteria of independence laid down in Section 149(6) of the Companies Act, 2013 and the rules made thereunder and Listing Regulations.

All the Independent Directors of the Company have registered themselves with the Indian Institute of Corporate Affairs ("IICA"). Further, as per the declarations received, all the Independent Directors of Company have either passed or were exempted to clear online proficiency test as per the first proviso to Rule 6(4) of the MCA Notification dated October 22, 2019 and December 18, 2020.

Accordingly, the Company has taken on record, the Statement of Declaration of Independence, as submitted by all the Independent Directors.

In the opinion of the Board of Directors, all Independent Directors of the Company fulfils the conditions specified in the Act and Rules made thereunder.

FAMILIARISATION PROGRAMMES

The Company has in place a structured Familiarisation Programme for its Independent Directors in accordance with the requirements of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. At the time of their appointment, the Independent Directors are familiarised with the Company's business model, organisational structure, operations, industry dynamics, regulatory framework, governance practices, roles, rights, responsibilities and duties under the applicable laws.

The Company also conducts periodic presentations and interactive sessions to update the Independent Directors on the Company's business performance, strategic initiatives, operational developments, risk management framework, regulatory changes and other significant matters. Senior management personnel make presentations to the Board and its Committees to enable the Independent Directors to gain a comprehensive understanding of the Company's operations and the environment in which it operates.

These familiarisation programmes facilitate meaningful participation by the Independent Directors in the deliberations of the Board and its Committees and assist them in effectively discharging their fiduciary and statutory responsibilities.

The details of the Familiarisation Programme for Independent Directors are available on the website of the Company at www.chandandiagnostic.com.

COMMITTEES OF BOARD

The Board has constituted various Committees in accordance with the provisions of the Companies Act, 2013 and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), wherever applicable.

During the year under review, the Company continued to strengthen its corporate governance framework. Although certain provisions relating to Corporate Governance under Regulations 17 to 27, clauses (b) to (i) of sub-regulation (2) of Regulation 46 and Paras C, D and E of Schedule V of the SEBI Listing Regulations were not mandatorily applicable to the Company for the year under review, the Company voluntarily adopted and complied with the applicable corporate governance requirements to uphold high standards of transparency, accountability and governance.

The Board has ensured compliance with the applicable provisions of the Companies Act, 2013, including the appointment of Independent Directors (including a Woman Independent Director) and the constitution of the mandatory Board Committees. The Board functions either directly or through its committees, which oversee specific areas of governance and operations and discharge their responsibilities in accordance with their respective terms of reference.

As on March 31, 2026, the following Committees of the Board were in place:

- Audit Committee
- Nomination and Remuneration Committee
- Stakeholders' Relationship Committee
- Corporate Social Responsibility Committee

COMPOSITION OF COMMITTEE, MEETING AND ATTENDANCE OF EACH MEMBER AT MEETINGS

The Board has constituted various Committees in accordance with the applicable provisions of the Companies Act, 2013 and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), wherever applicable. These Committees function within their respective terms of reference approved by the Board and assist the Board in discharging its responsibilities effectively.

During the financial year under review, there was no change in the composition of the Audit Committee, Nomination and Remuneration Committee, Stakeholders' Relationship Committee and Corporate Social Responsibility Committee. The composition of the Committees remained in compliance with the applicable provisions of the Companies Act, 2013 and the SEBI Listing Regulations, wherever applicable.

1. Audit Committee

The Audit Committee is constituted in accordance with the provisions of Section 177 of the Companies Act, 2013. The Committee assists the Board in discharging its oversight responsibilities with regard to the integrity of the Company's financial statements, internal financial controls, risk management systems, internal and statutory audit processes, compliance with legal and regulatory requirements, related party transactions and the adequacy of internal control systems. The Committee also reviews the financial reporting process to ensure that the financial statements are accurate, complete and presented with transparency and integrity.

During the financial year under review, 5 (five) Audit Committee Meeting(s) were held.

NAME OF MEMBER	CATEGORY	DESIGNATION	MEETINGS HELD	ELIGIBLE TO ATTEND	ATTENDED
Amit Gupta	Independent Director	Chairman	5	5	5
Brahma Nand Bhartiya	Independent Director	Member	5	5	5
Vinod Jain	Independent Director	Member	5	5	5
Amar Singh	Managing Director	Member	5	5	5

All recommendations made by the Audit Committee during the year were accepted by the Board of Directors.

The Company Secretary and Compliance Officer acts as the Secretary to the Committee.

2. Nomination and Remuneration Committee

The Nomination and Remuneration Committee ("NRC") has been constituted pursuant to the provisions of Section 178 of the Companies Act, 2013. The Committee is responsible for identifying and recommending persons qualified to become Directors and Key Managerial Personnel, formulating the criteria for determining qualifications, positive attributes and independence of Directors, recommending remuneration policies for Directors, Key Managerial Personnel and Senior Management Personnel, evaluating the performance of the Board, its committees and individual Directors, and overseeing succession planning.

During the financial year under review, 2 (Two) Nomination and Remuneration Committee Meeting(s) were held.

NAME OF MEMBER	CATEGORY	DESIGNATION	MEETINGS HELD	ELIGIBLE TO ATTEND	ATTENDED
Brahma Nand Bhartiya	Independent Director	Chairman	2	2	2
Amit Gupta	Independent Director	Member	2	2	2
Vinod Jain	Independent Director	Member	2	2	2
Vinay Lamba	Non-Executive Director	Member	2	2	2

The Company Secretary and Compliance Officer acts as the Secretary to the Committee.

3. Stakeholders' Relationship Committee

The Stakeholders' Relationship Committee has been constituted in accordance with the provisions of Section 178 of the Companies Act, 2013. The Committee oversees and resolves the grievances of shareholders and other security holders, including matters relating to transfer and transmission of securities, dematerialisation, issue of duplicate share certificates, non-receipt of annual reports, dividends and other investor service matters. The Committee also reviews measures taken for effective exercise of voting rights and initiatives for strengthening investor relations.

During the financial year under review, 1 (one) Stakeholders' Relationship Committee Meeting(s) were held.

NAME OF MEMBER	CATEGORY	DESIGNATION	MEETINGS HELD	ELIGIBLE TO ATTEND	ATTENDED
Vinay Lamba	Non-Executive Director	Chairman	1	1	1
Amar Singh	Managing Director	Member	1	1	1
Brahma Nand Bhartiya	Independent Director	Member	1	1	1
Vinod Jain	Independent Director	Member	1	1	1

The Company Secretary and Compliance Officer acts as the Secretary to the Committee.

4. Corporate Social Responsibility Committee

The Corporate Social Responsibility ("CSR") Committee has been constituted in accordance with the provisions of Section 135 of the Companies Act, 2013. The Committee is responsible for formulating and recommending the Corporate Social Responsibility Policy to the Board, recommending the amount of expenditure to be incurred on CSR activities, monitoring the implementation of approved CSR projects and programmes, and ensuring compliance with the applicable statutory requirements relating to Corporate Social Responsibility.

During the financial year under review, 1 (one) Corporate Social Responsibility Committee Meeting(s) were held.

NAME OF MEMBER	CATEGORY	DESIGNATION	MEETINGS HELD	ELIGIBLE TO ATTEND	ATTENDED
Amar Singh	Managing Director	Chairman	1	1	1
Brahma Nand Bhartiya	Independent Director	Member	1	1	1
Vinay Lamba	Non-Executive Director	Member	1	1	1

The Company Secretary and Compliance Officer acts as the Secretary to the Committee.

The terms of reference of the aforesaid Committees are in line with the applicable provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, wherever applicable, and are reviewed by the Board from time to time to ensure continued effectiveness and regulatory compliance.

POLICY ON DIRECTORS' APPOINTMENT AND REMUNERATION

The Board, based on the recommendation of the Nomination and Remuneration Committee, has framed a policy for the selection and appointment of Directors and Senior Management Personnel and their remuneration.

The Company's policy relating to the Directors appointment, payment of remuneration and discharge of their duties is available on the website of the Company at <https://chandandiagnostics.com/>.

BOARD EVALUATION

Pursuant to the provisions of the Companies Act, 2013 and the corporate governance requirements as prescribed by Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 ("SEBI Listing Regulations"), peer evaluation of all Board members, annual performance evaluation of their own performance, as well as the evaluation of the work of Board's Committees was undertaken.

The evaluation process was as follows:

- Evaluation Criteria

This evaluation is led by the Chairman of the Nomination and Remuneration Committee with a specific focus on the performance and effective functioning of the Board and its Committees. The evaluation process, inter alia, considers attendance of Directors at Board and committee meetings, acquaintance with business, communication inter se board members, the time spent by each of the Board members, core competencies, personal characteristics, accomplishment of specific responsibilities and expertise.

- Performance Evaluation of the individual directors including Independent Directors

The Chairman of the Nomination and Remuneration Committee conducted the evaluation process, inter alia, based on attendance of Directors at Board and committee meetings, acquaintance with business, communication inter se board members, the time spent by each of the Board members, core competencies, personal characteristics, accomplishment of specific responsibilities and expertise.

The report on the performance evaluation of the Individual Directors was reviewed by the Board and feedback was given to the Directors. The performance of each director was satisfactory.

- Board of Directors

The performance of the Board was evaluated by the Board after seeking inputs from all the Directors on the basis of the criteria such as the Board composition and structure, effectiveness of Board processes, information and functioning etc.

- Performance Evaluation of the Committee

The performance of the Committees was evaluated by the Board after seeking inputs from the Committee Members on the basis of the criteria such as the composition of Committees, effectiveness of committee meetings, etc.

Outcome of Evaluation:

Board of the Company was satisfied with the functioning of the Board and its Committees. The Committees are functioning well and besides covering the Committees' terms of reference, as mandated by law, important issues are brought up and discussed in the Committee meetings. The Board was also satisfied with the contribution of Directors, in their individual capacities.

DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to section 134(5) of the Companies Act, 2013, the board of directors, to the best of their knowledge and ability, confirm that:

- In preparation of annual accounts for the year ended March 31, 2026, the applicable accounting standards have been followed and that no material departures have been made from the same;
- The Directors selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for that year;
- The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- The Directors had prepared the annual accounts for the year ended March 31, 2026 on going concern basis.
- The Directors have laid down the internal financial controls to be followed by the Company and that such Internal Financial Controls are adequate and were operating effectively; and
- The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively
- The Board confirms that the cost records have been prepared, reviewed, and approved as per applicable Cost Accounting Standards and are adequate for audit.

STATUTORY AUDITORS

Statutory Auditors

Pursuant to Section 139 of the Act, M/s. MSNT & Associates LLP, Chartered Accountants (Firm Registration No. 018542C), were appointed as the Statutory Auditors of the Company for a term of five consecutive years, to hold office from 1 April 2023 until 31 March 2028.

Pursuant to Section 141 of the Act and the rules made thereunder, the Company has received a certificate from the Statutory Auditors, together with their peer review certificate, confirming that they are eligible to continue in office and are not disqualified in any manner from continuing as Statutory Auditors.

The Auditors' Report on the standalone and consolidated financial statements for the financial year ended 31 March 2026 does not contain any qualification, reservation, adverse remark or disclaimer. The notes to the accounts referred to in the Auditors' Report are self-explanatory and do not call for any further comments. The Auditors' Report forms part of this Annual Report.

Secretarial Auditors

Pursuant to Section 204 of the Act and the rules made thereunder, the Board appointed M/s. Umesh Kumar & Associates, Practising Company Secretaries (Membership No. 21567, CP No. 8361, Peer Review No. 1895/2022), to conduct the secretarial audit of the Company for the financial year 2025-26. The Secretarial Audit Report in Form MR-3 is annexed to this Report as Annexure I.

The Secretarial Audit Report does not contain any qualification, reservation or adverse remark and therefore does not call for any further comments.

The appointment of the Secretarial Auditor for a term of five consecutive financial years, and the placing of that appointment before the members for approval, should be reviewed in the light of the amendments to Regulation 24A of the SEBI Listing Regulations, to the extent applicable to the Company.

Internal Auditors

Pursuant to Section 138 of the Act read with the Companies (Accounts) Rules, 2014, the Company has appointed M/s. Renu Agrawal & Co., Chartered Accountants (Firm Registration No. 018547C), as the Internal Auditors of the Company for the financial year 2025-26.

The Internal Auditors carry out periodic internal audits of the Company's operations, financial and accounting systems, internal controls and compliance processes. The internal audit reports, together with the management's responses and corrective actions, are periodically reviewed by the Audit Committee, which monitors the adequacy and effectiveness of the Company's internal control framework and risk management systems.

Cost Auditors and Cost Records

The Company has maintained the cost records prescribed under Section 148(1) of the Act read with the Companies (Cost Records and Audit) Rules, 2014, to the extent applicable.

The cost audit for the financial year ended 31 March 2026 is being conducted by M/s. Rahul Jain & Associates, Cost Accountants (Firm Registration No. 101515), appointed as the Cost Auditors of the Company. The Cost Audit Report for the financial year 2025-26 will be submitted by the Cost Auditors within the prescribed time and, upon receipt, the Company will file the same with the Central Government within the statutory time limit.

ANNUAL RETURN

Pursuant to Section 92 (3) read with Section 134 (3) (a) of the Companies Act, 2013, read with Rule 12 of the Companies (Management and Administration) Rules, 2014, the Annual Return for the year ending on March 31, 2026 is available on the Company's website and can be accessed at <https://chandandiagnostics.com/investors.php>

PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186 OF THE COMPANIES ACT, 2013

The particulars of loans given, investment made, or guarantee given or security provided and the purpose for which the loan or guarantee or security is proposed to be utilized as per the provisions of Section 186 of the Companies Act, 2013 are disclosed in the notes to account to the financial statements for the FY 2025-26.

DISCLOSURE ON RELATED PARTY'S TRANSACTIONS

All Related Party transactions that were entered into during the FY 2025-2026 were on arm's length basis and in the ordinary course of business. There are no materially significant related party transactions made by the Company with related parties which may have a potential conflict of interest with the company.

All the related party transactions are in compliance with the Accounting Standards issued by ICAI and further details are mentioned in the notes of the Financial Statements.

All Related party transactions are placed before the Audit Committee for approval as per the Related Party Transactions Policy of the Company as approved by the Board. The policy is also uploaded on the website of the Company & can be accessed through the link <https://www.chandandidiagnostic.com>.

Since, all the related party transactions that were entered into during the financial year 2025-2026 were on an arm's length basis and were in the ordinary course of business and there was no material related party transaction entered by the Company during the year as per Related Party Transactions Policy, details are required to be provided in the Form AOC-2 prescribed under clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014. Particulars of contracts or arrangements with related parties referred to in sub-section (1) of section 188 in the prescribed form (Form AOC-2) are attached as "Annexure-II"

The details of the transaction with related parties are provided in the notes to accompanying financial statements.

CORPORATE GOVERNANCE

The Company is committed to maintaining high standards of Corporate Governance and continuously endeavors to adopt and implement emerging best governance practices in the interest of all its stakeholders. Although the provisions relating to Corporate Governance under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are not mandatorily applicable to the Company in terms of Regulation 15(2), the Company has voluntarily adopted and complied with the applicable Corporate Governance requirements. Accordingly, the Report on Corporate Governance forms part of this Annual Report as "Annexure VII"

SEBI COMPLAINTS REDRESS SYSTEM (SCORES)

The investor complaints are processed in a centralized web-based complaints redress system. The salient features of this system are centralized database of all complaints, online upload of Action Taken Reports (ATRs) by the concerned companies and online viewing by investors of actions taken on the complaint and its current status. Your Company has been registered on SCORES and makes every effort to resolve all investor complaints received through SCORES or otherwise within the statutory time limit from the receipt of the complaint. The Company has not received any complaint on the SCORES during financial year 2025-26.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO

The details of conservation of energy, technology absorption, foreign exchange earnings and outgo stipulated under Section 134(3)(m) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014 is annexed herewith as “Annexure-III” and the same forms part of this report.

RISK MANAGEMENT

The Company is not required to constitute a Risk Management Committee under Regulation 21 of the SEBI Listing Regulations. However, pursuant to Section 134(3)(n) of the Act, the Company has in place a Risk Management Policy which provides for the identification of elements of risk which, in the opinion of the Board, may threaten the existence of the Company, together with risk assessment and minimisation procedures.

The risk management plan is reviewed by the Board from time to time and suitable changes are made as necessary. The principal risks to which the Company is exposed, and the mitigation measures adopted, are discussed in the Management Discussion and Analysis Report annexed as Annexure VI.

CHANGE IN THE NATURE BUSINESS

There has been no change in the nature of business of the Company in the Financial Year under review.

DISCLOSURE UNDER INSOLVENCY AND BANKRUPTCY CODE, 2016 (31 OF 2016)

During the year under review, neither any application was made nor is any proceeding pending against the Company under the Insolvency and Bankruptcy Code, 2016.

CORPORATE SOCIAL RESPONSIBILITY

Your Company's CSR initiatives align with the core purpose afore stated by prioritizing in areas of skilling, education, and environment sustainability. The Annual Report on CSR activities pursuant to the provisions of section 134 and 135 of the Act read with rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014 and rule 9 of the Companies (Accounts) Rules, 2014 is annexed to this Directors' Report as 'Annexure IV'.

The Chief Financial Officer of the Company has certified that the funds disbursed have been utilized for the purpose and in a manner approved by the Board for FY 2026

The CSR policy is hosted on the Company's website at www.chandandidiagnostic.com.

WHISTLE BLOWER POLICY/ VIGIL MECHANISM

To meets the requirement under Section 177(9) and (10) of the Companies Act, 2013 and Regulation 22 of the SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015, the Company has adopted a Vigil Mechanism/ Whistle Blower Policy with a view to provide a vigilance mechanism for the directors and employees of the Company to raise concern of any violations of legal or regulatory requirements, incorrectness or misinterpretation of any financial statements and reports etc. The purpose of this Policy is to encourage the Company's directors and employees who

have concerns about suspected misconduct, to come forward and express these concerns without fear of punishment or unfair treatment.

Likewise, under this policy, we have prohibited discrimination, retaliation or harassment of any kind against any employee who, based on the employee's reasonable belief that such conduct or practice have occurred or are occurring, reports that information or participates in the said investigation. The Whistle Blower Policy is displayed on the Company's website at www.chandandidiagnostic.com.

No individual in the Company has been denied access to the Audit Committee or its Chairman during the FY 2025-26

There were no instances of reporting under the Whistle Blower.

The Whistle Blower Policy of the Company is available on the website of the Company at www.chandandidiagnostic.com.

PREVENTION OF INSIDER TRADING

The Company has adopted a Code of Conduct for Prevention of Insider Trading with a view to regulate trading in securities by the Directors and designated employees of the Company. The Code requires pre-clearance for dealing in the Company's shares and prohibits the purchase or sale of Company shares by the Directors and the designated employees while in possession of unpublished price sensitive information in relation to the Company and during the period when the Trading Window is closed. The Board is responsible for implementation of the Code. The Code is displayed on the Company's website at www.chandandidiagnostic.com.

PROCEEDINGS INITIATED/PENDING AGAINST YOUR COMPANY UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016

There are no proceedings initiated/pending against your Company under the Insolvency and Bankruptcy Code, 2016 which materially impact the Business of the Company.

DETAILS OF REPORTING OF FRAUD BY AUDITOR

There are no instances of Fraud/ Suspected Fraud committed against the Company by the Officers or employees of the Company has been detected by the Auditor as required under Section 143(12) of the Companies Act, 2013 read with Rule 13 of the Companies (Audit and Auditors) Rules, 2014.

INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY

According to Section 134(5) (e) of the Companies Act, 2013 the term "Internal Financial Control (IFC)" means the policies and procedures adopted by the Company for ensuring the orderly and efficient conduct of its business, The Company believes that internal control is a necessary prerequisite of Governance and that freedom should be exercised within a framework of checks and balances. The Company has a well-established internal control framework, which is designed to continuously assess the adequacy, effectiveness and efficiency of financial and operational controls. The financial control framework includes internal controls, delegation of authority procedures, segregation of duties, system access controls and document filing and storage procedures.

The management is committed to ensure an effective internal control environment, commensurate with the size, scale and complexity of the business, which provides an assurance on compliance with internal policies, applicable laws, regulations and protection of resources and assets. The control system ensures that the Company's assets are safeguarded and protected and also takes care to see that revenue leakages and losses to the Company are prevented

and our income streams are protected. The control system enables reliable financial reporting. The Audit Committee reviews adherence to internal control systems and internal audit reports.

They have been designed to provide reasonable assurance with regard to recording and providing reliable financial and operational information, complying with applicable statutes, safeguarding assets from unauthorized use, executing transactions with proper authorization and ensure compliance of corporate policies. It has continued its efforts to align all its processes and controls with global best practices.

PUBLIC DEPOSIT

The Company has not accepted any deposits from Shareholders and Public falling within the ambit of Section 73 of the Companies Act, 2013 and rules made there under. Hence, the directives issued by the Reserve Bank of India & the Provision of Section 73 to 76 of the Company Act, 2013 or any other relevant provisions of the Act and the Rules there under are not applicable.

There were no unclaimed or unpaid deposits as on 31st March, 2026.

LISTING AND DEPOSITORY FEES

Your Company has paid Annual Listing fees for the financial year 2025-2026 to National Stock Exchange of India Limited (NSE) according to the prescribed norms and regulations. Company has also paid Annual Custody fee to National Securities Depository Limited and Issuer fee to Central Depository Services (India) Limited for the financial year 2025-2026.

CODE OF CONDUCT

Commitment to ethical professional conduct is a must for every employee, including Board Members and Senior Management Personnel of the Company. The Code is intended to serve as a basis for ethical decision-making in conduct of professional work. The Code of Conduct enjoins that each individual in the organization must know and respect existing laws, accept and provide appropriate professional views, and be upright in his conduct and observe corporate discipline. The duties of Directors including duties as an Independent Director as laid down in the Companies Act, 2013 also form part of the Code of Conduct. All Board Members and Senior Management Personnel affirm compliance with the Code of Conduct annually as “Annexure – V”.

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

The Management’s Discussion and Analysis Report for the year under review, as stipulated under regulation 34 (3) and Part B of schedule V of the SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015 is annexed to this Annual Report as “Annexure – VI”.

DISCLOSURE ON SECRETARIAL STANDARDS

During the period under review, applicable Secretarial Standards, i.e. SS-1 and SS-2, relating to ‘Meetings of the Board of Directors’ and ‘General Meetings’, respectively, issued by The Institute of Company Secretaries of India have been duly followed by the Company and have devised proper systems to ensure compliance with the provisions of all applicable Secretarial Standards and that such systems are adequate and operating effectively.

PARTICULARS OF EMPLOYEES

The information required under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are annexed as Annexure VII and forms part of this Report.

The statement containing names of top ten employees in terms of remuneration drawn and the particulars of employees as required under Section 197(12) of the Act read with Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, is provided in a separate annexure forming part of this report. Further, the report and the accounts are being sent to the Members excluding the aforesaid annexure. In terms of Section 136 of the Act, the said annexure is opened for inspection in electronic form. Any Member interested in obtaining a copy of the same may write to the Company Secretary.

DETAILS OF FRAUD REPORTED BY THE AUDITORS

During the year under review, the Statutory Auditors and Internal Auditor have not reported any instances of fraud committed in the Company by its officers or employees.

DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION

There was no one time settlement by the Company with the Banks or Financial Institutions during the year under review, thus, the details of difference between amount of the valuation done at the time of one-time settlement and the valuation done while taking loan from the Banks or Financial Institutions along with the reasons thereof are not applicable.

POLICY AGAINST SEXUAL HARASSMENT

Your Company has always believed in providing safe and harassment free workplace for every individual working in its premises through various interventions and practices. The Company ensures that the work environment at all its locations is conducive to fair, safe and harmonious relations between employees. It strongly believes in upholding the dignity of all its employees, irrespective of their gender or seniority. Discrimination and harassment of any type are strictly prohibited.

SEXUAL HARASSMENT POLICY

The Company has adopted a policy for Prevention, Prohibition and Redressal of Sexual Harassment of Women at Workplace in line with the requirements of the Sexual Harassment of Women at the Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH Act). The Company has complied with the provisions relating to constitution of internal complaints committee (ICC) under the POSH Act. All women employees are covered under this policy. ICC has been set up to redress complaints received regarding sexual harassment.

An Internal Complaint Committee (ICC) is in place as per the requirements of the said Act to redress complaints received regarding sexual harassment. All employees (permanent, contractual, temporary, trainees) are covered under this policy. No case has been reported during the year under review.

The details of the complaints received during the year under review were as follows:

NO. OF COMPLAINTS PENDING AT THE BEGINNING OF THE YEAR	0
No. of Complaints Received and Resolved during the year	0
No. of Complaints Pending at the End of the Year	0

STATEMENT ON COMPLIANCE WITH THE MATERNITY BENEFIT ACT, 1961

The Company has complied with the provisions of the Maternity Benefit Act, 1961, including all rules and amendments made thereunder, during the financial year ended March 31, 2026.

EMPLOYEE DEMOGRAPHICS DISCLOSURE

As on March 31, 2026, the employee strength of the Company was as follows:

The above figures include all permanent employees of the Company as on the year-end.

GENDER	NO. OF EMPLOYEES
Male	1050
Female	375
Transgender	0
Total	1425

WEBSITE OF THE COMPANY

Your Company maintains a website www.chandandidiagnostic.com where detailed information of the Company and specified details in terms of the Companies Act, 2013 and SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been provided.

GENERAL

Your Directors state that no disclosure or reporting is required in respect of the following matters

as there were no transactions on these items during the year under review:

- Issue of equity shares with differential rights as to dividend, voting or otherwise.
- Issue of shares (including sweat equity shares) to employees of the Company under any scheme.

The Company does not have any scheme of provision of money for the purchase of its own shares by employees or by trustees for the benefit of employees.

ACKNOWLEDGEMENT

Your Directors wish to place on record their gratitude for the valuable guidance and support rendered by the Government of India, various State Government departments, Banks and stakeholders, including, but not limited to,

shareholders, customers and suppliers, among others. We place on record, our appreciation of the contribution made by our employees at all levels.

The Directors take this opportunity to place on record their deep sense of appreciation for the total commitment, dedication and hard work put in by the employees of the Company. Lastly, your directors are deeply grateful for the continuous confidence and faith shown by the members of the Company.

For & On Behalf of Board of Directors
Chandan Healthcare Limited

SD/-

Asmita Singh
(Managing Director)
DIN: 01098055

SD/-

Amar Singh
(Managing Director)
DIN:01096328

Date: 07/09/2026

Place: -Lucknow

ANNEXURES I–III · SECRETARIAL AUDIT REPORT

03

Annexure-I

Form No. MR-3 SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED MARCH 31, 2026

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014]

To,

The Members,

Chandan Healthcare Limited

Biotech Park, Sector G, Jankipuram,

Kursi Road, Lucknow, Uttar Pradesh - 226021

I have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Chandan Healthcare Limited (CIN: L85110UP2003PLC193493) (hereinafter called the company). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the company has, during the audit period covering the financial year ended on March 31st, 2026 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2026 according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the rules made thereunder;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings (Not applicable to the Company during the Audit Period);
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'): -

- The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993, as applicable up to 15 December 2025, and the Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 2025, applicable with effect from 16 December 2025, to the extent applicable to the Company as amended from time to time regarding the Companies Act and dealing with client;
- (b) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 as amended from time to time;
- (c) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time;
- (d) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time;
- (e) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended from time to time;
- (f) The Securities and Exchange Board of India (Depositories and participants) Regulations, 2018 as amended from time to time;
- (g) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018 as amended from time to time; (Not applicable to the Company during the Audit Period);
- (h) The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (Not applicable to the Company during the Audit Period);
- (j) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021 (Not applicable to the Company during the Audit Period);
- (k) The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021 (Not applicable to the Company during the Audit Period);
- (vi) Other laws as may be applicable to the company,

I have also examined compliance with the applicable provisions of the following:

- (i) Secretarial Standards with regard to Meetings of Board of Directors (SS-1) and General Meetings (SS- 2) issued by The Institute of Company Secretaries of India;
- (ii) The Listing Agreements entered into by the Company with National Stock Exchange of India Limited (NSE)

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

I further report that

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through and based on the information given by the company, I report there were no instances of any dissenting members' views being captured or recorded as part of the minutes.

I further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

I further report that during the audit period there were following specific events/actions having a major bearing on the Company' affairs in pursuance of the laws, rules, regulations, guidelines etc., referred to above:

- The Company has increased its Authorised Share Capital from ₹25,00,00,000/- (Rupees Twenty-Five Crore only), comprising 2,50,00,000 Equity Shares of ₹10/- each, to ₹30,00,00,000/- (Rupees Thirty Crore only), comprising 3,00,00,000 Equity Shares of ₹10/- each, by creation of an additional 50,00,000 Equity Shares of ₹10/- each, ranking pari passu with the existing Equity Shares, pursuant to the approval of the Members and in accordance with the applicable provisions of the Companies Act, 2013.
- The Company has allotted 44,50,000 Fully Convertible Warrants on a preferential basis at an issue price of ₹234/- per warrant, each warrant being convertible into one Equity Share of face value of ₹10/- each, pursuant to the Special Resolution passed by the Members at the Extra-Ordinary General Meeting held on 06 November 2025 and the in-principle approvals obtained from the National Stock Exchange of India Limited.

Disclosure

This Report is to be read with our letter of even date which is annexed as Annexure A and forms an integral part of this Report.

Date: 27.08.2026
Place: New Delhi

For Umesh Kumar & Associates
(Company Secretaries)
SD/-
(CS Umesh Kumar)

Prop.

C. P. No. 8361
M. No. 21567

ICSI Unique Code: I2009DE661900
Peer Review Cert. No. 1895/2022
UDIN: A021567H001250685

“Annexure – A”

[Annexure to the Secretarial Audit Report of M/s. Chandan Healthcare Limited for the Financial Year ended 31st March, 2026]

- Maintenance of Secretarial Records is the responsibility of the Management of the Company. My responsibility is to express an opinion on these Secretarial Records based on my audit.
- Compliance of the applicable laws and ensuring the authenticity of documents and information furnished are the responsibilities of the management of the company.
- I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial Records. The verification was done on test basis to ensure that correct facts are reflected in Secretarial Records. I believe that the processes and practices, I followed, provide a reasonable basis for my opinion.
- I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company. The compliance of applicable financial laws including Direct and Indirect Tax laws by the Company has not been reviewed in this Audit as same are subject to review by the Statutory Auditors and other designated professionals
- Wherever required, I have obtained the Management representation about the compliance of laws, rules and regulations and happening of events, etc.
- The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of Management. My examination was limited to the verification of procedures on test basis.
- The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the Management has conducted the affairs of the Company.
- During the course of my examination of the books and records of the Company, that has been carried out in accordance with generally accepted practices in India, We have neither come across any instance of fraud on or by the Company, nor the Company has noticed and reported any such case during the year.
- The contents of this Report has to be read in conjunction with and not in isolation of the observations, if any, in the report(s) furnished/to be furnished by any other auditor(s)/ agencies/authorities with respect to the Company.

Date: 27.08.2026
Place: New Delhi

For Umesh Kumar & Associates
(Company Secretaries)
SD/-
(CS Umesh Kumar)
Prop.

C. P. No. 8361
M. No. 21567
ICSI Unique Code: I2009DE661900
Peer Review Cert. No. 1895/2022
UDIN: A021567H001250685

Annexure II FORM AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Name of the Company: Chandan Healthcare Limited

1. Details of contracts or arrangements or transactions not at arm's length basis

Number of contracts or arrangements or transactions not at arm's length basis: Nil

PARTICULARS	DETAILS
Corporate identity number (CIN) / FCRN / LLPIN / FLLPIN / PAN / passport for individuals or any other registration number	Not applicable
Name(s) of the related party	Not applicable
Nature of relationship	Not applicable
Nature of contracts, arrangements or transactions	Not applicable
Duration of the contracts, arrangements or transactions	Not applicable
Salient terms of the contracts or arrangements or transactions including actual or expected contractual amount	Not applicable
Justification for entering into such contracts or arrangements or transactions	Not applicable
Date of approval by the Board (DD/MM/YYYY)	Not applicable
Amount paid as advances, if any	Not applicable
Date on which the resolution was passed in general meeting as required under the first proviso to Section 188 (DD/MM/YYYY)	Not applicable
SRN of Form MGT-14	Not applicable

2. Details of material contracts or arrangements or transactions at arm's length basis

Number of contracts or arrangements or transactions at arm's length basis: 11

1. Chandan Hospital Limited

CORPORATE IDENTITY NUMBER (CIN) OR PAN	U85110UP1995PLC018739
Name of the related party	Chandan Hospital Limited
Nature of relationship	Entity under the common control of the promoter group
Nature of contracts, arrangements or transactions	Sale of services and goods
Duration of the contracts, arrangements or transactions	Recurring transactions during FY 2025-26
Salient terms including actual or expected contractual amount	Sales during FY 2025-26: Rs. 579.54 lakh
Date of approval by the Board (DD/MM/YYYY)	27/05/2025
Amount paid as advances, if any	Nil

2. Chandan Pharmacy Limited

CORPORATE IDENTITY NUMBER (CIN) OR PAN	U47721UP2017PLC193492
Name of the related party	Chandan Pharmacy Limited
Nature of relationship	Subsidiary company
Nature of contracts, arrangements or transactions	Sale and purchase of goods and services
Duration of the contracts, arrangements or transactions	Recurring transactions during FY 2025-26
Salient terms including actual or expected contractual amount	Sales: Rs. 28.17 lakh; Purchases: Rs. 21.74 lakh
Date of approval by the Board (DD/MM/YYYY)	27/05/2025
Amount paid as advances, if any	Nil

3. Cendana Pharmaceuticals Private Limited

CORPORATE IDENTITY NUMBER (CIN) OR PAN	U24239UP2022PTC161589
Name of the related party	Cendana Pharmaceuticals Private Limited
Nature of relationship	Entity under the common control of the promoter group
Nature of contracts, arrangements or transactions	Sale and purchase of goods and services
Duration of the contracts, arrangements or transactions	Recurring transactions during FY 2025-26
Salient terms including actual or expected contractual amount	Sales: Rs. 9.03 lakh; Purchases: Rs. 35.19 lakh
Date of approval by the Board (DD/MM/YYYY)	27/05/2025
Amount paid as advances, if any	Nil

4. Chandan Super Speciality Hospital Limited

CORPORATE IDENTITY NUMBER (CIN) OR PAN	U86100UP2023PLC183925
Name of the related party	Chandan Super Speciality Hospital Limited
Nature of relationship	Entity under the common control of the promoter group
Nature of contracts, arrangements or transactions	Sale of services and goods
Duration of the contracts, arrangements or transactions	Recurring transactions during FY 2025-26
Salient terms including actual or expected contractual amount	Sales during FY 2025-26: Rs. 184.15 lakh
Date of approval by the Board (DD/MM/YYYY)	27/05/2025
Amount paid as advances, if any	Nil

5. Indra Diagnostic Centre & Blood Bank Limited

CORPORATE IDENTITY NUMBER (CIN) OR PAN	U85196UP1992PLC014075
Name of the related party	Indra Diagnostic Centre & Blood Bank Limited
Nature of relationship	Wholly owned subsidiary company
Nature of contracts, arrangements or transactions	Sale of services and goods
Duration of the contracts, arrangements or transactions	Recurring transactions during FY 2025-26
Salient terms including actual or expected contractual amount	Sales during FY 2025-26: Rs. 15.40 lakh
Date of approval by the Board (DD/MM/YYYY)	27/05/2025

CORPORATE IDENTITY NUMBER (CIN) OR PAN	U85196UP1992PLC014075
Amount paid as advances, if any	Nil

6. Dr. Amar Singh

CORPORATE IDENTITY NUMBER (CIN) OR PAN	PAN: AGQPS5396H
Name of the related party	Amar Singh
Nature of relationship	Managing Director of the Company
Nature of contracts, arrangements or transactions	Managerial remuneration
Duration of the contracts, arrangements or transactions	Recurring during FY 2025-26
Salient terms including actual or expected contractual amount	Remuneration paid or payable during FY 2025-26: Rs. 46.71 lakh
Date of approval by the Board (DD/MM/YYYY)	27/05/2025
Amount paid as advances, if any	Nil

7. Mrs. Asmita Singh

CORPORATE IDENTITY NUMBER (CIN) OR PAN	PAN: AWSPS3853M
Name of the related party	Asmita Singh
Nature of relationship	Managing Director of the Company
Nature of contracts, arrangements or transactions	Managerial remuneration
Duration of the contracts, arrangements or transactions	Recurring during FY 2025-26
Salient terms including actual or expected contractual amount	Remuneration paid or payable during FY 2025-26: Rs. 84.89 lakh
Date of approval by the Board (DD/MM/YYYY)	27/05/2025
Amount paid as advances, if any	Nil

8. Mr. Rajeev Kumar Nain

CORPORATE IDENTITY NUMBER (CIN) OR PAN	PAN: AIVPN6380K
Name of the related party	Rajeev Kumar Nain
Nature of relationship	Key Managerial Personnel – Chief Financial Officer, Company Secretary and Compliance Officer
Nature of contracts, arrangements or transactions	Remuneration
Duration of the contracts, arrangements or transactions	Recurring during FY 2025-26
Salient terms including actual or expected contractual amount	Remuneration paid or payable during FY 2025-26: Rs. 47.99 lakh
Date of approval by the Board (DD/MM/YYYY)	27/05/2025
Amount paid as advances, if any	Nil

9. Mr. Vikas Lamba

CORPORATE IDENTITY NUMBER (CIN) OR PAN	PAN: ACLPL2389Q
Name of the related party	Vikas Lamba
Nature of relationship	Relative of a Director / promoter group
Nature of contracts, arrangements or transactions	Remuneration – office or place of profit
Duration of the contracts, arrangements or transactions	Recurring during FY 2025-26
Salient terms including actual or expected contractual amount	Remuneration paid or payable during FY 2025-26: Rs. 8.04 lakh
Date of approval by the Board (DD/MM/YYYY)	27/05/2025
Amount paid as advances, if any	Nil

Note: All the transactions set out above were entered into in the ordinary course of business and on an arm's length basis, and were approved by the Audit Committee. Omnibus approval of the Audit Committee was obtained for the recurring transactions where applicable.

For & On Behalf of Board of Directors
Chandan Healthcare Limited

SD/-

Asmita Singh
(Managing Director)
DIN: 01098055

SD/-

Amar Singh
(Managing Director)
DIN: 01096328
Date: 07/09/2026
Place: -Lucknow

Annexure III

DISCLOSURE OF THE PARTICULARS WITH RESPECT TO CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO AS REQUIRED UNDER SECTION 134(3)(M) OF THE COMPANIES ACT, 2013 READ WITH RULE 8(3) OF THE COMPANIES (ACCOUNTS) RULES, 2014

- CONSERVATION OF ENERGY

- The steps taken or impact on conservation of energy;

The Company has taken various steps for minimization of energy consumption by putting continuous efforts towards optimization of operating and processing activities, upgradation and modernization of plant equipment etc.

- The steps taken by the company for utilizing alternate sources of energy: NIL
- The capital investment on energy conservation equipment; NIL

- TECHNOLOGY ABSORPTION

From B: Disclosure of particulars with respect to Technology absorption Technology, absorption, adaptation and innovation

- Efforts made towards technology absorption: NIL
- The benefits derived like product improvement, cost reduction, product development or import substitution: NIL
- In case of imported technology (imported during the last three years reckoned from the

beginning of the financial year)- NIL

- the details of technology imported;
- the year of import;
- whether the technology been fully absorbed;
- if not fully absorbed, areas where absorption has not taken place, and the reasons thereof;
- The expenditure incurred on Research and Development:

- FOREIGN EXCHANGE EARNING AND OUTGO

PARTICULARS	FY 2025-26	FY 2024-25
Foreign Exchange earnings	-	-
Foreign Exchange outgo	-	-

For & On Behalf of Board of Directors
Chandan Healthcare Limited

Asmita Singh
(Managing Director)
DIN: 01098055

Amar Singh
(Managing Director)
DIN: 01096328

Date: 07/09/2026

Place: -Lucknow

Annexure IV

ANNUAL REPORT ON CORPORATE SOCIAL RESPONSIBILITY

[Pursuant to clause (o) of Sub-Section 3 of Section 134 of the Act, Section 135 read with and Companies (Corporate Social Responsibility Policy) Rules, 2014, as amended]

- Brief Outline on the CSR Policy of the Company:

The purpose of Corporate Social Responsibility (CSR) Policy of the Company is to devise an appropriate strategy and focus for its CSR initiatives and lay down the broad principles on the basis of which it will fulfill its CSR objectives. The main objective of CSR Policy of the Company is to demonstrate commitment to the common good through responsible business practices and good governance; set appropriate standards of quality in the delivery of services in the social sector by creating robust processes and replicable models; to operate its business in an economically, socially and environmentally sustainable manner, while recognizing the interests of all its stakeholders.

- Composition of CSR Committee:

PARTICULARS	NAME OF MEMBERS	DESIGNATION / NATURE OF DIRECTORSHIP	NUMBER OF MEETINGS OF CSR COMMITTEE HELD DURING THE YEAR	NUMBER OF MEETINGS OF CSR COMMITTEE ATTEND DURING THE YEAR
1.	Amar Singh	Managing Director (Chairperson)	1	1
2.	Brahma Nand Bhartiya	Independent Director (Member)	1	1
3.	Vinay Lamba	Non-executive Director (Member)	1	1

- Provide the web-link where Composition of CSR Committee, CSR Policy by the Board is disclosed on the website of the Company:

The Composition of CSR Committee, Company's CSR Policy and CSR projects are available on the website of the Company

Composition of CSR Committee : <https://chandandidiagnostic.com>

Company's CSR Policy : <https://chandandidiagnostic.com>

- Provide the execution summary along with web-link(s) of Impact Assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8, if applicable:
- (a) Average net profit of the company as per sub-section 5 of Section 135: Rs. 2792.80 lacs
- Two percent of average net profit of the Company as per sub-section 5 of Section 135: Rs. 55.86 lacs
- Surplus arising out of the CSR projects or programmes or activities of the previous financial years: Nil
- Amount required to be set off for the financial year, if any: Nil

Total CSR obligation for the financial year [(b)+(c)-(d)]: Rs. 55.86 lacs

- (a) CSR amount spent or unspent for the financial year:

TOTAL AMOUNT SPENT FOR THE FINANCIAL YEAR 2025-26 (IN RS.)	AMOUNT UNSPENT (IN RS.)				
	Total Amount transferred to Unspent CSR Account as per Section 135(6)		Amount Transferred to any fund specified under Schedule VII as per second provision to Section 135(5)		
	Amount	Date of Transfer	Name of Fund	Amount	Date of Transfer
55.86 lacs	-	-		-	-

- Details of CSR amount spent against ongoing projects for the financial year: NIL

SI. NO.	NAME OF THE PROJECT	ITEM FROM THE LIST OF ACTIVITIES IN SCHED- ULE VII TO THE ACT	LOCAL AREA (YES/NO)	LOCATION OF THE PROJECT		PROJECT DURATION
				State	District	
-	-	-	-	-	-	-

AMOUNT ALLOCATED FOR THE PROJECT (IN RS.)	AMOUNT SPENT IN THE CURRENT FINANCIAL YEAR (IN RS.)	AMOUNT TRANSFERRED TO UNSPENT CSR ACCOUNT FOR THE PROJECT AS PER SECTION 135(6)	MODE OF IMPLEMENTATION DIRECT (YES /NO)	MODE OF IMPLEMENTATION THROUGH IMPLEMENTING AGENCY	
				Name	CSR Registration
-	-	-	-	-	-

- Details of CSR amount spent against other than ongoing projects for the financial year:

SI. NO.	NAME OF THE PROJECT	ITEM FROM THE LIST OF ACTIVITIES IN SCHED- ULE VII TO THE ACT	LOCAL AREA (YES/NO)	LOCATION OF THE PROJECT		PROJECT DURATION
				State	District	
1	Chandan CSR Activity	Promoting education, including special education and employment enhancing vocation skills	Yes	Uttar Pradesh	Lucknow	1 years

AMOUNT ALLOCATED FOR THE PROJECT (IN RS.)	AMOUNT SPENT IN THE CURRENT FINANCIAL YEAR (IN RS.)	AMOUNT TRANSFERRED TO UNSPENT CSR ACCOUNT FOR THE PROJECT AS PER SECTION 135(6)	MODE OF IMPLEMENTATION DIRECT (YES /NO)	MODE OF IMPLEMENTATION THROUGH IMPLEMENTING AGENCY	
				Name	CSR Registration
55.86 Lacs	55.86 Lacs	Nil	No	Chandan Singh Foundation	CSR00060005

- Amount spent in Administrative Overheads:
- Amount spent on Impact Assessment, if applicable:
- Total amount spent for the Financial Year 2025-26 [(a)+(b)+(c)]:
- Details of CSR amount spent or unspent for the financial year: Nil

TOTAL AMOUNT SPENT FOR THE FINANCIAL YEAR 2025-2026 (IN RS.)	AMOUNT UNSPENT (IN RS.)				
	Total Amount transferred to Un- spent CSR Account as per Section 135(6)		Amount transferred to any fund specified under Schedule VII as per second provision to Section 135 (5)		
	Amount	Date of Transfer	Name of Fund	Amount	Date of Transfer
-	-	-	-	-	-

- Excess amount for set-off, if any:

SI. NO.	PARTICULAR	AMOUNT (IN RS.) LAKH
(i)	Two percent of average net profit of the Company as per section 135(5)	55.86
(ii)	Total amount spent for the Financial Year	55.86
(iii)	Excess amount spent for the financial year [(ii)-(i)]	0.00
		The CSR Committee recommended & Board has approved Rs. 55.86 lakh as CSR Expenditure for FY 2025-26
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous Financial Years, if any	-
(v)	Amount available for set off in succeeding Financial Years [(iii)-(iv)]	0.00

- Details of Unspent CSR amount for the preceding three financial years: NIL

SI. NO.	PRECEDING FINANCIAL YEAR	AMOUNT TRANSFERRED TO UNSPENT CSR ACCOUNT UNDER SECTION 135(6) (IN RS.)	BALANCE AMOUNT IN UN- SPENT CSR ACCOUNT UNDER SUB SECTION (6) OF SECTION 135 (IN RS.)	AMOUNT SPENT IN THE REPORT- ING FINANCIAL YEAR (IN RS.)	AMOUNT TRANSFERRED TO ANY FUND SPECIFIED UNDER SCHED- ULE VII AS PER SECTION 135(6) IF ANY	AMOUNT REMAINING TO BE SPENT IN SUCCEEDING FINANCIAL YEARS (IN RS.)	DEFI- CIEN- CY,IF ANY
1	2022-23	-	-	-	-	-	-
2	2023-24	-	-	-	-	-	-
3	2024-25	-	-	-	-	-	-

- Whether any capital assets have been created or acquired through Corporate Social Responsibility amount spent in the Financial Year:

If yes, enter the number of Capital assets created/ acquired:

Furnish the details relating to such asset(s) so created or acquired through Corporate Social Responsibility amount spent in the Financial Year: NIL

SI. NO.	SHORT PARTICULARS OF THE PROPERTY OR ASSETS(S)	PIN CODE OF THE PROPERTY OR ASSET(S)	DATE OF CREATION	DATE OF CREATION	DETAILS OF ENTITY/ AUTHORITY/ BENEFICIARY OF THE REGISTERED OWNER		
(1)	(2)	(3)	(4)	(5)	(6)		
					CSR Registration Number, If Applicable	Name	Registered Address

Specify the reason(s), if the Company has failed to spend two percent of the average net profit as per section 135(5):
NA

- Implementing Agency – Related Party Disclosure

The corporate social responsibility expenditure for the financial year 2025-26 was incurred through Chandan Singh Foundation (CSR Registration No. CSR00060005), which is a related party of the Company. The amount of Rs. 55.86 lakhs disbursed to the Foundation during the year has accordingly been disclosed in the related party note forming part of the financial statements.

The Board confirms that the contribution to the Foundation was made solely towards the corporate social responsibility activities approved by the Board on the recommendation of the Corporate Social Responsibility Committee, that the Foundation has been engaged as an implementing agency in accordance with Rule 4(1) of the Companies (Corporate Social Responsibility Policy) Rules, 2014, and that the Chief Financial Officer has certified the utilisation of the funds for the purpose and in the manner approved by the Board.

For & On Behalf of Board of Directors

Chandan Healthcare Limited

SD/-

Asmita Singh

(Managing Director)

DIN: 01098055

SD/-

Amar Singh

(Managing Director)

DIN: 01096328

Date: 07/09/2026

Place: -Lucknow

Annexure V DECLARATION ON CODE OF CONDUCT

To,

The Members of Chandan Healthcare Limited

This is to certify that the Company has laid down a Code of Conduct (the Code) for all Board Members and Senior Management Personnel of the Company and a copy of the Code is put on the website of the Company viz www.chandandiagnostic.com.

It is further confirmed that all Board Members and Senior Management Personnel have affirmed compliance with the Code of Conduct for Board of Directors and Senior Management Personnel, as approved by the Board, for the financial year ended on March 31, 2026.

For & On Behalf of Board of Directors
Chandan Healthcare Limited

SD/-

Asmita Singh
(Managing Director)
DIN: 01098055

SD/-

Amar Singh
(Managing Director)
DIN: 01096328

Date: 07/09/2026

Place: -Lucknow

MANAGEMENT DISCUSSION & ANALYSIS REPORT

For the financial year ended 31 March 2026

[Pursuant to Regulation 34(2)(e) read with Part B of Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

1. Industry Structure and Developments

The Company operates in the Indian diagnostic services industry, comprising pathology (laboratory) testing and radiology (imaging) services, and in the adjacent retail pharmacy business. The diagnostics industry in India remains highly fragmented, with a large share of volumes still served by standalone laboratories and hospital-based departments, and a smaller but steadily growing share served by organised regional and national chains.

Several structural drivers continue to support the shift of volumes towards organised players. Rising incomes and health awareness have increased the demand for preventive health check-ups. The burden of lifestyle and chronic conditions has grown, and these conditions require repeat testing over long periods. Insurance penetration and government-funded health schemes have widened access to formal diagnostic care. Accreditation by the National Accreditation Board for Testing and Calibration Laboratories and by the National Accreditation Board for Hospitals and Healthcare Providers has become an increasingly important basis on which referring physicians, insurers and government procurement agencies select providers, and this favours chains with the scale to maintain accredited quality systems across multiple locations.

Public-private partnership models, under which State health departments and health corporations contract private operators to provide diagnostic and imaging services within government facilities, have expanded the addressable market and have become a distinct route to volume growth for organised chains.

At the same time, the industry is competitive and price-sensitive. Digital-first aggregators and hospital chains compete for the same retail customer, and price competition in high-volume routine tests continues to compress realisations. Success therefore depends on the ability to build density in chosen geographies, to maintain turnaround times, and to add higher-value specialised testing to the menu.

2. Business Overview

The Company is a diagnostics and pharmacy services provider and is a key entity within the Chandan Group. It offers pathology and radiology services through accredited laboratories and imaging centres, supported by two central reference laboratories at Lucknow in Uttar Pradesh and Haldwani in Uttarakhand. The service portfolio spans blood and other laboratory investigations, magnetic resonance imaging, computed tomography, X-ray, ultrasound, electrocardiography and other specialised investigations.

The Company's roots date to the establishment of its first diagnostic centre in Lucknow in 1991. Over the intervening period the network has expanded beyond Uttar Pradesh into a multi-state footprint, and the Company has progressively added accreditations, online reporting, retail pharmacy and, most recently, franchising and public-private partnership operations.

Network and operating parameters

Key operating parameters of the network as at 31 March 2026, drawn from the Company's reconciled unit master, are set out below:

PARAMETER	AS AT 31 MARCH 2026
Comprehensive diagnostic centres	23
Diagnostic centres	16

PARAMETER	AS AT 31 MARCH 2026
Standalone laboratories	25
Radiology laboratories	14
Franchise centres	235
Total diagnostic centres and laboratories	313
States and Union Territories	16
Districts	62
Tests performed during the year	Over 88 lakhs
NABL accredited laboratories	16
NABH accredited radiology centres	6
AERB licensed radiology centres	38
Centres certified to ISO 9001:2015	All centres

Accreditation profile of the network.

The network is distributed across 16 States and Union Territories and 62 districts. Uttar Pradesh, the Company's home State, accounts for 173 of the 313 centres and laboratories, with Uttarakhand at 28 and Delhi at 26 forming the next largest clusters.

The Company states that it has served over 30 million patients and performed over 150 million tests since inception.

Channels

The Company operates a diversified model addressing three customer segments:

- Retail (B2C) – walk-in and home-collection patients served through the Company's own centres, collection points and franchise network, supported by online reporting through the Chandan 24x7 application.
- Institutional (B2B) – arrangements with hospitals, nursing homes, corporate clients and smaller laboratories for which the Company processes samples using its central reference laboratory infrastructure.
- Government (B2G) – public-private partnership contracts under which the Company provides diagnostic and radiology services within government health facilities. During the year the Company was awarded ten public-private partnership contracts in radiology in Punjab, Haryana and Assam, entered into arrangements with the Punjab Health Corporation and the Haryana Medical Corporation, and with the National Health Mission at Guwahati.

Developments during the year

- Geographic expansion into new metropolitan and State markets, including first diagnostic centres at Kolkata (West Bengal), Mumbai (Maharashtra), Bengaluru (Karnataka), Kurukshetra (Haryana) and Raipur (Chhattisgarh), two centres at Chandigarh, centres at Ahmedabad, Vadodara and Surat in Gujarat, and centres at Kota and Udaipur in Rajasthan.
- Entry into the franchise business, taking the franchise network beyond 325 centres.
- Commencement of online services in both diagnostics and pharmacy.
- An exclusive strategic partnership with Jeena Sikho Lifecare Limited to establish diagnostic centres across that company's existing and upcoming hospitals and clinics.
- Incorporation of Chandan Healthcare Projects Private Limited as a wholly owned subsidiary.
- Allotment of 44,50,000 fully convertible warrants on a preferential basis, aggregating up to Rs. 104.13 crore.

3. Opportunities and Threats

Opportunities

- Continued migration of volumes from unorganised laboratories to accredited chains, in which the Company's sixteen NABL accredited laboratories and pan-India presence position it favourably.
- The asset-light franchise model, which allows the network to be extended into new districts with limited capital deployment.
- Expansion of public-private partnership arrangements with State health departments, which provide contracted volumes and support utilisation of imaging assets.
- Cross-selling between the diagnostics and retail pharmacy businesses and the wider Chandan Group hospital network.
- Addition of higher-value specialised and molecular testing, including through the genome sequencing laboratory being established at Lucknow.
- Growth in home collection and digital channels, supported by the Company's online reporting application.

Threats

- Intense price competition in routine pathology testing from regional laboratories, hospital-based departments and digital-first aggregators, which may compress realisations per test.
- Dependence on referring physicians, whose referral patterns can shift.
- Regulatory intensity, including accreditation requirements, Atomic Energy Regulatory Board licensing for radiology equipment, clinical establishment registration, drug licensing for the pharmacy business and bio-medical waste rules. Any lapse can interrupt operations at a location.
- Concentration risk in the event that public-private partnership contracts are not renewed or are re-tendered on less favourable terms.
- Execution risk associated with rapid multi-state expansion and with the franchise model, including the maintenance of consistent quality standards across franchised locations.
- Cost pressure from imported reagents, consumables and equipment, and exposure to exchange rate movements to the extent that such inputs are procured in foreign currency.

4. Segment-wise or Product-wise Performance

The Company is engaged principally in the business of providing diagnostic services, which in the opinion of the management constitutes a single reportable segment in accordance with the applicable accounting standard on segment reporting. The Group nonetheless manages its business through three identifiable service lines, and the performance of each on a consolidated basis is set out below.

(Rs. in Lakhs, except test counts and per-test revenue)

SERVICE LINE	REVENUE FROM OPERATIONS	SHARE OF REVENUE (%)	TESTS PERFORMED	REVENUE PER TEST (RS.)
Pathology	11,947.83	43.23	84,15,059	141.98
Radiology	3,669.59	13.28	4,03,867	908.61
Retail pharmacy	12,022.01	43.50	Not applicable	Not applicable
Total	27,639.44	100.00	88,18,926	—

Pathology accounted for the largest share of test volume, at 84.15 lakh investigations during the year, at an average realisation of Rs. 141.98 per test. Radiology, while contributing 4.04 lakh investigations, carries a materially higher

realisation of Rs. 908.61 per investigation and is therefore an important contributor to margin relative to its share of volume. The retail pharmacy business carried on by Chandan Pharmacy Limited contributed 43.50% of consolidated revenue from operations but operates at a substantially lower margin, with a profit after tax of Rs. 322.26 lakhs on total income of Rs. 12,064.63 lakhs, and this is the principal reason for the difference between the standalone and consolidated profit margins of the Group.

Best performing location in each category

(Rs. in Lakhs)

CATEGORY	LOCATION	SERVICE LINE	REVENUE	TESTS
Comprehensive diagnostic centre	Indira Nagar, Lucknow	Pathology	761.34	5,35,032
Comprehensive diagnostic centre	Indira Nagar, Lucknow	Radiology	236.20	46,273
Diagnostic centre	Vijay Khand, Gomti Nagar, Lucknow	Pathology	95.47	1,03,852
Diagnostic centre	Vijay Khand, Gomti Nagar, Lucknow	Radiology	8.47	2,677
Radiology laboratory	Vijay Khand, Gomti Nagar, Lucknow	Radiology	104.77	13,287
Standalone laboratory	Pithoragarh, Uttarakhand	Pathology	391.21	3,34,955
Franchise centre	Shahjahanpur, Uttar Pradesh	Pathology	18.00	23,104

5. Financial Performance and Analysis

Standalone results

(Rs. in Lakhs)

PARTICULARS	FY 2025-26	FY 2024-25	CHANGE (%)
Revenue from operations	15,664.73	12,916.42	21.28
Other income	412.50	204.89	101.33
Total income	16,077.23	13,121.31	22.53
Profit before depreciation, finance cost and tax	5,055.62	3,815.69	32.49
Depreciation	951.43	642.24	48.14
Finance cost	442.89	356.90	24.09
Exceptional and extraordinary items	270.97	—	Not comparable
Profit before tax	3,390.33	2,816.55	20.37
Profit after tax	2,534.13	2,077.80	21.96

Consolidated results

(Rs. in Lakhs)

PARTICULARS	FY 2025-26	FY 2024-25	CHANGE (%)
Revenue from operations	27,639.44	23,012.08	20.11
Other income	427.85	293.51	45.77
Total income	28,067.29	23,305.59	20.43
Profit before depreciation, finance cost and tax	5,684.37	4,338.63	31.02
Depreciation	977.98	674.48	45.00
Finance cost	588.19	457.60	28.54
Exceptional and extraordinary items	291.54	–	Not comparable
Profit before tax	3,826.66	3,206.55	19.34
Profit after tax	2,855.36	2,351.63	21.42

Discussion

Standalone revenue from operations grew 21.28% during the year, driven by the addition of centres in new States, the expansion of the franchise network, the commencement of public-private partnership contracts in radiology and higher volumes at existing centres. Operating profit before depreciation, finance cost and tax grew faster than revenue, at 32.49%, taking the margin on total income from 29.08% to 31.44%. The improvement reflects better fixed-cost absorption at existing centres, an improved mix and continued cost discipline.

Depreciation rose 48.14% on a standalone basis, reflecting the capitalisation during the year of imaging and laboratory equipment and of the new central reference laboratories at Ayodhya and Ashiyana funded from the Initial Public Offer proceeds. Finance cost rose 24.09%, broadly in line with the increase in the asset base.

The Company recorded exceptional and extraordinary items of Rs. 270.97 lakhs on a standalone basis and Rs. 291.54 lakhs on a consolidated basis during the year, against nil in the previous year.

Standalone profitability bridge for FY 2025-26.

Profit after tax grew 21.96% on a standalone basis and 21.42% on a consolidated basis. After the share of non-controlling interests of Rs. 149.61 lakhs, arising principally from the 46.44% minority holding in Chandan Pharmacy Limited, profit attributable to the owners of the Company was Rs. 2,705.75 lakhs against Rs. 2,217.09 lakhs in the previous year, an increase of 22.04%. The attributable profit margin on consolidated total income improved from 9.51% to 9.64%.

The consolidated margin is lower than the standalone margin because the retail pharmacy business carried on by Chandan Pharmacy Limited operates at a profit-after-tax margin of 2.67% on total income, against 15.76% for the standalone diagnostics business, while contributing 43.50% of consolidated revenue from operations.

6. Key Financial Ratios

The key financial ratios of the Company on a standalone basis for the financial year 2025-26, together with the comparatives for the immediately preceding financial year, are set out below. In terms of Part B of Schedule V of the SEBI Listing Regulations, an explanation has been provided for every ratio in respect of which the change from the previous year is twenty-five per cent or more.

RATIO	FY 2025-26	FY 2024-25	CHANGE (%)	EXPLANATION WHERE THE CHANGE IS 25% OR MORE
Current ratio (times)	3.53	2.52	39.92	Attributable to the substantial increase in current assets during the year, which rose from Rs. 7,310.67 lakhs to Rs. 10,385.37 lakhs while current liabilities remained broadly unchanged.
Debt service coverage ratio (times)	2.89	2.20	31.07	Attributable to the substantial increase in profitability during the year, earnings before interest and tax having risen from Rs. 3,134.33 lakhs to Rs. 4,065.20 lakhs against a broadly unchanged debt service obligation.
Return on equity (%)	17.59	25.75	(31.68)	Attributable to the growth in the equity base being higher than the corresponding increase in profit after tax, following the funds raised on listing and the amount received against the share warrants allotted during the year.
Net capital turnover ratio (times)	2.10	2.93	(28.10)	Attributable to the increase in working capital deployed outpacing the growth in revenue, working capital having risen from Rs. 4,412.19 lakhs to Rs. 7,442.62 lakhs.
Net debt equity ratio (times)	0.23	0.28	(15.25)	Not applicable
Inventory turnover ratio (days)	39.23	33.63	16.65	Not applicable
Trade receivables turnover (days)	130.63	153.11	(14.68)	Not applicable
Trade payables turnover ratio (days)	41.54	46.65	(10.95)	Not applicable
Net profit ratio (%)	16.18	16.09	0.56	Not applicable
Return on capital employed (%)	22.56	28.03	(19.49)	Not applicable
Operating profit margin (%)	31.45	29.08	8.13	Not applicable
Interest coverage ratio (times)	9.18	8.78	4.52	Not applicable

Basis of computation

RATIO	NUMERATOR AND DENOMINATOR
Current ratio	Total current assets divided by current liabilities, current liabilities being total current liabilities less current maturities of non-current borrowings and lease obligations.
Net debt equity ratio	Net debt divided by equity. Net debt comprises non-current and current borrowings and non-current and current lease liabilities, less current investments, cash and cash equivalents and other bank balances including non-current earmarked balances. Equity comprises equity share capital, other equity and hybrid perpetual securities.
Debt service coverage ratio	Earnings before interest and tax divided by debt service. Debt service comprises finance costs excluding interest on current borrowings, less interest income, dividend income from current investments, net gain or loss on sale of current investments and interest income from group companies, plus scheduled principal repayments of non-current borrowings and lease obligations excluding prepayments made during the period.
Return on equity	Profit after tax divided by average equity.
Inventory turnover ratio	365 divided by the quotient of cost of goods sold or sales and average inventory, average inventory being the mean of the opening and closing balances.
Trade receivables turnover ratio	365 divided by the quotient of net credit sales and average trade receivables, net credit sales being gross credit sales less sales returns.
Trade payables turnover ratio	365 divided by the quotient of net credit purchases and average trade payables, net credit purchases being gross credit purchases less purchase returns.
Net capital turnover ratio	Net sales divided by average working capital, working capital being current assets less current liabilities.
Net profit ratio	Profit after tax divided by turnover.
Return on capital employed	Earnings before interest and tax divided by average capital employed. Earnings before interest and tax comprise profit before tax adjusted for exceptional items and finance costs, less interest income, dividend income from current investments and net gain or loss on sale of current investments. Capital employed comprises equity share capital, other equity, hybrid perpetual securities, non-current and current borrowings, current maturities of long-term debt and leases, and deferred tax liabilities.
Operating profit margin	Profit before depreciation, finance cost and tax divided by total income, consistent with the basis adopted by the Company in its internal reporting.
Interest coverage ratio	Earnings before interest and tax divided by finance cost.

Return on net worth

The return on net worth of the Company, computed as profit after tax divided by average equity, decreased from 25.75% in the financial year 2024-25 to 17.59% in the financial year 2025-26, a decline of 31.68%. The decline is attributable to the expansion of the equity base at a faster rate than the growth in profit after tax. Average equity increased from Rs. 8,069.15 lakhs to Rs. 14,405.42 lakhs, reflecting the retention of profits, the funds raised on the listing of the equity shares and the amount received against the fully convertible warrants allotted on a preferential

basis during the year, while profit after tax increased from Rs. 2,077.80 lakhs to Rs. 2,534.13 lakhs. The Board expects the return on equity to improve as the newly raised capital is deployed and the recently commissioned centres reach maturity.

7. Risks and Concerns

The Company has a Risk Management Policy under which risks that may threaten the existence of the Company are identified and mitigation measures are put in place. The principal risks identified, and the measures adopted, are summarised below:

RISK	DESCRIPTION	MITIGATION
Competitive and pricing risk	Price competition in routine pathology testing may compress realisations.	Focus on accredited quality, turnaround time and menu breadth; expansion of higher-value specialised testing; density-led expansion in chosen geographies.
Regulatory and accreditation risk	Operations are subject to accreditation standards, radiology equipment licensing, clinical establishment registration, drug licensing and bio-medical waste rules.	In-house quality team applying current industry quality controls; maintenance of NABL, NABH, AERB and ISO certifications; periodic internal audit of compliance processes.
Execution and expansion risk	Rapid multi-state and franchise expansion may strain quality, systems and working capital.	Standardised operating protocols; central reference laboratory model; staged capital deployment; monitoring of Initial Public Offer and preferential issue proceeds by the Audit Committee.
Contract concentration risk	Public-private partnership contracts may not be renewed or may be re-tendered on less favourable terms.	Diversification across retail, institutional and government channels and across multiple States and contracting authorities.
Human resource risk	The business depends on qualified pathologists, radiologists and technicians, who are in limited supply.	Continuous training and education; structured career development; retention initiatives.
Technology and data risk	Dependence on laboratory information systems, online reporting and patient data.	Access controls and system controls within the internal control framework; protection of confidential client information as a stated core value.

8. Internal Control Systems and their Adequacy

The Company has a well-established internal control framework commensurate with the size, scale and complexity of its operations. The framework includes internal controls, delegation of authority procedures, segregation of duties, system access controls and document filing and storage procedures, and is designed to provide reasonable assurance regarding the reliability of financial and operational information, compliance with applicable statutes, safeguarding of assets from unauthorised use, execution of transactions with proper authorisation and compliance with corporate policies.

M/s. Renu Agrawal & Co., Chartered Accountants, act as the Internal Auditors of the Company and carry out periodic internal audits of operations, financial and accounting systems, internal controls and compliance processes. The internal audit reports, together with management responses and corrective actions, are reviewed periodically by the Audit Committee, which monitors the adequacy and effectiveness of the internal control framework and the risk management systems.

9. Human Resources and Industrial Relations

The Company regards its people and its reputation as its principal assets, and nurtures its employees through continuous training and education. The work environment at all locations is maintained so as to be conducive to fair, safe and harmonious relations between employees, and the dignity of every employee is upheld irrespective of gender or seniority.

As at 31 March 2026 the Company had 1,425 permanent employees on its rolls on a standalone basis, comprising 1,052 male employees and 375 female employees. Industrial relations remained cordial throughout the year under review.

10. Outlook

The Company intends to accelerate its expansion through a combination of owned centres and franchised collection centres, and to deepen its presence in the States it has recently entered. Over the next three years the Company aims to establish more than one hundred laboratories under its “One District, One Lab” initiative and to expand its franchise network to over one thousand centres.

In line with its commitment to innovation and clinical excellence, the Company is establishing a state-of-the-art genome sequencing laboratory at Lucknow, expected to be operational during 2026, which will enhance its capabilities in advanced molecular diagnostics and precision healthcare.

The Company also expects to derive continued benefit from its strategic partnership with Jeena Sikho Lifecare Limited, from the further award of public-private partnership contracts, and from the deployment of the proceeds of the Initial Public Offer and the preferential issue of warrants towards network expansion and general corporate purposes.

11. Cautionary Statement

Statements in this Management Discussion and Analysis Report describing the Company’s objectives, projections, estimates and expectations may constitute forward-looking statements within the meaning of applicable securities laws and regulations. Actual results could differ materially from those expressed or implied. Important factors that could influence the Company’s operations include economic conditions affecting demand and supply, price conditions in the domestic and international markets, changes in government regulations, tax laws and other statutes, and other incidental factors. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statement on the basis of any subsequent development, information or event.

For & On Behalf of Board of Directors
Chandan Healthcare Limited

SD/-

Asmita Singh
(Managing Director)
DIN: 01098055

SD/-

Amar Singh
(Managing Director)
DIN: 01096328

Date: 07/09/2026
Place: -Lucknow

ANNEXURE-VII PARTICULARS OF EMPLOYEES

Disclosures pertaining to remuneration and other details as required under Section 197(12) of the Companies Act, 2013 read with Rules made there under;

A. Information as per Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014:

- The ratio of remuneration of each director to the median remuneration of employees for the Financial Year and the Percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the Financial Year:

(Amount in 'Lakhs')

NAME OF DIRECTOR/ KMPS	DESIGNATION	NATURE OF PAYMENT	RATIO AGAINST MEDIAN (2025-26) M=RS. 153540	% INCREASE / (DECREASE)
Mr. Amar Singh	Chairman & Managing Director	Remuneration	30.33:1	(74.05%)
Mrs. Asmita Singh	Managing Director	Remuneration	55.12:1	1.06%
Mr. Vinay Lamba	Non-Executive Director	NA	NA	(100.00%)
Mr. Rajeev Kumar Nain	CFO, Company Secretary & Compliance Officer	Remuneration	31.16:1	(1.13%)

- During the Financial Year 2025-26, there was no employee of the Company who was in receipt of remuneration at a rate which, in the aggregate, was in excess of that drawn by the Managing Director or Whole-time Director or Manager and who held, either by himself/herself or along with his/her spouse and dependent children, not less than two per cent of the equity shares of the Company.
- Details of employee drawing gross remuneration of Rs.102 lakh or more per annum during the Financial Year 2025-26

During the Financial Year 2025-26, there was no employee of the Company who, if employed throughout the financial year, was in receipt of remuneration of Rs.102 lakh or more per annum.

a) Median remuneration of employees

The median remuneration of employees for the Financial Year 2025-26 was Rs. 1,53,540, as compared to Rs. 1,47,679 in the previous financial year, representing an increase of 3.97%.

As on March 31, 2026, there were 1,425 permanent employees on the rolls of the Company.

b) Average percentile increase in the salaries of employees other than managerial personnel and comparison with managerial remuneration

The total remuneration of employees increased by 8.00%, whereas the average managerial remuneration decreased by 36.50% during the Financial Year 2025-26 as compared to the previous financial year.

The increase in total employee remuneration during the Financial Year 2025-26 was primarily attributable to the increase in the number of employees and revision in the pay scales of employees, as compared to the Financial Year 2024-25.

The decrease in managerial remuneration during the Financial Year 2025–26 was primarily attributable to the reduction in remuneration paid to the managerial personnel, namely Mr. Amar Singh, Chairman & Managing Director, and Mrs. Asmita Singh, Managing Director, during the year as compared to the previous financial year.

The Company affirms that the remuneration paid is in accordance with the Remuneration Policy of the Company.

c) Affirmation

The Company affirms that the remuneration paid during the financial year 2025-26 is in accordance with the Remuneration Policy of the Company.

B. Information as per Rule 5(2) and Rule 5(3)

(i) Employees drawing remuneration of Rs. 1.02 crore or more per annum

During the financial year 2025-26 there was no employee of the Company who, if employed throughout the financial year, was in receipt of remuneration of Rs. 1.02 crore or more per annum.

(ii) Employees drawing remuneration of Rs. 8.50 lakh or more per month

During the financial year 2025-26 there was no employee of the Company who, if employed for a part of the financial year, was in receipt of remuneration of Rs. 8.50 lakh or more per month.

(iii) Employees drawing remuneration in excess of that of the Managing Directors and holding two per cent or more of the equity shares

During the financial year 2025-26 there was no employee of the Company who was in receipt of remuneration at a rate which, in the aggregate, was in excess of that drawn by the Managing Directors and who held, either alone or together with his or her spouse and dependent children, not less than two per cent of the equity shares of the Company except as mentioned in (iv) Statement of the top ten employees in terms of remuneration drawn below

(iv) Statement of the top ten employees in terms of remuneration drawn

SR.	NAME	DESIGNATION	REMUNERATION (₹) (ANNUAL)	QUAL./ EXP.	DOJ	AGE	PREVIOUS EMPLOYMENT	EQUITY HOLDING	RELATIONSHIP WITH DIRECTOR
1	Mrs. Asmita Singh	Managing Director	84.89	Post Graduate	03-09-2003	41	None	167600	Daughter of Mr. Amar Singh
2	Mr. Rajeev Kumar Nain	CFO, Company Secretary & Compliance Officer	47.99	CA/CS	28-07-2014	45	None	132600	None
3	Mr. Amar Singh	Chairman & Managing Director	46.71	Post Graduate	03-09-2003	68	None	2346260	Father of Mrs. Asmita Singh
4	Amit Srivastava	Director (Corporate Business)	50.95	Doctor of Business Administration	01-03-2024	48	None	342240	None
5	Vijay Singh	Director (IT)	44.89	Graduate	01-04-2006	59	None	899400	None
6	Shweta Lamba	Director (Accounts)	34.5	Graduate	01-04-2006	52	None	419400	None
7	Rajeev Lochan	Director (Sales)	29.85	Graduate	01-04-2006	61	None	290400	None
8	Ajeet Kumar Maurya	Vice President (IT)	28.80	Post Graduate	01-04-2008	43	None	0	None
9	G B Singh	Branch Manager	19.80	Intermediate	01-04-2006	56	None	217950	None

SR.	NAME	DESIGNATION	REMUNERATION (₹) (ANNUAL)	QUAL./ EXP.	DOJ	AGE	PREVIOUS EMPLOYMENT	EQUITY HOLDING	RELATIONSHIP WITH DIRECTOR
10	Sanjeev Chawla	Head (Corporate)	19.79	Graduate	01-04-2008	50	None	0	None

For & On Behalf of Board of Directors
Chandan Healthcare Limited

SD/-

Asmita Singh
(Managing Director)
DIN: 01098055

SD/-

Amar Singh
(Managing Director)
DIN: 01096328
Date: 07/09/2026
Place: -Lucknow

REPORT ON CORPORATE GOVERNANCE

05

Annexure VIII – Report on Corporate Governance

For the financial year ended 31 March 2026

Basis on which this Report is furnished

The equity shares of the Company are listed on the Emerge Platform of the National Stock Exchange of India Limited. In terms of Regulation 15(2)(b) of the SEBI Listing Regulations, the provisions of Regulations 17 to 27, clauses (b) to (i) of sub-regulation (2) of Regulation 46 and paragraphs C, D and E of Schedule V are not mandatorily applicable to a listed entity whose specified securities are listed on the SME platform.

The Board of Directors has nonetheless resolved that the Company shall voluntarily adopt and comply with those requirements, in the interest of transparency and of parity of disclosure with entities listed on the main board. Consistent with that decision, the Company has filed the quarterly and annual Corporate Governance Compliance Reports with the National Stock Exchange of India Limited under Regulation 27(2) and has affirmed compliance with each of the applicable regulations therein.

This Report on Corporate Governance is accordingly furnished voluntarily, and follows the form and content prescribed by paragraph C of Schedule V to the SEBI Listing Regulations in full. Where a requirement does not apply to the Company for a reason other than its listing on the SME platform — principally the thresholds by market capitalisation in Regulations 21, 34(2)(f) and 43A — that position is stated at the relevant place in this Report.

1. Company's Philosophy on Corporate Governance

The Company believes that sound corporate governance is essential to building and retaining the trust of its patients, referring physicians, employees, business partners, lenders and shareholders. Its governance philosophy rests on transparency of disclosure, accountability of the Board and management, fairness to all stakeholders, and compliance with applicable law in both letter and spirit. The Board discharges its responsibilities directly and through its Committees, each of which functions within terms of reference approved by the Board and reviewed from time to time.

2. Board of Directors

(a) Composition and category

As at 31 March 2026 the Board comprised six Directors, of whom two are Executive Directors designated as Managing Directors, one is a Non-Executive Non-Independent Director and three are Non-Executive Independent Directors. The Company has a regular Chairperson, who is an Executive Director and a Promoter. The composition of the Board is in compliance with Regulation 17 of the SEBI Listing Regulations.

SR	NAME OF DIRECTOR	DIN	CATEGORY	AGE	INITIAL DATE OF APPOINTMENT	DATE OF RE-APPOINTMENT
1	Dr. Amar Singh	01096328	Executive Director – Chairperson & Managing Director; related to Promoter	68	03-09-2003	30-03-2024
2	Mrs. Asmita Singh	01098055	Executive Director – Managing Director	41	03-09-2003	30-03-2024

SR	NAME OF DIRECTOR	DIN	CATEGORY	AGE	INITIAL DATE OF APPOINTMENT	DATE OF RE-APPOINTMENT
3	Mr. Vinay Lamba	01220153	Non-Executive – Non-Independent Director	60	03-09-2003	–
4	Mr. Amit Gupta	00583538	Non-Executive – Independent Director	49	13-08-2024	–
5	Mr. Vinod Jain	10701178	Non-Executive – Independent Director	68	13-08-2024	–
6	Mr. Brahma Nand Bhartiya	10729411	Non-Executive – Independent Director	71	13-08-2024	–

Each of the three Independent Directors has been appointed for a tenure of 60 months from 13 August 2024. No Director ceased to hold office during the year under review, and no Director was appointed during the year.

None of the Directors is disqualified from being appointed or continuing as a Director under Section 164 of the Companies Act, 2013, and the Company has received a declaration to that effect from each of them.

(b) Inter-se relationships between Directors

Mr. Amar Singh, Managing Director of the Company, is the father of Mrs. Asmita Singh, Managing Director of the Company. Save as disclosed above, none of the other Directors is related to any other Director of the Company.

(c) Directorships and committee positions held in other entities

SR	NAME OF DIRECTOR	DIRECTORSHIPS IN LISTED ENTITIES (INCLUDING THIS ENTITY)	INDEPENDENT DIRECTORSHIPS IN LISTED ENTITIES (INCLUDING THIS ENTITY)	MEMBERSHIPS OF AUDIT / STAKEHOLDERS' COMMITTEES (INCLUDING THIS ENTITY)	CHAIRPERSONSHIPS OF AUDIT / STAKEHOLDERS' COMMITTEES (INCLUDING THIS ENTITY)
1	Dr. Amar Singh	1	0	2	0
2	Mrs. Asmita Singh	1	0	0	0
3	Mr. Vinay Lamba	1	0	1	1
4	Mr. Amit Gupta	1	1	1	1
5	Mr. Vinod Jain	1	1	2	0
6	Mr. Brahma Nand Bhartiya	1	1	2	0

None of the Directors holds directorships in more than the number of listed entities permitted by Regulation 17A, or memberships or chairpersonships of committees in excess of the limits prescribed by Regulation 26(1).

(d) Board meetings and attendance

During the financial year 2025-26 the Board met 11 (eleven) times. The maximum interval between any two consecutive meetings did not exceed one hundred and twenty days, and the requirement of quorum was met at every meeting.

DATE OF MEETING	MAXIMUM GAP FROM PREVIOUS MEETING (DAYS)	TOTAL NUMBER OF DIRECTORS	DIRECTORS PRESENT	INDEPENDENT DIRECTORS PRESENT
27-05-2025	61	6	6	3
05-08-2025	70	6	3	0

DATE OF MEETING	MAXIMUM GAP FROM PREVIOUS MEETING (DAYS)	TOTAL NUMBER OF DIRECTORS	DIRECTORS PRESENT	INDEPENDENT DIRECTORS PRESENT
05-09-2025	31	6	3	3
10-10-2025	35	6	4	1
14-11-2025	35	6	4	1
31-12-2025	47	6	4	1
20-01-2026	20	6	4	1
31-01-2026	11	6	4	1
03-02-2026	3	6	4	1
14-02-2026	11	6	4	1
26-02-2026	12	6	4	1

The attendance of each Director at the meetings of the Board and at the last Annual General Meeting was as follows:

SR	NAME OF DIRECTOR	MEETINGS HELD DURING TENURE	MEETINGS ATTENDED	PERCENTAGE	ATTENDANCE AT LAST AGM
1	Dr. Amar Singh	11	11	100.00	Yes
2	Mrs. Asmita Singh	11	11	100.00	Yes
3	Mr. Vinay Lamba	11	11	100.00	Yes
4	Mr. Amit Gupta	11	9	81.82	Yes
5	Mr. Vinod Jain	11	1	9.09	Yes
6	Mr. Brahma Nand Bhartiya	11	1	9.09	Yes

(e) Skills, expertise and competencies

The Board of Directors comprises individuals with diverse and complementary skills, expertise and experience across healthcare, medical administration, business management, marketing, technical operations, company law, corporate governance, labour laws and social services. The Board collectively possesses the requisite knowledge, experience and competencies to effectively discharge its responsibilities and provide strategic direction to the Company.

Mr. Amar Singh, Promoter, Chairman and Managing Director, is a medical professional holding a degree of Bachelor of Medicine and Bachelor of Surgery (MBBS) and has over two decades of experience in the healthcare industry. He has been associated with the Company since its inception and is responsible for overseeing the overall operations and providing strategic direction to the Company. His key competencies include healthcare management, business strategy, operational oversight and organisational leadership.

Ms. Asmita Singh, Promoter and Managing Director, holds a Bachelor of Business Administration and a Master of Business and has over two decades of experience in marketing. She has been associated with the Company since its inception and is responsible for operational excellence and strengthening the Company's marketing and business development strategies. Her key competencies include marketing, business development, operational management, strategic planning and leadership.

Mr. Vinay Lamba, Non-Executive Director, has undergone training from the Marine Engineering and Research Institute, Calcutta and holds a Certificate of Competency as Marine Engineer Officer Class I of a Motorship. He has experience in technical operations and has previously been associated with Indra Diagnostic Centre and Blood Bank Limited as Operations Head. His key competencies include technical operations, engineering coordination, equipment performance assessment, procurement strategy, asset management and operational planning.

Mr. Amit Gupta, Director, is a qualified Company Secretary and the proprietor of Amit Gupta & Associates, Company Secretaries. He has professional expertise in company law, corporate governance, secretarial compliance and corporate affairs. He has also served as Chairman of the Lucknow Chapter of the Institute of Company Secretaries of India, demonstrating his professional leadership and commitment to corporate governance and professional development. His key competencies include corporate governance, regulatory compliance, company law, secretarial practices and corporate affairs.

Mr. Brahma Nand Bhartiya, Director, has extensive experience in labour administration and labour law, having served in the Uttar Pradesh Labour Department and subsequently as an Officer on Special Duty with the Building and Other Construction Workers Board. He has also worked as a Senior Labour Law Consultant and has advised various organisations on labour laws, standing orders, statutory licences, labour compliances and BOCW matters. His key competencies include labour laws, statutory compliance, labour administration, regulatory advisory and industrial relations.

Dr. Vinod Jain, Director, is a medical professional, surgeon, teacher, researcher, administrator and social activist with extensive experience in the healthcare and medical education sector. He has held various academic and administrative positions, including Dean, Faculty of Paramedical Sciences, at King George's Medical University, Lucknow. He has contributed significantly to medical education, healthcare training, research, public health initiatives and healthcare administration. His key competencies include healthcare administration, medical education, clinical expertise, research, public health, institutional management and social leadership.

The Board, through its diverse professional backgrounds and complementary expertise, provides effective oversight and strategic guidance to the Company and contributes towards its long-term growth, governance and sustainable development.

(f) Confirmation regarding Independent Directors

The Company has received a declaration from each Independent Director under Section 149(7) of the Act and Regulation 25(8) confirming that they meet the criteria of independence laid down in Section 149(6) of the Act and Regulation 16(1)(b) of the SEBI Listing Regulations, and that they are not aware of any circumstance or situation which could impair their ability to discharge their duties with an objective independent judgement. In the opinion of the Board, the Independent Directors fulfil the conditions specified in the SEBI Listing Regulations and are independent of the management. All the Independent Directors have registered themselves in the Independent Directors' Data Bank maintained by the Indian Institute of Corporate Affairs.

No Independent Director resigned before the expiry of his tenure during the year under review.

3. Audit Committee

The Audit Committee is constituted in accordance with Section 177 of the Act and Regulation 18 of the SEBI Listing Regulations. It has a regular Chairperson, who is an Independent Director. All members were appointed on 26 August 2024 and there was no change in the composition during the year under review.

Meetings and attendance

The Committee met 5 (five) times during the financial year 2025-26. The requirement of quorum was met at every meeting and the gap between two consecutive meetings did not exceed one hundred and twenty days.

SR	NAME OF MEMBER	CATEGORY	POSITION	MEETINGS ATTENDED
1	Mr. Amit Gupta	Non-Executive Independent Director	Chairperson	5
2	Mr. Vinod Jain	Non-Executive Independent Director	Member	5
3	Mr. Brahma Nand Bhartiya	Non-Executive Independent Director	Member	5

SR	NAME OF MEMBER	CATEGORY	POSITION	MEETINGS ATTENDED
4	Dr. Amar Singh	Executive Director	Member	5

4. Nomination and Remuneration Committee

The Committee is constituted in accordance with Section 178 of the Act and Regulation 19 of the SEBI Listing Regulations, and has a regular Chairperson who is an Independent Director. All members were appointed on 26 August 2024 and there was no change in the composition during the year.

Meetings and attendance

The Committee met 2 (two) times during the financial year 2025-26, meeting held on 5 May 2025 and 9 October 2025. The requirement of quorum was met at every meeting.

SR	NAME OF MEMBER	CATEGORY	POSITION	MEETINGS ATTENDED
1	Mr. Brahma Nand Bhartiya	Non-Executive Independent Director	Chairperson	2
2	Mr. Amit Gupta	Non-Executive Independent Director	Member	2
3	Mr. Vinod Jain	Non-Executive Independent Director	Member	2
4	Mr. Vinay Lamba	Non-Executive Non-Independent Director	Member	2

Performance evaluation criteria for Independent Directors

The performance of the Independent Directors is evaluated on criteria including attendance at meetings of the Board and its Committees, acquaintance with the business of the Company, communication with other Board members, the time devoted to the affairs of the Company, core competencies, personal attributes, the discharge of specific responsibilities and expertise, and the independence of judgement brought to bear on the deliberations of the Board.

5. Stakeholders' Relationship Committee

The Committee is constituted in accordance with Section 178 of the Act and Regulation 20 of the SEBI Listing Regulations, and has a regular Chairperson. All members were appointed on 26 August 2024 and there was no change in the composition during the year.

Meetings and attendance

The Committee met 1 (one) time during the financial year 2025-26, on 31 March 2026. The requirement of quorum was met.

SR	NAME OF MEMBER	CATEGORY	POSITION	MEETINGS ATTENDED
1	Mr. Vinay Lamba	Non-Executive Non-Independent Director	Chairperson	1
2	Mr. Vinod Jain	Non-Executive Independent Director	Member	1
3	Mr. Brahma Nand Bhartiya	Non-Executive Independent Director	Member	1
4	Dr. Amar Singh	Executive Director	Member	1

Name and designation of the Compliance Officer

Mr. Rajeev Kumar Nain, Company Secretary, is the Compliance Officer of the Company and acts as the Secretary to the Committee.

Investor complaints during the year

PARTICULARS	NUMBER OF COMPLAINTS
Complaints pending at the beginning of the year	Nil
Complaints received during the year	Nil
Complaints disposed of during the year	Nil
Complaints remaining unresolved at the end of the year	Nil

The Company is registered on the SEBI Complaints Redress System (SCORES) under registration identification number SEBIE/UC25/NAIN/015341/1. No complaint was received through SCORES or otherwise during the financial year 2025-26 and no complaint was pending at the close of the year.

6. Corporate Social Responsibility Committee

The Committee is constituted in accordance with Section 135 of the Act and has a regular Chairperson. All members were appointed on 26 August 2024 and there was no change in the composition during the year. The Committee met 2 (two) time during the financial year 2025-26, on 27 May 2025 and 31 March 2026, and the requirement of quorum was met.

SR	NAME OF MEMBER	CATEGORY	POSITION	MEETINGS ATTENDED
1	Dr. Amar Singh	Executive Director	Chairperson	2
2	Mr. Brahma Nand Bhartiya	Non-Executive Independent Director	Member	2
3	Mr. Vinay Lamba	Non-Executive Non-Independent Director	Member	2

7. Risk Management Committee

The constitution of a Risk Management Committee under Regulation 21 of the SEBI Listing Regulations applies to the top one thousand listed entities by market capitalisation. The Company is not covered by that requirement and accordingly no Risk Management Committee has been constituted. The Company nonetheless has a Risk Management Policy in place under Section 134(3)(n) of the Act, and the identification and mitigation of risk is overseen by the Board and by the Audit Committee.

8. Meetings of Independent Directors

During the financial year 2025-26 the Independent Directors met twice, on 4 August 2025 and 23 February 2026, without the presence of the Executive Directors or of management personnel. All three Independent Directors attended both meetings. At these meetings the Independent Directors reviewed the performance of the Non-Independent Directors and of the Board as a whole, the performance of the Chairperson taking into account the views of the Executive and Non-Executive Directors, and the quality, quantity and timeliness of the flow of information between the management and the Board.

SR	DATE OF MEETING	NUMBER OF INDEPENDENT DIRECTORS ON THE DATE OF THE MEETING	ATTENDED	PERCENTAGE
1	04-08-2025	3	3	100.00
2	23-02-2026	3	3	100.00

9. Familiarisation Programme for Independent Directors

The Company familiarises its Independent Directors with the Company at the time of their appointment and on a continuing basis, covering the business model, the nature of the industry, the regulatory environment, the organisational structure, the operations of the diagnostics and pharmacy businesses, the risk management framework and the roles, rights and responsibilities of Independent Directors. Senior management personnel make presentations to the Board and to its Committees on business performance, strategic initiatives, operational developments and regulatory change. Details of the familiarisation programme are available on the website of the Company.

10. Remuneration of Directors

The remuneration of the Executive Directors is determined by the Board on the recommendation of the Nomination and Remuneration Committee, within the limits approved by the members and subject to the provisions of the Act. The criteria for making payments to Non-Executive Directors are disclosed on the website of the Company.

(Rs. in Lakhs)

NAME OF DIRECTOR	CATEGORY	SALARY, PERQUISITES AND ALLOWANCES	SITTING FEES	TOTAL
Dr. Amar Singh	Executive Director	46.71	Nil	46.71
Mrs. Asmita Singh	Executive Director	84.89	Nil	84.89
Mr. Vinay Lamba	Non-Executive Non-Independent	Nil	Nil	Nil
Mr. Amit Gupta	Independent Director	Nil	2.16	2.16
Mr. Vinod Jain	Independent Director	Nil	1.08	1.08
Mr. Brahma Nand Bhartiya	Independent Director	Nil	2.16	2.16

None of the Non-Executive Directors holds any equity share, convertible instrument or stock option of the Company, save as disclosed in the shareholding pattern. The Company has not granted any stock option to any Director. There is no severance fee payable to any Director and no performance-linked incentive has been paid during the year.

11. General Body Meetings

(a) Annual General Meetings

FINANCIAL YEAR	DATE	VENUE / MODE	SPECIAL RESOLUTIONS PASSED
2024-25	29-09-2025	Other Audio Visual Means (OAVM)	Nil
2023-24	20/09/2024	Biotech Park, Sector- G, Jankipuram, Kursi Road, Lucknow-226021	Raising of Capital Through an Initial Public Offering

FINANCIAL YEAR	DATE	VENUE / MODE	SPECIAL RESOLUTIONS PASSED
2022-23	30/09/2023	Biotech Park, Sector- G, Jankipuram, Kursi Road, Lucknow-226021	Nil

(b) Extraordinary General Meeting

An Extraordinary General Meeting of the members was held on 6 November 2025, at which the authorised share capital of the Company was increased from Rs. 25,00,00,000 to Rs. 30,00,00,000 and Clause V of the Memorandum of Association was altered accordingly.

(c) Postal ballot

No resolution was passed by postal ballot.

12. Means of Communication

PARTICULARS	DETAILS
Quarterly, half-yearly and annual results	Submitted to the National Stock Exchange of India Limited within the time prescribed and hosted on the website of the Company at https://chandandidiagnostic.com/investors.php
Newspaper publication	Financial results are published in the newspapers namely in Jansatta (Hindi) and Financial Express (English) and the publications are hosted on the website of the Company.
Website	www.chandandidiagnostic.com . The information required by Regulation 46(2) is hosted in a separate section of the website, and Regulation 46(3) as to accuracy and timely updating has been complied with.
Presentations to analysts and institutional investors	The schedule of analyst and institutional investor meets, and the presentations made, are hosted at https://chandandidiagnostic.com/investors.php
Audio and video recordings and transcripts of earnings calls	Hosted at https://chandandidiagnostic.com/investors.php
NEAPS	All periodic and event-based disclosures are filed electronically with the National Stock Exchange of India Limited.

13. General Shareholder Information

PARTICULARS	DETAILS
Annual General Meeting – date, time and venue	On 30-09-2026 at 04:00 P.M. at Reg Off. Add: Biotech Park, Sector- G, Jankipuram, Kursi Road, Lucknow-226021
Financial year	1 April 2025 to 31 March 2026
Book closure / record date	NA
Dividend payment date	Not applicable; no dividend has been recommended for the year
Stock exchange on which listed	Emerge Platform of the National Stock Exchange of India Limited
NSE symbol	CHANDAN
ISIN	INE0B2N01016
MSEI symbol	Not listed

PARTICULARS	DETAILS
Listing fees	Paid for the financial year 2025-26
Registrar and Share Transfer Agent	KFin Technologies Limited, 301, The Centrium, 3rd Floor 57, Lal Bahadur Shastri Road, Nav Pada, Kurla (West) Mumbai – 400 070, Maharashtra, India
Share transfer system	In terms of Regulation 40 of the SEBI Listing Regulations, transfer of securities is effected only in dematerialised form through the depositories.
Dematerialisation of shares	98.85% of the issued and paid-up capital was held in dematerialised form as at 31 March 2026
Outstanding convertible instruments	44,50,000 fully convertible warrants allotted on 3 February 2026, each convertible into one equity share of Rs. 10 within 18 months of allotment. None had been converted as at 31 March 2026.
Credit rating	During the year under review, the Company obtained a credit rating from CRISIL Ratings Limited for an instrument aggregating to Rs. 20.00 crore. The instrument was assigned a rating of CRISIL BBB- with a Stable outlook. The credit rating was assigned and the same was disclosed to the Stock Exchange(s) and made available on the Company's website on May 10, 2025.
Commodity price risk and hedging	Not applicable
Plant and centre locations	313 diagnostic centres and laboratories and 40 retail pharmacy stores across 16 States and Union Territories and 62 districts, with central reference laboratories at Lucknow (Uttar Pradesh) and Haldwani (Uttarakhand)
Address for correspondence	Biotech Park, Kursi Road, Lucknow, Uttar Pradesh – 226021, Telephone No.: +91 9918575999 Website: www.chandandiagnostic.com Email id: secretarial@chandan.co.in

(a) Market price data

DATE	SERIES	OPEN	HIGH	LOW	PREV. CLOSE	LTP	CLOSE	VWAP	52W H	52W L	VOLUME	VALUE	NO. OF TRADES
30-Mar-26	SM	231.1	234.85	216.55	231.1	217.8	219.4	225.85	358	150.3	61,600	1,39,12,600.00	75
27-Mar-26	SM	240.05	240.05	230	243.05	230	231.1	234.83	358	150.3	53,600	1,25,86,920.00	64
25-Mar-26	SM	246	250	240	241.2	240	243.05	245.69	358	150.3	36,800	90,41,240.00	43
24-Mar-26	SM	253.95	253.95	239.7	246	240	241.2	244.05	358	150.3	24,800	60,52,400.00	30
23-Mar-26	SM	245.5	251.5	241.1	250	246	246	246.39	358	150.3	74,400	1,83,31,760.00	38
20-Mar-26	SM	245.35	254	243.9	245.95	250	250	247.26	358	150.3	28,800	71,21,200.00	33
19-Mar-26	SM	250.1	250.1	244	251.9	246	245.95	245.5	358	150.3	35,200	86,41,680.00	26
18-Mar-26	SM	246.7	252	242.5	243.25	250	251.9	249.94	358	150.3	25,600	63,98,440.00	17
17-Mar-26	SM	250	250	240.05	244.8	240.05	243.25	246.01	358	150.3	29,600	72,81,800.00	33
16-Mar-26	SM	250	250	243	252.35	243	244.8	246.16	358	150.3	24,800	61,04,800.00	30
13-Mar-26	SM	260	263.5	250	263.1	254.95	252.35	256.51	358	150.3	31,200	80,03,160.00	35

DATE	SERIES	OPEN	HIGH	LOW	PREV. CLOSE	LTP	CLOSE	VWAP	52W H	52W L	VOLUME	VALUE	NO. OF TRADES
12-Mar-26	SM	258	266	253	260.35	263.1	263.1	260.21	358	150.3	11,200	29,14,320.00	13
11-Mar-26	SM	279.95	280	255.5	254	258	260.35	267.63	358	150.3	1,84,800	4,94,58,400.00	38
10-Mar-26	SM	258	258.2	251	250.65	253	254	255.89	358	150.3	23,200	59,36,720.00	22
09-Mar-26	SM	257.95	257.95	238	261	248	250.65	249.97	358	150.3	2,25,600	5,63,93,040.00	106
06-Mar-26	SM	263	266.7	260	263	261	261	263.17	358	140	17,600	46,31,760.00	20
05-Mar-26	SM	259.2	265.8	259.2	258.8	263	263	262.28	358	140	21,600	56,65,200.00	23
04-Mar-26	SM	253.4	259.2	246.65	257	259.2	258.8	254.29	358	140	26,400	67,13,160.00	33
02-Mar-26	SM	257.7	259.9	252.1	260.1	257	257	255.53	358	140	20,800	53,14,920.00	23
27-Feb-26	SM	265	265.05	255.7	267	260	260.1	262.13	358	140	31,200	81,78,360.00	34
26-Feb-26	SM	274	274	267	270.8	267	267	270.69	358	140	22,400	60,63,360.00	26
25-Feb-26	SM	268	274.8	268	268.95	271	270.8	271.15	358	140	8,000	21,69,160.00	10
24-Feb-26	SM	263	269.8	262	268	268.95	268.95	265.6	358	140	21,600	57,36,880.00	25
23-Feb-26	SM	263.6	269.8	263.6	263.75	268	268	267.38	358	140	13,600	36,36,400.00	17
20-Feb-26	SM	268.1	268.4	262.6	273.9	262.6	263.75	265.92	358	140	15,200	40,42,040.00	18
19-Feb-26	SM	275	275	270.05	275.85	273.9	273.9	272.89	358	140	7,200	19,64,800.00	9
18-Feb-26	SM	274.85	279.9	270	271.85	275.05	275.85	274.87	358	140	33,600	92,35,760.00	37
17-Feb-26	SM	265	272.3	265	261.85	272.3	271.85	269.89	358	140	15,200	41,02,280.00	19
16-Feb-26	SM	281	281	260	284.5	261.5	261.85	266.1	358	140	1,68,800	4,49,17,000.00	187
13-Feb-26	SM	300	300	283	295.75	283.85	284.5	291.7	358	140	64,000	1,86,68,920.00	68
12-Feb-26	SM	296.55	296.55	294.5	296.55	296.55	295.75	295.6	358	140	9,600	28,37,720.00	10
11-Feb-26	SM	301	303.5	295	301.6	296.55	296.55	298.88	358	140	23,200	69,34,040.00	28
10-Feb-26	SM	300	304	298	296.95	301.6	301.6	301.49	358	140	21,600	65,12,160.00	27
09-Feb-26	SM	280	307	280	271.85	297	296.95	295.36	358	140	64,000	1,89,02,800.00	67
06-Feb-26	SM	262.05	272	262.05	263.45	272	271.85	269.54	358	140	34,400	92,72,160.00	32
05-Feb-26	SM	270	270	262	270.35	262	263.45	267.7	358	140	20,000	53,53,960.00	13
04-Feb-26	SM	272.9	272.9	260	270.7	270.5	270.35	265.77	358	140	17,600	46,77,600.00	22
03-Feb-26	SM	274.95	275	264	261	273	270.7	269.02	358	140	28,000	75,32,640.00	35
02-Feb-26	SM	263	263	256	263.25	261	261	260.19	358	140	5,600	14,57,080.00	7
01-Feb-26	SM	272	272	260	266.1	263	263.25	265.69	358	140	14,400	38,25,880.00	17
30-Jan-26	SM	273.85	273.85	262.1	274	266	266.1	267.14	358	140	28,800	76,93,720.00	30
29-Jan-26	SM	267.35	276.4	262.05	262.55	274	274	271.75	358	140	26,400	71,74,080.00	32
28-Jan-26	SM	258	267	258	261.05	262.55	262.55	263.02	358	140	18,400	48,39,640.00	19

DATE	SERIES	OPEN	HIGH	LOW	PREV. CLOSE	LTP	CLOSE	VWAP	52W H	52W L	VOLUME	VALUE	NO. OF TRADES
27-Jan-26	SM	266.2	267	260.1	266.2	260.2	261.05	262.21	358	140	12,000	31,46,520.00	15
23-Jan-26	SM	267	268.5	261.25	266.8	268.5	266.2	265.91	358	140	44,800	1,19,12,760.00	33
22-Jan-26	SM	265	270	259.1	251.75	265.2	266.8	265.05	358	140	12,000	31,80,560.00	15
21-Jan-26	SM	250.05	262	247	257.65	250	251.75	253.23	358	140	37,600	95,21,440.00	45
20-Jan-26	SM	262.95	265	253.2	260.65	256.2	257.65	259.96	358	140	39,200	1,01,90,360.00	45
19-Jan-26	SM	272.6	287.2	258.95	267.35	259.05	260.65	266.7	358	140	81,600	2,17,63,000.00	94
16-Jan-26	SM	300	301.25	260	295.35	277.7	267.35	277.82	358	140	1,48,000	4,11,17,920.00	167
14-Jan-26	SM	298	299	294.1	297	294.1	295.35	297.26	358	140	19,200	57,07,400.00	24
13-Jan-26	SM	305	305	297	300.05	297	297	303.01	358	140	17,600	53,32,960.00	18
12-Jan-26	SM	292.1	306.2	292.05	298.05	304.9	300.05	300.6	358	140	42,400	1,27,45,520.00	46
09-Jan-26	SM	296	308.45	291.4	295.05	300	298.05	299.29	358	140	8,000	23,94,320.00	10
08-Jan-26	SM	308.7	308.7	290.05	308.7	295.05	295.05	297.84	358	140	22,400	66,71,720.00	28
07-Jan-26	SM	310	317.65	308	306.75	308	308.7	311.05	358	140	18,400	57,23,360.00	21
06-Jan-26	SM	315.5	315.5	300.45	315	306.5	306.75	307.49	358	140	24,800	76,25,680.00	31
05-Jan-26	SM	317	317	311.3	316.5	315	315	315.38	358	140	6,400	20,18,400.00	8
02-Jan-26	SM	318.05	320	315	316.6	315	316.5	318.07	358	140	23,200	73,79,320.00	26
01-Jan-26	SM	318.6	320.8	315.25	324.55	315.25	316.6	318.32	358	140	22,400	71,30,440.00	22
31-Dec-25	SM	318	328.75	317.5	316.75	323.05	324.55	323.55	358	140	12,000	38,82,640.00	14
30-Dec-25	SM	319	325	315.25	319	315.5	316.75	318.57	358	140	16,000	50,97,120.00	20
29-Dec-25	SM	323	323	313.45	325.85	319	319	317.85	358	140	16,800	53,39,880.00	20
26-Dec-25	SM	328	329.9	320.1	320.1	326.1	325.85	326.37	358	140	65,600	2,14,09,560.00	71
24-Dec-25	SM	294.05	328.95	291.25	293.75	325.95	320.1	315.71	358	140	75,200	2,37,41,600.00	93
23-Dec-25	SM	295.8	298.95	290	294.35	294.05	293.75	293.4	358	140	23,200	68,06,880.00	27
22-Dec-25	SM	290.05	297.45	290.05	290	296	294.35	294.1	358	140	4,000	11,76,400.00	5
19-Dec-25	SM	287	290	286	283.65	290	290	287.83	358	140	4,800	13,81,600.00	6
18-Dec-25	SM	281.95	290	272	283.95	282.5	283.65	281.94	358	140	52,000	1,46,60,680.00	63
17-Dec-25	SM	291.15	291.15	280	291.15	283.05	283.95	284.81	358	140	57,600	1,64,05,200.00	71
16-Dec-25	SM	290	299.9	290	293.9	290	291.15	293.5	358	140	20,800	61,04,760.00	25
15-Dec-25	SM	298	298	290.5	295.95	293.6	293.9	295.38	358	140	22,400	66,16,560.00	28
12-Dec-25	SM	294.15	300	293.5	293.1	295.5	295.95	295.42	358	140	10,400	30,72,400.00	12
11-Dec-25	SM	301.95	301.95	290.3	299.25	293	293.1	295.39	358	140	12,800	37,80,960.00	16
10-Dec-25	SM	310.3	313.95	298.5	303.3	298.5	299.25	305.07	358	140	12,000	36,60,840.00	15

DATE	SERIES	OPEN	HIGH	LOW	PREV. CLOSE	LTP	CLOSE	VWAP	52W H	52W L	VOLUME	VALUE	NO. OF TRADES
09-Dec-25	SM	291.1	310	287	290.7	304	303.3	298.62	358	140	42,400	1,26,61,44 0.00	47
08-Dec-25	SM	315.1	315.1	284.2	321	287	290.7	298.21	358	140	1,83,200	5,46,31,84 0.00	198
05-Dec-25	SM	322.5	326	321	321.1	321	321	323.95	358	140	16,800	54,42,320. 00	13
04-Dec-25	SM	324.8	325	321.1	322.75	321.1	321.1	322.56	358	140	6,400	20,64,360. 00	8
03-Dec-25	SM	317.5	324	309	319.55	322.95	322.75	314.26	358	140	52,800	1,65,93,16 0.00	62
02-Dec-25	SM	338	338	318	338.1	318.55	319.55	324.66	358	140	1,15,200	3,74,00,40 0.00	73
01-Dec-25	SM	336.5	342.25	331.15	333.15	338.9	338.1	336.61	358	140	13,600	45,77,880. 00	16
28-Nov-25	SM	338.4	339.95	331.35	338.4	332.25	333.15	335.34	358	140	19,200	64,38,480. 00	18
27-Nov-25	SM	330.85	350.95	325	324.6	334	338.4	337.04	358	140	36,000	1,21,33,56 0.00	43
26-Nov-25	SM	325	331	321	323	331	324.6	324.99	358	140	42,400	1,37,79,40 0.00	46
25-Nov-25	SM	326.8	327.9	322.4	323.5	323	323	325.02	358	140	24,000	78,00,480. 00	18
24-Nov-25	SM	336.95	336.95	322.05	329.7	327.65	323.5	327.35	358	140	34,400	1,12,60,84 0.00	33
21-Nov-25	SM	332.4	340.9	328	332.3	331.8	329.7	334.04	358	140	27,200	90,85,960. 00	33
20-Nov-25	SM	347.2	348	331	347.2	331	332.3	336.49	358	140	29,600	99,60,080. 00	36
19-Nov-25	SM	340	352	340	338.55	350	347.2	346.75	358	140	64,000	2,21,91,84 0.00	69
18-Nov-25	SM	349.8	358	336	337.3	336	338.55	347.37	358	140	1,31,200	4,55,75,48 0.00	138
17-Nov-25	SM	330	348.95	320.6	313.4	334.5	337.3	333.2	355	140	1,17,600	3,91,84,48 0.00	125
14-Nov-25	SM	319.85	319.85	313	311.65	313	313.4	316.33	355	140	18,400	58,20,480. 00	23
13-Nov-25	SM	318.95	318.95	311.65	314.45	311.65	311.65	315.06	355	140	7,200	22,68,440. 00	9
12-Nov-25	SM	311	324	310.35	311.7	316	314.45	316.88	355	140	45,600	1,44,49,76 0.00	50
11-Nov-25	SM	323.6	328	309.95	332	310.35	311.7	315.32	355	140	90,400	2,85,04,76 0.00	106
10-Nov-25	SM	329.9	334	322	329.9	330	332	328.52	355	140	19,200	63,07,520. 00	24
07-Nov-25	SM	330	333	314.35	326.1	327	329.9	324.51	355	140	66,400	2,15,47,48 0.00	76
06-Nov-25	SM	347.95	348	324.95	332.9	327	326.1	329.12	355	140	59,200	1,94,83,64 0.00	59
04-Nov-25	SM	320.05	353	315	318.55	333.7	332.9	328.4	355	140	84,800	2,78,48,48 0.00	97
03-Nov-25	SM	310	334.75	310	326	317	318.55	323.88	355	140	36,000	1,16,59,72 0.00	38
01-Aug-25	SM	256	265	252	256.65	256.8	255.2	258.83	279	140	49,600	1,28,37,76 0.00	56
31-Jul-25	SM	249	259.5	249	250.3	257	256.65	255.14	279	140	12,000	30,61,640. 00	15
30-Jul-25	SM	279	279	243.65	259.85	250.7	250.3	256.12	279	140	78,400	2,00,79,68 0.00	85
29-Jul-25	SM	256.25	273.4	255	256.25	258	259.85	264.04	273.4	140	62,400	1,64,76,36 0.00	65
28-Jul-25	SM	249.1	270	249.1	247.05	259.95	256.25	259.62	270	140	84,000	2,18,08,36 0.00	100
25-Jul-25	SM	258	259.75	243.55	256.3	247	247.05	249.86	265	140	75,200	1,87,89,24 0.00	90

DATE	SERIES	OPEN	HIGH	LOW	PREV. CLOSE	LTP	CLOSE	VWAP	52W H	52W L	VOLUME	VALUE	NO. OF TRADES
24-Jul-25	SM	244.45	265	239.2	238.25	255.1	256.3	250.62	265	140	2,34,400	5,87,45,16 0.00	243
23-Jul-25	SM	223.95	242.9	223.8	222.65	239.25	238.25	233.93	242.9	140	1,87,200	4,37,92,60 0.00	201
22-Jul-25	SM	220.4	228	220.4	216.7	223.85	222.65	223.74	228	140	78,400	1,75,41,04 0.00	96
21-Jul-25	SM	211.5	219.8	211.5	213.2	218	216.7	216.84	224.6	140	61,600	1,33,57,12 0.00	71
18-Jul-25	SM	214.2	216	208.2	208.8	211	213.2	211.97	224.6	140	36,000	76,30,920. 00	45
17-Jul-25	SM	205	212.4	204.95	198.25	209.1	208.8	209.38	224.6	140	1,30,400	2,73,03,76 0.00	134
16-Jul-25	SM	199.55	200.65	191.05	201.8	198.35	198.25	197.17	224.6	140	48,800	96,22,000. 00	52
15-Jul-25	SM	207	207	201.3	204.9	201.3	201.8	204.01	224.6	140	17,600	35,90,560. 00	13
14-Jul-25	SM	208	208	202.55	205.1	204.9	204.9	205.59	224.6	140	6,400	13,15,800. 00	8
11-Jul-25	SM	209	210	204	208	204	205.1	206.63	224.6	140	29,600	61,16,360. 00	31
10-Jul-25	SM	211.8	214	207	211.8	208	208	210.7	224.6	140	32,000	67,42,400. 00	33
09-Jul-25	SM	206.8	218.95	205.15	204.25	213.35	211.8	212.03	224.6	140	74,400	1,57,74,88 0.00	85
08-Jul-25	SM	203.6	207	203	199	203	204.25	205.1	224.6	140	31,200	63,99,200. 00	37
07-Jul-25	SM	197.05	201.5	197.05	197.3	199	199	198.24	224.6	140	32,800	65,02,200. 00	19
04-Jul-25	SM	203.3	206.95	196.1	203.3	196.35	197.3	199.75	224.6	140	46,400	92,68,320. 00	40
03-Jul-25	SM	205	210	202.25	204.45	204	203.3	205.45	224.6	140	62,400	1,28,19,88 0.00	71
02-Jul-25	SM	190.15	209.95	187.5	191.4	203.5	204.45	199.38	224.6	140	60,000	1,19,63,04 0.00	70
01-Jul-25	SM	186	192.95	186	186.25	192.95	191.4	189.44	224.6	140	26,400	50,01,320. 00	32
30-Jun-25	SM	193	194.95	184.5	191.9	186	186.25	189.4	224.6	140	82,400	1,56,06,96 0.00	90
27-Jun-25	SM	196.1	198.45	189.9	196.1	191.5	191.9	191.93	224.6	140	28,800	55,27,480. 00	33
26-Jun-25	SM	200	201	196	197.7	196.1	196.1	196.92	224.6	140	59,200	1,16,57,56 0.00	25
25-Jun-25	SM	205	205	196.95	201.75	198.45	197.7	200.79	224.6	140	21,600	43,37,160. 00	24
24-Jun-25	SM	198	207.9	198	194.5	203.45	201.75	202.79	224.6	140	61,600	1,24,91,56 0.00	74
23-Jun-25	SM	199.95	199.95	190	200.45	194.5	194.5	193.97	224.6	140	56,800	1,10,17,68 0.00	65
20-Jun-25	SM	201.05	205.4	198	201.3	200	200.45	200.6	224.6	140	35,200	70,61,200. 00	32
19-Jun-25	SM	214.5	217	198.2	214.6	198.2	201.3	208.06	224.6	140	49,600	1,03,19,84 0.00	60
18-Jun-25	SM	210	224.6	206.5	211.3	211.6	214.6	214.19	224.6	140	49,600	1,06,24,00 0.00	58
17-Jun-25	SM	205	217.9	205	207.9	212	211.3	213.91	217.9	140	76,000	1,62,56,88 0.00	82
16-Jun-25	SM	201	209	198.55	201.95	209	207.9	206.04	215.4	140	55,200	1,13,73,32 0.00	63
13-Jun-25	SM	195.15	207.9	195.15	202.85	201	201.95	203.6	215.4	140	67,200	1,36,81,76 0.00	70
12-Jun-25	SM	200	205	200	199.4	202.85	202.85	201.88	215.4	140	67,200	1,35,66,00 0.00	49
11-Jun-25	SM	189.2	208	188.45	186.9	200	199.4	197.96	215.4	140	1,80,000	3,56,32,60 0.00	174

DATE	SERIES	OPEN	HIGH	LOW	PREV. CLOSE	LTP	CLOSE	VWAP	52W H	52W L	VOLUME	VALUE	NO. OF TRADES
10-Jun-25	SM	188.65	191	185.5	183.35	188	186.9	188.25	215.4	140	1,07,200	2,01,80,440.00	105
09-Jun-25	SM	184	185	180	184	184	183.35	183.07	215.4	140	36,800	67,37,000.00	39
06-Jun-25	SM	183	185	182.85	180.1	184	184	183.95	215.4	140	36,000	66,22,320.00	42
05-Jun-25	SM	188.9	190	179	187.1	180	180.1	183.55	215.4	140	48,800	89,57,040.00	58
04-Jun-25	SM	189	190.8	184.95	189.4	187.95	187.1	186.68	215.4	140	26,400	49,28,440.00	30
03-Jun-25	SM	181.35	192.8	181.35	182.85	189.4	189.4	187.9	215.4	140	53,600	1,00,71,280.00	60
02-Jun-25	SM	184.9	186.5	181	184.95	181	182.85	183.83	215.4	140	42,400	77,94,280.00	30
30-May-25	SM	185.4	187.2	183	185.5	184.95	184.95	185.31	215.4	140	19,200	35,57,880.00	22
29-May-25	SM	192	192	184	187.25	185.9	185.5	187.96	215.4	140	28,000	52,62,800.00	34
28-May-25	SM	189	195.9	185	195.15	188	187.25	191.44	215.4	140	90,400	1,73,06,200.00	84
27-May-25	SM	188.3	198.6	184	182.4	192	195.15	192.24	215.4	140	1,83,200	3,52,17,720.00	159
26-May-25	SM	180.15	194	180.15	180.15	184	182.4	186.7	215.4	140	76,000	1,41,89,280.00	78
23-May-25	SM	183.05	185.95	179	181.75	180.3	180.15	181.93	215.4	140	19,200	34,92,960.00	23
22-May-25	SM	179.2	186.8	179.2	183.8	181.75	181.75	184.08	215.4	140	7,200	13,25,360.00	9
21-May-25	SM	184.9	186.8	182.3	181.95	184	183.8	183.81	215.4	140	13,600	24,99,880.00	16
20-May-25	SM	185.4	191	181.9	182.1	182.1	181.95	183.52	215.4	140	11,200	20,55,400.00	14
19-May-25	SM	173.95	190	172	173.95	182.35	182.1	181.95	215.4	140	32,800	59,67,920.00	38
16-May-25	SM	178	179	173.2	179	173.2	173.95	176.81	215.4	140	45,600	80,62,680.00	55
15-May-25	SM	182	182	178	181.5	179	179	179.6	215.4	140	32,000	57,47,160.00	27
14-May-25	SM	181	184.7	170	182.2	180.05	181.5	176.45	215.4	140	1,56,000	2,75,26,600.00	120
13-May-25	SM	183	189	180	185	180	182.2	184.88	215.4	140	25,600	47,32,920.00	21
12-May-25	SM	177.1	186	150.3	172.3	185	185	178.29	215.4	140	16,000	28,52,600.00	19
09-May-25	SM	191	191	170	176.05	171.5	172.3	173.42	215.4	140	20,800	36,07,200.00	24
08-May-25	SM	177.75	180.5	176.05	182	176.05	176.05	178.64	215.4	140	16,800	30,01,120.00	21
07-May-25	SM	186.9	187	181.9	187	182	182	182.82	215.4	140	9,600	17,55,080.00	8
06-May-25	SM	187	187	187	187	187	187	187	215.4	140	1,600	2,99,200.00	2
05-May-25	SM	184.55	187	184.55	185.05	187	187	186.76	215.4	140	8,000	14,94,040.00	10
02-May-25	SM	184	185.05	184	184	185.05	185.05	184.35	215.4	140	2,400	4,42,440.00	3
30-Apr-25	SM	193.3	193.3	184	188.55	184	184	186.78	215.4	140	4,800	8,96,560.00	6
29-Apr-25	SM	194	194.95	187.95	193.95	188	188.55	190.44	215.4	140	25,600	48,75,160.00	30
28-Apr-25	SM	195.2	195.3	192	193.75	193.95	193.95	194.25	215.4	140	15,200	29,52,560.00	18
25-Apr-25	SM	199	199	188.05	201.7	193	193.75	192.75	215.4	140	35,200	67,84,680.00	43

DATE	SERIES	OPEN	HIGH	LOW	PREV. CLOSE	LTP	CLOSE	VWAP	52W H	52W L	VOLUME	VALUE	NO. OF TRADES
24-Apr-25	SM	196	205	196	196	197.65	201.7	200.9	215.4	140	36,000	72,32,520.00	39
23-Apr-25	SM	198	200	196	197.5	196	196	198.89	215.4	140	32,000	63,64,480.00	29
22-Apr-25	SM	194	203.9	192	194.2	197	197.5	197.45	215.4	140	31,200	61,60,360.00	39
21-Apr-25	SM	185.5	202.7	185.5	202	194.5	194.2	192.55	215.4	140	63,200	1,21,69,320.00	69
17-Apr-25	SM	202.05	204	201	202.05	203	202	201.99	215.4	140	42,400	85,64,200.00	34
16-Apr-25	SM	206.05	210	200	206.25	201.95	202.05	203.1	215.4	140	71,200	1,44,60,480.00	83
15-Apr-25	SM	210.85	215.4	204.95	210.85	210.5	206.25	208.17	215.4	140	53,600	1,11,57,800.00	64
11-Apr-25	SM	211	213.85	207.25	213.4	210.8	210.85	210.63	214.5	140	30,400	64,03,000.00	34
09-Apr-25	SM	214.5	214.5	203.55	205.75	213.5	213.4	210.3	214.5	140	55,200	1,16,08,400.00	57
08-Apr-25	SM	200.05	211	200.05	199	207	205.75	206.38	212.4	140	31,200	64,39,000.00	37
07-Apr-25	SM	188	205	188	205.85	199	199	200.13	212.4	140	35,200	70,44,640.00	37
04-Apr-25	SM	208	209.85	202.15	209.25	205	205.85	206.41	212.4	140	43,200	89,16,880.00	50
03-Apr-25	SM	177.8	212.4	177	177	209.8	209.25	196.83	212.4	140	2,36,000	4,64,51,280.00	268
02-Apr-25	SM	178.05	180	175.5	175.5	177	177	177.14	201.5	140	17,600	31,17,720.00	22
01-Apr-25	SM	176.5	186.7	174	181	174	175.5	178.34	201.5	140	24,800	44,22,720.00	31

(b) Distribution of shareholding and shareholding pattern

The shareholding pattern of the Company as at 31 March 2026 has been filed with the National Stock Exchange of India Limited under Regulation 31 and is hosted on the website of the Company at <https://chandandiagnostics.com/uploads/SHP-31-03-2026.pdf>

14. Related Party Disclosures – Paragraph A of Schedule V

Paragraph A of Schedule V to the SEBI Listing Regulations is not excluded by Regulation 15(2) and applies to the Company of its own force. Disclosure of the amounts at the year end, and of the maximum amount outstanding during the year, is set out below.

(Rs. in Lakhs)

PARTICULARS	OUTSTANDING AT THE YEAR END	MAXIMUM OUTSTANDING DURING THE YEAR
Loans and advances in the nature of loans to subsidiaries	Nil	Nil
Loans and advances in the nature of loans to associates	Nil	Nil
Loans and advances in the nature of loans to firms or companies in which Directors are interested	Nil	Nil
Investments by the loanee in the shares of the Company or of its subsidiaries, where a loan or advance in the nature of a loan has been made	Nil	Nil

No loan or other form of debt was advanced by the Company, directly or indirectly, to any promoter, member of the promoter group, Director or Key Managerial Personnel or to any entity controlled by them during the year, and no guarantee, comfort letter or security was provided by the Company in connection with any debt availed by any of them.

15. Other Disclosures

PARTICULARS	DETAILS
Materially significant related party transactions	There were no materially significant related party transactions during the year having a potential conflict with the interest of the Company at large. All related party transactions were placed before the Audit Committee and, where applicable, omnibus approval was obtained. Details are set out in Form AOC-2 annexed as Annexure II and in the notes to the financial statements. The corporate social responsibility contribution of Rs. 55.86 lakhs to Chandan Singh Foundation, a related party, is separately disclosed in the Board's Report and in Annexure IV.
Approval for material related party transactions	No transaction required the approval of the members under Regulation 23(4) during the year.
Non-compliance, penalties and strictures	No fine or penalty was imposed on the Company by the stock exchange, the Securities and Exchange Board of India or any statutory authority on any matter relating to the capital markets during the year under review except the Company incurred a fine of ₹10,000 in September 2025 for one instance of non-compliance under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Ongoing tax litigation or disputes	There was no ongoing tax litigation or dispute pending as at 31 March 2026.
Vigil mechanism and whistle blower policy	Established under Regulation 22. No person was denied access to the Audit Committee or its Chairperson during the year.
Policy for determining material subsidiaries	Adopted by the Board and hosted at https://chandandiagnostic.com/uploads/Policy-on-Material-Subsidiaries.pdf . The corporate governance requirements applicable to the unlisted material subsidiary have been complied with.
Policy on related party transactions	Adopted by the Board and hosted at https://chandandiagnostic.com/uploads/Policy%20on%20Dealing%20with%20Related%20Party%20Transactions.pdf
Loans, guarantees, comfort letters and securities to promoters, promoter group, directors, key managerial personnel or entities controlled by them	Nil. No loan or other form of debt was advanced, no guarantee or comfort letter was provided and no security was given by the Company, directly or indirectly, to or in connection with any debt availed by any of the said persons during the year.
Cyber security incidents	There was no cyber security incident, breach, or loss of data or documents during the year under review, as reported under Regulation 27(2)(ba).
Acquisition of shares or voting rights in unlisted companies	The Company incorporated Chandan Healthcare Projects Private Limited on 8 March 2026 by subscribing to 100% of its initial share capital. This is a fresh incorporation and not an acquisition from any existing shareholder.
Utilisation of funds raised through preferential allotment	Disclosed in the Board's Report under the heading "Statement of Deviation(s) or Variation(s)" and reviewed by the Audit Committee.
Certificate from a Practising Company Secretary on non-disqualification of Directors	Attached

PARTICULARS	DETAILS
Recommendation of any Committee not accepted by the Board	There was no instance during the year in which the Board did not accept a recommendation of any Committee which is mandatorily required.
Total fees paid to the statutory auditor	Rs. 7.08 lacs
Disclosure under the Sexual Harassment of Women at Workplace Act	No complaint was filed, disposed of or pending during the financial year 2025-26. Details are set out in the Board's Report.
Compliance with accounting standards	The Company has followed the accounting standards specified under Section 133 of the Act in the preparation of its financial statements.

Requirements that remain inapplicable notwithstanding voluntary adoption

The following do not apply to the Company by reason of thresholds unconnected with its listing on the SME platform, and are therefore not covered by the voluntary adoption recorded at the beginning of this Report:

REQUIREMENT	BASIS OF NON-APPLICABILITY
Constitution of a Risk Management Committee	Regulation 21 – applies to the top one thousand listed entities by market capitalisation
Business Responsibility and Sustainability Report	Regulation 34(2)(f) – applies to the top one thousand listed entities by market capitalisation
Dividend Distribution Policy	Regulation 43A – applies to the top one thousand listed entities by market capitalisation
Annual Secretarial Compliance Report	Although Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the Company, being listed on the SME Platform, the Company, as a good governance practice, voluntarily obtained the Annual Secretarial Compliance Report for FY 2025-26 from a Practising Company Secretary, reaffirming its commitment to robust corporate governance and regulatory compliance.

16. Disclosures on the Website under Regulation 46(2)

The information required by Regulation 46(2) is hosted in a separate identifiable section of the website of the Company:

ITEM	WEB ADDRESS
Details of business	https://chandandiagnostics.com/chandan-group.php
Memorandum and Articles of Association	https://chandandiagnostics.com/uploads/MOA.pdf and /uploads/AOA.pdf
Brief profile of the Board of Directors	https://chandandiagnostics.com/uploads/Director%20profile-.pdf
Terms and conditions of appointment of Independent Directors	https://chandandiagnostics.com/uploads/Terms%20and%20conditions%20of%20Appointment%20of%20ID.pdf
Composition of the Committees of the Board	https://chandandiagnostics.com/uploads/Committees.pdf
Code of conduct of the Board and senior management	https://chandandiagnostics.com/uploads/CODE%20OF%20BUSINESS%20CONDUCT%20AND%20ETHICS.pdf
Vigil mechanism and Whistle Blower Policy	https://chandandiagnostics.com/uploads/Vigil%20Mechanism%20&%20Whistle%20Blower%20Policy.pdf
Criteria for making payments to Non-Executive Directors	https://chandandiagnostics.com/uploads/Criteria_or_Policy_for_making_payments_to_NED.pdf

ITEM	WEB ADDRESS
Policy on dealing with related party transactions	https://chandandiagnostic.com/uploads/Policy%20on%20Dealing%20with%20Related%20Party%20Transactions.pdf
Policy for determining material subsidiaries	https://chandandiagnostic.com/uploads/Policy-on-Material-Subsidiaries.pdf
Familiarisation programme for Independent Directors	https://chandandiagnostic.com/uploads/Familiarisation_Programme.pdf
Email address and contact details for grievance redressal	https://chandandiagnostic.com/uploads/Investor%20Grievance.pdf
Financial results	https://chandandiagnostic.com/investors.php
Shareholding pattern	https://chandandiagnostic.com/uploads/SHP-31-03-2026.pdf
Advertisements under Regulation 47(1)	Hosted on the website of the Company
Credit rating obtained	https://chandandiagnostic.com/uploads/CRISIL%20Credit%20Rating-10-05-2025.pdf
Separate audited financial statements of each subsidiary	https://chandandiagnostic.com/investors.php
Materiality policy under Regulation 30(4) and contact details of the KMP authorised under Regulation 30(5)	Hosted on the website of the Company
Statements of deviation or variation under Regulation 32	Hosted on the website of the Company
Annual return under Section 92 of the Act	Hosted on the website of the Company

The following items are not applicable to the Company: details of agreements entered into with media companies or their associates; the new and old name of the listed entity; employee benefit scheme documents under the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; and the Annual Secretarial Compliance Report, which was not applicable during the period under review as the Company is listed on the SME platform.

17. Annual Affirmations under Regulation 27(2)

The Company has affirmed compliance with the following requirements in the annual Corporate Governance Compliance Report filed with the National Stock Exchange of India Limited for the financial year ended 31 March 2026:

PARTICULARS	REGULATION	COMPLIANCE STATUS
Appointment of Independent Directors in terms of the criteria of independence and eligibility	16(1)(b)	Complied
Board composition, meetings, quorum, review of compliance reports, succession planning, code of conduct, fees and compensation, minimum information, compliance certificate, risk assessment, performance evaluation and recommendation of the Board	17(1) to 17(11)	Complied
Maximum number of directorships	17A	Complied
Composition, meetings and role of the Audit Committee	18(1) to 18(3)	Complied
Composition, quorum, meetings and role of the Nomination and Remuneration Committee	19(1) to 19(4)	Complied
Composition, meetings and role of the Stakeholders' Relationship Committee	20(1) to 20(4)	Complied

PARTICULARS	REGULATION	COMPLIANCE STATUS
Composition, role, meetings, quorum and gap between meetings of the Risk Management Committee	21(1) to 21(3C)	Not applicable
Vigil mechanism	22	Complied
Policy for related party transactions, prior or omnibus approval of the Audit Committee, and disclosure of related party transactions on a consolidated basis	23(1) to 23(9)	Complied
Approval for material related party transactions	23(4)	Not applicable
Corporate governance requirements with respect to the subsidiaries of the listed entity	24(1) to 24(6)	Complied
Annual Secretarial Compliance Report	24A	Not applicable/Submitted Voluntary
Maximum tenure, appointment through special resolution, meetings, familiarisation and declarations of Independent Directors	25(2) to 25(9)	Complied
Alternate director to an Independent Director; Directors and Officers insurance; confirmation on resignation of an Independent Director	25(1), 25(10), 25(11)	Not applicable
Memberships in committees, affirmation of compliance with the code of conduct, and obligations of directors and senior management	26(1) to 26(5)	Complied
Approval for compensation or profit sharing in connection with dealings in securities	26(6)	Not applicable
Vacancies in respect of Key Managerial Personnel	26A(1) to 26A(3)	Not applicable

18. Compliance Certificates

(a) Certificate under Regulation 17(8)

The certificate from the Managing Director and the Chief Financial Officer in terms of Regulation 17(8) read with Part B of Schedule II of the SEBI Listing Regulations, in respect of the financial year ended 31 March 2026, was placed before the Board of Directors.

CERTIFICATE BY THE MANAGING DIRECTOR AND CHIEF FINANCIAL OFFICER

Pursuant to Regulation 17(8) read with Schedule II Part B of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we, the undersigned, hereby certify that:

We have reviewed the financial statements and the cash flow statement of Chandan Healthcare Limited for the financial year ended 31 March 2026 and that to the best of our knowledge and belief:

- a. these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
- b. these statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.

To the best of our knowledge and belief, there are no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company's code of conduct.

We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting and have disclosed to the Auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps taken or proposed to be taken to rectify these deficiencies.

We have indicated to the Auditors and the Audit Committee:

- a. significant changes in internal control over financial reporting during the year;
- b. significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
- c. instances of significant fraud, if any, of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

For Chandan Healthcare Limited

SD/-

Amar Singh
Managing Director
DIN: 01096328

SD/-

Rajeev Kumar Nain
Chief Financial Officer

Place: Lucknow

Date: 29.05.2026

(b) Certificate on compliance with the conditions of corporate governance

To,

The Members

CHANDAN HEALTHCARE LIMITED

Biotech Park, Sector G, Jankipuram, Kursi Road,
Lucknow, Uttar Pradesh-226021

I have examined the compliance of conditions of Corporate Governance by Chandan Healthcare Limited ("the Company") having CIN: L85110UP2003PLC193493 for the year ended March 31, 2026, as stipulated in Regulations 17-27 and clause (b) to (i) of Regulation 46 (2) and paragraphs C, D and E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure requirements) Regulations, 2015, as amended, ('Listing Regulations') pursuant to the Listing Agreement of the Company with Stock exchange(s).

The compliance of conditions of Corporate Governance is the responsibility of the management. This examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of the Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In my opinion and to the best of my information and according to the explanations given to me, I certify that the Company has complied with the conditions of Corporate Governance as stipulated in Regulations 17-27 and clause (b) to (i) of Regulation 46 (2) and paragraphs C, D and E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure requirements) Regulations, 2015 pursuant to the Listing Agreement of the said Company with stock exchange(s).

I further state that such compliance is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

DATE: 26.08.2026
PLACE: NOIDA

FOR AKSHAT GARG & ASSOCIATES
(COMPANY SECRETARIES)
SD/-
(CS AKSHAT GARG)
PROP.
C. P. NO. 10655
M. NO. F9161
PR NO.: 2918/2023
UDIN: F009161H001233626

(d) Certificate of Non-Disqualification of Directors

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI

(Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,

The Members of

CHANDAN HEALTHCARE LIMITED

Biotech Park, Sector G, Jankipuram, Kursi Road,
Lucknow, Uttar Pradesh-226021

I have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Chandan Healthcare Limited having CIN: L85110UP2003PLC193493 and having its registered office at Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh-226021 (hereinafter referred to as 'the Company'), produced before me by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10 (i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In my opinion and to the best of my information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to me by the Company & its officers, I hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on March 31, 2026 have been debarred or disqualified from being appointed or continuing as Directors of Companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs and any other Statutory Authority/ies.

S. NO.	NAME OF DIRECTOR	DIN	DATE OF APPOINTMENT
1.	Mr. Amar Singh	01096328	03/09/2003
2.	Ms. Asmita Singh	01098055	03/09/2003
3.	Mr. Vinay Lamba	01220153	03/09/2003
4.	Mr. Amit Gupta	00583538	13/08/2024
5.	Mr. Vinod Jain	10701178	13/08/2024
6.	Mr. Brahma Nand Bhartiya	10729411	13/08/2024

The responsibility for ensuring the eligibility and appointment / continuity of each Director on the Board with the management of the Company. My responsibility is limited to expressing an opinion based on the verification of relevant records and information provided. This certificate does not constitute an assurance regarding the future viability of the Company, nor does it comment on the efficiency or effectiveness with which the management has conducted the affairs of the Company.

DATE: 26.08.2026 PLACE: NOIDA	FOR AKSHAT GARG & ASSOCIATES (COMPANY SECRETARIES) SD/- (CS AKSHAT GARG) PROP. C. P. NO. 10655 M. NO. F9161 PR NO.: 2918/2023 UDIN: F009161H001233714
--	--

(d) Declaration on compliance with the Code of Conduct

The declaration by the Chairman and Managing Director confirming that all members of the Board and Senior Management Personnel have affirmed compliance with the Code of Conduct for the financial year ended 31 March 2026 is annexed to the Board's Report as Annexure V.

19. Compliance Officer

PARTICULARS	DETAILS
Name	Mr. Rajeev Kumar Nain
Designation	Company Secretary and Compliance Officer
Place	Lucknow
Contact details	Telephone No.: +91 9918575999 Email id: secretarial@chandan.co.in

Annexure IX – Form AOC-1

Statement containing the salient features of the financial statements of subsidiaries, associate companies and joint ventures

[Pursuant to the first proviso to sub-section (3) of Section 129 read with Rule 5 of the Companies (Accounts) Rules, 2014]

Name of the Company: Chandan Healthcare Limited

Part A – Subsidiaries

Number of subsidiaries: 4

(Amounts in Rs. Lakhs)

PARTICULARS	SUBSIDIARY 1	SUBSIDIARY 2	SUBSIDIARY 3	SUBSIDIARY 4
CIN or other registration number	U85196UP1992PLC014075	U47721UP2017PLC193492	U85195UP1997PLC022929	U86100UP2026PTC245152
Name of the subsidiary	Indra Diagnostic Centre & Blood Bank Limited	Chandan Pharmacy Limited	Chandan Diagnostic Limited	Chandan Healthcare Projects Private Limited
Date since when subsidiary was acquired	30/06/2017	26/02/2022	31/03/2017	08/03/2026
Provision pursuant to which the company has become a subsidiary	Section 2(87)(ii)	Section 2(87)(ii)	Section 2(87)(ii)	Section 2(87)(ii)
Reporting period, if different from that of the holding company	Not applicable	Not applicable	Not applicable	Not applicable
Reporting currency	INR	INR	INR	INR
Exchange rate as at the last date of the financial year	Not applicable	Not applicable	Not applicable	Not applicable
Share capital	491.69	32.30	96.86	NA
Reserves and surplus	(156.90)	1,094.40	(48.62)	NA
Total assets	37.07	6,807.76	48.69	NA
Total liabilities	35.91	5,681.06	0.45	NA
Investments	31.00	610.15	–	NA
Turnover	–	12,022.02	–	Nil
Profit / (loss) before taxation	(0.93)	437.38	(0.13)	NA
Provision for taxation	–	115.10	–	NA
Profit / (loss) after taxation	(0.93)	322.28	(0.13)	NA
Proposed dividend	–	–	–	–
Percentage of shareholding	100.00	53.56	67.99	NA

Subsidiaries which are yet to commence operations: 1

SL. NO.	CIN OR OTHER REGISTRATION NUMBER	NAME OF THE SUBSIDIARY
1	U86100UP2026PTC245152	Chandan Healthcare Projects Private Limited

Subsidiaries which have been liquidated or have ceased to be subsidiaries during the year: Nil

Part B – Associates and Joint Ventures

[Statement pursuant to Section 129(3) of the Companies Act, 2013 in relation to associate companies and joint ventures]

Number of associates and joint ventures: Nil

SL. NO.	PARTICULARS	DETAILS
1	Name of the associate or joint venture	Not applicable
2	Latest audited balance sheet date	Not applicable
3	Date on which the associate or joint venture was associated or acquired	Not applicable
4	Shares of the associate or joint venture held by the Company at the year end – number, amount of investment and extent of holding	Not applicable
5	Description of how there is significant influence	Not applicable
6	Reason why the associate or joint venture is not consolidated	Not applicable
7	Net worth attributable to the shareholding as per the latest audited balance sheet	Not applicable
8	Profit or loss for the year – considered in consolidation and not considered in consolidation	Not applicable

Associates or joint ventures which are yet to commence operations: Nil

Associates or joint ventures which have been liquidated or have ceased to be associates or joint ventures during the year: Nil

Note: Form AOC-1 is required to be signed by the persons who sign the financial statements in terms of Section 134(1) of the Act, which normally includes the Chief Financial Officer and the Company Secretary in addition to the Directors.

SD/- DR. AMAR SINGH (MANAGING DIRECTOR) DIN: 01096328	SD/- MRS. ASMITA SINGH (MANAGING DIRECTOR) DIN: 01098055	SD/- MR. RAJEEV KUMAR NAIN (CHIEF FINANCIAL OFFICER & COMPANY SECRETARY)
--	---	---

Date: 07/09/2026

Place: Lucknow

STANDALONE FINANCIAL RESULTS & STATEMENTS

06

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of quarterly/half yearly and year to date standalone financial results of M/s. Chandan Healthcare Limited (the “Company”) for the quarter ended March 31, 2026, and for the year ended March 31, 2026 (the “Statement”), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”).

In our opinion and to the best of our information and according to the explanations given to us, the Statement.

- Is presented in accordance with the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive profit and other financial information for the quarter ended March 31, 2026, as well as year to date results for the period from April 1 2025 to 31 March 2026.

Basis for Opinion

We conducted our audit in accordance with the Standard on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibility under those Standards is further described in the Auditor’s Responsibility for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statement under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis of our opinion.

Management’s Responsibilities for the Standalone Financial Results

The Statement have been prepared on the basis of the standalone financial statements. The Company’s Board of Directors are responsible for the preparation of the Statement that give a true and fair view of the net profit and other comprehensive profit and other financial information in accordance with the recognition and measurement principles laid down in Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern

basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial control with reference to financial statements in place and operating effectiveness of such control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended March 31, 2026, being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026, and the unaudited year – to date figures up to the First nine months of the current financial year as per books of accounts.

As Per MCA Notification dated 16th February 2015, companies whose shares are listed on SME exchange as referred to in chapter XB of the SEBI (Issue of capital & disclosures requirement) regulation 2009 are exempted from the compulsory requirement of adoption of IND AS. As the company is covered under the exempted category, it has not adopted IND AS for the preparation of financial statement.

Figures for the previous periods/year have been regrouped, restated and/or reclassified whenever considered necessary to make them comparable to the current periods.

Our opinion on the statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial information certified by the Board of Directors.

For MSNT & ASSOCIATES LLP

Chartered Accountants

Firm Registration No.018542C/C400322

Navodit Tyagi

Partner

Membership No.-533375

UDIN No: 26533375VKAQQE6163

Place: Noida

Date: 29/05/2026

Audited Standalone Financial Statements as at 31st March, 2026

(ALL AMOUNTS ARE IN ₹ NEAREST LAKHS OR DECIMALS THEREOF, UNLESS OTHERWISE STATED)

Audited Standalone Statement of Assets & Liabilities as at 31st March, 2026

Particulars	Note No.	Figures As At 31st March, 2026	Figures As At 31st March, 2025
I. EQUITY AND LIABILITIES			
(1) Shareholder's funds			
(a) Share capital	3	2,445.21	2,445.21
(b) Reserves and surplus	4	14,182.75	9,626.41
(c) Money received against share warrants	5	111.25	-
(2) Share application money pending allotment	-	-	-
(3) Minority interest	-	-	-
(4) Non-current liabilities			
(a) Long-term borrowings	6	2,897.34	2,214.46
(b) Deferred tax liabilities(net)	7	235.54	190.33
(c) Other long-term liabilities	8	2.20	2.45
(d) Long term provisions	9	413.86	313.01
(5) Current liabilities			
(a) Short-term borrowings	10	1,004.89	1,105.92
(b) Trade payables	11		
(i) Total outstanding dues of micro & small enterprises.		397.32	257.82
(ii) Total outstanding dues of creditors other than micro & small enterprises.		609.33	776.16
(c) Other current liabilities	12	834.99	693.47
(d) Short term provisions	13	96.22	65.11
TOTAL		23,230.90	17,690.35
II. ASSETS			
(1) Non- current assets			
(a) Property, plant & equipments & intangible assets	14		
(i) Property, plant & equipments		9,574.33	7,148.48
(ii) Intangible assets		-	-

(ALL AMOUNTS ARE IN ₹ NEAREST LAKHS OR DECIMALS THEREOF, UNLESS OTHERWISE STATED)

Audited Standalone Statement of Assets & Liabilities as at 31st March, 2026

(iii) Capital work in progress		1,189.89	410.12
(iv) Intangible assets under development		-	-
(b) Non-current investments	15	1,779.26	2,598.61
(c) Deferred tax assets(net)	-	-	-
(d) Long -term loans and advances	16	100.00	-
(e) Other non-current assets	17	202.05	222.47
(2) Current assets			
(a) Current investments	18	639.30	1,059.00
(b) Inventories	19	1,623.18	1,711.99
(c) Trade receivables	20	4,421.50	3,131.03
(d) Cash and bank balances	21	313.56	603.10
(e) Short-term loans and advances	22	2,649.37	295.93
(f) Other current assets	23	738.46	509.62
TOTAL		23,230.90	7,690.35
As per our report of even date attached		For & on behalf of the board of directors	
For M/s MSNT & Associates LLP		CHANDAN HEALTHCARE LIMITED	
Chartered accountants			
Firm registration no.:- 018542C/C400322		SD/-	SD/-
		Amar Singh	Asmita Singh
SD/-		Managing director	Managing director
Navodit Tyagi		DIN. : - 01096328	DIN. : - 01098055
Partner		Place:- Lucknow	Place:- Lucknow
Membership No. :- 533375		Date:- 29th May 2026	Date:- 29th May 2026
UDIN No. :- 26533375VKAQQE6163			
Place :- Noida		SD/-	
Date :- 29th May 2026		Rajeev Nain	
		CFO & Company secretary	
		Date :- 29 th May 2026	
		Place :- Lucknow	

AUDITED STANDALONE STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH, 2026

Particulars	Note No.	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
I. Revenue from operations	24	15,664.73	12,916.42
II. Other income	25	412.50	204.89
III. Total revenue(I+II)		16,077.23	13,121.31
IV. Expenses:			
Cost of material consumed	26	2,281.00	1,542.19
Purchase of stock-in-trade	27	568.45	446.61
Change in inventories of finished goods,work-in-progress and stock-in-trade.	28	48.65	(19.18)
Employee benefits expense.	29	3,865.05	3,338.56
Finance Costs	30	442.89	356.90
Depreciation and amortisation expense	14	951.43	642.24
Other expenses	31	4,258.46	3,997.44
Total expenses (IV)		12,415.93	10,304.76
V. Profit/(loss) before exceptional & extraordinary items and tax (III-IV)		3,661.30	2,816.55
VI. Exceptional items		270.97	-
VII. Profit/(loss) before extraordinary items and tax (V-VI)		3,390.33	2,816.55
VIII. Extraordinary items		-	-
IX. Profit(loss) before tax (VII-VIII)		3,390.33	2,816.55
X. Tax expense of continuing operation: -	-		
Current tax-for the year		780.51	683.00
Current tax-Adjustment for earlier years		30.48	17.14
Deferred tax		45.21	38.61
Tax expense(X)		856.20	738.75
XI. Profit(loss) for the period from continuing operations(after tax) (IX-X)		2,534.13	2,077.80
XII. Profit/(loss) from discontinuing operations		-	-
XIII. Tax expense of discontinuing operations		-	-
XIV. Profit/(loss) from discontinuing operations (after tax) (XII-XIII)		-	-

AUDITED STANDALONE STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH, 2026

Particulars	Note No.	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
XV. Share of (profit)/ loss transferred to minority interest		-	-
XVI. Profit/ (Loss) after tax attributable to owners of the company (XI+XIV+XV)		2,534.13	2,077.80
XVII. Earnings per equity share:			
(1) Basic		10.36	10.10
(2) Diluted	32	10.08	10.10
The notes referred to above form an integral part of the balance sheet.			
As per our report of even date attached		For & on behalf of the board of directors	
For M/s MSNT & Associates LLP		CHANDAN HEALTHCARE LIMITED	
Chartered accountants			
Firm registration no. :- 018542C/C400322		SD/-	SD/-
		Amar Singh	Asmita Singh
SD/-		Managing director	Managing director
Navodit Tyagi		DIN. :- 01096328	DIN. :- 01098055
Partner		Place :- Lucknow	Place :- Lucknow
Membership no. :- 533375		Date :- 29th May 2026	Date :- 29th May 2026
UDIN no. :- 26533375VKAQQE6163			
Place :- Noida			SD/-
Date :- 29th May 2026			Rajeev Nain
			CFO & Company secretary
			Date :- 29th May 2026
			Place :- Lucknow

AUDITED STANDALONE STATEMENT OF CASH FLOW FOR THE YEAR ENDED 31ST MARCH, 2026

Particulars	Figures For the Year Ended 31st March, 2026	Figures For the Year Ended 31st March, 2025
A. Cash flow arising from operating activities		
Profit / (Loss) before tax	3,390.33	2,816.55
Adjustments related to non-cash & non operating transactions:		
Non cash transactions		
Depreciation & amortisation of fixed assets	951.43	642.24
Bad Debts & Balances written off/written back	26.47	(82.47)
Preliminary expenses written off	-	-
Re-measurement (gains) / loss on defined benefit plans	136.47	71.77
Provision for doubtful debts-CFS	(18.71)	15.28
Provision for obsolete inventories-CFS	(0.33)	10.10
Loss(gain) on account of foreign exchange fluctuations	-	-
Other non-cash transactions (specify nature)	-	-
Non-operating transactions	-	-
Interest on borrowing	436.70	341.17
Loss/(profit) on the sale of property, plant & equipments & intangible assets	-	-
Loss/(profit) on the sale of investments	-	-
Interest income	(386.87)	(45.32)
Dividend income	-	-
Other non-operating transactions (specify nature)	-	-
Operating profit/(loss) before working capital changes	4,535.48	3,769.32
Adjustment for change in working capital:		
(Increase) / Decrease in inventories	89.14	(1,076.28)
(Increase) / Decrease in trade receivables	(1,298.23)	(658.77)
(Increase) / Decrease in other current assets	(208.42)	(327.37)
(Decrease) / Increase in trade payables	(27.33)	426.26
(Decrease) / Increase in other current liabilities	181.97	(756.47)
Net cash (used in) / generated from operating activities	3,272.61	1,376.69
Income taxes refund / (paid), net	(856.20)	(738.75)
Net cash flow from operating activities(A)	2,416.42	637.94
B. Cash flow arising from investing activities		
Sale/(Purchase) of tangible and intangible assets	(4,157.05)	(3,848.04)
Sale/(Purchase) of non current & current investments	(1,214.39)	(2,283.76)
Interest income	386.87	45.32
Dividend income	-	-
Net cash flow from investing activities(B)	(4,984.57)	(6,086.48)
C. Cash Flow Arising From Financing Activities		
Proceeds from issuance of share capital(Including share Warrants)	2,133.46	6,227.13
Proceeds from/(Payment of) long term & short term borrowings	581.85	412.54

AUDITED STANDALONE STATEMENT OF CASH FLOW FOR THE YEAR ENDED 31ST MARCH, 2026

Particulars	Figures For the Year Ended 31st March, 2026	Figures For the Year Ended 31st March, 2025
Finance cost paid (including processing fees)	(436.70)	(341.17)
Dividend paid	-	(300.00)
Net cash flow from financing activities(C)	2,278.61	5,998.50
Net increase/decrease in cash or cash equivalents(A+B+C)	(289.54)	549.96
Cash and cash equivalents at the beginning of the period	603.10	53.14
Cash and cash equivalents at the end of the period	313.56	603.10
As per our report of even date attached	For & on behalf of the board of directors	
For M/s MSNT & Associates LLP	CHANDAN HEALTHCARE LIMITED	
Chartered accountants		
	SD/-	SD/-
SD/-	Amar Singh	Asmita Singh
Navodit Tyagi	Managing director	Managing director
Partner	DIN. :- 01096328	DIN. :- 01098055
Membership no. :- 533375	Place :- Lucknow	Place :- Lucknow
UDIN no. :- 26533375VKAQQE6163	Date :- 29th May 2026	Date :- 29th May 2026
Place :- Noida		
Date :- 29th May 2026		SD/-
		Rajeev Nain
		CFO & Company secretary
		Place :- 29th May 2026
		Date :- Lucknow

(ALL AMOUNTS ARE IN ₹ NEAREST LAKHS OR DECIMALS THEREOF, UNLESS OTHERWISE STATED)

Notes To Standalone Financial Statements for the Year Ended 31st March, 2026
Note No. :- 1 : Corporate information

Chandan Healthcare Limited, established on September 3, 2003, specializes in operating state-of-the-art laboratories that offer comprehensive pathological investigations. Our services encompass biochemistry, hematology, histopathology, microbiology, and immunology. Additionally, we provide an extensive array of radiology services, including CT scans, X-rays, and MRIs. Committed to accuracy and reliability, Chandan Healthcare supports healthcare professionals and patients by delivering essential diagnostic services.

Note No. :- 2 : Summary of Significant accounting policies

a) Basis of Preparation of Financial Statements

The financial statements have been prepared in accordance with the historical cost convention, accrual basis, and going concern assumption, as mandated by generally accepted accounting principles (GAAP) in India. GAAP encompasses the mandatory accounting standards specified under Section 133 of the Companies Act, 2013, in conjunction with Rule 7 of the Companies (Accounts) Rules, 2014, and the relevant provisions of the Act (to the extent notified).

Accounting policies have been applied consistently throughout, except where the initial adoption of a new accounting standard or a revision to an existing accounting standard necessitates a change in the previously applied accounting policy.

The financial statements are prepared in accordance with Schedule III of the Companies Act, 2013, which significantly influences their disclosure and presentation. Comparative figures for the previous year have been regrouped or reclassified, as necessary, to align with the current year's classification and disclosure requirements.

The standalone financial statements were approved by the Board of Directors and authorised for issue on May 29, 2026.

b) Use of Estimates

The preparation and presentation of financial statements necessitate the use of estimates and assumptions that impact the reported amounts of assets, liabilities, and contingent liabilities as of the financial statement date, as well as the reported revenues and expenses for the reporting period. Any variances between actual results and estimates are recognized in the period in which they become known or materialize.

Accounting estimates are subject to periodic revisions, and actual results may differ from these estimates. Adjustments to estimates are made when management becomes aware of changes in the circumstances affecting the estimates. Such changes are reflected in the financial statements for the period in which they occur, and their impact is disclosed in the notes to the financial statements if deemed material.

c) Functional and presentation currency

These standalone financial statements are presented in Indian Rupees (Rs.), which is also the Company's functional currency. All amounts have been rounded to the nearest lakhs, unless otherwise indicated.

d) Current and non-current classification:

"The Company classifies an asset as current when:

- it expects to realise the asset, or intends to sell or consume it, in its normal operating cycle;
- it expects to realise the asset within twelve months after the reporting period;
- it holds the asset primarily for the purpose of trading; or
- the asset is cash or cash equivalent unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. All other assets are classified as non-current."

"A liability is classified as a current when

- it is expected to be settled in the Company's normal operating cycle;
- the liability is due to be settled within twelve months from the reporting period;
- it is held primarily for the purposes of being trading; - it does not hold an unconditional right to defer settlement of the liability for at least twelve months after the reporting period. Terms of a liability that could, at the option of the counter party, result in its settlement by the issue of equity instruments do not affect its classification. All other liabilities are classified as non-current."

The operating cycle is the time between the acquisition of assets for processing and realisation in cash or cash equivalents. The Company's normal operating cycle is twelve months.

e) Significant accounting policies

i.) Revenue recognition

Revenue from the sale of goods is recognized when ownership, along with all significant risks and rewards, has been transferred to the buyer, and when there is no significant uncertainty regarding the amount of consideration to be received from the sale.

Revenue from the sale of services is recognized using the completed service contract method, provided there is no significant uncertainty regarding the amount of consideration to be received for rendering the service.

Sales are accounted for net of amounts recovered towards GST and sales returns.

Sales returns are recorded upon the actual receipt of returned goods or the settlement of claims.

Revenue arising from the use by others of enterprise resources yielding interest and dividends should only be recognised when no significant uncertainty as to measurability or collectability exists. These revenues are recognised on the following bases:

Interest: On a time, proportion basis taking into account the amount outstanding and the rate applicable.

Dividends: When the owner's right to receive payment is established.

ii.) Inventories

Inventories comprise of diagnostic kits, reagents, laboratory chemicals and consumables, these are measured at lower of cost and net realisable value. The cost of inventories is based on the first in first out (FIFO) cost formula and includes expenditure incurred in acquiring the inventories and other costs incurred in bringing them to their present location and condition. Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs necessary to make the sale. The comparison of cost and net realisable value is made on an item-by-Item basis.

iii.) Property, plant & equipments

The cost of an item of property, plant and equipment shall be recognised as an asset if, and only if it is probable that future economic benefit associated with the item will flow to the Company and the cost of the item can be measured reliably. Items of property, plant and equipment (including capital-work-in progress) are measured at cost, which includes capitalised borrowing costs, less accumulated depreciation and any accumulated impairment losses. Freehold land is carried at historical cost less any accumulated impairment losses.

Cost of an item of property, plant and equipment comprises its purchase price, including non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the items to its working conditions for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.

The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labour, any other costs directly attributable to bringing the item to working condition for its intended use, and estimated costs of dismantling and removing the item and restoring the site on which it is located.

Any gain or loss on disposal of an item of property, plant and equipment is recognised in profit or loss.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of asset.

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Company and the cost of the item can be measured reliably.

iv.) Intangible assets

Intangible assets that are acquired, are recognized at cost initially and carried at cost less accumulated amortization and accumulated impairment loss, if any. Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates.

v.) Depreciation & Amortisation

Depreciation is recognised so as to write off the cost of assets (other than freehold land) less their residual values over their useful lives.

The Company has charged depreciation on property, plant & equipment (PPE) based on the Straight linen Method (SLM) as per useful life specified in schedule II of the Companies Act, 2013.

Amortisation is calculated to write off the cost of intangible assets over their estimated useful lives using the straight-line method (SLM) and is included in depreciation and amortisation expense in statement of profit and loss.

Depreciation and amortisation on additions and deletions are restricted to the period of use.

Residual value is considered to be 5% on all the tangible assets.

Assets costing below Rs. 5,000 are depreciated using depreciation rate at 100%.

Depreciation and amortisation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

vi.) Employee benefits

Short-term employee benefits

Short term employee benefits are measured on an undiscounted basis and expensed as the related service is provided. A short-term liability is recognised if the Company has a present legal or constructive obligation to pay the amount as a result of past service provided by the employee and the obligation can be estimated reliably.

Defined contribution plans

A defined contribution plan is a post-employment benefit plan where the company's legal or constructive obligation is limited to the amount that it contributes to a separate legal entity. The company makes specified monthly contributions towards government administered provident fund scheme and employees' state insurance ('ESI') scheme. The company makes specified monthly contributions towards government administered provident fund scheme and employees' state insurance ('ESI') scheme. Obligations for contributions to defined contribution plans are expensed as an employee benefits expense in statement of profit and loss in the period in which the related services are rendered by employees.

Defined benefit plans

A defined benefit plan is a post-employment benefit plan other than a defined contribution plan. The company has a defined benefit plan namely gratuity for all its employees. Liability for defined benefit plan is provided on the basis of valuations, as at the balance sheet date, carried out by an independent actuary. The actuarial valuation method used by independent actuary for measuring the liability is the Projected Unit Credit Method. Actuarial gains and losses due to changes in actuarial assumptions and are recognised immediately in the profit and loss account as income or expense. Current and non-current liabilities are recognised on the basis of actuarial report.

vii.) Lease

Lease contracts entered by the company majorly pertains for buildings taken on operating lease to conduct its business in the ordinary course. Leases where the lessor effectively retains substantially all the risks and benefits of the leased assets are classified as operating leases. Operating lease payments are recognized in the statement of profit and loss on a straight-line basis over the lease term. Lease agreements are renewable for further period or periods on terms and

condition as mutually agreed with the lessor. Variation or escalations clauses in lease rentals are made as per mutually agreed terms and conditions with the lessor.

viii.) Impairment of assets

An asset is treated as impaired when the carrying cost of assets exceeds its recoverable value. An impairment loss is charged to the statement of profit and loss in the year in which an asset is identified as impaired. The impairment loss recognised in prior accounting period is increased/ reversed where there has been change in the estimate of recoverable value. The recoverable value is the higher of the assets' net selling price and value in use. At each reporting date, the Company reviews the carrying amount of assets, to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

ix.) Investments

Current Investments are carried at lower of cost and market value computed Investment wise. Long Term Investments are stated at cost or fair value. Provision for diminution in the value of long-term investments is made only if such a decline is other than temporary in the opinion of the management.

x.) Income-tax

Provision for income tax is made on the basis of taxable income for the year at current rates. Tax expense comprises of current tax and deferred tax at the applicable enacted or substantively enacted rates. Current tax represents the amount of income tax payable/ recoverable in respect of the taxable income/ loss for the reporting period. Deferred tax represents the effect of timing difference between taxable income and accounting income for the reporting period that originate in one period and are capable of reversal in one or more subsequent periods.

The deferred tax asset is recognised and carried forward only to the extent that there is a reasonable certainty that the assets will be realised in future. However, where there is unabsorbed depreciation or carried forward loss under taxation laws, deferred tax assets are recognised only if there is virtual certainty of realisation of assets.

Minimum Alternate Tax (MAT) paid in a year is charged to the statement of profit and Loss as current tax. The company recognizes the MAT credit available as an asset only to the extent that there is convincing evidence that the company will pay the normal income tax during the specified period i.e., period for which MAT credit is allowed to be carried forward.

xi.) Provision, contingent liabilities and contingent assets

A provision is recognised when the company has a present obligation (legal or constructive) as a result of past event and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on Management's estimate for the amount required to settle the obligation at the balance sheet date.

Contingent liability is a possible obligation arising from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity or a present obligation that arises from past events but is not recognized because it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation or the amount of the obligation cannot be measured with sufficient reliability. The Company does not recognize a contingent liability but discloses its existence in the financial statements.

Contingent assets are neither recognised nor disclosed in the financial statements, since this may result in the recognition of income that may never be realised. However, when the realisation of income is virtually certain, then the related asset is not a contingent asset and is recognized.

Provisions, contingent liabilities and contingent assets are reviewed at each balance sheet date.

xii.) Earnings per share

Basic Earnings per share

Basic Earnings Per Share ('EPS') is calculated by dividing the profit attributable to the equity shareholders of the company by the weighted average number of equity shares outstanding during the year.

Diluted Earnings per share

Diluted earnings per share is computed by dividing the profit (considered in determination of basic earnings per share) after considering the effect associated with dilutive potential equity shares by the weighted average number of equity shares considered for deriving basic earnings per share adjusted for the weighted average number of equity shares that would have been issued upon conversion of all dilutive potential equity shares.

xiii.) Cash flow statement

Cash flows are reported using the indirect method, whereby profit for the year is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows are segregated into operating, investing and financing activities. The Company considers all highly liquid investments that are readily convertible to known amounts of cash to be cash equivalents.

xiv.) Cash and cash equivalents

Cash and cash equivalents in the balance sheet and cash flow statement consists of cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities less than three months which are readily convertible to known amounts of cash and which are subject to insignificant risk of changes in value.

xv.) Dividend

The company recognises a liability for any dividend declared but not distributed at the end of the reporting period, when the distribution is authorised and the distribution is no longer at the discretion of the company on or before the end of the reporting period.

xvi.) Related parties transactions

The company has a policy to recognize and identify related party transactions; disclosures of related party transactions have been made wherever applicable.

xvii.) Foreign Currency Transactions

Foreign exchange transactions are recorded at the rates prevailing on the date of transactions. Exchange rate differences arising on foreign exchange transactions settled during the year are recognized in the statement of profit and loss for the year. Monetary assets and liabilities denominated in foreign currencies as at the balance sheet date are translated at the closing exchange rates on that date and the resultant exchange differences are recognized in the statement of profit and loss. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency should be reported using the exchange rate at the date of the transaction. Non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency should be reported using the exchange rates that existed when the values were determined.

xviii.) Borrowing Costs

Borrowing costs that are attributable to acquisition, construction or production of qualifying assets are capitalised as part of such assets. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are recognised as an expense in the period in which they are incurred.

xix.) Events after reporting date

Where events occurring after the balance sheet date provide evidence of conditions that existed at the end of the reporting period, the impact of such events is adjusted within the financial statements. Otherwise, events after the balance sheet date of material size or nature are only disclosed.

NOTE NO. :- 3 : SHARE CAPITAL

a. Information on authorised, issued, subscribed and paid-up shares

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Authorised		
Equity shares with voting rights	3,000.00	2,500.00
(Current year : 30000000 equity shares of Rs.10/- each)		
(Previous year : 25000000 equity shares of Rs.10/- each)		
Total...	3,000.00	2,500.00
Issued		
Equity shares with voting rights	2,445.21	2,445.21
(Current year : 24452064 equity shares of Rs.10/- each)		
(Previous year : 24452064 equity shares of Rs.10/- each)		
Total...	2,445.21	2,445.21
Subscribed and fully paid		
Equity shares with voting rights FP	2,445.21	2,445.21
(Current year : 24452064 equity shares of Rs.10/- each)		
(Previous year : 24452064 equity shares of Rs.10/- each)		
Total...	2,445.21	2,445.21

PARTICULARS	FIGURES AS AT 31ST MARCH, 2026			FIGURES AS AT 31ST MARCH, 2025		
	No of shares	Paid up value per share	Amount	No of shares	Paid up value per share	Amount
Equity shares with voting rights, subscribed and fully paid						
Shares outstanding at the beginning of the year	2,44,52,064	10	2,445	2,00,00,000.00	10.00	2,000.00
Add: Fresh shares issued during the year	-	-	-	44,52,064.00	10.00	445.21
Add: Bonus shares issued during the year	-	-	-	-	-	-

PARTICULARS	FIGURES AS AT 31ST MARCH, 2026			FIGURES AS AT 31ST MARCH, 2025		
	No of shares	Paid up value per share	Amount	No of shares	Paid up value per share	Amount
Less: Shares forfeited/bought back during the year	-	-	-	-	-	-
Shares outstanding at the end of the year	2,44,52,064	10	24,45,20,640	2,44,52,064.00	10.00	2,445.21
b. Rights, preferences and restrictions of different classes of shares including restrictions on the distribution of dividends and the repayment of capital						
Equity shares with voting rights, subscribed and fully paid						
As to dividend:	The shareholders are entitled to receive dividend in proportion to the amount paid up on the equity shares held by them.					
As to repayment of capital:	In the event of liquidation of the company, the holders of equity shares will be entitled to receive any of the remaining assets of the company after distribution of all preferential amounts. The distribution will be in proportion of the number of shares held by the shareholders.					
As to voting:	The company has only one class of shares referred to as equity shares having a par value of Rs. 10/-. Each holder of the equity share is entitled to one vote per share.					

C. DETAILS OF SHAREHOLDERS HOLDING MORE THAN 5% SHARES OF THE COMPANY

Name of shareholder	Figures As At 31st March, 2026			Figures As At 31st March, 2025		
	No of shares	Paid up value per share	Percentage (%)	No of shares	Paid up value per share	Percentage (%)
Equity shares with voting rights, subscribed and fully paid						
Name of shareholder						
- Amar Anita Holdings (India) Private Limited	41,28,064.00	10	16.88%	41,24,064.00	10	16.87%
- Amar Singh	23,46,260.00	10	9.60%	23,25,460.00	10	9.51%
- Vinay Lamba	15,84,800.00	10	6.48%	15,84,800.00	10	6.48%
- Other shareholders*	1,63,92,940.00	10	67.04%	1,64,17,740.00	10	67.14%
Total...	2,44,52,064.00		100%	2,44,52,064.00		100%
*Other shareholders, each holding less than 5% of the total shares, are included here to ensure reconciliation of the total share count with the notes provided above.						
d. Disclosure of shareholding of promoters:						
As at 31st March, 2026						
Name of promoter	No of shares as at the beginning of year	Addition	Deletion	No of shares as at the end of year	% of total shares	% Change during the year
Equity shares with voting rights, subscribed and fully paid						
Name of promoter*						
-Alok Singh	300000.00	-	-	3,00,000.00	1.50%	0.00%
-Amar Singh	2325460.00	20,800.00	-	23,46,260.00	11.73%	0.89%
-AmarAnita Holdings (India) Pvt Ltd	4124064.00	4,000.00	-	41,28,064.00	20.64%	0.10%

C. DETAILS OF SHAREHOLDERS HOLDING MORE THAN 5% SHARES OF THE COMPANY

Name of shareholder	Figures As At 31st March, 2026			Figures As At 31st March, 2025		
-Asmita Singh	167600.00	-	-	1,67,600.00	0.84%	0.00%
-Shaleen Solanki	900000.00	-	-	9,00,000.00	4.50%	0.00%
-Vijay Singh	899400.00	-	-	8,99,400.00	4.50%	0.00%
-Vinay Lamba	1584800.00	-	-	15,84,800.00	7.92%	0.00%
d. Disclosure of shareholding of promoters:						
As at 31st March, 2025						
Name of promoter	No of shares as at the beginning of year	Addition	Deletion	No of shares as at the end of year	% of total shares	% Change during the year
Equity shares with voting rights, subscribed and fully paid						
Name of promoter*						
-Alok Singh	3,00,000.00	-	-	3,00,000.00	1.23%	0.00%
-Amar Singh	23,19,860.00	5,600.00	-	23,25,460.00	9.51%	0.24%
-AmarAnita Holdings (India) Pvt Ltd	58,43,000.00	-	17,18,936.00	41,24,064.00	16.87%	-29.42%
-Asmita Singh	1,62,000.00	5,600.00	-	1,67,600.00	0.69%	3.46%
-Shaleen Solanki	9,00,000.00	-	-	9,00,000.00	3.68%	0.00%
-Vijay Singh	8,99,400.00	-	-	8,99,400.00	3.68%	0.00%
-Vinay Lamba	15,84,800.00	-	-	15,84,800.00	6.48%	0.00%
*Individuals designated or to be designated by the company as promoters in its annual return.						
Note No. :- 4 : Reserves and surplus						
Particulars				Figures As At 31st March, 2026	Figures As At 31st March, 2025	
Securities premium account						
Securities premium account				7,804.13	5,781.92	
Total A				7,804.13	5,781.92	
Surplus/Retained earning						
Opening balance Reserves & Surplus				3,844.49	2,066.69	
Less :- Dividend on equity shares				-	(300.00)	
Less: Minority Interest in Opening Reserve & Surplus(Credit Balance)-R&S				-	-	
Add: Minority Interest in opening Reserve & Surplus(Debit Balance)-R&S				-	-	
Add: Parent Interest in pre-acquisition loss-R&S				-	-	
Less: Parent Interest in pre-acquisition profit-R&S				-	-	
Less :- Issue of bonus share				-	-	
Add :- Transfer from				-	-	
Less :- Transfer to				-	-	
Add :- Profit/(Loss) for the period				2,534.13	2,077.80	
Total B				6,378.62	3,844.49	
Closing balance (A+B)				14,182.75	9,626.41	

NOTE NO. :- 6 : LONG-TERM BORROWINGS			
a. Reconciliation of current and non current portion of long term liabilities			
Particulars	Figures As At 31st March, 2025		
	Non current	Current	Total
Secured			
Term loans			
- From banks LTBS	2,214.46	734.29	2,948.75
- From other parties LTBS	-	-	-
Unsecured			
- From other parties LTBUS	-	-	-
Total...	2,214.46	734.29	2,948.75

B. OTHER DISCLOSURE ON TERM LOAN							
Particulars	Figures as at the end of 31st March, 2026		Figures as at the end of 31st March, 2025		Details of repayment terms and maturity*		Nature of Security
	Amount	ROI	Amount	ROI	Particulars	Terms	
Secured							
Term Loan from Bank							
Indusind Bank [732000008552]	-	-	40.82	8.75%	Sanction date	01-07-2022	The loan is secured by a first pari passu charge on the assets acquired using the proceeds of this loan, establishing a primary security interest.
					Principal amount	340.24	
					EMI amount	10.74	
					Loan period (Month)#	36.00	
					Last Instalment date	07/08/2025	
Yes Bank Limited [MEN00180126]	30.00	9.00%	50.31	9.00%	Sanction date	21-07-2022	
					Principal amount	96.66	
					EMI amount	2.00	
					Loan period (Month)#	60.00	
					Last Instalment date	22/07/2027	
Yes Bank Limited [MEN001801285372]	6.67	7.95%	10.86	7.95%	Sanction date	09-08-2022	
					Principal amount	20.20	
					EMI amount	0.42	
					Loan period (Month)#	60.00	

B. OTHER DISCLOSURE ON TERM LOAN							
Particulars	Figures as at the end of 31st March, 2026		Figures as at the end of 31st March, 2025		Details of repayment terms and maturity*		Nature of Security
					Last Instalment date	22/08/2027	
HDFC Loan A/c No. [800450335]	79.23	9.50%	146.96	9.50%	Sanction date	22-08-2024	The loan is secured by the following: 1. Primary Security:- A first pari passu charge on the assets acquired with the proceeds of the loan. This gives the lender a primary claim on these assets, ensuring that their security interest is prioritized above other claims. 2. Personal Guarantee: A guarantee provided by all directors of the borrowing entity, holding them personally liable for the loan obligations in the event of default by the borrowing entity.
					Principal amount	178.13	
					EMI amount	6.50	
					Loan period (Month)#	31	
					Last Instalment date	07/04/2027	
HDFC Loan A/c No. [800450336]	-	-	2.45	9.50%	Sanction date	22-08-2024	
					Principal amount	9.57	
					EMI amount	1.24	
					Loan period (Month)#	8	
					Last Instalment date	07/05/2025	
HDFC Loan A/c No. [800487587]	15.23	9.50%	29.46	9.50%	Sanction date	22-08-2024	
					Principal amount	35.99	
					EMI amount	1.35	
					Loan period (Month)#	30.00	
					Last Instalment date	07/03/2027	
HDFC Loan A/c No. [99903818]	-	-	9.17	9.50%	Sanction date	22-08-2024	
					Principal amount	22.43	
					EMI amount	2.34	

B. OTHER DISCLOSURE ON TERM LOAN							
Particulars	Figures as at the end of 31st March, 2026		Figures as at the end of 31st March, 2025		Details of repayment terms and maturity*		Nature of Security
					Loan period (Month)#	10	
					Last Instalment date	07/07/2025	
Axis bank Loan A/c No. [9250600510136 19]	361.09	8.80%	-	-	Sanction date	23-05-2025	PLANT AND MACHINERY 1 UNIT OF GE
					Principal amount	384.20	MADE REFURBISHED MRI MACHINE
					EMI amount	8.30	MODEL SIGMA HDXT WITH STANDARD
					Loan period (Month)#	60	ACCESSORIES FROM MEDISER SCAN
					Last Instalment date	05/07/2030	TECHNOLOGY PVT LTD
Axis bank Loan A/c No. [9250600534470 29]	277.30	8.05%	-	-	Sanction date	30/12/2025	PLANT AND MACHINERY-1 NO. OF PREOWNED GE CT SCAN SYSTEM "OPTIMA 660" 64 / 128 SLICE
					Principal amount	306.49	
					EMI amount	648811.00	
					Loan period (Month)#	60.00	
					Last Instalment date	05/08/2030	
Axis bank Loan A/c No. [9250600534481 32]	116.76	8.05%	-	-	Sanction date	30/12/2025	PLANT AND MACHINERY-1 NO. OF PREOWNED GE CT SCAN SYSTEM "OPTIMA 660" 128 SLICE
					Principal amount	116.76	
					EMI amount	247166.00	
					Loan period (Month)#	29/02/1900	
					Last Instalment date	05/10/2029	
Axis bank Loan A/c No. [9250600534506 85]	116.76	8.05%	-	-	Sanction date	30/12/2025	PLANT AND MACHINERY-1 NO. OF PREOWNED
					Principal amount	116.76	GE CT SCAN SYSTEM "OPTIMA
					EMI amount	247166.00	660" 64 / 128 SLICE
					Loan period (Month)#	29/02/1900	
					Last Instalment date	05/10/2029	

B. OTHER DISCLOSURE ON TERM LOAN							
Particulars	Figures as at the end of 31st March, 2026		Figures as at the end of 31st March, 2025		Details of repayment terms and maturity*		Nature of Security
HDFC Loan A/c No. [164897649]	437.19	9.75%	-	-	Sanction date	03/09/2025	
					Principal amount	475.00	
					EMI amount	10.03	
					Loan period (Month)#	60.00	
					Last Instalment date	06/09/2030	
HDFC Loan A/c No. [167167201]	5.97	9.49%	-	-	Sanction date	02/01/2026	Hypothecation of New Four-Wheeler.
					Principal amount	613000.00	
					EMI amount	12755.00	
					Loan period (Month)#	60.00	
					Last Instalment date	07/01/2031	
HDFC Loan A/c No. [167868048]	5.97	9.49%	-	-	Sanction date	02/01/2026	Hypothecation of New Four-Wheeler.
					Principal amount	613000.00	
					EMI amount	12755.00	
					Loan period (Month)#	60.00	
					Last Instalment date	07/01/2031	
ICICI Bank Loan A/c No. [LDLUC00051942 402]	2.55	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	255150.00	
					EMI amount	5316.00	
					Loan period (Month)#	60.00	
					Last Instalment date	01/03/2031	
ICICI Bank Loan A/c No. [LDLUC00051942 411]	2.79	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	278775.00	
					EMI amount	5808.00	
					Loan period (Month)#	60.00	
					Last Instalment date	01/03/2031	
ICICI Bank Loan A/c No. [LDLUC00051942 413]	21.26	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	2126250.00	
					EMI amount	44293.00	

B. OTHER DISCLOSURE ON TERM LOAN							
Particulars	Figures as at the end of 31st March, 2026		Figures as at the end of 31st March, 2025		Details of repayment terms and maturity*		Nature of Security
					Loan period (Month)#	60.00	
					Last Instalment date	01/03/2031	
ICICI Bank Loan A/c No [LDLUC00051942 476]	13.70	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	1370250.00	
					EMI amount	28545.00	
					Loan period (Month)#	60.00	
					Last Instalment date	01/03/2031	
ICICI Bank Loan A/c No. [LDLUC00051942 479]	3.21	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	321300.00	
					EMI amount	6694.00	
					Loan period (Month)#	60.00	
					Last Instalment date	01/03/2031	
ICICI Bank Loan A/c No [LDLUC00052067 840]	66.15	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	6615000.00	
					EMI amount	137339.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/03/2031	
ICICI Bank Loan A/c No [LDLUC00052067 859]	16.44	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	1644300.00	
					EMI amount	34139.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/03/2031	
ICICI Bank Loan A/c No [LDLUC00052067 932]	28.92	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	2891700.00	
					EMI amount	60037.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/03/2031	

B. OTHER DISCLOSURE ON TERM LOAN							
Particulars	Figures as at the end of 31st March, 2026		Figures as at the end of 31st March, 2025		Details of repayment terms and maturity*		Nature of Security
ICICI Bank Loan A/c No [LDLUC00052067 947]	3.64	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	363825.00	
					EMI amount	7554.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/03/2031	
ICICI Bank Loan A/c No. [LDLUC00052067 990]	32.89	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	3288600.00	
					EMI amount	68278.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/03/2031	
ICICI Bank Loan A/c No [LDLUC00052068 088]	3.29	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	328860.00	
					EMI amount	6828.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/03/2031	
ICICI Bank Loan A/c No [LDLUC00052068 101]	3.64	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	363825.00	
					EMI amount	7554.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/03/2031	
ICICI Bank Loan A/c No [LDLUC00052107 671]	14.82	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	1482300.00	
					EMI amount	30894.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/04/2031	
ICICI Bank Loan A/c No [LDLUC00052107 679]	27.23	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment

B. OTHER DISCLOSURE ON TERM LOAN							
Particulars	Figures as at the end of 31st March, 2026		Figures as at the end of 31st March, 2025		Details of repayment terms and maturity*		Nature of Security
					Principal amount	2722500.00	
					EMI amount	56741.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/04/2031	
ICICI Bank Loan A/c No [LDLUC00052107 681]	14.00	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	1399500.00	
					EMI amount	29168.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/04/2031	
ICICI Bank Loan A/c No [LDLUC00052107 691]	14.00	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	1399500.00	
					EMI amount	29168.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/04/2031	
PNB LOAN A/c No. [241400CN00000 057]	1,414.29	8.80%	1,552.44	8.80%	Sanction date	27-07-2024	The loan is secured by a first pari passu charge on the assets acquired using the proceeds of this loan, establishing a primary security interest.
					Principal amount	1,650.00	
					EMI amount	19.64	
					Loan period (Month)#	84	
					Last Instalment date	30/04/2032	
PNB LOAN A/c No. [241400NG00259 653]	12.77	8.80%	15.84	8.80%	Sanction date	04-10-2024	Hypothecation of New Four-Wheeler.
					Principal amount	17.00	
					EMI amount	0.35	
					Loan period (Month)#	60.00	
					Last Instalment date	30/09/2030	

B. OTHER DISCLOSURE ON TERM LOAN							
Particulars	Figures as at the end of 31st March, 2026		Figures as at the end of 31st March, 2025		Details of repayment terms and maturity*		Nature of Security
PNB LOAN A/c No[241400CH000 00028]	752.72	7.95%	1,090.44	7.95%	Sanction date	31-03-2023	The loan is secured by: 1. A first pari passu charge on the assets acquired with the proceeds of the loan. 2. The personal guarantee of all directors of the borrowing entity. 3. The corporate guarantee of AmarAnita Holdings (India) Pvt Ltd.
					Principal amount	1,530.00	
					EMI amount	39.36	
					Loan period (Month)#	48.00	
					Last Instalment date	31/03/2028	
Total...	3,900.45		2,948.75				
Less:- Current maturities of all long-term borrowings	(1,003.11)		(734.29)				
Total...	2,897.34		2214.46				
* These are with respect to the balance sheet date.							
# The figures are presented in absolute terms and are not expressed in lakhs.							

NOTE NO. :- 5 : MONEY RECEIVED AGAINST SHARE WARRANTS		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Money received against share warrants	111.25	-
Total...	111.25	-
a. Disclosures on share warrants		
Particulars	Disclosures	
Name of Company	Chandan Healthcare Limited	
Nature of Instrument	44,50,000 Convertible Warrants	
Date of Board Approval	10 October 2025	
Date of Shareholders Approval (EGM)	06 November 2025	
Allotment Date	04 February 2026	
Issue Price per Warrant	₹234 per warrant	
Face Value of Equity Share	₹10 per equity share	
Premium per Equity Share	₹224 per equity share	

NOTE NO. :- 5 : MONEY RECEIVED AGAINST SHARE WARRANTS		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Total Issue Size	₹104,13,00,000	
Number of Warrants Issued	44,50,000 warrants	
Terms of Conversion	1 warrant convertible into 1 fully paid-up equity share	
Conversion Period	Within 18 months from allotment date	
Upfront Amount Payable	25% of warrant issue price at allotment	
Balance Amount Payable	75% payable within 18 months	
Exercise / Conversion Price	₹234 per warrant	
Rights Attached	Equity shares allotted upon conversion shall rank pari passu with existing equity shares including voting and dividend rights	
Voting Rights before Conversion	No voting rights until conversion into equity shares	
Dividend Rights before Conversion	Not applicable prior to conversion	
Whether Warrants are Transferable	Subject to applicable SEBI ICDR Regulations and Companies Act provisions	
Whether Amount is Forfeitable	Yes, upfront amount liable to forfeiture in case of non-exercise within prescribed period	
Status as on Reporting Date	Outstanding	
Purpose of Issue	Business expansion, acquisitions and general corporate purposes	
Business Expansion Utilisation	₹44.50 Crore	
Acquisition Utilisation	₹50.00 Crore	
General Corporate Purpose Utilisation	₹9.63 Crore	
Relevant Date under SEBI ICDR	07 October 2025	

NOTE NO. :- 7 : DEFERRED TAX LIABILITIES (NET)		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Deferred tax liabilities (Net)	235.54	190.33
Total...	235.54	190.33
a. Disclosures regarding the components of net deferred tax liabilities		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Provision for gratuity	(122.20)	294.78
Provision for doubtful debts	(0.46)	(95.17)
Provision for obsolete inventories	(4.03)	(5.17)
Provision for leave encashment	(6.17)	-
W.D.V of property, plant & equipments & intangible assets	368.41	(4.12)
Total...	235.54	190.33

NOTE NO. :- 8 : OTHER LONG -TERM LIABILITIES		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Trade payables		

NOTE NO. :- 8 : OTHER LONG -TERM LIABILITIES		
- Total outstanding dues of micro enterprises and small enterprises OLTL	-	-
- Total outstanding dues of other than micro enterprises and small enterprises OLTL	-	-
Other long-term liabilities		
- Trade deposits and security deposits which are not in the nature of borrowings OLTL	2.20	2.45
- Others(Specifying the nature) OLTL	-	-
Total...	2.20	2.45

NOTE NO. :- 9 : LONG TERM PROVISIONS		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Provision for gratuity LTP	413.86	313.01
Others (specifying the nature) LTP	-	-
Total...	413.86	313.01

a. Details of employee benefits as required by the accounting standard 15 (revised) employee benefits are as under:

The company has classified the various benefits provided to employee's as under: -

I. Defined contribution plans

a. Employee's provident fund.

b. Employee's state insurance.

During the year, the company has recognised the following amounts in the profit and loss account:

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Employers' contribution to provident fund*	47.20	84.26
Employers' contribution to employee's state insurance*	42.61	27.34
Total...	89.81	111.60

* Included in Contribution to Provident and Other Funds (Refer Note No. 28 Employee benefits expense)

II. Defined benefit plans

Gratuity disclosures as per accounting standard-15

(i) Table Showing Changes in Present Value of Obligations

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Present value of the obligation at the beginning of the period	378.12	317.73
Interest cost	25.52	23.04
Current service cost	92.75	61.16
Past Service Cost	270.97	-
Benefits paid (if any)	(4.52)	(11.38)

NOTE NO. :- 9 : LONG TERM PROVISIONS		
Actuarial (gain)/loss	(277.29)	(12.43)
Present value of the obligation at the end of the period	485.55	378.12
(ii) Key results (The amount to be recognized in the Balance Sheet):		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Present value of the obligation at the end of the period	485.55	378.12
Fair value of plan assets at end of period	-	-
Net liability/(asset) recognized in Balance Sheet and related analysis	485.55	378.12
Funded Status - Surplus/ (Deficit)	(485.55)	(378.12)
(iii) Expense recognized in the statement of Profit and Loss:		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Interest cost	25.52	23.04
Current service cost	92.75	61.16
Past Service Cost	270.97	-
Expected return on plan asset	-	-
Net actuarial (gain)/loss recognized in the period	(277.29)	(12.43)
Expenses to be recognized in P&L #	111.95	71.77
# Included in Provision for gratuity (Refer Note No. 28 Employee benefits expense)		
(iv) Current & Non Current Liability :		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Current Liability (Short Term)^	71.70	65.11
Non Current Liability (Long Term)	413.86	313.01
Total Liability	485.55	378.12
^ Included in Provision for gratuity (Refer Note No. 12 Short term provisions)		
(v) Reconciliation of liability in balance sheet		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Opening gross defined benefit liability/ (asset)	378.12	317.73
Expenses to be recognized in P&L	111.95	71.77
Benefits paid (if any)	(4.52)	(11.38)
Closing gross defined benefit liability/ (asset)	485.55	378.12
(vi) Actuarial assumptions provided by the company and employed for the calculations are tabulated:		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Discount rate	7.00 % per annum	7.00 % per annum
Salary Growth Rate	8.00 % per annum	8.00 % per annum

NOTE NO. :- 9 : LONG TERM PROVISIONS		
Mortality	IALM 2012-14	IALM 2012-14
Expected rate of return	-	-
Attrition / Withdrawal Rate (per Annum)	10.00% p.a.	10.00% p.a.

NOTE NO. :- 10 : SHORT-TERM BORROWINGS				
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025		
Secured				
Loans repayable on demand				
- From banks-Overdraft(OD) SSTB	-	70.51		
- From banks-Cash credit(CC) SSTB	1.78	301.12		
- From other parties SSTB	-	-		
Current maturities of all long-term borrowings				
- From banks SSTB_CMLTB	1,003.11	734.29		
- From other parties SSTB_CMLTB	-	-		
Other loans and advances in the nature of loan (specify nature) SSTB	-	-		
	1,004.89	1,105.92		
Particulars	Figures As At 31st March, 2026		Figures As At 31st March, 2025	
	Amount	Nature of security and other terms	Amount	Nature of security and other terms
Secured				
Loans repayable on demand				
- From banks-Overdraft(OD) SSTB	-		70.51	Sanctioned against FDs with ICIC Bank
- From banks-Cash credit(CC) SSTB	1.78	Hypothecation of stock and book debt	301.12	Hypothecation of stock and book debt
- From other parties SSTB				
Loans and advances from related parties SSTB	-		-	

NOTE NO. :- 11 : TRADE PAYABLES							
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025					
Trade payables							
- Total outstanding dues of micro enterprises and small enterprises CL	397.32	257.82					
- Total outstanding dues of other then micro enterprises and small enterprises CL	609.33	776.16					
	1,006.65	1,033.98					
a. Trade payables ageing schedule							
As at 31st March, 2026							
Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of payment				TOTAL
			Less than 1 year	1-2 years	2-3 years	More than 3 years	
Not Disputed							
--MSME	-	397.32	-	-	-	-	397.32
--Others	-	-	609.33	-	-	-	609.33
Disputed							
--MSME	-	-	-	-	-	-	-
--Others	-	-	-	-	-	-	-
Total...	-	397.32	609.33	-	-	-	1,006.65
Name of promoter							
Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of payment				TOTAL
			Less than 1 year	1-2 years	2-3 years	More than 3 years	
Not Disputed							
--MSME	-	257.82	-	-	-	-	257.82
--Others	-	-	776.16	-	-	-	776.16
Disputed							
--MSME	-	-	-	-	-	-	-
--Others	-	-	-	-	-	-	-
Total...	-	257.82	776.16	-	-	-	1,033.98
b. Disclosure as per MSMED Act, 2006							
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025					
Payable							

NOTE NO. :- 11 : TRADE PAYABLES							
Principle overdue as per MSMED Act,2006.	-	-					
Principle not due as per MSMED Act,2006.	397.32	257.82					
Interest payable under section 16 of MSMED Act, 2006							
- On principle paid beyond due date as per MSMED Act,2006	-	-					
- On principle payable beyond due date as per MSMED Act,2006	-	-					
- Carried forward from the last year	-	-					
Other interest	-	-					
Total...	397.32	257.82					
Paid							
Principle paid beyond the due date as per MSMED Act,2006	-	-					
Interest paid under section 16 of MSMED Act, 2006	-	-					
Total...	-	-					

NOTE NO. :- 12 : OTHER CURRENT LIABILITIES		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Current maturities of finance lease obligations OCL	-	-
Interest accrued but not due on borrowings OCL	-	-
Interest accrued and due on borrowings OCL	10.76	-
Income received in advance OCL	-	-
Unpaid dividends OCL	-	-
Application money received for allotment of securities and due for refund and interest accrued thereon OCL	-	-
Trade deposits and security deposits which are not in the nature of borrowings OCL	-	-
Advances from customers OCL	14.25	345.34
TDS payable OCL	41.36	43.54

NOTE NO. :- 12 : OTHER CURRENT LIABILITIES		
GST payable OCL	4.82	3.43
Salary, Bonus, Gratuity, Reimbursements etc. payable to staff OCL	348.50	216.43
Contribution towards PF payable OCL	8.55	13.88
Contribution towards ESI payable OCL	4.96	2.96
Income tax payable OCL	361.25	14.58
Other payables (specify nature) OCL	40.54	53.31
Total...	834.99	693.47

NOTE NO. :- 13 : SHORT TERM PROVISIONS		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Provision for employee benefits		
Provision for gratuity STP	71.70	65.11
Others		
Other provision(specify nature) STP	24.52	-
	96.22	65.11
a. Disclosures regarding the Other provision(specify nature)		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Provision for leave encashment	24.52	-

NOTE NO. :- 14 : PROPERTY, PLANT & EQUIPMENTS & INTANGIBLE ASSETS									
Description	Gross block				Accumulated depreciation			Net block	
	Figures as at the beginning of 1st April, 2025	Additions during the year	Disposals during the year	Figures as at the end of 31st March, 2026	Figures as at the beginning of 1st April, 2025	For the year	Figures as at the end of 31st March, 2026	Figures as at the end of 31st March, 2026	Figures as at the end of 31st March, 2025
Tangible Assets									
Capital Work-in-progress :									
Building	410.12	779.77	-	1,189.89	-	-	-	1,189.89	410.12
Property, plant and equipment									
Computers	533.86	153.03	-	686.89	417.64	95.10	512.74	174.15	116.22
Electric Installation	108.96	3.08	-	112.04	40.92	9.88	50.80	61.24	68.03
Office Interior & Renovation	805.77	1,051.41	-	1,857.18	318.27	87.69	405.95	1,451.22	487.51
Buildings	321.50	-	-	321.50	100.25	9.98	110.24	211.27	221.25

NOTE NO. :- 14 : PROPERTY, PLANT & EQUIPMENTS & INTANGIBLE ASSETS									
Description	Gross block				Accumulated depreciation			Net block	
Plant and equipment	8,588.72	1,885.25	-	10,473.97	2,644.02	628.86	3,272.88	7,201.09	5,944.70
Furniture and fixtures	176.75	41.80	-	218.55	130.81	17.27	148.07	70.48	45.95
Vehicles	160.82	45.01	-	205.83	84.67	18.05	102.72	103.11	76.15
Office equipment	452.71	197.70	-	650.41	264.04	84.60	348.64	301.77	188.67
Total...	11,559.22	4,157.04	-	15,716.26	4,000.61	951.43	4,952.04	10,764.22	7,558.60
Previous Year...	7,711.18	3,848.04	-	11,559.23	3,358.38	642.24	4,000.61	7,558.61	4,352.80

NOTE NO. :- 15 : NON-CURRENT INVESTMENTS									
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025							
Investment property NCI	-	-							
Investments in equity instruments NCI	1,032.54	1,031.54							
Banks deposits with more than twelve months maturity NCI	746.72	1,567.07							
Less: Provision for other than temporary diminution in the value of non current investments NCI	-	-							
Less: Adjustments to the carrying amount of investments on account of revaluation etc NCI	-	-							
Add: Adjustments to the carrying amount of investments on account of revaluation etc NCI	-	-							
Total...	1,779.26	2,598.61							
a. Disclosure on investment in equity instrument									
31st March, 2026									
Name of body corporate	Nature of Investment	Paid up value/share	Fully or partly paid	(%) holding	No of shares (in lakh)	Issue price	Amount	Basis of Valuation	Quoted/ Unquoted Investment
Chandan Diagnostic Limited,	Subsidiaries	10	Fully paid	67.99%	6.59	10	65.85	Cost	Unquoted

NOTE NO. :- 15 : NON-CURRENT INVESTMENTS									
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025							
Chandan Pharmacy Limited	Subsidiaries	10	Fully paid	53.56%	1.73	274	474.00	Cost	Unquoted
Indra Diagnostic Centre and Blood Bank Limited	Subsidiaries	10	Fully paid	100.00%	49.17	10	491.69	Cost	Unquoted
Chandan Healthcare Projects Private Limited	Subsidiaries	10	Fully paid	100.00%	0.10	10	1.00	Cost	Unquoted
Total...					57.58		1,032.54		
31st March, 2025									
Name of body corporate	Nature of Investment	Paid up value/share	Fully or partly paid	(%) holding	No of shares (in lakh)	Issue price	Amount	Basis of Valuation	Quoted/ Unquoted Investment
Chandan Diagnostic Limited,	Subsidiaries	10	Fully paid	67.99%	6.59	10	65.85	Cost	Unquoted
Chandan Pharmacy Limited	Subsidiaries	10	Fully paid	53.56%	1.73	274	474.00	Cost	Unquoted
Indra Diagnostic Centre and Blood Bank Limited	Subsidiaries	10	Fully paid	100.00%	49.17	10	491.69	Cost	Unquoted
Total...							1,031.54		
Note No. :- 0 : Deferred tax Assets (Net)									
Particulars						Figures As At 31st March, 2026		Figures As At 31st March, 2025	
Deferred tax assets(Net)						-		-	
Total...						-		-	

NOTE NO. :- 16 : LONG -TERM LOANS AND ADVANCES		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Secured, considered good		
Capital Advances SLTLA	-	-
Loans and advances to related parties SLTLA	-	-
Other loans and advances (specify nature) SLTLA	-	-
Unsecured, considered good		
Capital Advances USLTLA	100.00	-
Total...	100.00	-
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025

NOTE NO. :- 16 : LONG -TERM LOANS AND ADVANCES

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Unsecured, considered good		
Capital Advances	-	-
Advance for Land	100.00	-
Note No. :- 17 : Other non-current assets		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Secured, considered good		
Long term trade receivables (including trade receivables on deferred credit terms) SONCA	-	-
Security Deposits SONCA	-	-
Advance to supplier SLTLA	-	-
Advance to employees SLTLA	-	-
Others (specify nature) SONCA	-	-
Unsecured, considered good		
Long term trade receivables (including trade receivables on deferred credit terms) USONCA	-	-
Security Deposits USONCA	148.15	168.57
Advance to supplier USLTLA	-	-
Advance to employees USITLA	-	-
Income tax refund due USLTLA	53.90	53.90
Others (specify nature) USONCA	-	-
Total...	202.05	222.47

NOTE NO. :- 18 : CURRENT INVESTMENTS

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Investment property CI	-	-
Investments in equity instruments CI	-	-
Investments in preference shares CI	-	-
Investments in government or trust securities CI	-	-
Investments in debentures or bonds redeemable within 12 month CI	-	-
Investments in mutual funds CI	-	-
Investments in partnership firms CI	-	-
Application money paid towards securities CI	-	-
Investment in LLP CI	-	-
Other non-current investments(specify nature) CI	-	-

NOTE NO. :- 18 : CURRENT INVESTMENTS		
Bank deposits with more than three months maturity CI	639.30	1,059.00
Less: Provision for other than temporary diminution in the value of non current investments CI	-	-
Less: Adjustments to the carrying amount of investments on account of revaluation etc CI	-	-
Add: Adjustments to the carrying amount of investments on account of revaluation etc CI	-	-
Total...	639.30	1,059.00

NOTE NO. :- 19 : INVENTORIES		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Raw materials CI	-	-
Packing materials CI	-	-
Work-in-progress CI	-	-
Finished goods CI	-	-
Stock-in-trade CI	43.56	92.21
Stores, spares and consumables CI	1,595.65	1,636.14
Loose tools CI	-	-
Goods- In- Transit CI	-	-
Purchased intermediates and components consumed In the manufacturing activities of company CI	-	-
Others (specify nature) CI	-	-
Less: Provision for stock obsolescence CI	(16.03)	(16.36)
Total...	1,623.18	1,711.99

NOTE NO.:- 20: TRADE RECEIVABLES								
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025						
Secured, considered good								
Trade receivables STR	-	-						
Unsecured, considered good								
Trade receivables USTR	4,423.31	3,151.55						
Doubtful								

NOTE NO.:- 20: TRADE RECEIVABLES

Trade receivables DDTR	-	-						
Less: Provision for bad and doubtful trade receivables DDTR	(1.81)	(20.52)						
Total...	4,421.50	3,131.03						
31st March, 2026								
Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of receipt					TOTAL
			Less than 6 Month	6 Months - 1 year	1-2 years	2-3 years	More than 3 years	
UnDisputed								
Trade Receivables – considered good	-	1,654.92	2,764.77	-	-	-	-	4,419.69
Trade Receivables – considered doubtful	-	-	1.81	-	-	-	-	1.81
Disputed								
Trade Receivables – considered good	-	-	-	-	-	-	-	-
Trade Receivables – considered doubtful	-	-	-	-	-	-	-	-
Total...	-	1,654.92	2,766.58	-	-	-	-	4,421.50
31st March, 2025								
Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of receipt					TOTAL
			Less than 6 Month	6 Months - 1 year	1-2 years	2-3 years	More than 3 years	
UnDisputed								
Trade Receivables – considered good	-	554.83	2,555.68	-	-	-	-	3,110.51
Trade Receivables – considered doubtful	-	-	20.52	-	-	-	-	20.52
Disputed								
Trade Receivables – considered good	-	-	-	-	-	-	-	-
Trade Receivables – considered doubtful	-	-	-	-	-	-	-	-
Total...	-	554.83	2,576.20	-	-	-	-	3,131.03

NOTE NO.:- 21: CASH AND BANK BALANCES

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Cash and cash equivalents		
Balances with banks	225.20	550.27
Cheques, drafts on hand	-	-
Demand Deposit With Bank	-	-
Cash on hand	88.36	52.83
Total...	313.56	603.10

NOTE NO. :- 22 : SHORT-TERM LOANS AND ADVANCES

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Secured, considered good		
Loans and advances to related parties SSTLA	-	-
Other loans and advances (specify nature) SSTLA	-	-
Unsecured, considered good		
Loans and advances to related parties USSTLA	2,649.37	295.93
Other loans and advances (specify nature) USSTLA	-	-
Total...	2,649.37	295.93

NOTE NO. :- 23 : OTHER CURRENT ASSETS

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Secured		
Input tax credit(ITC)-GST SOCA	3.57	0.98
Security Deposits SOCA	-	-
Prepaid expenses SOCA	15.16	41.59
Other(specify nature) SOCA	-	-
Unsecured		
Security Deposits USOCA	329.32	-
Other(specify nature) USOCA	-	-
Advance to supplier USSTLA	290.54	84.65
Advance to employees USSTLA	99.87	382.40
Total...	738.46	509.62

NOTE NO. :- 24 : REVENUE FROM OPERATIONS

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Sale of products	686	484

NOTE NO. :- 24 : REVENUE FROM OPERATIONS

Sale of services	14,977	12,430
Other operating revenues		
Sale of scrap	2	2
Less: Excise duty	-	-
Total...	15,665	12,916

NOTE NO. :- 25 : OTHER INCOME

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
On current investments		
Interest on fixed deposits C	173.27	45.32
Other		
Interest from customers on amounts overdue	-	-
Other Interest Income	213.59	-
Net gain/(loss) on sale of property, plant & equipments & intangible assets	-	-
Gain on account of foreign exchange flauctuations	-	-
Share of profits/(losses) in a partnership firm/LLP	-	-
Bad Debts Recovered & Reversal of Payable Write-Off(Net)	0.33	156.33
Write back of excess provisions	19.05	-
Other non-operating income	6.26	3.24
Total...	412.50	204.89

NOTE NO. :- 26 : COST OF MATERIAL CONSUMED

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Raw materials consumed	-	-
Stores, spares and consumables consumed	2,281.00	1,542.19
Packing materials consumed	-	-
Purchased intermediates and components consumed In the manufacturing activities of company	-	-
Total...	2,281.00	1,542.19

Consumption disclosed in Note is on the basis of derived figures rather then actual records of issue.

NOTE NO. :- 27 : PURCHASE OF STOCK-IN-TRADE

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
-------------	--	--

NOTE NO. :- 27 : PURCHASE OF STOCK-IN-TRADE

Purchase of stores, spares and consumables	568.45	446.61
Total...	568.45	446.61

NOTE NO. :- 28 : CHANGE IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND STOCK-IN-TRADE.

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Opening stock:		
Finished goods OS	-	-
Work-in-progress OS	-	-
Stock-in-trade OS	92.21	73.03
	92.21	73.03
Closing stock:		
Finished goods CS	-	-
Work-in-progress CS	-	-
Stock-in-trade CS	43.56	92.21
	43.56	92.21
Total...	48.65	(19.18)

NOTE NO. :- 29 : EMPLOYEE BENEFITS EXPENSE.

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Salaries and wages	3,635.02	3,142.17
Contribution to provident and other funds	89.80	111.60
Provision for gratuity	111.95	71.77
Expense on employee stock option scheme (ESOP) and employee stock purchase plan (ESPP)	-	-
Provision for leave encashment	24.52	-
Staff welfare expense	3.76	13.02
Total...	3,865.05	3,338.56

NOTE NO. :- 30 : FINANCE COSTS

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Interest expense on borrowings	403.90	317.78
Other borrowing costs		
Loan processing charges	11.44	19.27
Bank charges	27.55	19.85
Dividend on redeemable preference shares	-	-

NOTE NO. :- 30 : FINANCE COSTS		
Applicable net gain/loss on foreign currency transactions and translation	-	-
Total...	442.89	356.90

NOTE NO. :- 31 : OTHER EXPENSES		
Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Repair & maintenance- Plant & equipments	192.21	116.61
Repair & maintenance-Building	59.50	36.17
Repair & maintenance - Other	134.75	83.84
Bad debts & Payable Written off(Net)	26.80	73.85
Payment to auditors	24.91	13.38
Rent	903.01	508.72
Electricity expenses	403.60	256.95
Fuel expenses	92.38	59.75
Travelling and conveyance	388.29	1,013.25
Legal and professional fees (professional fees to doctor consultants and others) & other related expenditures	1,406.96	1,250.87
Books, periodicals & certifications	1.54	0.94
Commission expenses	3.40	-
Advertisement, publicity, marketing & business promotion expenses	47.99	44.93
Provision for doubtful debts	-	15.28
Provision for obsolete inventories	-	10.10
Communication expenses (Telephone & internet expenses)	60.50	44.94
Insurance	6.61	5.08
Postage & courier charges	5.95	4.15
Rates and taxes	65.39	26.77
Outsourced testing expenses	163.46	83.63
CSR Expenses	55.86	12.48
Discount to customers	-	-
Printing and Stationary Expenses	-	-
Other miscellaneous expenses	215.35	335.75
Total	4,258.46	3,997.44
*Audit fee includes in legal and Professional fees		
a. Payment to the auditor		
Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
For Statutory Audit Fees	7.08	2.36

NOTE NO. :- 31 : OTHER EXPENSES		
For Cost Audit Fees	1.70	1.25
For Internal Audit Fees	10.88	8.00
For Secretarial Audit Fees	1.70	1.25
For Tax Audit Fees	3.54	-
Total...	24.90	12.86
b. Prior period items		
Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Rent	1.38	1.75
Electricity expenses	3.57	1.99
Communication expenses(Telephone & internet expenses)	0.88	2.33
Rates and taxes	3.14	0.06
Other miscellaneous expenses	19.66	12.50
Total...	28.62	18.62
c. Disclosure of expenditure in foreign currency during the financial year.		
Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Royalty	-	-
Legal, professional and consultancy charges	-	-
Interest	-	-
Other matters(Specify nature)	-	-
Total...	-	-

NOTE NO. :- 32 : EARNING PER SHARE		
Basic/Diluted earnings per share are calculated by dividing the Net profit or Loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.		
Basic EPS		
Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Numerator		
Earning available to equity shareholders(EAESH)	2,534.13	2,077.80
Denominator		
Weighted average outstanding equity share capital	244.52	205.73
Earnings Per Rupees of Equity Share Capital (Basic)	10.36	10.10
Diluted EPS		

NOTE NO. :- 32 : EARNING PER SHARE

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Numerator		
Earning available to equity shareholders(EAESH)	2,534.13	2,077.80
Denominator		
Weighted average outstanding equity share capital	251.35	205.73
Earnings Per Rupees of Equity Share Capital (Diluted)	10.08	10.10

NOTE NO.: - 39: DISCLOSURE REGARDING TRANSACTIONS WITH RELATED PARTIES IN TERMS OF ACCOUNTING STANDARD- 18

Name of the related party	Nature of the relationship 31st March 2026	Nature of the relationship 31st March 2025
A. Enterprises that directly or indirectly control/controlled by/under common control with, the reporting enterprise		
Chandan Diagnostic Limited- PAN: AABCC9315J	Subsidiary Company	Subsidiary Company
Chandan Hospital Limited - PAN: AABCC9314K	Entity under common control of promoter group	Entity under common control of promoter group
Indira Diagnostic Centre & Blood Bank Limited - PAN: AABCI0214L	Wholly Owned Subsidiary Company	Wholly Owned Subsidiary Company
Chandan Pharmacy Limited - PAN: AAHCC1459M	Subsidiary Company	Subsidiary Company
Cendana Pharmaceuticas Private Limited - PAN: AAKCC1991P	Entity under common control of promoter group	Entity under common control of promoter group
Amaranita Holdings (I) Private Limited - PAN: AAHCA1540R	Entity under common control of promoter group	Entity under common control of promoter group
Chandan Singh Foundation - PAN: AAATC2479F	Entity under common control of promoter group	Entity under common control of promoter group
Healthrely Private Limited- PAN:AAGCH9438N	Entity under common control of promoter group	Entity under common control of promoter group
Chandan Cancer Institute Limited-PAN:AALCC9159N	Entity under common control of promoter group	Entity under common control of promoter group
Chandan Super Speciality Hospital Limited- PAN: AALCC1234A	Entity under common control of promoter group	Entity under common control of promoter group
AMARANITA HOSPITALITY PRIVATE LIMITED: ABFCA4827Q	Entity under common control of promoter group	-
CHANDAN HEALTHCARE PROJECTS PRIVATE LIMITED: AANCC6242L	Subsidiary Company	-

NOTE NO.: - 39: DISCLOSURE REGARDING TRANSACTIONS WITH RELATED PARTIES IN TERMS OF ACCOUNTING STANDARD- 18

Chandan Cradle Limited- PAN : AANCC3763A (Earlier Know as Chandan Fertility Limited)	Entity under common control of promoter group	-	
B. Individuals owning, directly or indirectly, an interest in the voting power of the reporting enterprise that gives them control or significant influence over the enterprise, and relatives of any such individual			
Dr Amar Singh - PAN: AGQPS5396H - DIN: 01096328	Managing director of company (MD)	Managing director of company (MD)	
Asmita Singh - PAN: AWSPS3853M - DIN: 01098055	Managing director of company (MD)	Director of company	
Virendra Singh - PAN: AFSPS0571B - DIN: 01099343	Relative of Promoter	Director of company*	
Vinay Lamba - PAN: AAXPL5673R - DIN: 01220153	Director of company	Director of company	
Vijay Singh - PAN: AILPS1503P - DIN: 02778087	Promoter	Director of company*	
Aasti Singh - PAN: FRPPS0695A - DIN: 06973933	Relative of director/Promoter	Director of company	
Anant Singh - PAN: AWSPS3852L - DIN: 00969364	Relative of director/Promoter	Director of company	
Rajeev Nain - PAN: AIVPN6380K	Key managerial personnel (CFO & Company secretary)	Key managerial personnel (CFO & Company secretary)	
Anita Singh - PAN: ARVPS1208G	Relative of director/Promoter	Relative of director	
Vishal Lamba - PAN: ABUPL4208N	Relative of director	Relative of director	
Ajai Singh - PAN: AHNPS7885B	Relative of director	Relative of director	
Nisha Lamba - PAN: AATPL6545J	Relative of director	Relative of director	
Pragya Singh - PAN: DIVPS5075J	Relative of KMP	Relative of KMP	
Shaivalini Singh - PAN: CURPS9141R	Relative of Promoter	Relative of director*	
Vikash Lamba - PAN: ACLPL2389Q	Relative of director/Promoter	Relative of director	
Shailendra Singh- PAN CBEPS0038M	Relative of director	-	
# During the financial year, the company divested its investments in certain subsidiaries and associates. As a result of these transactions, these entities are no longer classified as subsidiaries or associates in the company's financial statements.			
* During the financial year, the individual ceased to serve as a director			
a. Details of transactions with related parties and amounts (receivable)/payable as at the beginning and end of the year:			
Name of related party	Nature of Transaction	Standalone figures for the year ended 31st March, 2026	Standalone figures for the year ended 31st March, 2025

NOTE NO.: - 39: DISCLOSURE REGARDING TRANSACTIONS WITH RELATED PARTIES IN TERMS OF ACCOUNTING STANDARD- 18

Aasti Singh	Opening Balance Payable(Receivable)	(0.00)	(0.00)
	Dividend for the Year	-	1.05
	Payment	0.00	(1.27)
	Receipt	-	-
	Reimburshment	-	0.22
	Professional fee	-	-
	Closing Balance Payable(Receivable)	(0.00)	(0.00)
Dr Amar Singh	Opening Balance Payable(Receivable)	3.32	16.63
	Dividend for the Year	-	34.80
	Professional fee	-	-
	Receipt	63.75	20.00
	Bonus for the Year	-	-
	Salary	46.71	180.00
	Payment	(223.64)	(247.99)
	Reimbursement	128.59	(0.12)
	Closing Balance Payable(Receivable)	18.72	3.32
Anant Singh	Opening Balance Payable(Receivable)	(0.00)	(0.00)
	Salary	-	-
	Dividend for the Year	-	1.58
	Reimbursement	1.37	
	Advance	-	-
	Payment	(1.37)	(1.58)
	Closing Balance Payable(Receivable)	0.00	(0.00)

NOTE NO.: - 39: DISCLOSURE REGARDING TRANSACTIONS WITH RELATED PARTIES IN TERMS OF ACCOUNTING STANDARD- 18

Asmita Singh	Opening Balance Payable(Receivable)	4.82	3.97
	Dividend for the Year	-	2.43
	Deposit	-	-
	Reimbursement	0.04	4.24
	Receipt	22.56	-
	Bonus for the Year	-	-
	Salary	84.89	84.00
	Payment	(115.05)	(89.82)
	Closing Balance Payable(Receivable)	(2.75)	4.82
Vinay Lamba	Opening Balance Payable(Receivable)	-	6.36
	Payment	-	(51.39)
	Advance	-	-
	Reimbursement	(0.00)	(0.64)
	Dividend for the Year	-	23.77
	Bonus for the Year	-	-
	Salary	-	21.90
	Closing Balance Payable(Receivable)	(0.00)	-
Rajeev Nain	Opening Balance Payable(Receivable)	2.91	2.22
	Dividend for the Year	-	1.91
	Reimbursement	0.92	6.64
	Gratuity	-	-
	Professional fee	-	-
	Payment	(49.33)	(56.40)

NOTE NO.: - 39: DISCLOSURE REGARDING TRANSACTIONS WITH RELATED PARTIES IN TERMS OF ACCOUNTING STANDARD- 18

	Salary	47.99	48.54
	Closing Balance Payable(Receivable)	2.49	2.91
Ajai Singh	Opening Balance Payable(Receivable)	-	-
	Dividend for the Year	-	1.50
	Reimbursement	-	0.16
	Payment	-	(1.66)
	Closing Balance Payable(Receivable)	-	-
Nisha Lamba	Opening Balance Payable(Receivable)	-	-
	Dividend for the Year	-	3.35
	Salary	-	-
	Receipt	-	-
	Payment	-	(3.35)
	Closing Balance Payable(Receivable)	-	-
Vikas Lamba	Opening Balance Payable(Receivable)	-	-
	Dividend for the Year	-	7.50
	Payment	(18.04)	(13.99)
	Advance	-	-
	Salary	8.04	-
	Gratuity	-	-
	Reimbursement	8.66	6.49
	Receipt	-	-
	Closing Balance Payable(Receivable)	(1.34)	-
Vishal Lamba	Opening Balance Payable(Receivable)	-	-

NOTE NO.: - 39: DISCLOSURE REGARDING TRANSACTIONS WITH RELATED PARTIES IN TERMS OF ACCOUNTING STANDARD- 18

	Dividend for the Year		2.32
	Advance		-
	Loan		-
	Salary		-
	Gratuity		-
	Payment	(1.62)	(18.76)
	Reimbursement	1.62	16.45
	Closing Balance Payable(Receivable)	-	-
Anshu Lamba	Opening Balance Payable(Receivable)	-	-
	Dividend for the Year	-	3.00
	Salary	-	-
	Reimbursement	-	-
	Payment	-	(3.00)
	Closing Balance Payable(Receivable)	-	-
Deepa Lamba	Opening Balance Payable(Receivable)	-	-
	Dividend for the Year	-	1.38
	Salary	8.00	
	Payment	(6.53)	(1.38)
	Closing Balance Payable(Receivable)	1.47	-
Shailendra Singh	Opening Balance Payable(Receivable)	-	-
	Salary	-	-
	Dividend for the Year	-	-
	Reimbursement	1.37	-

NOTE NO.: - 39: DISCLOSURE REGARDING TRANSACTIONS WITH RELATED PARTIES IN TERMS OF ACCOUNTING STANDARD- 18

	Advance	-	-
	Payment	(1.37)	-
	Closing Balance Payable(Receivable)	0.00	-
Chandan Hospital Limited	Opening Balance Payable(Receivable)	(160.64)	849.58
	Opening Balance Loan Payable(Receivable)	-	-
	Opening Balance Investment in equity share capital	-	-
	Receipt	4,286.73	1,849.80
	Dividend Income	-	-
	Loan Interest income	(133.41)	-
	Loan receipt	-	-
	Loan Payment	(1,300.00)	-
	Sales	(579.54)	(1,032.94)
	Share sales	-	-
	Share purchase	-	-
	Payment	(2,900.36)	(1,827.07)
	Closing Balance Investment in equity share capital	-	-
	Closing Balance Loan Payable(Receivable)	(1,433.41)	-
	Closing Balance Payable(Receivable)	646.19	(160.64)
Chandan Pharmacy Limited	Opening Balance Payable(Receivable)	(3.78)	2.92
	Opening Balance Loan Payable(Receivable)	-	-
	Opening Balance Investment in equity share capital	(474.00)	(474.00)
	Sales	(28.17)	(57.46)
	Purchase	21.74	21.68

NOTE NO.: - 39: DISCLOSURE REGARDING TRANSACTIONS WITH RELATED PARTIES IN TERMS OF ACCOUNTING STANDARD- 18

	Receipt	10.96	54.38
	Loan Interest income	(24.58)	-
	Loan receipt	742.03	-
	Loan Payment	(1,603.70)	-
	Dividend Income	-	-
	Share sales	-	-
	Payment	(1.45)	(25.30)
	Closing Balance Investment in equity share capital	(474.00)	(474.00)
	Closing Balance Loan Payable(Receivable)	(886.25)	-
	Closing Balance Payable(Receivable)	(0.71)	(3.78)
Chandan Singh Foundation	Opening Balance Payable(Receivable)	-	-
	Opening Balance Loan Payable(Receivable)	(295.93)	-
	Opening Balance Investment in equity share capital	-	-
	Loan Interest income	(33.78)	-
	Loan receipt	-	150.00
	Loan Payment	-	(445.93)
	CSR	55.86	12.48
	Payment	(71.19)	(12.48)
	Closing Balance Investment in equity share capital	-	-
	Closing Balance Loan Payable(Receivable)	(329.71)	(295.93)
	Closing Balance Payable(Receivable)	(15.33)	-
Chandan Diagnostic Limited	Opening Balance Payable(Receivable)	-	-
	Opening Balance Investment in equity share capital	(65.85)	(65.85)

NOTE NO.: - 39: DISCLOSURE REGARDING TRANSACTIONS WITH RELATED PARTIES IN TERMS OF ACCOUNTING STANDARD- 18

	Share sales		-
	Sales		0.32
	Receipt		-
	Payment	(1.01)	(0.32)
	Closing Balance Investment in equity share capital	(65.85)	(65.85)
	Closing Balance Payable(Receivable)	(1.01)	-
Indra Diagnostic Centre & Blood Bank Limited	Opening Balance Payable(Receivable)	344.30	4.57
	Opening Balance Investment in equity share capital	(491.69)	(491.69)
	Sales	(15.40)	(340.28)
	Share sales	0.01	-
	Receipt	15.65	680.00
	Payment	(344.84)	-
	Closing Balance Investment in equity share capital	(491.68)	(491.69)
	Closing Balance Payable(Receivable)	(0.30)	344.30
Cendana Pharmaceuticals	Opening Balance Payable(Receivable)	(199.65)	4.57
	Receipt	170.26229	24.02
	Payment	(35.97)	(165.45)
	Cheque Issued But Not Cleared		(1.18)
	Purchase	35.19	178.60
	Sales	(9.03)	(240.21)
	Closing Balance Payable(Receivable)	(39.19)	(199.65)
Chandan Super Speciality Hospital Limited	Opening Balance Payable(Receivable)	(7.91)	-
	Receipt	185.08	97.69

NOTE NO. :- 39: DISCLOSURE REGARDING TRANSACTIONS WITH RELATED PARTIES IN TERMS OF ACCOUNTING STANDARD- 18

	Payment		(1.78)
	Sales	(184.15)	(103.82)
	Closing Balance Payable(Receivable)	(6.98)	(7.91)
Amaranita Holdings (India) Private Limited	Opening Balance Payable(Receivable)	-	0.20
	Opening Balance Investment in equity share capital	-	584.30
	Share sales	-	(584.30)
	Professional Fee	-	-
	Comission	-	-
	Dividend	-	87.65
	Receipt	-	5.58
	Payment	-	(93.43)
	Closing Balance Investment in equity share capital	-	-
	Closing Balance Payable(Receivable)	-	-
CHANDAN HEALTHCARE PROJECTS PRIVATE LIMITED	Opening Balance Payable(Receivable)	-	-
	Opening Balance Investment in equity share capital	-	-
	Share sales	-	-
	Share Purchase	(1.00)	-
	Receipt	-	-
	Payment	-	-
	Closing Balance Investment in equity share capital	(1.00)	-
	Closing Balance Payable(Receivable)	-	-

NOTE NO. :- 34 : ANALYTICAL RATIOS

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025	% Variance	Reason for more than 25% variance
-------------	---	---	------------	-----------------------------------

NOTE NO. :- 34 : ANALYTICAL RATIOS

Current Ratio: Total current assets/Current liabilities					39.92%	As a result of the substantial increase in current assets for the year.
Current assets	10,385.37	3.53	7,310.67	2.52		
Current liabilities: Total current liabilities - Current maturities of non- current borrowings and lease obligations	2,942.75		2,898.48			
Net Debt Equity Ratio: Net debts/ Average equity	3,902.23		3,320.38			-
Net debt: Non- current borrowings + Current borrowings + Non-current and current lease liabilities - Current investments - Cash and cash equivalents - Other balances with banks (including non- current earmarked balances)	16,739.21	0.23	12,071.62	0.28	-15.25%	
Equity: Equity share capital + Other equity + Hybrid perpetual securities						
Debt service coverage ratio: EBIT/Debt Service	4,065.20		3,134.33		31.07%	As a result of the substantial increase in profitability for the current year.
EBIT		2.89		2.20		

NOTE NO. :- 34 : ANALYTICAL RATIOS

Debt service: Finance costs (excluding interest on current borrowings) - Interest income - Dividend income from current investments - Net gain/(loss) on sale of current investments - Interest income from group companies + Scheduled principal repayments of non-current borrowings and lease obligations (excluding prepayments during the period).	1,408.79		1,423.70			
Return on Equity (%): Profit after tax (PAT)/ Average Equity	2,534.13		2,077.80		-31.68%	As a result of growth in the equity base was higher than the corresponding increase in profit after tax
PAT	14,405.42	17.59%	8,069.15	25.75%		
Equity: Equity share capital + Other equity + Hybrid perpetual securities						
Inventory turnover ratio(in days): 365/(COGS or Sale/Average inventory)	6,14,579.70	39.23	4,34,426.65	33.63	16.65%	-
COGS	15,664.73		12,916.42			
Average inventory: (Opening + Closing balance) / 2						
Trade receivables turnover ratio (in days): 365/(Net Credit Sales/Average accounts receivable)	13,78,336.73		9,70,284.98		-14.68%	-
Net credit sales: Gross credit sales - sales return	10,551.12	130.63		153.11		

NOTE NO. :- 34 : ANALYTICAL RATIOS

Average trade debtors: (Opening + Closing balance) / 2			6,337.26			
Trade payables turnover ratio (in days): 365/(Net credit purchases/Average trade payables)	1,19,563.05	41.54	3,00,398.65	46.65	(0.11)	-
Net credit purchase: Gross credit purchase - purchase return	2,878.09		6,439.49			
Average trade payable: (Opening + Closing balance) / 2						
Net capital turnover ratio: Net Sales/Average working capital					-28.10%	As a result of reduction in revenue growth relative to the increase in working capital deployed.
Net sales: Gross total sales - sales return	15,664.73	2.10	12,916.42	2.93		
Working capital: Current assets - Current liabilities	7,442.62		4,412.19			
Net profit ratio (%): Net profit after tax/Turnover	2,534.13		2,077.80		0.56%	-
PAT	15,664.73	16.18%	12,916.42	16.09%		
Net sales: Gross total sales - sales return						
Return on Capital Employed (%): EBIT/Average capital employed					-19.49%	-
EBIT: Profit before taxes +/- Exceptional items + finance costs - Interest income - dividend income from current investments - Net gain/(loss) on sale of current investments	4,065.20	22.56%	3,134.33	28.03%		

NOTE NO. :- 34 : ANALYTICAL RATIOS

Capital Employed: Equity share capital + Other equity + Hybrid perpetual securities + Non current borrowings + Current borrowings + Current maturities of long-term debt and leases + Deferred tax liabilities or (Tangible Net Worth + Total Debt + Deferred tax liability)	18,016.72		11,183.26			
--	-----------	--	-----------	--	--	--

NOTE NO. :- 35 : CONTINGENT LIABILITIES AND COMMITMENTS

Particulars	Figures for the year ended 31st March, 2026		Figures for the year ended 31st March, 2025	
	No of cases	Amount	No of cases	Amount
Claims against the company not acknowledged as debts				
1) District consumer disputes redressal forum	24	397.34	13	62.49
2) State consumer disputes redressal commission	1	-	1	-
3) Labour court	3	5.45	3	5.45
4) District and session court	25	93.62	20	61.55
Direct tax matters	2	373.30	1	137.75
Guarantees				
Guarantee provided to the HDFC Bank of India in relation to borrowings undertaken by Chandan Hospital Limited.	10	1,223.67	10	1,223.67
Guarantee provided to the HDFC Bank of India in relation to borrowings undertaken by Chandan Pharmacy Limited.	1	227.76	1	227.76
Total...	66	2,321.14	49	1,718.67

NOTE NO. :- 36 : SEGMENT REPORTING										
Primary segments - Business Segments										
The company primarily operates state-of-the-art laboratories providing comprehensive pathological investigations and radiology services. Other activities conducted by the company are ancillary to its main business and do not significantly impact the financial statements. Consequently, in accordance with Accounting Standard 17 on Segment Reporting, the company has identified a single reportable business segment: "Diagnostics Services." As a result, segment information has not been disclosed.										
Secondary segments - Geographical Segments										
The company operates primarily in India and there is no other significant geographical segment.										
Note No. :- 37 : CSR expenditure										
Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025								
Gross amount required to be spent by the company during the year.	55.86	12.46								
Gross amount spent by the company during the year.	55.86	12.48								
Shortfall / (Excess)	-	(0.02)								
a. Disclosure on nature of CSR activities undertaken by the companies										
Particulars	Figures For The Year Ended 31st March, 2026					Figures For The Year Ended 31st March, 2025				
	Paid in cash	Paid via bank	Paid in kind	Payable	Total	Paid in cash	Paid via bank	Paid in kind	Payable	Total
Promoting education	-	55.86	-	-	55.86	-	12.48	-	-	12.48

Note No. :- 38 : Other statutory information

In the opinion of the board of directors, the current assets, loans and advances have a value on realization in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet.

Balances with trade receivables / trade payables and loans & advances are subject to confirmation.

Previous year's figures have been regrouped /rearranged wherever necessary to make them comparable with current year's figures.

The company does not have any benami property, where any proceeding has been initiated or pending against the company for holding any benami property.

The company does not have any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956 during the financial year.

The company has not traded or invested in Crypto Currency or Virtual Currency during the financial year.

The company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies (ROC) beyond the statutory period.

The company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.

The company has not received any fund from any person(s) or entity(ies), including foreign entities (funding party) with the understanding (whether recorded in writing or otherwise) that the company shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the funding party (ultimate beneficiaries) or (b) provide any guarantee, security or the like on behalf of the ultimate beneficiaries.

The company does not have any transaction to report that is not recorded in the books of accounts and that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

The company has not been declared as wilful defaulter by any bank or financial institution or other lender.

The company does not have any immovable property (other than properties where the company is the lessee and the lease agreements are duly executed in favour of the lessee) whose title deeds are not held in the name of the company.

The company confirms that the quarterly returns or statements of current assets, filed with banks or financial institutions in relation to borrowings secured by current assets, are in agreement with the books of accounts.

Independent Auditor's Report on Quarterly/half yearly and Year to Date Audited Consolidated financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,

The Board of Directors,

Chandan Healthcare Limited,

Lucknow

CONSOLIDATED FINANCIAL RESULTS & STATEMENTS

07

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying Statement of quarterly/half yearly and year to date Consolidated Financial Results of M/s. Chandan Healthcare Limited (hereinafter referred to as the “Holding company”) and its subsidiaries (holding company and its subsidiaries together referred to as “the Group”), (“the Statement”), being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/ financial information of subsidiaries, the Statement:

- includes the results of the following entities:
 - Chandan Pharmacy Limited.
 - Chandan Diagnostic Limited.
 - Indira Diagnostic Centre & Blood Bank Limited.
 - Chandan Healthcare Projects Private Limited.
- is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated net profit after tax and other comprehensive profit and other financial information of the Group for the quarterly ended March 31, 2025, and for the period from April 01, 2025 to March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in “Other Matter” paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management’s Responsibilities for the Consolidated Financial Results

The Statement, which is the responsibility of the Holding Company’s management and has been approved by the Holding Company’s Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Holding Company’s Board of Directors are responsible for the preparation and presentation of Statement that give a true and fair view of the net profit and other comprehensive profit and other financial information of the Group in accordance with the recognition and measurement principles laid down in Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group entities are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the statement represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

The consolidated annual financial results include the audited financial results of four subsidiaries. The financial statements of these subsidiaries reflect the Group's share of total assets of Rs. 7,229.44 lakhs (before consolidation adjustments) as at 31st March, 2026, the Group's share of total revenue from operations of Rs. 12,064.73 lakhs (before consolidation adjustments), the Group's share of total income of Rs. 351.05 lakhs (before consolidation adjustments), and the Group's share of net cash Inflows of Rs. 27.03 lakhs (before consolidation adjustments) for the year ended on that date. Out of these four subsidiaries, the financial statements of Chandan Pharmacy Limited have been audited by us, while the financial statements of the other three subsidiaries have been audited by their respective independent auditors. The independent auditors' reports on the financial statements of these three entities have been furnished to us by the management, and our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the reports of such auditors and the procedures performed by us as stated in the paragraph above.

The Statement includes the results for the Quarter ended March 31, 2026, being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026, and the unaudited year – to date figures up to the first 9 months of the current financial year as per books of accounts.

As Per MCA Notification dated 16th February 2015, companies whose shares are listed on SME exchange as referred to in chapter XB of the SEBI (Issue of capital & disclosures requirement) regulation 2009 are exempted from the compulsory requirement of adoption of IND AS. As the company is covered under the exempted category, it has not adopted IND AS for the preparation of financial statement.

Figures for the previous periods/year have been regrouped, restated and/or reclassified whenever considered necessary to make them comparable to the current periods.

Our opinion on the statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial information certified by the Board of Directors.

For MSNT & ASSOCIATES LLP

Chartered Accountants

Firm Registration No.018542C/C400322

SD/-

Navodit Tyagi

Partner

Membership No.-533375

UDIN No: 26533375SHEYQZ6542

Audited Consolidated Financial Statements as At 31st March, 2026

(ALL AMOUNTS ARE IN ₹ NEAREST LAKHS OR DECIMALS THEREOF, UNLESS OTHERWISE STATED)

Audited Consolidated Statement of Assets & Liabilities As At 31st March, 2026

Particulars	Note No.	Figures As At 31st March, 2026	Figures As At 31st March, 2025
I. EQUITY AND LIABILITIES			
(1) Shareholder's funds			
(a) Share capital	3	2,445.21	2,445.21
(b) Reserves and surplus	4	14,543.04	9,815.09
(c) Money received against share warrants	5	111.25	-
(2) Share application money pending allotment	0	-	-
(3) Minority interest	6	530.20	380.57
(4) Non-current liabilities			
(a) Long-term borrowings	7	2,897.34	2,214.46
(b) Deferred tax liabilities(net)	8	235.54	190.33
(c) Other long-term liabilities	9	2.20	2.45
(d) Long term provisions	10	460.48	343.69
(5) Current liabilities			
(a) Short-term borrowings	11	2,477.27	2,601.92
(b) Trade payables	12		
(i) Total outstanding dues of micro & small enterprises.		1,617.01	604.13
(ii) Total outstanding dues of creditors other than micro & small enterprises.		2,473.22	1,990.04
(c) Other current liabilities	13	1,052.10	438.78
(d) Short term provisions	14	106.97	69.04
TOTAL		28,951.83	21,095.71
II. ASSETS			
(1) Non- current assets			
(a) Property, plant & equipment & intangible assets	15		
(i) Property, plant & equipment		9,680.81	7,191.99
(ii) Intangible assets		443.28	443.28
(iii) Capital work in progress		1,198.83	410.12
(iv) Intangible assets under development		-	-
(b) Non-current investments	16	784.93	1,731.50
(c) Deferred tax assets(net)	17	26.27	18.04
(d) Long -term loans and advances	18	100.00	-
(e) Other non-current assets	19	246.75	253.85
(2) Current assets			

(ALL AMOUNTS ARE IN ₹ NEAREST LAKHS OR DECIMALS THEREOF, UNLESS OTHERWISE STATED)

Audited Consolidated Statement of Assets & Liabilities As At 31st March, 2026

(a) Current investments	20	1,211.25	1,583.65
(b) Inventories	21	3,373.90	3,137.07
(c) Trade receivables	22	8,640.21	4,725.89
(d) Cash and bank balances	23	358.21	620.71
(e) Short-term loans and advances	24	1,763.12	410.68
(f) Other current assets	25	1,124.27	568.93
TOTAL		28,951.83	21,095.71
As per our report of even date attached		For & on behalf of the board of directors	
For M/s MSNT & Associates LLP		CHANDAN HEALTHCARE LIMITED	
Chartered accountants			
Firm registration no. :- 018542C/C400322		SD/-	SD/-
		Amar Singh	Asmita Singh
SD/-		Managing director	Managing director
Navodit Tyagi		DIN. :- 01096328	DIN. :- 01098055
Partner		Place :- Lucknow	Place :- Lucknow
Membership no. :- 533375		Date :- 29.05.2026	Date :- 29.05.2026
UDIN no. :- 26533375SHEYQZ6542			
Place :- Noida			SD/-
Date :- 29.05.2026			Rajeev Nain
			CFO & Company secretary
			Place :- Lucknow
			Date :- 29.05.2026

(ALL AMOUNTS ARE IN ₹ NEAREST LAKHS OR DECIMALS THEREOF, UNLESS OTHERWISE STATED)

Audited Consolidated Statement of Profit and Loss for the Year Ended 31st March, 2026

Particulars	Note No.	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
I. Revenue from operations	26	27,639.44	23,012.08
II. Other income	27	427.85	293.51
III. Total revenue(I+II)		28,067.29	23,305.59
IV. Expenses:			
Cost of material consumed	28	2,286.65	1,545.88
Purchase of stock-in-trade	29	11,359.87	9,498.14
Change in inventories of finished goods, work-in-progress and stock-in-trade.	30	(278.05)	(282.32)
Employee benefits expense.	31	4,419.65	3,886.11
Finance Costs	32	588.19	457.60
Depreciation and amortisation expense	15	977.98	674.48

(ALL AMOUNTS ARE IN ₹ NEAREST LAKHS OR DECIMALS THEREOF, UNLESS OTHERWISE STATED)

Audited Consolidated Statement of Profit and Loss for the Year Ended 31st March, 2026

Other expenses	33	4,594.80	4,319.15
Total expenses (IV)		23,949.09	20,099.04
V. Profit/(loss) before exceptional & extraordinary items and tax (III-IV)		4,118.20	3,206.55
VI. Exceptional items		291.54	-
VII. Profit/(loss) before extraordinary items and tax (V-VI)		3,826.66	3,206.55
VIII. Extraordinary items		-	-
IX. Profit(loss) before tax (VII- VIII)		3,826.66	3,206.55
X. Tax expense of continuing operation: -	-		
Current tax-for the year		903.83	813.44
Current tax-Adjustment for earlier years		30.48	17.14
Deferred tax		36.99	24.34
Tax expense(X)		971.30	854.92
XI. Profit(loss) for the period from continuing operations (after tax) (IX-X)		2,855.36	2,351.63
XII. Profit/(loss) from discontinuing operations		-	-
XIII. Tax expense of discontinuing operations		-	-
XIV. Profit/(loss) from discontinuing operations (after tax) (XII-XIII)		-	-
XV. Share of (profit)/ loss transferred to minority interest		(149.62)	(134.55)
XVI. Profit/ (Loss) after tax attributable to owners of the company (XI+XIV+XV)		2,705.74	2,217.08
XVII. Earnings per equity share:			
(1) Basic		11.07	10.78
(2) Diluted	34	10.76	10.78

Significant accounting policies and notes to financial statements.

The notes referred to above form an integral part of the balance sheet.

As per our report of even date attached		For & on behalf of the board of directors	
For M/s MSNT & Associates LLP		CHANDAN HEALTHCARE LIMITED	
Chartered accountants			
Firm registration no.:- 018542C/C400322		SD/-	SD/-
		Amar Singh	Asmita Singh
SD/-		Managing director	Managing director
Navodit Tyagi		DIN. :- 01096328	DIN. :- 01098055
Partner		Place :- Lucknow	Place :- Lucknow
Membership no. :- 533375		Date :- 29.05.2026	Date :- 29.05.2026
UDIN no. :- 26533375SHEYQZ6542			SD/-
Place :- Noida			Rajeev Nain
Date :- 29.05.2026			CFO & Company secretary

(ALL AMOUNTS ARE IN ₹ NEAREST LAKHS OR DECIMALS THEREOF, UNLESS OTHERWISE STATED)

Audited Consolidated Statement of Profit and Loss for the Year Ended 31st March, 2026

Place :- Lucknow

Date :29.05.2026

(ALL AMOUNTS ARE IN ₹ NEAREST LAKHS OR DECIMALS THEREOF, UNLESS OTHERWISE STATED)

Audited Consolidated Standalone Statement of Cash Flow For The Year Ended 31st March, 2026

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
A. Cash flow arising from operating activities		
Profit / (Loss) before tax	3,826.66	3,206.55
Adjustments related to non-cash & non-operating transactions:		
Non cash transactions		
Depreciation & amortisation of fixed assets	977.98	674.48
Bad Debts & Balances written off/written back	23.78	(124.17)
Preliminary expenses written off	-	-
Re-measurement (gains) / loss on defined benefit plans	160.50	84.27
Provision for doubtful debts-CFS	(18.53)	15.35
Provision for obsolete inventories-CFS	0.74	26.72
Loss(gain) on account of foreign exchange fluctuations	-	-
Other non-cash transactions (specify nature)	-	-
Non-operating transactions	-	-
Interest on borrowing	582.00	441.86
Loss/(profit) on the sale of property, plant & equipment & intangible assets	-	-
Loss/(profit) on the sale of investments	-	-
Interest income	(399.36)	(72.98)
Dividend income	-	-
Other non-operating transactions (specify nature)	-	-
Operating profit/(loss) before working capital changes	5,153.77	4,252.08
Adjustment for change in working capital:		
(Increase) / Decrease in inventories	(237.55)	(1,339.42)
(Increase) / Decrease in trade receivables	(3,919.57)	(1,496.39)
(Increase) / Decrease in other current assets	(556.47)	(299.92)
(Decrease) / Increase in trade payables	1,496.06	646.97
(Decrease) / Increase in other current liabilities	652.50	(1,183.74)
Net cash (used in) / generated from operating activities	2,588.74	579.57
Income taxes refund / (paid), net	(971.31)	(854.90)
Net cash flow from operating activities(A)	1,617.44	(275.33)

B. Cash flow arising from investing activities			
Sale/(Purchase) of tangible and intangible assets		(4,255.51)	(3,870.48)
Sale/(Purchase) of non-current & current investments		(133.47)	(2,406.99)
Interest income		399.36	72.98
Dividend income		-	-
Net cash flow from investing activities(B)		(3,989.63)	(6,204.49)
C. Cash Flow Arising from Financing Activities			
Proceeds from issuance of share capital (Including share Warrants)		2,133.46	6,227.13
Proceeds from/ (Payment of) long term & short-term borrowings		558.23	1,225.27
Finance cost paid (including processing fees)		(582.00)	(441.86)
Dividend paid		-	(300.00)
Net cash flow from financing activities(C)		2,109.69	6,710.54
Net increase/decrease in cash or cash equivalents(A+B+C)		(262.50)	230.72
Cash and cash equivalents at the beginning of the period		620.71	389.99
Cash and cash equivalents at the end of the period		358.21	620.71
As per our report of even date attached	For & on behalf of the board of directors		
For M/s MSNT & Associates LLP	CHANDAN HEALTHCARE LIMITED		
Chartered accountants			
	Amar Singh	Asmita Singh	
Navodit Tyagi	Managing director	Managing director	
Partner	DIN. :- 01096328	DIN. :- 01098055	
Membership no. :- 533375	Place :- Lucknow	Place :- Lucknow	
UDIN no. :- 26533375SHEYQZ6542	Date :- 29.05.2026	Date :- 29.05.2026	
Place :- Noida			
Date :- 29.05.2026			
	Rajeev Nain		
	CFO & Company secretary		
	Place :- Lucknow		
	Date :- 29.05.2026		

NOTE NO. :- 1 : CORPORATE INFORMATION

Chandan Healthcare Limited, established on September 3, 2003, specializes in operating state-of-the-art laboratories that offer comprehensive pathological investigations. Our services encompass biochemistry, hematology, histopathology, microbiology, and immunology. Additionally, we provide an extensive array of radiology services, including CT scans, X-rays, and MRIs. Committed to accuracy and reliability, Chandan Healthcare supports healthcare professionals and patients by delivering essential diagnostic services.

NOTE NO. :- 2 : SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

a) Basis of Preparation of Financial Statements

The financial statements have been prepared in accordance with the historical cost convention, accrual basis, and going concern assumption, as mandated by generally accepted accounting principles (GAAP) in India. GAAP encompasses the mandatory accounting standards specified under Section 133 of the Companies Act, 2013, in conjunction with Rule 7 of the Companies (Accounts) Rules, 2014, and the relevant provisions of the Act (to the extent notified).

Accounting policies have been applied consistently throughout, except where the initial adoption of a new accounting standard or a revision to an existing accounting standard necessitates a change in the previously applied accounting policy.

The financial statements are prepared in accordance with Schedule III of the Companies Act, 2013, which significantly influences their disclosure and presentation. Comparative figures for the previous year have been regrouped or reclassified, as necessary, to align with the current year's classification and disclosure requirements.

The Consolidated Financial Statements were approved by the Board of Directors and authorised for issue on May 29, 2026.

b) Use of Estimates

The preparation and presentation of financial statements necessitate the use of estimates and assumptions that impact the reported amounts of assets, liabilities, and contingent liabilities as of the financial statement date, as well as the reported revenues and expenses for the reporting period. Any variances between actual results and estimates are recognized in the period in which they become known or materialize.

Accounting estimates are subject to periodic revisions, and actual results may differ from these estimates. Adjustments to estimates are made when management becomes aware of changes in the circumstances affecting the estimates. Such changes are reflected in the financial statements for the period in which they occur, and their impact is disclosed in the notes to the financial statements if deemed material.

c) Functional and presentation currency

These standalone financial statements are presented in Indian Rupees (Rs.), which is also the Company's functional currency. All amounts have been rounded to the nearest lakhs, unless otherwise indicated.

d) Current and non-current classification:

The Company classifies an asset as current when:

- it expects to realise the asset, or intends to sell or consume it, in its normal operating cycle;
 - it expects to realise the asset within twelve months after the reporting period;
 - it holds the asset primarily for the purpose of trading; or
 - the asset is cash or cash equivalent unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.
- All other assets are classified as non current.

A liability is classified as a current when

- it is expected to be settled in the Company's normal operating cycle;
 - the liability is due to be settled within twelve months from the reporting period;
 - it is held primarily for the purposes of being trading;
 - it does not hold an unconditional right to defer settlement of the liability for at least twelve months after the reporting period. Terms of a liability that could, at the option of the counter party, result in its settlement by the issue of equity instruments do not affect its classification.
- All other liabilities are classified as non-current.

The operating cycle is the time between the acquisition of assets for processing and realisation in cash or cash equivalents. The Company's normal operating cycle is twelve months.

e) Significant accounting policies

i.) Revenue recognition

Revenue from the sale of goods is recognized when ownership, along with all significant risks and rewards, has been transferred to the buyer, and when there is no significant uncertainty regarding the amount of consideration to be received from the sale.

Revenue from the sale of services is recognized using the completed service contract method, provided there is no significant uncertainty regarding the amount of consideration to be received for rendering the service.

Sales are accounted for net of amounts recovered towards GST and sales returns.

Sales returns are recorded upon the actual receipt of returned goods or the settlement of claims.

Revenue arising from the use by others of enterprise resources yielding interest and dividends should only be recognised when no significant uncertainty as to measurability or collectability exists. These revenues are recognised on the following bases:

Interest: On a time proportion basis taking into account the amount outstanding and the rate applicable.

Dividends: When the owner's right to receive payment is established.

ii.) Inventories

Inventories comprise of diagnostic kits, reagents, laboratory chemicals and consumables, these are measured at lower of cost and net realisable value. The cost of inventories is based on the first in first out (FIFO) cost formula and includes expenditure incurred in acquiring the inventories and other costs incurred in bringing them to their present location and condition. Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs necessary to make the sale. The comparison of cost and net realisable value is made on an item-by-item basis.

iii.) Property, plant & equipments
The cost of an item of property, plant and equipment shall be recognised as an asset if, and only if it is probable that future economic benefit associated with the item will flow to the Company and the cost of the item can be measured reliably. Items of property, plant and equipment (including capital-work-in progress) are measured at cost, which includes capitalised borrowing costs, less accumulated depreciation and any accumulated impairment losses. Freehold land is carried at historical cost less any accumulated impairment losses.
Cost of an item of property, plant and equipment comprises its purchase price, including non refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the items to its working conditions for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.
The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labour, any other costs directly attributable to bringing the item to working condition for its intended use, and estimated costs of dismantling and removing the item and restoring the site on which it is located.
Any gain or loss on disposal of an item of property, plant and equipment is recognised in profit or loss.
An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of asset.
Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Company and the cost of the item can be measured reliably.
iv.) Intangible assets
Intangible assets that are acquired, are recognized at cost initially and carried at cost less accumulated amortization and accumulated impairment loss, if any. Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates.
v.) Depreciation & Amortisation
Depreciation is recognised so as to write off the cost of assets (other than freehold land) less their residual values over their useful lives.
The Company has charged depreciation on property, plant & equipment (PPE) based on the Straight linen Method(SLM) as per useful life specified in schedule II of the Companies Act, 2013.
Amortisation is calculated to write off the cost of intangible assets over their estimated useful lives using the straight line method (SLM) and is included in depreciation and amortisation expense in statement of profit and loss.
Depreciation and amortisation on additions and deletions are restricted to the period of use.
Residual value is considered to be 5% on all the tangible assets.
Assets costing below Rs. 5,000 are depreciated using depreciation rate at 100%.
Depreciation and amortisation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.
vi.) Employee benefits
Short-term employee benefits
Short term employee benefits are measured on an undiscounted basis and expensed as the related service is provided. A short term liability is recognised if the Company has a present legal or constructive obligation to pay the amount as a result of past service provided by the employee and the obligation can be estimated reliably.
Defined contribution plans
A defined contribution plan is a post-employment benefit plan where the company's legal or constructive obligation is limited to the amount that it contributes to a separate legal entity. The company makes specified monthly contributions towards government administered provident fund scheme and employees' state insurance ('ESI') scheme. The company makes specified monthly contributions towards government administered provident fund scheme and employees' state insurance ('ESI') scheme. Obligations for contributions to defined contribution plans are expensed as an employee benefits expense in statement of profit and loss in the period in which the related services are rendered by employees.
Defined benefit plans
A defined benefit plan is a post-employment benefit plan other than a defined contribution plan. The company has a defined benefit plan namely gratuity for all its employees. Liability for defined benefit plan is provided on the basis of valuations, as at the balance sheet date, carried out by an independent actuary. The actuarial valuation method used by independent actuary for measuring the liability is the Projected Unit Credit Method. Actuarial gains and losses due to changes in actuarial assumptions and are recognised immediately in the profit and loss account as income or expense. Current and non current liabilities are recognised on the basis of actuarial report.
vii.) Lease
Lease contracts entered by the company majorly pertains for buildings taken on operating lease to conduct its business in the ordinary course. Leases where the lessor effectively retains substantially all the risks and benefits of the leased assets are classified as operating leases. Operating lease payments are recognized in the statement of profit and loss on a straight line basis over the lease term. Lease agreements are renewable for further period or periods on terms and condition as mutually agreed with the lessor. Variation or escalations clauses in lease rentals are made as per mutually agreed terms and conditions with the lessor.
viii.) Impairment of assets

An asset is treated as impaired when the carrying cost of assets exceeds its recoverable value. An impairment loss is charged to the statement of profit and loss in the year in which an asset is identified as impaired. The impairment loss recognised in prior accounting period is increased/ reversed where there has been change in the estimate of recoverable value. The recoverable value is the higher of the assets' net selling price and value in use. At each reporting date, the Company reviews the carrying amount of assets, to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

ix.) Investments

Current Investments are carried at lower of cost and market value computed Investment wise. Long Term Investments are stated at cost or fair value. Provision for diminution in the value of long term investments is made only if such a decline is other than temporary in the opinion of the management.

x.) Income-tax

Provision for income tax is made on the basis of taxable income for the year at current rates. Tax expense comprises of current tax and deferred tax at the applicable enacted or substantively enacted rates. Current tax represents the amount of income tax payable/ recoverable in respect of the taxable income/ loss for the reporting period. Deferred tax represents the effect of timing difference between taxable income and accounting income for the reporting period that originate in one period and are capable of reversal in one or more subsequent periods.

The deferred tax asset is recognised and carried forward only to the extent that there is a reasonable certainty that the assets will be realised in future. However, where there is unabsorbed depreciation or carried forward loss under taxation laws, deferred tax assets are recognised only if there is virtual certainty of realisation of assets.

Minimum Alternate Tax (MAT) paid in a year is charged to the statement of profit and Loss as current tax. The company recognizes the MAT credit available as an asset only to the extent that there is convincing evidence that the company will pay the normal income tax during the specified period i.e., period for which MAT credit is allowed to be carried forward.

xi.) Provision, contingent liabilities and contingent assets

A provision is recognised when the company has a present obligation (legal or constructive) as a result of past event and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on Management's estimate for the amount required to settle the obligation at the balance sheet date.

Contingent liability is a possible obligation arising from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity or a present obligation that arises from past events but is not recognized because it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation or the amount of the obligation cannot be measured with sufficient reliability. The Company does not recognize a contingent liability but discloses its existence in the financial statements.

Contingent assets are neither recognised nor disclosed in the financial statements, since this may result in the recognition of income that may never be realised. However, when the realisation of income is virtually certain, then the related asset is not a contingent asset and is recognized.

Provisions, contingent liabilities and contingent assets are reviewed at each balance sheet date.

xii.) Earnings per share

Basic Earnings per share

Basic Earnings Per Share ('EPS') is calculated by dividing the profit attributable to the equity shareholders of the company by the weighted average number of equity shares outstanding during the year.

Diluted Earnings per share

Diluted earnings per share is computed by dividing the profit (considered in determination of basic earnings per share) after considering the effect associated with dilutive potential equity shares by the weighted average number of equity shares considered for deriving basic earnings per share adjusted for the weighted average number of equity shares that would have been issued upon conversion of all dilutive potential equity shares.

xiii.) Cash flow statement

Cash flows are reported using the indirect method, whereby profit for the year is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows are segregated into operating, investing and financing activities. The Company considers all highly liquid investments that are readily convertible to known amounts of cash to be cash equivalents.

xiv.) Cash and cash equivalents

Cash and cash equivalents in the balance sheet and cash flow statement consists of cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities less than three months which are readily convertible to known amounts of cash and which are subject to insignificant risk of changes in value.

xv.) Dividend

The company recognises a liability for any dividend declared but not distributed at the end of the reporting period, when the distribution is authorised and the distribution is no longer at the discretion of the company on or before the end of the reporting period.

xvi.) Related parties transactions

The company has a policy to recognize and identify related party transactions; disclosures of related party transactions have been made wherever applicable.

xvii.) Foreign Currency Transactions

Foreign exchange transactions are recorded at the rates prevailing on the date of transactions. Exchange rate differences arising on foreign exchange transactions settled during the year are recognized in the statement of profit and loss for the year. Monetary assets and liabilities denominated in foreign currencies as at the balance sheet date are translated at the closing exchange rates on that date and the resultant exchange differences are recognized in the statement of profit and loss. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency should be reported using the exchange rate at the date of the transaction. Non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency should be reported using the exchange rates that existed when the values were determined.

xviii.) Borrowing Costs

Borrowing costs that are attributable to acquisition, construction or production of qualifying assets are capitalised as part of such assets. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are recognised as an expense in the period in which they are incurred.

xix.) Events after reporting date

Where events occurring after the balance sheet date provide evidence of conditions that existed at the end of the reporting period, the impact of such events is adjusted within the financial statements. Otherwise, events after the balance sheet date of material size or nature are only disclosed.

NOTE NO. :- 3 : SHARE CAPITAL		
a. Information on authorised, issued, subscribed and paid-up shares		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Authorised		
Equity shares with voting rights	3,000.00	2,500.00
(Current year : 30000000 equity shares of Rs.10/- each)		
(Previous year : 25000000 equity shares of Rs.10/- each)		
Total...	3,000.00	2,500.00
Issued		
Equity shares with voting rights	2,445.21	2,445.21
(Current year : 24452064 equity shares of Rs.10/- each)		
(Previous year : 24452064 equity shares of Rs.10/- each)		
Total...	2,445.21	2,445.21
Subscribed and fully paid		
Equity shares with voting rights FP	2,445.21	2,445.21
(Current year : 24452064 equity shares of Rs.10/- each)		
(Previous year : 24452064 equity shares of Rs.10/- each)		
Total...	2,445.21	2,445.21

PARTICULARS	FIGURES AS AT 31ST MARCH, 2026			FIGURES AS AT 31ST MARCH, 2025		
	No of shares	Paid up value per share	Amount	No of shares	Paid up value per share	Amount
Equity shares with voting rights, subscribed and fully paid						
Shares outstanding at the beginning of the year	2,44,52,064	10	2,445.21	2,00,00,000.00	10.00	2,000.00
Add: Fresh shares issued during the year	-	-	-	44,52,064.00	10.00	445.21
Add: Bonus shares issued during the year	-	-	-	-	-	-
Less: Shares forfeited/bought back during the year	-	-	-	-	-	-
Shares outstanding at the end of the year	2,44,52,064	10	24,45,20,640	2,44,52,064.00	10.00	2,445.21

b. Rights, preferences and restrictions of different classes of shares including restrictions on the distribution of dividends and the repayment of capital

Equity shares with voting rights, subscribed and fully paid						
As to dividend:	The shareholders are entitled to receive dividend in proportion to the amount paid up on the equity shares held by them.					
As to repayment of capital:	In the event of liquidation of the company, the holders of equity shares will be entitled to receive any of the remaining assets of the company after distribution of all preferential amounts. The distribution will be in proportion of the number of shares held by the shareholders.					
As to voting:	The company has only one class of shares referred to as equity shares having a par value of Rs. 10/-. Each holder of the equity share is entitled to one vote per share.					

c. Details of shareholders holding more than 5% shares of the Company

Name of shareholder	Figures As At 31st March, 2026			Figures As At 31st March, 2025		
	No of shares	Paid up value per share	Percentage (%)	No of shares	Paid up value per share	Percentage (%)
Equity shares with voting rights, subscribed and fully paid						
Name of shareholder						
- Amar Anita Holdings (India) Private Limited	41,28,064.00	10	16.88%	41,24,064.00	10	16.87%
- Amar Singh	23,46,260.00	10	9.60%	23,25,460.00	10	9.51%
- Vinay Lamba	15,84,800.00	10	6.48%	15,84,800.00	10	6.48%
- Other shareholders*	1,63,92,940.00	10	67.04%	1,64,17,740.00	10	67.14%
Total...	2,44,52,064.00		100%	2,44,52,064.00		100%

*Other shareholders, each holding less than 5% of the total shares, are included here to ensure reconciliation of the total share count with the notes provided above.

d. Disclosure of shareholding of promoters:

As at 31st March, 2026						
Name of promoter	No of shares as at the beginning of year	Addition	Deletion	No of shares as at the end of year	% of total shares	% Change during the year
Equity shares with voting rights, subscribed and fully paid						
Name of promoter*						
-Alok Singh	300000.00	-	-	3,00,000.00	1.50%	0.00%
-Amar Singh	2325460.00	20,800.00	-	23,46,260.00	11.73%	0.89%
-AmarAnita Holdings (India) Pvt Ltd	4124064.00	4,000.00	-	41,28,064.00	20.64%	0.10%
-Asmita Singh	167600.00	-	-	1,67,600.00	0.84%	0.00%
-Shaleen Solanki	900000.00	-	-	9,00,000.00	4.50%	0.00%
-Vijay Singh	899400.00	-	-	8,99,400.00	4.50%	0.00%
-Vinay Lamba	1584800.00	-	-	15,84,800.00	7.92%	0.00%

d. Disclosure of shareholding of promoters:

As at 31st March, 2025						
Name of promoter	No of shares as at the beginning of year	Addition	Deletion	No of shares as at the end of year	% of total shares	% Change during the year
Equity shares with voting rights, subscribed and fully paid						
Name of promoter*						
-Alok Singh	3,00,000.00	-	-	3,00,000.00	1.23%	0.00%
-Amar Singh	23,19,860.00	5,600.00	-	23,25,460.00	9.51%	0.24%
-AmarAnita Holdings (India) Pvt Ltd	58,43,000.00	-	17,18,936.00	41,24,064.00	16.87%	-29.42%
-Asmita Singh	1,62,000.00	5,600.00	-	1,67,600.00	0.69%	3.46%
-Shaleen Solanki	9,00,000.00	-	-	9,00,000.00	3.68%	0.00%
-Vijay Singh	8,99,400.00	-	-	8,99,400.00	3.68%	0.00%
-Vinay Lamba	15,84,800.00	-	-	15,84,800.00	6.48%	0.00%

*Individuals designated or to be designated by the company as promoters in its annual return.

NOTE NO. :- 4 : RESERVES AND SURPLUS

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
-------------	--------------------------------	--------------------------------

NOTE NO. :- 4 : RESERVES AND SURPLUS

Securities premium account		
Securities premium account	7,804.13	5,781.92
Total A	7,804.13	5,781.92
Surplus/Retained earning		
Opening balance Reserves & Surplus	4,033.17	2,116.09
Less :- Dividend on equity shares	-	(300.00)
Less: Minority Interest in Opening Reserve & Surplus(Credit Balance)-R&S	-	-
Add: Minority Interest in opening Reserve & Surplus(Debit Balance)-R&S	-	-
Add: Parent Interest in pre-acquisition loss-R&S	-	-
Less: Parent Interest in pre-acquisition profit-R&S	-	-
Less :- Issue of bonus share	-	-
Add :- Transfer from	-	-
Less :- Transfer to	-	-
Add :- Profit/(Loss) for the period	2,705.74	2,217.08
Total B	6,738.91	4,033.17
Closing balance (A+B)	14,543.04	9,815.09

NOTE NO. :- 7 : LONG-TERM BORROWINGS

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Secured		
Bonds LTBS	-	-
Debentures LTBS	-	-
Term loans		
- From banks LTBS	2,897.34	2,214.46
- From other parties LTBS	-	-
Deferred payment liabilities		
- Deferred GST/Income tax liabilities LTBS	-	-
- Defferred payments for the acquisition of tangible and intangible assets LTBS	-	-
Deposits		
- Deposits accepted from the public LTBS	-	-
- Inter company deposits LTBS	-	-
- Other deposits in the nature of borrowings LTBS	-	-
Loans and advances from related parties LTBS	-	-
Finance lease obligation due beyond 12 months LTBS	-	-
Other loans and advances LTBS	-	-
Unsecured		
Bonds LTBUS	-	-
Debentures LTBUS	-	-

NOTE NO. :- 7 : LONG-TERM BORROWINGS

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Term loans		
- From banks LTBUS	-	-
- From other parties LTBUS	-	-
Deferred payment liabilities		
- Deferred GST/Income tax liabilities LTBUS	-	-
- Defferred payments for the acquisition of tangible and intangible assets LTBUS	-	-
Deposits		
- Deposits accepted from the public LTBUS	-	-
- Inter company deposits LTBUS	-	-
- Other deposits in the nature of borrowings LTBUS	-	-
Loans and advances from related parties LTBUS	-	-
Finance lease obligation due beyond 12 months LTBUS	-	-
Other loans and advances LTBUS	-	-
Total...	2,897.34	2,214.46
a. Reconciliation of current and non current portion of long term liabilities		

Particulars	Figures As At 31st March, 2026			Figures As At 31st March, 2025		
	Non current	Current	Total	Non current	Current	Total
Secured						
Term loans						
- From banks LTBS	2,897.34	1,278.11	4,175.45	2,214.46	734.29	2,948.75
- From other parties LTBS	-	-	-	-	-	-
Unsecured						
- From other parties LTBUS	-	-	-	-	-	-
Total...	2,897.34	1,278.11	4,175.45	2,214.46	734.29	2,948.75

B. OTHER DISCLOSURE ON TERM LOAN

Particulars	Figures as at the end of 31st March, 2026		Figures as at the end of 31st March, 2025		Details of repayment terms and maturity*		Nature of Security
	Amount	ROI	Amount	ROI	Particulars	Terms	
Secured							
Term Loan from Bank							

B. OTHER DISCLOSURE ON TERM LOAN							
Particulars	Figures as at the end of 31st March, 2026		Figures as at the end of 31st March, 2025		Details of repayment terms and maturity*		Nature of Security
Indusind Bank [732000008552]	-	-	40.82	8.75%	Sanction date	01/07/2022	The loan is secured by a first pari passu charge on the assets acquired using the proceeds of this loan, establishing a primary security interest.
					Principal amount	340.24	
					EMI amount	10.74	
					Loan period (Month)#	36.00	
					Last Instalment date	07/08/2025	
Yes Bank Limited [MEN00180126]	30.00	9.00%	50.31	9.00%	Sanction date	21/07/2022	
					Principal amount	96.66	
					EMI amount	2.00	
					Loan period (Month)#	60.00	
					Last Instalment date	22/07/2027	
Yes Bank Limited [MEN001801285372]	6.67	7.95%	10.86	7.95%	Sanction date	09/08/2022	
					Principal amount	20.20	
					EMI amount	0.42	
					Loan period (Month)#	60.00	
					Last Instalment date	22/08/2027	
HDFC Loan A/c No. [800450335]	79.23	9.50%	146.96	9.50%	Sanction date	22/08/2024	The loan is secured by the following: 1. Primary Security:- A first pari passu charge on the assets acquired with the proceeds of the loan. This gives the lender a primary claim on these assets, ensuring that their security interest is prioritized above other claims. 2. Personal Guarantee: A guarantee provided by all directors of the borrowing entity, holding them personally liable for the loan obligations in the event of default by the borrowing entity.
					Principal amount	178.13	
					EMI amount	6.50	
					Loan period (Month)#	31	
					Last Instalment date	07/04/2027	
HDFC Loan A/c No. [800450336]	-	-	2.45	9.50%	Sanction date	22/08/2024	
					Principal amount	9.57	

B. OTHER DISCLOSURE ON TERM LOAN							
Particulars	Figures as at the end of 31st March, 2026		Figures as at the end of 31st March, 2025		Details of repayment terms and maturity*		Nature of Security
					EMI amount	1.24	
					Loan period (Month)#	8	
					Last Instalment date	07/05/2025	
HDFC Loan A/c No. [800487587]	15.23	9.50%	29.46	9.50%	Sanction date	22/08/2024	
					Principal amount	35.99	
					EMI amount	1.35	
					Loan period (Month)#	30.00	
					Last Instalment date	07/03/2027	
HDFC Loan A/c No. [99903818]	-	-	9.17	9.50%	Sanction date	22/08/2024	
					Principal amount	22.43	
					EMI amount	2.34	
					Loan period (Month)#	10	
					Last Instalment date	07/07/2025	
Axis bank Loan A/c No. [9250600510 13619]	361.09	8.80%	-	-	Sanction date	23/05/2025	PLANT AND MACHINERY 1 UNIT OF GE
					Principal amount	384.20	MADE REFURBISHED MRI MACHINE
					EMI amount	8.30	MODEL SIGMA HDXT WITH STANDARD
					Loan period (Month)#	60	ACCESSORIES FROM MEDISER SCAN
					Last Instalment date	05/07/2030	TECHNOLOGY PVT LTD
Axis bank Loan A/c No. [9250600534 47029]	277.30	8.05%	-	-	Sanction date	30/12/2025	PLANT AND MACHINERY-1 NO. OF PREOWNED GE CT SCAN SYSTEM "OPTIMA 660" 64 / 128 SLICE
					Principal amount	306.49	
					EMI amount	648811.00	
					Loan period (Month)#	60.00	
					Last Instalment date	05/08/2030	
Axis bank Loan A/c No. [9250600534 48132]	116.76	8.05%	-	-	Sanction date	30/12/2025	PLANT AND MACHINERY-1 NO. OF PREOWNED GE CT SCAN SYSTEM "OPTIMA 660" 128 SLICE
					Principal amount	116.76	
					EMI amount	247166.00	
					Loan period (Month)#	29/02/1900	
					Last Instalment date	05/10/2029	

B. OTHER DISCLOSURE ON TERM LOAN							
Particulars	Figures as at the end of 31st March, 2026		Figures as at the end of 31st March, 2025		Details of repayment terms and maturity*		Nature of Security
Axis bank Loan A/c No. [9250600534 50685]	116.76	8.05%	-	-	Sanction date	30/12/2025	PLANT AND MACHINERY-1 NO. OF PREOWNED
					Principal amount	116.76	GE CT SCAN SYSTEM "OPTIMA
					EMI amount	247166.00	660" 64 / 128 SLICE
					Loan period (Month)#	29/02/1900	
					Last Instalment date	05/10/2029	
HDFC Loan A/c No. [164897649]	437.19	9.75%	-	-	Sanction date	03/09/2025	
					Principal amount	475.00	
					EMI amount	10.03	
					Loan period (Month)#	60.00	
					Last Instalment date	06/09/2030	
HDFC Loan A/c No. [167167201]	5.97	9.49%	-	-	Sanction date	02/01/2026	Hypothecation of New Four Wheeler.
					Principal amount	613000.00	
					EMI amount	12755.00	
					Loan period (Month)#	60.00	
					Last Instalment date	07/01/2031	
HDFC Loan A/c No. [167868048]	5.97	9.49%	-	-	Sanction date	02/01/2026	Hypothecation of New Four Wheeler.
					Principal amount	613000.00	
					EMI amount	12755.00	
					Loan period (Month)#	60.00	
					Last Instalment date	07/01/2031	
ICICI Bank Loan A/c No. [LDLUC00051 942402]	2.55	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	255150.00	
					EMI amount	5316.00	
					Loan period (Month)#	60.00	
					Last Instalment date	01/03/2031	
ICICI Bank Loan A/c No. [LDLUC00051 942411]	2.79	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	278775.00	
					EMI amount	5808.00	
					Loan period (Month)#	60.00	
					Last Instalment date	01/03/2031	

B. OTHER DISCLOSURE ON TERM LOAN							
Particulars	Figures as at the end of 31st March, 2026		Figures as at the end of 31st March, 2025		Details of repayment terms and maturity*		Nature of Security
ICICI Bank Loan A/c No. [LDLUC00051 942413]	21.26	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	2126250.00	
					EMI amount	44293.00	
					Loan period (Month)#	60.00	
					Last Instalment date	01/03/2031	
ICICI Bank Loan A/c No [LDLUC00051 942476]	13.70	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	1370250.00	
					EMI amount	28545.00	
					Loan period (Month)#	60.00	
					Last Instalment date	01/03/2031	
ICICI Bank Loan A/c No. [LDLUC00051 942479]	3.21	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	321300.00	
					EMI amount	6694.00	
					Loan period (Month)#	60.00	
					Last Instalment date	01/03/2031	
ICICI Bank Loan A/c No [LDLUC00052 067840]	66.15	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	6615000.00	
					EMI amount	137339.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/03/2031	
ICICI Bank Loan A/c No [LDLUC00052 067859]	16.44	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	1644300.00	
					EMI amount	34139.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/03/2031	
ICICI Bank Loan A/c No [LDLUC00052 067932]	28.92	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	2891700.00	
					EMI amount	60037.00	
					Loan period (Month)#	60.00	

B. OTHER DISCLOSURE ON TERM LOAN							
Particulars	Figures as at the end of 31st March, 2026		Figures as at the end of 31st March, 2025		Details of repayment terms and maturity*		Nature of Security
					Last Instalment date	20/03/2031	
ICICI Bank Loan A/c No [LDLUC00052 067947]	3.64	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	363825.00	
					EMI amount	7554.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/03/2031	
ICICI Bank Loan A/c No. [LDLUC00052 067990]	32.89	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	3288600.00	
					EMI amount	68278.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/03/2031	
ICICI Bank Loan A/c No [LDLUC00052 068088]	3.29	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	328860.00	
					EMI amount	6828.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/03/2031	
ICICI Bank Loan A/c No [LDLUC00052 068101]	3.64	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	363825.00	
					EMI amount	7554.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/03/2031	
ICICI Bank Loan A/c No [LDLUC00052 107671]	14.82	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	1482300.00	
					EMI amount	30894.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/04/2031	
ICICI Bank Loan A/c No [LDLUC00052 107679]	27.23	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	2722500.00	
					EMI amount	56741.00	

B. OTHER DISCLOSURE ON TERM LOAN							
Particulars	Figures as at the end of 31st March, 2026		Figures as at the end of 31st March, 2025		Details of repayment terms and maturity*		Nature of Security
					Loan period (Month)#	60.00	
					Last Instalment date	20/04/2031	
ICICI Bank Loan A/c No [LDLUC00052 107681]	14.00	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	1399500.00	
					EMI amount	29168.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/04/2031	
ICICI Bank Loan A/c No [LDLUC00052 107691]	14.00	8.75%	-	-	Sanction date	19/01/2026	Hypothecation of financed medical equipment
					Principal amount	1399500.00	
					EMI amount	29168.00	
					Loan period (Month)#	60.00	
					Last Instalment date	20/04/2031	
PNB LOAN A/c No. [241400CN00 000057]	1,414.29	8.80%	1,552.44	8.80%	Sanction date	27/07/2024	The loan is secured by a first pari passu charge on the assets acquired using the proceeds of this loan, establishing a primary security interest.
					Principal amount	1,650.00	
					EMI amount	19.64	
					Loan period (Month)#	84	
					Last Instalment date	30/04/2032	
PNB LOAN A/c No. [241400NG00 259653]	12.77	8.80%	15.84	8.80%	Sanction date	04/10/2024	Hypothecation of New Four Wheeler.
					Principal amount	17.00	
					EMI amount	0.35	
					Loan period (Month)#	60.00	
					Last Instalment date	30/09/2030	
Punjab National Bank [241400CH00 000028]	752.72	7.95%	1,090.44	7.95%	Sanction date	31/03/2023	The loan is secured by: 1. A first pari passu charge on the assets acquired with the proceeds of the loan. 2. The personal guarantee of all directors of the borrowing entity. 3. The corporate guarantee of AmarAnita Holdings (India) Pvt Ltd.
					Principal amount	1,530.00	
					EMI amount	39.36	
					Loan period (Month)#	48.00	

B. OTHER DISCLOSURE ON TERM LOAN							
Particulars	Figures as at the end of 31st March, 2026		Figures as at the end of 31st March, 2025		Details of repayment terms and maturity*		Nature of Security
					Last Instalment date	31/03/2028	
Total...	3,900.45		2,948.75				
Less:- Current maturities of all long-term borrowings	(1,003.11)		(734.29)				
Total...	2,897.34		2214.46				
* These are with respect to the balance sheet date.							
# The figures are presented in absolute terms and are not expressed in lakhs.							

NOTE NO. :- 5 : MONEY RECEIVED AGAINST SHARE WARRANTS		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Money received against share warrants-BS	111.25	-
Total...	111.25	-
a. Disclosures on share warrants		
Particulars	Disclosures	
Name of Company	Chandan Healthcare Limited	
Nature of Instrument	44,50,000 Convertible Warrants	
Date of Board Approval	10 October 2025	
Date of Shareholders Approval (EGM)	06 November 2025	
Allotment Date	04 February 2026	
Issue Price per Warrant	₹234 per warrant	
Face Value of Equity Share	₹10 per equity share	
Premium per Equity Share	₹224 per equity share	
Total Issue Size	₹104,13,00,000	
Number of Warrants Issued	44,50,000 warrants	
Terms of Conversion	1 warrant convertible into 1 fully paid-up equity share	
Conversion Period	Within 18 months from allotment date	
Upfront Amount Payable	25% of warrant issue price at allotment	
Balance Amount Payable	75% payable within 18 months	
Exercise / Conversion Price	₹234 per warrant	
Rights Attached	Equity shares allotted upon conversion shall rank pari passu with existing equity shares including voting and dividend rights	
Voting Rights before Conversion	No voting rights until conversion into equity shares	
Dividend Rights before Conversion	Not applicable prior to conversion	
Whether Warrants are Transferable	Subject to applicable SEBI ICDR Regulations and Companies Act provisions	
Whether Amount is Forfeitable	Yes, upfront amount liable to forfeiture in case of non-exercise within prescribed period	
Status as on Reporting Date	Outstanding	
Purpose of Issue	Business expansion, acquisitions and general corporate purposes	
Business Expansion Utilisation	₹44.50 Crore	
Acquisition Utilisation	₹50.00 Crore	
General Corporate Purpose Utilisation	₹9.63 Crore	
Relevant Date under SEBI ICDR	07 October 2025	

NOTE NO. :- 6 : MINORITY INTEREST		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Opening Balance-MI	380.57	246.02
Minority Interest In Share Capital-MI	0.01	-
Add: Minority Interest in Opening Reserve & Surplus(Credit Balance)-MI	-	-
Less: Minority Interest in opening Reserve & Surplus(Debit Balance)-MI	-	-
Add: Minority Interest in current period Profit-MI	149.66	134.89
Less: Minority Interest in current period loss-MI	(0.04)	(0.34)
Total...	530.20	380.57

NOTE NO. :- 8 : DEFERRED TAX LIABILITIES(NET)		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Deferred tax liabilities(Net)	235.54	190.33
Total...	235.54	190.33
a. Disclosures regarding the components of net deferred tax liabilities		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Provision for gratuity	(122.20)	294.78
Provision for doubtful debts	(0.46)	(95.17)
Provision for obsolete inventories	(4.03)	(5.17)
Provision for leave encashment	(6.17)	-
W.D.V of property, plant & equipments & intangible assets	368.41	(4.12)
Total...	235.54	190.33

NOTE NO. :- 9 : OTHER LONG -TERM LIABILITIES		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Trade payables		
- Total outstanding dues of micro enterprises and small enterprises OLTL	-	-
- Total outstanding dues of other then micro enterprises and small enterprises OLTL	-	-
Other long-term liabilities		
- Trade deposits and security deposits which are not in the nature of borrowings OLTL	2.20	2.45
- Others(Specifying the nature) OLTL	-	-
Total...	2.20	2.45

NOTE NO. :- 10 : LONG TERM PROVISIONS		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025

NOTE NO. :- 10 : LONG TERM PROVISIONS		
Provision for gratuity LTP	460.48	343.69
Others(specifying the nature) LTP	-	-
Total...	460.48	343.69
a. Details of employee benefits as required by the accounting standard 15 (revised) employee benefits are as under:		
The company has classified the various benefits provided to employee's as under:-		
I. Defined contribution plans		
a. Employee's provident fund.		
b. Employee's state insurance.		
During the year, the company has recognised the following amounts in the profit and loss account:		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Employers' contribution to provident fund*	53.36	95.66
Employers' contribution to employee's state insurance*	49.41	31.96
Total...	102.77	127.61
* Included in Contribution to Provident and Other Funds (Refer Note No. 28 Employee benefits expense)		
II. Defined benefit plans		
Gratuity disclosures as per accounting standard-15		
(i) Table Showing Changes in Present Value of Obligations		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Present value of the obligation at the beginning of the period	412.73	340.43
Interest cost	27.95	24.68
Current service cost	105.10	70.47
Past Service Cost	291.54	-
Benefits paid (if any)	(6.05)	(11.97)
Actuarial (gain)/loss	(291.90)	(10.88)
Present value of the obligation at the end of the period	539.36	412.73
(ii) Key results (The amount to be recognized in the Balance Sheet):		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Present value of the obligation at the end of the period	539.36	412.73
Fair value of plan assets at end of period	-	-
Net liability/(asset) recognized in Balance Sheet and related analysis	539.36	412.73
Funded Status - Surplus/ (Deficit)	(539.36)	(412.73)
(iii) Expense recognized in the statement of Profit and Loss:		

NOTE NO. :- 10 : LONG TERM PROVISIONS

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Interest cost	27.95	24.68
Current service cost	105.10	70.47
Past Service Cost	291.54	-
Expected return on plan asset	-	-
Net actuarial (gain)/loss recognized in the period	(291.90)	(10.88)
Expenses to be recognized in P&L #	132.68	84.27
# Included in Provision for gratuity (Refer Note No. 28 Employee benefits expense)		
(iv) Current & Non Current Liability :		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Current Liability (Short Term)^	79.15	69.04
Non Current Liability (Long Term)	460.21	343.69
Total Liability	539.36	412.73
^ Included in Provision for gratuity (Refer Note No. 12 Short term provisions)		
(v) Reconciliation of liability in balance sheet		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Opening gross defined benefit liability/(asset)	412.73	340.43
Expenses to be recognized in P&L	132.68	84.27
Benefits paid (if any)	(6.05)	(11.97)
Closing gross defined benefit liability/(asset)	539.36	412.73
(vi) Actuarial assumptions provided by the company and employed for the calculations are tabulated:		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Discount rate	7.00 % per annum	7.00 % per annum
Salary Growth Rate	8.00 % per annum	8.00 % per annum
Mortality	IALM 2012-14	IALM 2012-14
Expected rate of return	-	-
Attrition / Withdrawal Rate (per Annum)	10.00% p.a.	10.00% p.a.

NOTE NO. :- 11 : SHORT-TERM BORROWINGS

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Secured		
Loans repayable on demand		
- From banks-Overdraft(OD) SSTB	-	70.51
- From banks-Cash credit(CC) SSTB	1,199.16	1,097.13

NOTE NO. :- 11 : SHORT-TERM BORROWINGS

- From other parties SSTB	-	-
Loans and advances from related parties SSTB	-	-
Deposits in the nature of borrowings SSTB	-	-
Current maturities of all long-term borrowings		
- From banks SSTB_CMLTB	1,278.11	734.29
- From other parties SSTB_CMLTB	-	-
Other loans and advances in the nature of loan (specify nature) SSTB	-	-
Unsecured		
Loans repayable on demand		
- From banks-Overdraft(OD) USSTB	-	-
- From banks-Cash credit(CC) USSTB	-	-
- From other parties USSTB	-	-
Loans and advances from related parties USSTB	-	699.99
Deposits in the nature of borrowings USSTB	-	-
Current maturities of all long-term borrowings		
- From banks USSTB_CMLTB	-	-
- From other parties USSTB_CMLTB	-	-
Other loans and advances in the nature of loan (specify nature) USSTB	-	-
Total..	2,477.27	2,601.92

Particulars	Figures As At 31st March, 2026		Figures As At 31st March, 2025	
	Amount	Nature of security and other terms	Amount	Nature of security and other terms
Secured				

Loans repayable on demand				
- From banks-Overdraft(OD) SSTB	-	Sanctioned against FDs with ICIC Bank	70.51	Sanctioned against FDs with ICIC Bank
- From banks-Cash credit(CC) SSTB	1,199.16	Hypothecation of stock and book debt	1,097.13	Hypothecation of stock and book debt
- From other parties SSTB				
Loans and advances from related parties SSTB	-		-	

NOTE NO. :- 12 : TRADE PAYABLES

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Trade payables		
- Total outstanding dues of micro enterprises and small enterprises CL	1,617.01	604.13
- Total outstanding dues of other then micro enterprises and small enterprises CL	2,473.22	1,990.04
Total	4,090.23	2,594.17

a. Trade payables ageing schedule

As at 31st March, 2026

Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of payment				TOTAL
			Less than 1 year	1-2 years	2-3 years	More than 3 years	
Not Disputed							
--MSME	-	1,617.01	-	-	-	-	1,617.01
--Others	-	-	2,473.22	-	-	-	2,473.22
Disputed							
--MSME	-	-	-	-	-	-	-
--Others	-	-	-	-	-	-	-
Total...	-	1,617.01	2,473.22	-	-	-	4,090.23
Name of promoter							
Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of payment				TOTAL
			Less than 1 year	1-2 years	2-3 years	More than 3 years	
Not Disputed							
--MSME	-	604.13	-	-	-	-	604.13

--Others	-	-	1,990.04	-	-	-	1,990.04
Disputed							
--MSME	-	-	-	-	-	-	-
--Others	-	-	-	-	-	-	-
Total...	-	604.13	1,990.04	-	-	-	2,594.17
b. Disclosure as per MSMED Act, 2006							
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025					
Payble							
Principle overdue as per MSMED Act,2006.	-	-					
Principle not due as per MSMED Act,2006.	1,617.01	604.13					
Interest payble under section 16 of MSMED Act, 2006							
- On principle paid beyond due date as per MSMED Act,2006	-	-					
- On principle payble beyond due date as per MSMED Act,2006	-	-					
- Carried forward from the last year	-	-					
Other interest	-	-					
Total...	1,617.01	604.13					
Paid							
Principle paid beyond the due date as per MSMED Act,2006	-	-					
Interest paid under section 16 of MSMED Act, 2006	-	-					
Total...	-	-					

NOTE NO.: - 13: OTHER CURRENT LIABILITIES

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Current maturities of finance lease obligations OCL	-	-
Interest accrued but not due on borrowings OCL	-	-
Interest accrued and due on borrowings OCL	21.10	-
Income received in advance OCL	-	-
Unpaid dividends OCL	-	-

NOTE NO. :- 13: OTHER CURRENT LIABILITIES

Application money received for allotment of securities and due for refund and interest accrued thereon OCL	-	-
Trade deposits and security deposits which are not in the nature of borrowings OCL	-	-
Advances from customers OCL	18.25	1.05
TDS payable OCL	48.40	45.90
GST payable OCL	21.90	23.14
Salary, Bonus, Gratuity, Reimbursements etc. payable to staff OCL	406.75	263.65
Contribution towards PF payable OCL	9.74	15.92
Contribution towards ESI payable OCL	5.70	3.42
Income tax payable OCL	479.72	32.39
Other payables (specify nature) OCL	40.54	53.31
Total...	1,052.10	438.78

NOTE NO. :- 14 : SHORT TERM PROVISIONS

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Provision for employee benefits		
Provision for gratuity STP	79.15	69.04
Others		
Provision for dividend STP	-	-
Provision for taxation STP	-	-
Provision for warranties STP	-	-
Other provision(specify nature) STP	27.82	-
	106.97	69.04
a. Disclosures regarding the Other provision(specify nature)		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Provision for leave encashment	27.82	-

NOTE NO. :- 15 : PROPERTY, PLANT & EQUIPMENTS & INTANGIBLE ASSETS

Description	Gross block				Accumulated depreciation			Net block	
	Figures as at the beginning of 1st April, 2025	Additions during the year	Disposals during the year	Figures as at the end of 31st March, 2026	Figures as at the beginning of 1st April, 2025	For the year	Figures as at the end of 31st March, 2026	Figures as at the end of 31st March, 2026	Figures as at the end of 31st March, 2025
Tangible Assets									

NOTE NO. :- 15 : PROPERTY, PLANT & EQUIPMENTS & INTANGIBLE ASSETS

Description	Gross block				Accumulated depreciation			Net block	
Capital Work-In-Progress(CWIP)									
Buildings	410.12	788.71	-	1,198.83	-	-	-	1,198.83	410.12
Total of Capital Work-In-Progress(CWIP) (A)	410.12	788.71	-	1,198.83	-	-	-	1,198.83	410.12
Property, plant and equipment									
Computers	541.52	164.11	-	705.64	423.39	98.69	522.08	183.56	118.14
Electric Installation	137.30	5.92	-	143.22	64.16	10.83	74.99	68.23	73.14
Office Interior & Renovation	833.19	1,110.88	-	1,944.07	331.22	96.00	427.23	1,516.84	501.96
Buildings	322.50	-	-	322.50	100.25	9.98	110.24	212.27	222.25
Plant and equipment	8,764.59	1,885.48	-	10,650.07	2,818.91	629.16	3,448.07	7,202.00	5,945.68
Furniture and fixtures	211.49	47.81	-	259.31	154.72	24.88	179.60	79.71	56.78
Vehicles	166.76	45.01	-	211.76	86.03	18.99	105.01	106.75	80.73
Office equipment	466.69	207.59	-	674.28	273.38	89.45	362.83	311.45	193.31
Total Tangible Assets (B)	12,264.29	5,044.22	-	17,308.51	4,252.06	977.98	5,230.04	9,680.81	7,191.99
Intangible Assets									
Goodwill	443.28	-	-	443.28	-	-	-	443.28	443.28

NOTE NO. :- 15 : PROPERTY, PLANT & EQUIPMENTS & INTANGIBLE ASSETS

Descripti on	Gross block				Accumulated depreciation			Net block	
Total Intangibl e Assets (C)	443.28	-	-	443.28	-	-	-	443.28	443.28
Total (A+B+C)	13,117.6 9	5,832.93	-	18,950.6 2	4,252.06	977.98	5,230.04	11,322.92	8,045.39
Previous Year...	8,427.43	3,870.61	0.13	12,297.9 1	3,578.04	674.48	4,252.52	8,045.39	4,849.39

NOTE NO. :- 16 : NON-CURRENT INVESTMENTS

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Investment property NCI	-	-
Investments in equity instruments NCI	-	114.75
Investments in preference shares NCI	-	-
Investments in government or trust securities NCI	-	-
Investments in debentures or bonds redeemable after 12 month NCI	-	-
Investments in mutual funds NCI	-	-
Investments in partnership firms NCI	-	-
Application money paid towards securities NCI	-	-
Investment in LLP NCI	-	-
Other non-current investments(specify nature) NCI	-	-

NOTE NO. :- 16 : NON-CURRENT INVESTMENTS

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Banks deposits with more than twelve months maturity NCI	784.93	1,616.75
Less: Provision for other than temporary diminution in the value of non current investments NCI	-	-
Less: Adjustments to the carrying amount of investments on account of revaluation etc NCI	-	-
Add: Adjustments to the carrying amount of investments on account of revaluation etc NCI	-	-
Total...	784.93	1,731.50

a. Disclosure on investment in equity instrument
31st March, 2026

Name of body corporate	Nature of Investment	Paid up value/share	Fully or partly paid	(%) holding	No of shares	Issue price	Amount	Basis of Valuation	Quoted/ Unquoted Investment
Total...					-		-		

31st March, 2025

Name of body corporate	Nature of Investment	Paid up value/share	Fully or partly paid	(%) holding	No of shares	Issue price	Amount	Basis of Valuation	Quoted/ Unquoted Investment
Chandan Institute of Medical Science Limited	Associates	10	Fully paid	1.59%	0.43	270	114.75	Valuers Value	Unquoted
Total...					0.43		114.75		

NOTE NO. :- 17 : DEFERRED TAX ASSETS(NET)		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Deferred tax assets(Net)	26.27	18.04
Total...	26.27	18.04
a. Disclosures regarding the components of net deferred tax liabilities		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Provision for gratuity	13.54	8.71
Provision for doubtful debts	0.06	0.02
Provision for Leave encashment	0.83	-
Provision for obsolete inventories	4.45	4.18
W.D.V of property, plant & equipments & intangible assets	7.38	5.13
Total...	26.27	18.04

NOTE NO. :- 18 : LONG -TERM LOANS AND ADVANCES		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Secured, considered good		
Capital Advances SLTLA	-	-
Loans and advances to related parties SLTLA	-	-
Other loans and advances (specify nature) SLTLA	-	-
Unsecured, considered good		
Capital Advances USLTLA	100.00	-
Loans and advances to related parties USLTLA	-	-
Other loans and advances (specify nature) USLTLA	-	-
Total...	100.00	-
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Unsecured, considered good		
Capital Advances	-	-
Advance for Land	100.00	-

NOTE NO. :- 19 : OTHER NON-CURRENT ASSETS		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Secured, considered good		
Long term trade receivables (including trade receivables on deferred credit terms) SONCA	-	-

NOTE NO. :- 19 : OTHER NON-CURRENT ASSETS		
Security Deposits SONCA	-	-
Advance to supplier SLTLA	-	-
Advance to employees SLTLA	-	-
Others (specify nature) SONCA	-	-
Unsecured, considered good		
Long term trade receivables (including trade receivables on deferred credit terms) USONCA	-	-
Security Deposits USONCA	192.67	199.77
Advance to supplier USLTLA	-	-
Advance to employees USITLA	-	-
Income tax refund due USLTLA	54.08	54.08
Others (specify nature) USONCA	-	-
Doubtful		
Long term trade receivables (including trade receivables on deferred credit terms) DDONCA	-	-
Security Deposits DDONCA	-	-
Advance to supplier DDLTLA	-	-
Advance to employees DDLTLA	-	-
Others (specify nature) DDONCA	-	-
Less: Provision for bad and doubtful other non-current assets DDONCA	-	-
Total...	246.75	253.85

NOTE NO. :- 20 : CURRENT INVESTMENTS		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Investment property CI	-	-
Investments in equity instruments CI	-	-
Investments in preference shares CI	-	-
Investments in government or trust securities CI	-	-
Investments in debentures or bonds redeemable within 12 month CI	-	-
Investments in mutual funds CI	-	-
Investments in partnership firms CI	-	-
Application money paid towards securities CI	-	-
Investment in LLP CI	-	-
Other non-current investments(specify nature) CI	-	-

NOTE NO. :- 20 : CURRENT INVESTMENTS		
Bank deposits with more than three months maturity CI	1,211.25	1,583.65
Less: Provision for other than temporary diminution in the value of non current investments CI	-	-
Less: Adjustments to the carrying amount of investments on account of revaluation etc CI	-	-
Add: Adjustments to the carrying amount of investments on account of revaluation etc CI	-	-
Total...	1,211.25	1,583.65

NOTE NO. :- 21 : INVENTORIES		
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Raw materials CI	-	-
Packing materials CI	-	-
Work-in-progress CI	-	-
Finished goods CI	-	-
Stock-in-trade CI	1,811.96	1,533.91
Stores, spares and consumables CI	1,595.65	1,636.14
Loose tools CI	-	-
Goods- In- Transit CI	-	-
Purchased intermediates and components consumed In the manufacturing activities of company CI	-	-
Others (specify nature) CI	-	-
Less: Provision for stock obsolescence CI	(33.71)	(32.98)
Total...	3,373.90	3,137.07

NOTE NO. :- 22 : TRADE RECEIVABLES								
Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025						
Secured, considered good								
Trade receivables STR	-	-						
Unsecured, considered good								
Trade receivables USTR	8,642.28	4,746.49						
Less: Provision for bad and doubtful trade receivables DDTR	(2.07)	(20.60)						

NOTE NO. :- 22 : TRADE RECEIVABLES

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025						
Total...	8,640.21	4,725.89						
31st March, 2026								
Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of receipt					TOTAL
			Less than 6 Month	6 Months - 1 year	1-2 years	2-3 years	More than 3 years	
UnDisputed								
Trade Receivables – considered good	-	2,749.47	5,888.67	-	-	-	-	8,638.14
Trade Receivables – considered doubtful	-	-	2.07	-	-	-	-	2.07
Disputed								
Trade Receivables – considered good	-	-	-	-	-	-	-	-
Trade Receivables – considered doubtful	-	-	-	-	-	-	-	-
Total...	-	2,749.47	5,890.74	-	-	-	-	8,640.21
31st March, 2025								
Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of receipt					TOTAL
			Less than 6 Month	6 Months - 1 year	1-2 years	2-3 years	More than 3 years	
UnDisputed								
Trade Receivables – considered good	-	559.41	4,145.88	-	-	-	-	4,705.29
Trade Receivables – considered doubtful	-	-	20.60	-	-	-	-	20.60
Disputed								
Trade Receivables – considered good	-	-	-	-	-	-	-	-
Trade Receivables – considered doubtful	-	-	-	-	-	-	-	-
Total...	-	559.41	4,166.48	-	-	-	-	4,725.89

NOTE NO. :- 23 : CASH AND BANK BALANCES

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Cash and cash equivalents		
Balances with banks	227.09	555.85
Cheques, drafts on hand	-	-
Demand Deposit With Bank	-	-
Cash on hand	131.12	64.86
Short term(Less then 3 month),highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value.	-	-
Bank deposits with Less than three months maturity	-	-
Others		
Balances with banks to the extent held as margin money or security against the borrowings, guarantees, other commitments	-	-
Repatriation restrictions, if any, in respect of cash and bank balances	-	-
Total...	358.21	620.71

NOTE NO. :- 24 : SHORT-TERM LOANS AND ADVANCES

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Secured, considered good		
Loans and advances to related parties SSTLA	-	-
Other loans and advances (specify nature) SSTLA	-	-
Unsecured, considered good		
Loans and advances to related parties USSTLA	1,763.12	410.68
Other loans and advances (specify nature) USSTLA	-	-
Doubtful		
Loans and advances to related parties DDSSTLA	-	-
Advance to supplier DDSTLA	-	-

Advance to employees DDSTLA	-	-
Other loans and advances (specify nature) DDSSTLA	-	-
Less: Provision for bad and doubtful loans and advances DDSTLA	-	-
Total...	1,763.12	410.68

NOTE NO. :- 25 : OTHER CURRENT ASSETS

Particulars	Figures As At 31st March, 2026	Figures As At 31st March, 2025
Secured		
Input tax credit(ITC)-GST SOCA	19.59	14.30
Security Deposits SOCA	-	-
Prepaid expenses SOCA	16.29	43.27
Advance to supplier SSTLA	-	-
Advance to employees SSTLA	-	-
Other(specify nature) SOCA	-	-
Unsecured		
Security Deposits USOCA	331.51	2.19
Other(specify nature) USOCA	2.97	-
Advance to supplier USSTLA	650.42	97.71
Advance to employees USSTLA	103.49	382.88
Income tax refund due USSTLA	-	28.58
Doubtful		
Advance to supplier DDSTLA	-	-
Advance to employees DDSTLA	-	-
Less: Provision for bad and doubtful other current assets USOCA	-	-
Total...	1,124.27	568.93

NOTE NO. :- 26 : REVENUE FROM OPERATIONS

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Sale of products	12,629	10,580
Sale of services	15,007	12,430
Other operating revenues		
Sale of scrap	4	2
Less: Excise duty	-	-
Total...	27,639	23,012

NOTE NO. :- 27 : OTHER INCOME

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
-------------	---	---

NOTE NO. :- 27 : OTHER INCOME

On current investments		
Interest on fixed deposits C	213.07	72.98
Dividends from subsidiary companies C	-	-
Dividends from other companies C	-	-
Net gain/(loss) on sale of investments C	-	-
On non current investments		
Interest on fixed deposits NC	-	-
Dividends from subsidiary companies NC	-	-
Dividends from other companies NC	-	-
Net gain/(loss) on sale of investments NC	-	-
Other		
Interest from customers on amounts overdue	-	-
Other Interest Income	186.28	-
Net gain/(loss) on sale of property, plant & equipments & intangible assets	-	-
Gain on account of foreign exchange fluctuations	-	-
Share of profits/(losses) in a partnership firm/LLP	-	-
Bad Debts Recovered & Reversal of Payable Write-Off(Net)	3.02	213.15
Write back of excess provisions	19.05	-
Other non-operating income	6.43	7.38
Total...	427.85	293.51

NOTE NO. :- 28 : COST OF MATERIAL CONSUMED

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Raw materials consumed	-	-
Stores,spares and consumables consumed	2,286.65	1,545.88
Packing materials consumed	-	-
Purchased intermediates and components consumed In the manufacturing activities of company	-	-
Total...	2,286.65	1,545.88

Consumption disclosed in Note is on the basis of derived figures rather than actual records of issue.

NOTE NO. :- 29 : PURCHASE OF STOCK-IN-TRADE

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Purchase of stores, spares and consumables	11,359.87	9,498.14

NOTE NO. :- 29 : PURCHASE OF STOCK-IN-TRADE

Total...	11,359.87	9,498.14
----------	-----------	----------

NOTE NO. :- 30 : CHANGE IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND STOCK-IN-TRADE.

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Opening stock:		
Finished goods OS	-	-
Work-in-progress OS	-	-
Stock-in-trade OS	1,533.91	1,251.59
	1,533.91	1,251.59
Closing stock:		
Finished goods CS	-	-
Work-in-progress CS	-	-
Stock-in-trade CS	1,811.96	1,533.91
	1,811.96	1,533.91
Total...	(278.05)	(282.32)

NOTE NO. :- 31 : EMPLOYEE BENEFITS EXPENSE.

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Salaries and wages	4,152.62	3,661.18
Contribution to provident and other funds	102.77	127.61
Provision for gratuity	132.68	84.27
Expense on employee stock option scheme (ESOP) and employee stock purchase plan (ESPP)	-	-
Provision for leave encashment	27.82	-
Staff welfare expense	3.76	13.05
Total...	4,419.65	3,886.11

NOTE NO. :- 32 : FINANCE COSTS

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Interest expense on borrowings	542.58	405.31
Other borrowing costs		
Loan processing charges	11.72	24.00
Bank charges	33.89	28.29
Dividend on redeemable preference shares	-	-

NOTE NO. :- 32 : FINANCE COSTS

Applicable net gain/loss on foreign currency transactions and translation	-	-
	588.19	457.60

NOTE NO. :- 33 : OTHER EXPENSES

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Repair & maintenance - Plant & equipments	199.07	125.35
Repair & maintenance-Building	60.39	40.45
Repair & maintenance - Other	150.87	99.48
Bad debts & Payble Writtenoff(Net)	26.80	88.98
Payment to auditors	33.92	20.80
Rent	1,065.73	636.55
Electricity expenses	415.50	264.07
Fuel expenses	92.38	59.75
Travelling and conveyance	423.31	1,034.41
Legal and professional fees (professional fees to doctor consultants and others) & other related expenditures	1,428.45	1,284.02
Books, periodicals & certifications	1.54	0.94
Commission expenses	3.40	-
Advertisement, publicity, marketing & business promotion expenses	90.11	93.79
Provision for doubtful debts	0.19	15.35
Provision for obsolete inventories	1.07	26.72
Communication expenses (Telephone & internet expenses)	68.42	51.76
Insurance	8.34	5.98
Postage & courier charges	5.97	4.16
Rates and taxes	65.89	26.78
Outsourced testing expenses	163.46	83.63
CSR Expenses	55.86	12.48
Discount to customers	1.80	4.76
Printing and Stationary Expenses	0.01	0.01
Other miscellaneous expenses	232.32	338.93
Total	4,594.80	4,319.15
*Audit fee includes in legal and Professional fees		
a. Payment to the auditor		
Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
For Statutory Audit Fees	12.08	9.36

NOTE NO. :- 33 : OTHER EXPENSES		
For Cost Audit Fees	3.18	1.25
For Internal Audit Fees	10.88	8.00
For Secretarial Audit Fees	1.70	1.25
For Tax Audit Fees	5.54	-
Total...	33.38	19.86
b. Prior period items		
Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Rent	2.05	3.69
Electricity expenses	3.79	2.28
Communication expenses (Telephone & internet expenses)	1.40	2.81
Rates and taxes	3.14	0.06
Other miscellaneous expenses	19.71	12.50
Total...	30.08	21.33
c. Disclosure of expenditure in foreign currency during the financial year.		
Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Royalty	-	-
Legal, professional and consultancy charges	-	-
Interest	-	-
Other matters(Specify nature)	-	-
Total...	-	-

NOTE NO. :- 34 : EARNING PER SHARE		
Basic/Diluted earnings per share are calculated by dividing the Net profit or Loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.		
Basic EPS		
Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Numerator		
Earning available to equity share holders(EAESH)	2,705.74	2,217.08
Denominator		
Weighted average outstanding equity share capital	244.52	205.73
Earnings Per Rupees of Equity Share Capital (Basic/ Diluted)	11.07	10.78
Dialuted EPS		

NOTE NO. :- 34 : EARNING PER SHARE

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Numerator		
Earning available to equity share holders(EAESH)	2,705.74	2,217.08
Denominator		
Weighted average outstanding equity share capital	251.35	205.73
Earnings Per Rupees of Equity Share Capital (Basic/ Diluted)	10.76	10.78

NOTE NO. :- 37 : CONTINGENT LIABILITIES AND COMMITMENTS

Particulars	Figures For The Year Ended 31st March, 2026		Figures For The Year Ended 31st March, 2025	
	No of cases	Amount	No of cases	Amount
Claims against the company not acknowledged as debts				
1) District consumer disputes redressal forum	24	397.34	13	62.49
2) State consumer disputes redressal commission	1	-	1	-
3) Labour court	3	5.45	3	5.45
4) District and session court	28	114.46	23	82.39
5) Delhi High Court	1	4.00	-	-
Direct tax matters	2	373.30	1	137.75
Guarantees				
Guarantee provided to the HDFC Bank of India in relation to borrowings undertaken by Chandan Hospital Limited.	10	1,223.67	10	1,223.67
Guarantee provided to the HDFC Bank of India in relation to borrowings undertaken by Chandan Pharmacy Limited.	1	227.76	1	227.76
Total...	70	2,345.98	52	1,739.51

NOTE NO. :- 38 : SEGMENT REPORTING**Primary segments - Business Segments**

The company primarily operates state-of-the-art laboratories providing comprehensive pathological investigations and radiology services. Other activities conducted by the company are ancillary to its main business and do not significantly impact the financial statements. Consequently, in accordance with Accounting Standard 17 on Segment Reporting, the company has identified a single reportable business segment: "Diagnostics Services." As a result, segment information has not been disclosed.

NOTE NO. :- 38 : SEGMENT REPORTING

Secondary segments - Geographical Segments

The company operates primarily in india and there is no other significant geographical segment.

NOTE NO. :- 39 : CSR EXPENDITURE

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
Gross amount required to be spent by the company during the year.	55.86	12.46
Gross amount spent by the company during the year.	55.86	12.48
Shortfall/(Excess)	-	(0.02)

a. Disclosure on nature of CSR activities undertaken by the companies

Particulars	Figures For The Year Ended 31st March, 2026					Figures For The Year Ended 31st March, 2025				
	Paid in cash	Paid via bank	Paid in kind	Payble	Total	Paid in cash	Paid via bank	Paid in kind	Payble	Total
Promoting education	-	55.86	-	-	55.86	-	12.48	-	-	12.48

NOTE NO. :- 40 : OTHER STATUTORY INFORMATION

In the opinion of the board of directors, the current assets, loans and advances have a value on realization in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet.

Balances with trade receivables / trade payables and loans & advances are subject to confirmation.

Previous year's figures have been regrouped /rearranged wherever necessary to make them comparable with current year's figures.

The company does not have any benami property, where any proceeding has been initiated or pending against the company for holding any benami property.

The company does not have any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956 during the financial year.

The company has not traded or invested in Crypto Currency or Virtual Currency during the financial year.

The company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies (ROC) beyond the statutory period.

The company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.

NOTE NO. :- 40 : OTHER STATUTORY INFORMATION

The company has not received any fund from any person(s) or entity(ies), including foreign entities (funding party) with the understanding (whether recorded in writing or otherwise) that the company shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the funding party (ultimate beneficiaries) or (b) provide any guarantee, security or the like on behalf of the ultimate beneficiaries.

The company does not have any transaction to report that is not recorded in the books of accounts and that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

The company has not been declared as wilful defaulter by any bank or financial institution or other lender.

The company does not have any immovable property (other than properties where the company is the lessee and the lease agreements are duly executed in favour of the lessee) whose title deeds are not held in the name of the company.

The company confirms that the quarterly returns or statements of current assets, filed with banks or financial institutions in relation to borrowings secured by current assets, are in agreement with the books of accounts.

NOTE NO. :- 42: DISCLOSURE REGARDING TRANSACTIONS WITH RELATED PARTIES IN TERMS OF ACCOUNTING STANDARD - 18

Name of the related party	Nature of the relationship 31st March 2026	Nature of the relationship 31st March 2025
A. Enterprises that directly or indirectly control/controlled by/under common control with, the reporting enterprise		
Chandan Diagnostic Limited- PAN: AABCC9315J	Subsidiary Company	Subsidiary Company
Chandan Hospital Limited - PAN: AABCC9314K	Entity under common control of promoter group	Entity under common control of promoter group
Indira Diagnostic Centre & Blood Bank Limited - PAN: AABCI0214L	Wholly Owned Subsidiary Company	Wholly Owned Subsidiary Company
Chandan Pharmacy Limited - PAN: AAHCC1459M	Subsidiary Company	Subsidiary Company
Cendana Pharmaceuticlas Private Limited - PAN: AAKCC1991P	Entity under common control of promoter group	Entity under common control of promoter group
Amaranita Holdings (I) Private Limited - PAN: AAHCA1540R	Entity under common control of promoter group	Entity under common control of promoter group
Chandan Singh Foundation - PAN: AAATC2479F	Entity under common control of promoter group	Entity under common control of promoter group
Healthrely Private Limited- PAN:AAGCH9438N	Entity under common control of promoter group	Entity under common control of promoter group
Chandan Cancer Institute Limited- PAN:AALCC9159N	Entity under common control of promoter group	Entity under common control of promoter group
Chandan Super Speciality Hospital Limited- PAN: AALCC1234A	Entity under common control of promoter group	Entity under common control of promoter group
AMARANITA HOSPITALITY PRIVATE LIMITED: ABFCA4827Q	Entity under common control of promoter group	-
CHANDAN HEALTHCARE PROJECTS PRIVATE LIMITED: AANCC6242L	Subsidiary Company	-
Chandan Cradle Limited- PAN : AANCC3763A (Earlier Know as Chandan Fertility Limited)	Entity under common control of promoter group	-
B. Individuals owning, directly or indirectly, an interest in the voting power of the reporting enterprise that gives them control or significant influence over the enterprise, and relatives of any such individual		
Dr Amar Singh - PAN: AGQPS5396H - DIN: 01096328	Managing director of company (MD)	Managing director of company (MD)
Asmita Singh - PAN: AWSPS3853M - DIN: 01098055	Managing director of company (MD)	Director of company
Virendra Singh - PAN: AFSPS0571B - DIN: 01099343	Relative of Promoter	Director of company*
Vinay Lamba - PAN: AAXPL5673R - DIN: 01220153	Director of company	Director of company
Vijay Singh - PAN: AILPS1503P - DIN: 02778087	Promoter	Director of company*
Aasti Singh - PAN: FRPPS0695A - DIN: 06973933	Relative of director/Promoter	Director of company
Anant Singh - PAN: AWSPS3852L - DIN: 00969364	Relative of director/Promoter	Director of company
Rajeev Nain - PAN: AIVPN6380K	Key managerial personnel (CFO & Company secretary)	Key managerial personnel (CFO & Company secretary)
Anita Singh - PAN: ARVPS1208G	Relative of director/Promoter	Relative of director
Vishal Lamba - PAN: ABUPL4208N	Relative of director	Relative of director

Name of the related party	Nature of the relationship 31st March 2026	Nature of the relationship 31st March 2025
Ajai Singh - PAN: AHNPS7885B	Relative of director	Relative of director
Nisha Lamba - PAN: AATPL6545J	Relative of director	Relative of director
Pragya Singh - PAN: DJVPS5075J	Relative of KMP	Relative of KMP
Shaivalini Singh - PAN: CURPS9141R	Relative of Promoter	Relative of director*
Vikash Lamba - PAN: ACLPL2389Q	Relative of director/Promoter	Relative of director
Shailendra Singh- PAN CBEPS0038M	Relative of director	-
Name of related party	Nature of Transaction	Standalone figures for the year ended 31st March, 2026
Aasti Singh	Opening Balance Payable(Receivable)	(0.00)
	Dividend for the Year	-
	Payment	0.00
	Receipt	-
	Reimbursement	-
	Professional fee	-
	Closing Balance Payable (Receivable)	(0.00)
Dr Amar Singh	Opening Balance Payable (Receivable)	3.32
	Dividend for the Year	-
	Professional fee	-
	Receipt	63.75
	Bonus for the Year	-
	Salary	46.71
	Payment	(223.64)
	Reimbursement	128.59
	Closing Balance Payable(Receivable)	18.72
Anant Singh	Opening Balance Payable(Receivable)	(0.00)
	Salary	-

Name of the related party	Nature of the relationship 31st March 2026	Nature of the relationship 31st March 2025
	Dividend for the Year	-
	Reimbursement	1.37
	Advance	-
	Payment	(1.37)
	Closing Balance Payable(Receivable)	0.00
Asmita Singh	Opening Balance Payable(Receivable)	4.82
	Dividend for the Year	-
	Deposit	-
	Reimbursement	0.04
	Receipt	22.56
	Bonus for the Year	-
	Salary	84.89
	Payment	(115.05)
	Closing Balance Payable(Receivable)	(2.75)
Vinay Lamba	Opening Balance Payable(Receivable)	-
	Payment	-
	Advance	-
	Reimbursement	(0.00)
	Dividend for the Year	-
	Bonus for the Year	-
	Salary	-
	Closing Balance Payable(Receivable)	(0.00)
Rajeev Nain	Opening Balance Payable(Receivable)	2.91
	Dividend for the Year	-

Name of the related party	Nature of the relationship 31st March 2026	Nature of the relationship 31st March 2025
	Reimbursement	0.92
	Gratuity	-
	Professional fee	-
	Payment	(49.33)
	Salary	47.99
	Closing Balance Payable(Receivable)	2.49
Ajai Singh	Opening Balance Payable(Receivable)	-
	Dividend for the Year	-
	Reimbursement	-
	Payment	-
	Closing Balance Payable(Receivable)	-
Nisha Lamba	Opening Balance Payable(Receivable)	-
	Dividend for the Year	-
	Salary	-
	Receipt	-
	Payment	-
	Closing Balance Payable(Receivable)	-
Vikas Lamba	Opening Balance Payable(Receivable)	-
	Dividend for the Year	-
	Payment	(18.04)
	Advance	-
	Salary	8.04
	Gratuity	-
	Reimbursement	8.66

Name of the related party	Nature of the relationship 31st March 2026	Nature of the relationship 31st March 2025
	Receipt	-
	Closing Balance Payable(Receivable)	(1.34)
Vishal Lamba	Opening Balance Payable(Receivable)	-
	Dividend for the Year	
	Advance	
	Loan	
	Salary	
	Gratuity	
	Payment	(1.62)
	Reimbursement	1.62
	Closing Balance Payable(Receivable)	-
Anshu Lamba	Opening Balance Payable(Receivable)	-
	Dividend for the Year	-
	Salary	-
	Reimbursement	-
	Payment	-
	Closing Balance Payable(Receivable)	-
Deepa Lamba	Opening Balance Payable(Receivable)	-
	Dividend for the Year	-
	Salary	8.00
	Payment	(6.53)
	Closing Balance Payable(Receivable)	1.47
Shailendra Singh	Opening Balance Payable(Receivable)	-
	Salary	-
	Dividend for the Year	-
	Reimbursement	1.37

Name of the related party	Nature of the relationship 31st March 2026	Nature of the relationship 31st March 2025
	Advance	-
	Payment	(1.37)
	Closing Balance Payable(Receivable)	0.00
Chandan Hospital Limited	Opening Balance Payable(Receivable)	(160.64)
	Opening Balance Loan Payable(Receivable)	-
	Opening Balance Investment in equity share capital	-
	Receipt	4,286.73
	Dividend Income	-
	Loan Interest income	(133.41)
	Loan receipt	-
	Loan Payment	(1,300.00)
	Sales	(579.54)
	Share sales	-
	Share purchase	-
	Payment	(2,900.36)
	Closing Balance Investment in equity share capital	-
	Closing Balance Loan Payable(Receivable)	(1,433.41)
	Closing Balance Payable(Receivable)	646.19
Chandan Pharmacy Limited	Opening Balance Payable(Receivable)	(3.78)
	Opening Balance Loan Payable(Receivable)	-
	Opening Balance Investment in equity share capital	(474.00)
	Sales	(28.17)
	Purchase	21.74
	Receipt	10.96

Name of the related party	Nature of the relationship 31st March 2026	Nature of the relationship 31st March 2025
	Loan Interest income	(24.58)
	Loan receipt	742.03
	Loan Payment	(1,603.70)
	Dividend Income	-
	Share sales	-
	Payment	(1.45)
	Closing Balance Investment in equity share capital	(474.00)
	Closing Balance Loan Payable(Receivable)	(886.25)
	Closing Balance Payable(Receivable)	(0.71)
Chandan Singh Foundation	Opening Balance Payable(Receivable)	-
	Opening Balance Loan Payable(Receivable)	(295.93)
	Opening Balance Investment in equity share capital	-
	Loan Interest income	(33.78)
	Loan receipt	-
	Loan Payment	-
	CSR	55.86
	Payment	(71.19)
	Closing Balance Investment in equity share capital	-
	Closing Balance Loan Payable(Receivable)	(329.71)
	Closing Balance Payable(Receivable)	(15.33)
Chandan Diagnostic Limited	Opening Balance Payable(Receivable)	-
	Opening Balance Investment in equity share capital	(65.85)
	Share sales	
	Sales	
	Receipt	

Name of the related party	Nature of the relationship 31st March 2026	Nature of the relationship 31st March 2025
	Payment	(1.01)
	Closing Balance Investment in equity share capital	(65.85)
	Closing Balance Payable(Receivable)	(1.01)
Indra Diagnostic Centre & Blood Bank Limited	Opening Balance Payable(Receivable)	344.30
	Opening Balance Investment in equity share capital	(491.69)
	Sales	(15.40)
	Share sales	0.01
	Receipt	15.65
	Payment	(344.84)
	Closing Balance Investment in equity share capital	(491.68)
	Closing Balance Payable(Receivable)	(0.30)
Cendana Pharmaceuticals Private Limited	Opening Balance Payable(Receivable)	(199.65)
	Receipt	170.26229
	Payment	(35.97)
	Cheque Issued But Not Cleared	
	Purchase	35.19
	Sales	(9.03)
	Closing Balance Payable(Receivable)	(39.19)
Chandan Super Speciality Hospital Limited	Opening Balance Payable(Receivable)	(7.91)
	Receipt	185.08
	Payment	
	Sales	(184.15)
	Closing Balance Payable(Receivable)	(6.98)
Amaranita Holdings (India) Private Limited	Opening Balance Payable(Receivable)	-
	Opening Balance Investment in equity share capital	-

Name of the related party	Nature of the relationship 31st March 2026	Nature of the relationship 31st March 2025
	Share sales	-
	Professional Fee	-
	Comission	-
	Dividend	-
	Receipt	-
	Payment	-
	Closing Balance Investment in equity share capital	-
	Closing Balance Payable(Receivable)	-
CHANDAN HEALTHCARE PROJECTS PRIVATE LIMITED	Opening Balance Payable(Receivable)	-
	Opening Balance Investment in equity share capital	-
	Share sales	-
	Share Purchase	(1.00)
	Receipt	-
	Payment	-
	Closing Balance Investment in equity share capital	(1.00)
	Closing Balance Payable(Receivable)	-

NOTICE OF ANNUAL GENERAL MEETING

NOTICE is hereby given that 23rd Annual General Meeting ("AGM") of the Members of Chandan Healthcare Limited ("Company") will be held on Wednesday, 30th September, 2026 at 04:00 P.M. (IST) through Video Conferencing ("VC"), OTHER AUDIO- VISUAL MEANS ("OAVM"), to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt:

- a. the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026 together with the Reports of the Board of Directors and Auditors thereon; and
- b. the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2026 together with the Reports of the Auditors thereon.

2. To appoint a Director in place of Mr. Amar Singh (DIN: 01096328), who retires by rotation and being eligible, offers himself, for re-appointment.

SPECIAL BUSINESS:

3. To ratify remuneration of the Cost Auditor for the financial year ending on March 31, 2027.

To consider and, if thought fit, to pass the following Resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 148 and other applicable provisions of the Companies Act, 2013, read with the Companies (Audit and Auditors) Rules, 2014 and other applicable Rules, if any, (including any statutory modification(s) or amendment(s) or re-enactment thereof for the time being in force), the remuneration of Rs. 1,25,000/- (Rupees One Lakh Twenty-Five Thousand Only) p.a. plus applicable taxes and reimbursement of out-of- pocket expenses, payable to M/s. Rahul Jain & Associates Cost Accountants, Ghaziabad (Firm Registration No. 101515), to audit the cost records of the Company for the financial year ending on March 31, 2027, as approved by the Board of Directors on the recommendation of the Audit Committee, be and is hereby ratified.

RESOLVED FURTHER THAT the Board of Directors, which term shall deem to include any Committee constituted by the Board, be and is hereby authorised to do all such acts, deeds, matters and take all such steps as may be considered necessary, proper or expedient to give effect to this Resolution."

4. To approve variation in the objects and utilisation of the proceeds of the preferential issue of convertible warrants.

To consider and, if thought fit, to pass the following Resolution as a Special Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 42 and 62(1)(c) and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Prospectus and Allotment of Securities) Rules, 2014 and the Companies (Share Capital and Debentures) Rules, 2014, the applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment thereof for the time being in force), and in partial modification of the special resolution passed by the members of the Company at the members meeting held on 06/11/2025 approving the issue of 44,50,000 convertible warrants on a preferential basis, the consent of the members be and is hereby accorded to vary the objects for which the proceeds of the said preferential issue are to be utilised, to the extent of Rs.50,00,00,000 out of the amount remaining unutilised as on date i.e. Rs. 50,00,00,000, from Acquisitions of business units, existing diagnostic centres equipment's, Labs and other related assets to Business Expansion by setting up new Diagnostic labs and comprehensive Diagnostic centres, in the manner and within the timelines set out in the Explanatory Statement annexed to this Notice.

RESOLVED FURTHER THAT save as aforesaid, all other terms and conditions of the said preferential issue of convertible warrants as approved by the members, including the issue price, the entitlement of the warrant holders, the conversion ratio and the period within which the warrants may be exercised, shall remain unchanged.

RESOLVED FURTHER THAT the Board of Directors of the Company, including any Committee thereof, be and is hereby authorised to do all such acts, deeds, matters and things, to make the requisite disclosures to the stock exchange under Regulation 32 of the SEBI Listing Regulations, and to execute all such documents, filings and writings as may be necessary, proper or expedient to give effect to this resolution."

5. To appoint Mr. Sanjay Srivastava (DIN: 11927967) as an Independent Director of the Company.

To consider and, if thought fit, to pass the following Resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152 and 160 read with Schedule IV and all other applicable provisions, if any, of the Companies Act, 2013 ("the Act") and the Companies (Appointment and Qualification of Directors) Rules, 2014, and the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), each as amended from time to time, Mr. Sanjay Srivastava (DIN: 11927967), who was recommended by the Nomination and Remuneration Committee and the Board of Directors for appointment as an Independent Director, who has submitted a declaration that he meets the criteria of independence as prescribed under Section 149(6) of the Act and Regulation 16(1)(b) of the SEBI Listing Regulations, who is eligible for appointment and who is not disqualified from being appointed as a Director in terms of Section 164 of the Act, and in respect of whom the Company has received a notice in writing under Section 160 of the Act from a Member proposing his candidature for the office of Director, be and is hereby appointed as an Independent Director of the Company, not liable to retire by rotation, to hold office for a term of five (5) consecutive years commencing from 30 September 2026 up to 29 September 2031.

RESOLVED FURTHER THAT Mr. Sanjay Srivastava be paid sitting fees for attending meetings of the Board of Directors and Committees thereof, and be reimbursed such expenses as are incurred by him for participation in Board and other meetings, within the limits prescribed under Section 197 of the Act read with Rule 4 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

RESOLVED FURTHER THAT the Board of Directors of the Company (including any Committee thereof) be and is hereby authorised to do all such acts, deeds, matters and things and to take all such steps as may be necessary, proper or expedient to give effect to this resolution."

BY ORDER OF THE BOARD FOR CHANDAN HEALTHCARE LIMITED

Rajeev Kumar Nain
Company Secretary & Compliance Officer
Membership No.: A35449

Date: 07.09.2026

Place: Lucknow

NOTES:

- Pursuant to the provisions of the Act and Rules made thereunder, the SEBI Listing Regulations read with circulars issued by the Ministry of Corporate Affairs (MCA) vide its General Circular No. 20/2020 dated May 05, 2020 in conjunction with Circular No. 14/2020 dated April 08, 2020 and 17/2020 dated April 13, 2020, 22/2020 dated June 15, 2020, 33/2020 dated September 28, 2020, 39/2020 dated December 31, 2020, 02/2021 dated January 13, 2021, 10/2021 dated June 23, 2021, 20/2021 dated December 08, 2021, 3/2022 dated May 5, 2022, 11/2022 dated December 28, 2022, 09/2023 dated September 25, 2023, 09/2024 dated September 19, 2024 and 03/2025 dated September 22, 2025 (hereinafter collectively referred to as MCA Circulars) and Securities and Exchange Board of India (SEBI) vide its Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020 read with Circular No. SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated January 15, 2021, SEBI/HO/CFD/CMD2/ CIR/P/2022/62 dated May 13, 2022 and SEBI/HO/CFD/PoD-2/P/CIR/2023/4 dated January 5, 2023, SEBI/HO/DDHS/P/CIR/2023/0164 dated October 6, 2023, SEBI/HO/CFD/CFD-PoD2/P/CIR/2023/167 dated October 7, 2023 and SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated October 3, 2024 (SEBI Circulars) (collectively referred to as the Circulars), Companies are allowed to hold AGM through VC/OAVM, without the physical presence of the Members at a common venue and also to send the Notice of AGM in electronic mode to those Members whose email addresses are registered with the company/depositories. Hence, in compliance with the aforesaid Circulars, the AGM of the Company is being held through VC/OAVM. The Registered Office of the Company shall be deemed to be the venue for the said AGM.
- An Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 (the Act) and the rules made thereunder, in respect of the Special Business to be transacted at the Annual General Meeting ("AGM") as set out under Item Nos. 3 to 5 above, is annexed herewith to and forms part of this Notice.
- The attendance of the members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Act. Pursuant to the provisions of the Act, a Member entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote on his/her behalf and the proxy need not be a Member of the Company. Since this AGM is being held pursuant to the MCA Circulars through VC/OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxy by the Members will not be available for this AGM and hence the Proxy Form, Attendance Slip and route map of AGM are not annexed to this Notice. However, Institutional/Corporate Members are entitled to appoint authorized representatives to attend the AGM through VC/OAVM and cast their votes through e-voting. Institutional/Corporate Members are requested to send a scanned copy (PDF/ JPEG format) of the Board Resolution authorizing its representatives to attend and vote at the AGM, pursuant to Section 113 of the Act, to Scrutinizer at acs@acsadvisors.in with a copy marked to einward.ris@kfintech.com.
- The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available to at least 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee and other Committees, as applicable and Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
- In accordance with the aforesaid Circulars, the Notice of the AGM has been sent only through electronic mode to the members who have registered their e-mail addresses with the Company/Depository Participants/ Company's Registrar and Transfer Agent (RTA). The Notice of AGM is also available on the Company's website at www.chandandidiagnostic.com, on the website of the Stock Exchange i.e. National Stock Exchange of India Limited (NSE) at www.nseindia.com and on the website of KFin Technologies Limited at <https://evoting.kfintech.com>.
- Registration of e-mail ID:

Members who have not registered their email IDs are requested to do so at the earliest. Members holding shares in:

Electronic mode can register their email ID by contacting their respective Depository Participant(s) ("DP").

Physical mode can register their email ID with the Company or our RTA KFin Technologies Limited. Requests can be emailed to secretarial@chandan.co.in or einward.ris@kfintech.com.

- Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) the Secretarial Standard on General Meetings (SS-2) issued by the ICSI and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs from time to time, the Company is providing facility of remote e-Voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with KFin Technologies Limited (Kfintech) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-Voting system as well as e-voting on the date of the AGM will be provided by Kfintech. The detailed instructions for e-voting and attending the AGM through VC/ OAVM mentioned in this Notice.
- All documents referred to in the Notice and Explanatory Statement will be available for inspection by the members, without any fees in electronic mode from the date of circulation of this Notice up to the date of the AGM. Members who wish to inspect such documents are requested to write to the Company by sending e-mail to secretarial@chandan.co.in
- The Register of Directors and Key Managerial Personnel and their shareholding maintained under Section 170 of the Act and the Register of Contracts or Arrangements in which Directors are interested maintained under Section 189 of the Act will be available electronically for inspection by the Members during the AGM. Members seeking inspection may send a request to secretarial@chandan.co.in.
- Members may cast their votes through electronic voting system from any place (remote e-voting). The remote e-voting period will commence at 9:00 a.m. (IST) on Sunday, September 27, 2026 and will end at 5:00 p.m. (IST) on Tuesday, September 29, 2026. In addition, the facility for voting through e-voting system shall also be made available during the AGM. Members attending the AGM who have not cast their vote by remote e-voting shall be eligible to cast their vote through e-voting during the AGM. Members who have voted through remote e-voting shall be eligible to attend the AGM, however, they shall not be eligible to vote at the meeting.
- The Board of Directors has appointed Mr. Akshat Garg, Partner of M/s Akshat Garg & Associates, as the 'Scrutinizer' to scrutinize the remote e-voting process and voting during the AGM in a fair and transparent manner.

The Scrutinizer shall immediately after the conclusion of voting at the AGM, unblock the votes cast through remote e-Voting (votes cast during the AGM and votes cast prior to the AGM) and make consolidated Scrutiniser's Report and submit the same to the Chairperson. The result of e-voting will be declared within two working days of the conclusion of the Meeting and the same, along with the consolidated Scrutiniser's Report, will be placed on the website of the Company: www.chandandiagnostics.com and the website of our E-Voting Service Provider (ESP) <https://evoting.kfintech.com> immediately. The result will simultaneously be communicated to the stock exchanges where the shares of the company are listed.

- Members can avail the facility of nomination in respect of securities held by them in physical form pursuant to the provision of Section 72 of the Act. Members desiring to avail this facility may send their nomination in the prescribed form duly filled-in to KFin Technologies Limited. Members holding shares in electronic mode may contact their respective Depository Participant (DP) for availing this facility.
- Members holding shares in identical order of names in more than one folio are requested to write to the Company's Registrars and Share Transfer Agents enclosing their share certificates to enable consolidation of their shareholdings in one folio. A consolidated share certificate will be issued to such members after making requisite changes.

- Pursuant to the directions/notifications of Securities and Exchange Board of India (SEBI) and Depositories, the demat account holders can operate their accounts if they had already provided Income Tax Permanent Account Number (PAN) either at the time of opening of the account or subsequently. In case they have not furnished the Income Tax Permanent Account Number to the Depository Participants, such demat account holders are requested to contact their DPs with a photocopy of the PAN Card (with original PAN Card for verification), so that the frozen demat accounts would be available for operation and further consequences of non-compliance with the aforesaid directives would be obviated. SEBI, vide Circular ref.no. MRD/Dop/Cir-05/2009 dated May 20, 2009 made it mandatory to have PAN particulars for registration of physical share transfer requests. Based on the directive contained in the said circulars, all share transfer requests are therefore to be accompanied with PAN details.
- Members are requested to intimate changes, if any, pertaining to their name, postal address, email address, telephone/ mobile numbers, Permanent Account Number (PAN), mandates, nominations, power of attorney, bank details such as, name of the bank and branch details, bank account number, MICR code, IFSC code, etc., to their DPs in case the shares are held by them in electronic form and to the Company/ Company's Registrar & Share Transfer Agent (RTA)- in case the shares are held by them in physical in form Form ISR – 1 and other forms pursuant to SEBI Circular dated 3rd November, 2021.
- Members may please note that SEBI vide Circular dated 25th January, 2022 has mandated the listed companies to issue securities only in dematerialized form only while processing service requests viz. issue of duplicate securities certificate; claim for unclaimed suspense account; renewal / exchange of securities certificate; endorsement; subdivision / splitting of securities certificate; consolidation of securities certificates / folios; transmission and transposition. Accordingly, Members are requested to make service requests by submitting a duly filled and signed Form ISR – 4, the format of which is available on the Company's website at <https://www.chandandiagnostics.com/investors/>
- The Company is in compliance with the SEBI circular no. SEBI/HO/OIAE/OIAE_IAD-1/P/CIR/2023/145 dated August 11, 2023, read with other relevant circulars regarding Online Dispute Resolution ("ODR") and the web-link for the same is made available on the website of the Company at www.chandandiagnostics.com

PROCEDURE FOR REMOTE E-VOTING AND E-VOTING DURING THE AGM:

- Pursuant to SEBI Circular no. SEBI/HO/CFD/CMD/ CIR/P/2020/242 dated 9th December, 2020 on "e-voting facility provided by Listed Companies", e-voting process has been enabled for all the individual demat account holders, through their demat account maintained with DPs. Members are advised to update their mobile number and e-mail id in their demat accounts in order to access e-voting facility. Individual demat account holders would be able to cast their vote without having to register again with the e-voting service provider (ESP) thereby not only facilitating seamless authentication but also ease and convenience of participating in e-voting process.
- In compliance with the provisions of Sections 108 of the Act read with the Rules as amended and Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), as amended from time to time, the Company is providing facility to the Members to exercise voting through electronic voting system ("remote e-voting") on the e-voting platform provided by KFin.

The Members may cast their votes remotely, using remote e-voting only on the dates mentioned hereunder. The instructions for remote e-voting forms part of this Notice.

- Facility to exercise vote through remote e-voting will be available during the following period:

COMMENCEMENT OF REMOTE E-VOTING	09:00 A.M. (IST) ON SUNDAY, SEPTEMBER 27, 2026
End of remote e-voting	05:00 P.M. (IST) on Tuesday, September 29, 2026

The remote e-voting module shall be disabled by KFin for voting thereafter. Once the vote on a resolution is cast by the Member, the Member shall not be allowed to change it subsequently or cast the vote again.

- During the above period, Members of the Company holding shares either in physical form or in dematerialised form, as on Friday, September 25, 2026, i.e., cut-off date, may cast their vote by remote e-voting.

- The voting rights of members shall be in proportion to their shares in the paid-up equity share capital of the Company as on the cut-off date i.e. Friday, September 25, 2026.
- The process and manner for remote e-voting is as under:

In compliance with the provisions of Section 108 of the Act, Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, Regulation 44 of the Listing Regulations read with SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 9th December, 2020 relating to 'e-voting Facility Provided by Listed Entities' ("SEBI e-voting Circular") the Members are provided with the facility to cast their vote electronically, through the remote e-voting services provided by KFin, on the resolutions set forth in this Notice. The instructions for remote e-voting are given herein below.

- E-voting process has been enabled for all the individual demat account holders, by way of single login credential, through their demat accounts / websites of Depositories / DPs in order to increase the efficiency of the voting process.
- Individual demat account holders would be able to cast their vote without having to register again with the E-voting Service Provider ("ESP") thereby not only facilitating seamless authentication but also ease and convenience of participating in e-voting process. Members are advised to update their mobile number and e-mail ID with their DPs to access e-voting facility.
- The process and manner of remote e-voting is explained below:
- Access to Depositories e-voting system in case of individual Members holding shares in demat mode.
- Access to KFin e-voting system in case of Members holding shares in physical and non-individual Members in demat mode.
- Access to Depositories e-voting system in case of individual Members holding shares in demat mode.

TYPE OF MEMBER	LOGIN
Individual Members holding securities in demat mode with NSDL	For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on the company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Existing Internet-based Demat Account Statement ("IDeAS") facility Users: Visit the e-services website of NSDL https://eservices.nsdl.com either on a personal computer or on a mobile. On the e-services home page click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. Thereafter enter the existing user id and password. After successful authentication, Members will be able to see e-voting services under 'Value Added Services'. Please click on "Access to e-voting" under e-voting services, after which the e-voting page will be displayed. Click on company name i.e. Chandan Healthcare Limited or ESP i.e. KFin. Members will be re-directed to KFin's website for casting their vote during the remote e-voting period. Those not registered under IDeAS: Visit https://eservices.nsdl.com for registering. Select "Register Online for IDeAS Portal" or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp Visit the e-voting website of NSDL https://www.evoting.nsdl.com. Once the home page of e-voting system is launched, click on the icon "Login" which is available under 'Shareholder / Member' section. A new screen will open.

MEMBERS WILL HAVE TO ENTER THEIR USER ID (I.E. THE SIXTEEN DIGIT DEMAT ACCOUNT NUMBER HELD WITH NSDL), PASSWORD / OTP AND A VERIFICATION CODE AS SHOWN ON THE SCREEN.

AFTER SUCCESSFUL AUTHENTICATION, MEMBERS WILL BE REDIRECTED TO NSDL DEPOSITORY SITE WHEREIN THEY CAN SEE E-VOTING PAGE.

CLICK ON COMPANY NAME I.E. CHANDAN HEALTHCARE LIMITED OR ESP NAME I.E KFin AFTER WHICH THE MEMBER WILL BE REDIRECTED TO ESP WEBSITE FOR CASTING THEIR VOTE DURING THE REMOTE E-VOTING PERIOD.

MEMBERS CAN ALSO DOWNLOAD THE NSDL MOBILE APP “NSDL SPEEDE” FACILITY BY SCANNING THE QR CODE MENTIONED BELOW FOR SEAMLESS VOTING EXPERIENCE.

TYPE OF MEMBER	LOGIN METHOD
Individual Members holding securities in demat mode with CDSL	Existing user who has opted for Electronic Access to Securities Information (“Easi/ Easiest”) facility: Visit https://web.cdslindia.com/myeasitoken/Home/Login or www.cdslindia.com. Click on New System Myeasi. Login to Myeasi option under quick login. Login with the registered user ID and password. Members will be able to view the e-voting Menu. The Menu will have links of KFin e-voting portal and will be redirected to the e-voting page of KFin to cast their vote without any further authentication. User not registered for Easi/ Easiest: Visit https://web.cdslindia.com/myeasi/Registration/EasiRegistration for registering. Proceed to complete registration using the DP ID, Client ID (BO ID), etc. After successful registration, please follow the steps given in point no. 1 above to cast your vote. Alternatively, by directly accessing the e-voting website of CDSL Visit www.cdslindia.com. Provide demat account number and PAN. System will authenticate user by sending OTP on registered mobile and email as recorded in the demat Account. After successful authentication, please enter the e-voting module of CDSL. Click on the e-voting link available against the name of the Company, viz. Chandan Healthcare Limited or select KFin. Members will be re-directed to the e-voting page of KFin to cast their vote without any further authentication.

TYPE OF MEMBER	LOGIN METHOD
Individual Members login through their demat accounts / website of DPs	Members can also login using the login credentials of their demat account through their DPs registered with the Depositories for e-voting facility. Once logged-in, Members will be able to view e-voting option. Upon clicking on e-voting option, Members will be redirected to the NSDL / CDSL website after successful authentication, wherein they will be able to view the e-voting feature. Click on options available against Chandan Healthcare Limited or ‘KFin’. Members will be redirected to e-voting website of KFin for casting their vote during the remote e-voting period without any further authentication.

Important note: Members who are unable to retrieve User ID / Password are advised to use Forgot user ID and Forgot Password option available at respective websites.

Helpdesk for Individual Members holding securities in demat mode for any technical issues related to login through Depository i.e., NSDL and CDSL.

LOGIN TYPE	HELPDESK DETAILS
Securities held with NSDL	Please contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 102 0990 and 1800 22 4430
Securities held with CDSL	Please contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022-23058738 or 022-23058542-43

- Access to KFin e-voting system in case of members holding shares in physical and non-individual members in demat mode.

Members whose e-mail IDs are registered with the Company / DPs, will receive an e-mail from KFin which will include details of E-Voting Event Number (EVEN), USER ID and password. They will have to follow the following process:

- Launch internet browser by typing the URL: <https://emeetings.kfintech.com>.
- Enter the login credentials (i.e., User ID and password). In case of physical folio, User ID will be EVEN (E-Voting Event Number) 10217, followed by folio number. In case of Demat account, User ID will be your DP ID and Client ID. However, if you are already registered with KFin for e-voting, you can use your existing User ID and password for casting the vote.
- After entering these details appropriately, click on “LOGIN”.
- You will now reach password change Menu wherein you are required to mandatorily change your password. The new password shall comprise of minimum 8 characters with at least one upper case (A- Z), one lower case (a-z), one numeric value (0-9) and a special character (@, #, \$, etc.,). The system will prompt you to change your password and update your contact details like mobile number, e-mail ID etc. on first login. You may also enter a secret question and answer of your choice to retrieve your password in case you forget it. It is strongly recommended that you do not share your password with any other person and that you take utmost care to keep your password confidential.
- You need to login again with the new credentials.
- On successful login, the system will prompt you to select the “EVEN” i.e., ‘Chandan Healthcare Limited’ and click on “Submit”
- On the voting page, enter the number of shares (which represents the number of votes) as on the Cut-off Date under “FOR/AGAINST” or alternatively, you may partially enter any number in “FOR” and partially “AGAINST” but the total number in “FOR/ AGAINST” taken together shall not exceed your total shareholding as mentioned herein above. You may also choose the option “ABSTAIN”. If the Member does not indicate either “FOR” or “AGAINST” it will be treated as “ABSTAIN” and the shares held will not be counted under either head.
- Members holding multiple folios/demat accounts shall choose the voting process separately for each folio/ demat accounts.
- In case you do not desire to cast your vote, it will be treated as abstained.
- You may then cast your vote by selecting an appropriate option and click on “Submit”.
- A confirmation box will be displayed. Click “OK” to confirm else “CANCEL” to modify. Once you have voted on the resolution, you will not be allowed to modify your vote. During the voting period, Members can login any number of times till they have voted on the resolution.

General Guidelines for Members:

- Institutional members (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution / Authority letter etc. with attested specimen signatures of the duly authorised signatory(ies) who are authorised to vote on their behalf. The documents should be emailed to einward.ris@kfintech.com and Scrutinizer at acs@acsadvisors.in with a copy marked to secretarial@chandan.co.in.

- In case of any query and/ or assistance required, Members may refer to the Help & Frequently Asked Questions (“FAQs”) available at the download section of <https://evoting.kfintech.com> or contact KFin at the email ID evoting@kfintech.com or call KFin’s toll free No.: 1800 309 4001 for any further clarifications/ technical assistance that may be required.

Instructions for all the shareholders, including Individual, other than Individual and Physical, for attending the AGM of the Company through VC/OAVM and e-Voting during the meeting.

- Member will be provided with a facility to attend the AGM through VC/OAVM platform provided by KFin. Members may access the same at <https://emeetings.kfintech.com/> by using the e-voting login credentials provided in the email received from the Company/KFin.
- After logging in, click on the Video Conference tab and select the EVEN of the Company. Click on the video symbol and accept the meeting etiquettes to join the meeting. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned above.
- Facility for joining AGM through VC/OAVM shall open at least 15 minutes before the commencement of the Meeting.
- Members will be required to grant access to the webcam to enable VC/OAVM.
- Further, Members connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
- The Members who have not cast their vote through remote e-voting shall be eligible to cast their vote through e-voting system available during the AGM. E-voting during the AGM is integrated with the VC/ OAVM platform. The Members may click on the voting icon displayed on the screen to cast their votes. A Member can opt for only single mode of voting i.e., through Remote e-voting or voting during the AGM. If a Member cast votes by both modes, then voting done through Remote e-voting shall prevail and vote during the AGM shall be treated as invalid.
- Institutional Members are encouraged to attend and vote during the AGM through VC/OAVM.
- In case a person has become a Member of the Company after dispatch of AGM Notice but on or before the cutoff date for E-voting, he/she may obtain the User ID and Password in the manner as mentioned below:
- If the mobile number of the member is registered against Folio No./DP ID Client ID, the member may send SMS: MYEPWD <space> E-Voting Event Number and Folio No. or DP ID ClientID to 9212993399.
- Example for NSDL: MYEPWD <SPACE>IN12345612345678
- Example for CDSL: MYEPWD <SPACE>1402345612345678
- Example for Physical: MYEPWD <SPACE>XXXX1234567890
- If the e-mail address or mobile number of the member is registered against the Folio No./DP ID Client ID, then on the home page of <https://evoting.kfintech.com/> the member may click “Forgot Password” and enter Folio No. or DP ID Client ID and PAN to generate a password.
- Members who may require any technical assistance or support before or during the AGM are requested to contact KFin at toll free number 1-800-309-4001 or write to them at evoting@kfintech.com.

OTHER INSTRUCTIONS:

- Speaker Registration:

The Members who wish to speak during the meeting may register themselves as speakers for the AGM to express their views. They can visit <https://emeetings.kfintech.com> and login through the user id and password provided in the mail received from KFin. On successful login, select ‘Speaker Registration’ which will be opened from Saturday, September 26, 2026, 9.00 AM IST to Monday, September 28, 2026, 5.00 PM IST. Members shall be provided a ‘queue number’ before the meeting. The Company reserves the right to restrict the speakers at the AGM to only those Members who have registered themselves, depending on the availability of time for the AGM.

- Post your Question:

The Members who wish to post their questions prior to the meeting can do the same by visiting <https://emeetings.kfintech.com>. Please login through the user id and password provided in the email received from KFinTech. On successful login, select 'Post Your Question' option which will be opened from Saturday, September 26, 2026, 9.00 AM IST to Tuesday, September 29, 2026, 5.00 PM IST.

- In case of any query and/or grievance, in respect of voting by electronic means, Members may refer to the Help & Frequently Asked Questions (FAQs) and E-voting user manual available at the download section of <https://evoting.kfintech.com> (KFinTech Website) or contact Mr. Sashi Mannava, Vice President at evoting@kfintech.com or call KFinTech's toll free No.1-800-309-4001 for any further clarifications.
- Online application for Investor Query:

Members are hereby notified that our RTA, KFin Technologies Limited (Formerly known as KFin Technologies Private Limited), basis the SEBI Circular (SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/72) dated Jun 08, 2023, have launched an online application which can be accessed at [https://ris.kfintech.com/default.aspx# > Investor Services > Investor Support](https://ris.kfintech.com/default.aspx#>Investor%20Services%20>Investor%20Support).

Members are requested to register / signup, using the Name, PAN, Mobile and email ID. Post registration, user can login via OTP and execute activities like, raising Service Request, Query, Complaints, check for status, KYC details, Dividend, Interest, Redemptions, e-Meeting and e-Voting details.

Quick link to access the signup page :<https://kprism.kfintech.com/signup>

- Senior Citizens - Investor Support

As part of the initiative, our RTA in order to enhance the investor experience for Senior Citizens, a Senior Citizens investor cell has been newly formed to assist exclusively the Senior Citizens in redressing their grievances, complaints and queries. The special cell closely monitors the complaints coming from Senior Citizens through this channel and handholds them at every stage of the service request till closure of the grievance.

Senior Citizens wishing to avail this service can send the communication with the below details . Senior Citizens (above 60 years of age) have to provide the following details :

- 1. ID proof showing Date of Birth
- 2. Folio Number
- 3. Company Name
- 4. Nature of Grievance

A dedicated Toll-free number for Senior Citizens can also be accessed at 1-800-309-4006 for any queries or information

BY ORDER OF THE BOARD FOR CHANDAN HEALTHCARE LIMITED

Rajeev Kumar Nain
Company Secretary & Compliance Officer
Membership No.: A35449
Date: 07.09.2026
Place: Lucknow

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013

ITEM NO. 3 – RATIFICATION OF REMUNERATION OF COST AUDITOR

The Board of Directors of the Company, on the recommendation of the Audit Committee, has approved the appointment of M/s Rahul Jain & Associates, Cost Accountants, as the Cost Auditor of the Company for the Financial Year ending 31 March 2027, at a remuneration of Rs. 125000 (P.A.) plus applicable taxes and reimbursement of out-of-pocket expenses, subject to ratification of such remuneration by the members of the Company.

In accordance with the provisions of Section 148(3) of the Companies Act, 2013 read with Rule 14 of the Companies (Audit and Auditors) Rules, 2014, the remuneration payable to the Cost Auditor is required to be ratified by the members of the Company.

Accordingly, the Board recommends the Ordinary Resolution set out at Item No. 3 of the accompanying Notice for approval of the members.

None of the Directors, Key Managerial Personnel of the Company or their relatives is concerned or interested, financially or otherwise, in the proposed resolution.

The Board recommends the Ordinary Resolution for approval by the members.

ITEM NO. 4 – APPROVAL FOR VARIATION IN THE OBJECTS AND UTILISATION OF THE PROCEEDS OF THE PREFERENTIAL ISSUE OF CONVERTIBLE WARRANTS

The members of the Company had, by a special resolution passed at the members meeting held on 06/11/2025, approved the issue and allotment of 44,50,000 convertible warrants, each convertible into one equity share of the Company of face value Rs.10/- each, at an issue price of Rs.234 per warrant, on a preferential basis, aggregating to Rs.1,04,13,00,000. The warrants were allotted on 03/02/2026. In terms of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, an amount equivalent to 25% of the issue price, aggregating Rs.260325000, was received by the Company on allotment, and the balance 75% is receivable upon exercise of the warrants, which may be exercised within a period of eighteen months from the date of allotment, i.e. on or before 03/08/2027.

The objects for which the proceeds of the said preferential issue were to be utilised were set out in the explanatory statement annexed to the notice convening the said meeting. The Company now proposes to vary those objects to the extent of the amount received and remaining unutilised, and to apply the same towards business expansion by setting up new diagnostic laboratories and comprehensive diagnostic centres, including expansion of the Company's diagnostic network and related infrastructure.

The details of the proposed variation are as follows:

Particulars	Details
Date of members' approval of the preferential issue	06/11/2025
Number of convertible warrants allotted and date of allotment	44,50,000 warrants allotted on 03/02/2026

Name(s) of the allottee(s)	Name of Allottee	Category	No. of Share Warrants allotted
	1. JEENA SIKHO LIFECARE LIMITED	Non-Promoter	18,00,000
	2. AMAR SINGH	Promoter & Managing Director	3,50,000
	3. NEGEN UNDISCOVERED VALUE FUND	Non-Promoter	4,00,000
	4. NEGEN CAPITAL SERVICES PRIVATE LIMITED	Non-Promoter	2,50,000
	5. COMPACT STRUCTURE FUND	Non-Promoter	3,50,000
	6. RASHMI SHARMA	Non-Promoter	4,00,000
	7. JAI GOYAL	Non-Promoter	2,00,000
	8. RESHMA PANWAR	Non-Promoter	2,00,000
	9. PIYUSH WADHWA	Non-Promoter	1,00,000
	10. DIVYA HITESH RAMBHIA	Non-Promoter	1,00,000
	11. AMAN WALIA	Non-Promoter	1,00,000
	12. NISHITH SADH	Non-Promoter	44,000
	13. DIVYA VARSHNEY	Non-Promoter	40,000
	14. SHAILENDRA SINGH	Promoter Group	25,000
	15. ASMITA SINGH	Promoter & Managing Director	25,000
	16. ANANT SINGH	Promoter Group	25,000
	17. AASTI SINGH	Promoter Group	25,000
	18. RAJNISH VARSHNEY	Non-Promoter	16,000
Issue price per warrant	Rs.234		
Total consideration for the preferential issue	Rs.1,04,13,00,000		
Amount received on allotment (25% of the issue price)	Rs.260325000		

Balance 75% receivable on exercise of the warrants	Rs. 78,09,75,000			
Last date for exercise of the warrants	03/08/2027 i.e. 18 months from the date of the allotment			
Number of warrants exercised / converted as on date	Nil			
Objects as stated in the explanatory statement to the notice convening the said meeting	S. N o.	Particulars	Total estimated amount to be utilized (INR In Crore)	Tentative timelines for utilization of net proceeds from the date of receipt of funds
	1.	Business Expansion	44,50,00,000	Within 2 Years from receipt of funds for the Warrants
	2.	Acquisitions	50,00,00,000	Within 2 Years from receipt of funds for the Warrants
	3.	General Corporate Purpose	9,63,00,000	Within 2 Years from receipt of funds for the Warrants
Amount utilised towards the said objects as on 30.06.2026	Rs.28,13,07,818			
Amount remaining unutilised as on end of the quarter 30.06.2026	Rs.5,79,92,182			
Amount proposed to be varied	Rs.50,00,00,000			
Proposed revised object	From Acquisitions of business units, existing diagnostic centres equipment's, Labs and other related assets to Business Expansion by setting up new Diagnostic labs and comprehensive Diagnostic centres			
Reason and justification for the proposed variation	The proposed variation does not involve the introduction of a new object. It only involves the reallocation of a portion of the unutilised proceeds originally earmarked for the acquisition of business units, existing diagnostic centres, equipment, laboratories and other related assets towards business expansion by setting up new diagnostic laboratories and comprehensive diagnostic centres. The proposed reallocation is being made to align the utilisation of the funds with the Company's current implementation plans and business requirements. The Company considers that establishing new diagnostic laboratories and comprehensive diagnostic centres will enable it to expand its diagnostic network, increase its service capacity and geographical presence, and support its long-term growth objectives.			
Proposed timeline for deployment towards the revised object	Within 2 years from the receipt of fund			
Risk factors, if any, associated with the revised object	The proposed variation only involves the reallocation of a portion of the unutilised proceeds from the acquisition of business units, existing diagnostic centres, equipment, laboratories and other related assets towards business expansion by setting up new diagnostic laboratories and comprehensive diagnostic centres.			
Source of funds for the revised object	Unutilised proceeds of the preferential issue of convertible warrants			

The proposed variation is being undertaken considering the Company's revised business expansion strategy, the opportunities available for establishing new diagnostic laboratories and comprehensive diagnostic centres, and the

Company's objective of expanding its diagnostic network and geographical presence through organic growth. The Board is of the view that the deployment of the unutilised proceeds towards the revised object is in the interest of the Company and its members.

The proposed variation does not alter the total quantum of funds raised through the preferential issue, does not involve any change in the business of the Company or in the objects clause of its Memorandum of Association, and does not affect the issue price, the conversion ratio or any other term of the warrants. The unutilised proceeds will continue to be deployed within the existing operations of the Company. Accordingly, the Board does not expect the proposed variation to have any material impact on the earnings or the cash flows of the Company. Pending deployment, the unutilised proceeds continue to be held in the monitored bank account(s) of the Company and earn interest at prevailing rates.

The Audit Committee has reviewed the proposed variation and the Board of Directors, at its meeting held on 7 September 2026, after considering the recommendation of the Audit Committee, has approved the same, subject to the approval of the members by way of a Special Resolution.

The variation, once approved, will be reported in the statement of deviation or variation submitted to the National Stock Exchange of India Limited under Regulation 32 of the SEBI Listing Regulations, which is placed before the Audit Committee for its review. Further, in terms of Regulation 32(7A) of the SEBI Listing Regulations, the Company will continue to disclose the utilisation of the proceeds of the preferential issue in its Annual Report every year until such proceeds are fully utilised.

Accordingly, the Board recommends the Special Resolution set out at Item No. 4 of the accompanying Notice for approval of the members.

Except the allottee(s) who are Directors/KMP or their relatives, if any, and to the extent of their respective shareholding in the Company, none of the Directors, Key Managerial Personnel of the Company or their relatives is concerned or interested, financially or otherwise, in the proposed resolution.

The Board recommends the Special Resolution for approval by the members.

ITEM NO. 5

APPOINTMENT OF MR. SANJAY SRIVASTAVA AS AN INDEPENDENT DIRECTOR

The Nomination and Remuneration Committee, and the Board of Directors, recommended the appointment of Mr. Sanjay Srivastava (DIN: 11927967) as an Independent Director of the Company for a term of five (5) consecutive years with effect from 30 September 2026 up to 29 September 2031, subject to the approval of the Members.

Mr. Sanjay Srivastava is a retired Additional Commissioner, State Goods and Services Tax, Government of Uttar Pradesh, with years of service in the field of taxation, indirect taxes, GST administration, regulatory affairs and public administration. Having regard to his qualifications, extensive experience and expertise in the aforesaid areas, the Board is of the view that his association would be of immense benefit to the Company.

The Company has received from Mr. Sanjay Srivastava:

- (i) his consent in writing to act as Director in Form DIR-2 pursuant to Rule 8 of the Companies (Appointment and Qualification of Directors) Rules, 2014;
- (ii) an intimation in Form DIR-8 to the effect that he is not disqualified from being appointed as a Director in terms of Section 164(2) of the Act;
- (iii) a declaration that he meets the criteria of independence as prescribed under Section 149(6) of the Act and Regulation 16(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"); and

(iv) a confirmation that he has not been debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other authority, in terms of the Circular dated 20 June 2018 issued by the National Stock Exchange of India Limited.

The Company has also received a notice in writing from a Member under Section 160 of the Act proposing his candidature for the office of Director. In terms of the second proviso to Section 160(1) of the Act, no deposit is required to accompany such notice in the case of a person recommended by the Nomination and Remuneration Committee for appointment as an Independent Director.

In the opinion of the Board, Mr. Sanjay Srivastava fulfils the conditions specified in the Act, the Rules made thereunder and the SEBI Listing Regulations for appointment as an Independent Director, and he is independent of the management of the Company. The Board is further of the opinion that he possesses the requisite integrity, expertise and experience (including the proficiency identified under sub-rule (1) of Rule 6 of the Companies (Appointment and Qualification of Directors) Rules, 2014). He is not related to any Director or Key Managerial Personnel of the Company. He shall not be liable to retire by rotation in terms of Section 149(13) of the Act.

Mr. Sanjay Srivastava will be entitled to sitting fees for attending meetings of the Board and Committees thereof and reimbursement of expenses incurred for participation in such meetings, within the limits prescribed under Section 197 of the Act.

A copy of the draft letter of appointment setting out the terms and conditions of appointment is available for inspection by the Members in electronic mode. Members seeking to inspect the same may send a request to secretarial@chandandian.co.in. The said draft letter is also available on the website of the Company at <https://chandandian.co.in>

The relevant details of Mr. Sanjay Srivastava, as required under Regulation 36(3) of the SEBI Listing Regulations and Secretarial Standard-2 on General Meetings issued by the Institute of Company Secretaries of India, are annexed to this Notice.

Save and except Mr. Sanjay Srivastava and his relatives, to the extent of their shareholding in the Company, if any, none of the Directors, Key Managerial Personnel of the Company or their respective relatives is, in any way, concerned or interested, financially or otherwise, in the resolution set out at Item No. 5 of the Notice.

The Board recommends the Ordinary Resolution set out at Item No. 5 of the Notice for approval by the Members.

ANNEXURE TO THE NOTICE

Details of the Director seeking re-appointment at the Annual General Meeting, pursuant to Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Secretarial Standard on General Meetings (SS-2) issued by the Institute of Company Secretaries of India

Particulars	Details
Name	Mr. Amar Singh
DIN	01096328
Date of birth	10/03/1958
Date of first appointment on the Board	03/09/2003
Qualification	Post Graduate
Experience and expertise in specific functional areas	He is the Promoter, Chairman and Managing Director of our company. He has been associated with the company since its inception, he was re-designated as Managing Director of the company on March 30, 2024. He holds a degree of Bachelor of Medicine and Bachelor of Surgery. He has over two decades of experience in the healthcare industry. At Chandan, he oversees the entire company's operations and sets its strategic direction. His responsibilities include setting business objectives, creating growth strategies, and guaranteeing the delivery of high-quality services to clients. Through his leadership, he ensures alignment between the company's goals and its operational practices.
Terms and conditions of re-appointment	Re-appointment as a Director liable to retire by rotation, on the existing terms and conditions
Remuneration last drawn (FY 2025-26)	Rs. 46.71 lakh
Remuneration proposed to be paid	No Change in the remuneration
Number of shares held in the Company	2349460
Relationship with other Directors, Manager and Key Managerial Personnel	Father of Mrs. Asmita Singh (Managing Director)
Number of Board meetings attended during FY 2025-26	11 out of 11

Directorships held in other companies	Sl No.	Names of the Companies	Designation
	1.	CHANDAN PHARMACY LIMITED	Director
	2.	AMARANITA HOLDINGS (INDIA) PRIVATE LIMITED	Director
	4.	CHANDAN HOSPITAL LIMITED	Managing Director
	5.	CHANDAN HEALTHCARE LIMITED	Managing Director
	6.	CHANDAN DIAGNOSTIC LIMITED	Director
	7.	CENDANA PHARMACEUTICALS PRIVATE LIMITED	Director
	8.	CHANDAN SUPER SPECIALITY HOSPITAL LIMITED	Director
	9.	HEALTHRELY PRIVATE LIMITED	Director
	10.	CHANDAN MULTI SUPER SPECIALITY HOSPITAL LIMITED	Director
	11.	CHANDAN CRADLE LIMITED	Director
	12.	CHANDAN HEALTHCARE PROJECTS PRIVATE LIMITED	Director
Membership / Chairmanship of Committees of other listed companies	Nil		
Listed entities from which he resigned in the preceding three financial years	Nil		

The particulars of Mr. Sanjay Srivastava, whose appointment is proposed at Item No. 5, are set out in the Explanatory Statement to Item No. 5 above and are not repeated here.

BY ORDER OF THE BOARD FOR CHANDAN HEALTHCARE LIMITED

Rajeev Kumar Nain
Company Secretary & Compliance Officer
Membership No.: A35449

Date: 07.09.2026

Place: Lucknow